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ABSTRACT 
A PDZ domain is a small, ~ 90 amino acid residue region of a protein that acts as a 
protein-protein interaction module. There are currently 267 known PDZ domain-
containing proteins in the human genome, with the predominant function of a PDZ 
domain being the recognition and binding of C-terminal motifs in partner proteins. 
Examples of well-studied multi PDZ domain-containing proteins are the postsynaptic 
density-95 protein (PSD-95) and the synapse-associated protein 97 (SAP97); 
different PSD-95 and SAP97 PDZ domain-mediated interactions have been 
implicated in a variety of pathological conditions. The interaction of the PSD-95 
PDZ domains with the 5-hydroxytryptamine receptor 2a (5-HT2a) & 2c (5-HT2c) 
variants is known to be important in inducing hyperalgesia in neuropathic pain; the 
PDZ-mediated interaction of SAP97 with the human papillomavirus type 18 
(HPV18) E6 protein is an important event in a p53-independent pathway of cervical 
carcinogenesis.  
As PDZ domains have been shown to bind small organic molecules and that the 
majority of free energy contributions of the PDZ domain interaction interface to 
binding, are due to a select few ‘hotspot’ regions; the development of novel, 
reversible small molecule inhibitors of the PSD-95 and SAP97 PDZ domains was 
deemed a viable research target. This was the overriding aim of the research 
programme detailed in this thesis and encompassed biophysical techniques such as: 
protein production, NMR spectroscopy, isothermal titration calorimetry (ITC), 
restraint-driven docking and structure determination methodologies. 
The PDZ-mediated interactions of 5-HT2a and 5-HT2c with the PSD-95 and SAP97 
PDZ1 & PDZ2 were confirmed using NMR spectroscopy and then, quantified by 
ITC. The structure of the physiologically relevant complex formed between PSD-95 
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PDZ1 and 5-HT2c was determined using NMR solution state spectroscopic 
determination methods; this is the first example of a PSD-95 PDZ – 5-HT2x complex 
structure. 
A systematic investigation into the interaction between the SAP97 PDZ2 domain and 
the HPV18 E6 protein was carried out by ITC; this process involved binding 
experiments utilising commercially acquired peptides of varying lengths and 
sequences, containing natural and non-natural amino acids.  
A variety of small organic molecules that bind to the PSD-95 PDZ1 domain have 
been developed by an NMR screening process. The PSD-95 PDZ1 binding affinity 
of two of the small molecules was determined by NMR spectroscopy and their 
inhibitory effect on the native PSD-95 PDZ1 – 5-HT2c interaction was quantified 
using ITC. The structure of the individual PSD-95 PDZ1 – small molecule 
complexes formed were determined by NMR restraint-driven docking, using the 
high-ambiguity driven docking (HADDOCK) programme; this is the first instance 
of HADDOCK being utilised to determine a PDZ domain – small molecule complex 
structure. 
The research detailed in this thesis alludes to the possibility that PSD-95 and SAP97 
PDZ domain-mediated interaction inhibition by a small molecule compound may not 
be a feasible research aim and that future PDZ domain inhibition research may need 
to be focus on other inhibitor structures i.e. β-strand peptidomimetics. 
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1. INTRODUCTION 
1.1 Protein-Protein Interactions 
The specific interaction between two proteins is a critical event in almost all 
biological processes (Sharma et al., 2002, Arkin and Wells, 2004); the key cellular 
operations of an individual protein are usually exerted through a protein-protein 
complex form, rather than in isolation (Berg, 2003). As a result of the vital role of 
protein-protein interactions (PPIs) in a wide-range of cellular processes, the 
formation of abnormal or undesirable PPIs has been implicated in a variety of 
pathological conditions (Arkin, 2005); thus, PPIs represent a large and attractive 
class of targets for human therapeutics (Gadek and Nicholas, 2003). The potential to 
interfere with PPIs is of the utmost importance, not just in the development of novel 
disease treatments but also in terms of developing our understanding of cell 
physiology; inhibition of a particular PPI and analysing the resultant cellular effect 
can elucidate the role of a specific protein or PPI (Cochran, 2001, Ockey and Gadek, 
2002).  
The vast majority of PPI inhibition research to-date has centred on the use of 
therapeutic antibodies, which are specific for their target and stable in human serum. 
An indication of the previous excitement in this therapeutic strategy is exhibited by 
the fact that over $5 billion was spent on antibody-based antagonists in the US in 
2005 (Arkin and Wells, 2004). However, there are a number of problems associated 
with the use of antibodies to inhibit PPIs; antibodies are not orally bioavailable, there 
are difficulties in their manufacture and they are not cell-permeable, so, intracellular 
PPI inhibition has been limited to antisense therapies (Arkin and Wells, 2004).  
On the other hand, if suitably designed, small ‘drug-like’ organic molecules can be 
administered orally and are able to cross the blood-brain barrier c.f. therapeutic 
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antibodies which are not capable of brain penetration. Thus, the disruption of PPI by 
a small organic molecule is currently of great therapeutic interest and importance 
(Toogood, 2002, Fry, 2006); however, the characteristics of the PPI interface mean 
that achieving this target presents a huge challenge, as the PPI interface is: 
 Usually vast, between 750 and 1500Å2 for each protein involved in the 
interaction (Wells and McClendon, 2007). 
 Generally flat and often lacks the grooves/pockets of typical proteins that 
bind small molecules (Wells and McClendon, 2007). 
 The binding regions are often non-contiguous and cannot be mimicked by a 
simple synthetic molecule (Wells and McClendon, 2007). 
Fortunately, however, it has been previously shown that it is often a subset of 
residues in the PPI interface that contribute most of the free energy to binding 
affinity (Clackson and Wells, 1995); this region of the interface is usually referred to 
as the ‘hotspot’ (Figure 1.1) and these ‘hotspots’ have been found to bind to both 
short peptide sequences and small organic molecules (Moreira et al., 2007). 
Therefore, the actual interface targeted in the drug discovery process by the small 
molecule is greatly reduced and so, disruption of PPI by small molecules has become 
a viable research target (Yin and Hamilton, 2005).  
Synapses of the central nervous system (CNS) are an example of a region in living 
organisms where the interaction between proteins is of vital importance to normal 
function; the synaptic system is discussed next. 
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Figure 1.1: The protein-protein interface between FLT1 and the vascular endothelial growth factor 
(VEGF). Alanine-scanning mutational analysis was performed and the figure shows the resultant 
change in binding free energy (∆∆G) compared to the wild-type protein. It can be seen that most of 
the free energy is contributed by a small number of residues (red); these residues of the respective 
protein are known as the ‘hotspots.’ Image taken and adapted from (Wells and McClendon, 2007). 
 
1.2 Synapses 
Synapses are functional connections between two excitable cells (or neurons) in the 
mammalian central nervous and circulatory systems; they allow information to be 
passed from one cell to the other with precision and speed (Cowan et al., 2001). 
Transmission of a signal at a synapse can occur via direct propagation of an electrical 
stimulant (electrical synapse) or via a chemical intermediate known as a 
neurotransmitter (chemical synapse). The subsequent description relating to synapses 
will refer mainly to a chemical synapse, referred to as synapse(s) for simplicity from 
now on (Cowan et al., 2001).  
Synapses are specialised junctions that consist of a pre-synaptic membrane with a 
post-synaptic membrane opposite, separated by a synaptic cleft (Figure 1.2) 
(Montgomery et al., 2004). Immediately behind the postsynaptic membrane is a 
protein dense region known as the postsynaptic density (PSD) (Ziff, 1997); this 
region contains numerous interlinking scaffold proteins, neurotransmitter 
receptors/ion channels and signalling molecules (Figure 1.2) (Montgomery et al., 
2004, Cowan et al., 2001). The strength of a synapse is dependent on the number of 
ion channels/receptors present, with previous research indicating that the number of 
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synaptic components present can vary according to synaptic activity/demands (Ziff, 
1997).  
The localisation and transport of neurotransmitter receptors and ion channels to/from 
the synapse occurs via PPIs involving a family of scaffold proteins called the 
postsynaptic density membrane-associated guanylate kinases (PSD-MAGUKs) 
(Kennedy, 1997, Chen et al., 2007a). 
 
 
Figure 1.2: A simplified version of the structure of a chemical synapse based on a figure in (Genoux 
and Montgomery, 2007). The figure shows how the synapse consists of presynaptic and postsynaptic 
neurons separated by the synaptic cleft; the protein rich postsynaptic density region (PSD, purple) of 
the postsynaptic neuron containing the neurotransmitter receptors (AMPAR and NMDAR [1.5], 
yellow and green respectively) and scaffold proteins (PSD-95 and SAP97, magenta and orange 
respectively [1.5]) has been identified. The transfer of a signal across the chemical synapse shown 
here occurs via a neurotransmitter chemical intermediate, glutamate in this instance; after the vesicle 
containing the glutamate fuses with the presynaptic membrane, it travels across the synaptic cleft and 
interacts with the desired receptor. 
  
1.3 Post-Synaptic Density Membrane-Associated Guanylate Kinases 
Postsynaptic density membrane-associated guanylate kinases (PSD-MAGUKs) 
predominantly function as organisers of neurotransmitter receptors/receptor-
associated signalling proteins at synapses; this organisation is achieved through the 
formation of PPIs (Gardoni et al., 2009). PSD-MAGUKs are usually localised to the 
PSD of synapses in the central nervous and circulatory systems; although they have 
been found in alternative locations (Cai et al., 2002, DeGiorgis et al., 2006). The 
Presynaptic 
Neuron 
Postsynaptic 
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Synaptic 
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most extensively studied PSD-MAGUKs are a subset known as the DLG 
(Drosophila tumour suppressor gene) family.  
The DLG subfamily of the PSD-MAGUKs are an example of a family of proteins 
that contain numerous different protein interaction domains (Figure 1.3); they 
comprise of three N-terminal PDZ domains, an L27 domain, an scr homology 3 (SH3) 
domain and an inactive C-terminal guanylate kinase domain (GUK) (Cousins et al., 
2008); all of which are possible sites of PPIs (Montgomery et al., 2004). Previous 
research has shown that the important DLG – receptor interaction in the receptor 
localisation/transfer processes is between one of the PDZ domains of the particular 
DLG protein and the extreme C-terminus of the specific binding partner protein (Cai 
et al., 2002, Blazer and Neubig, 2009).  
PDZ domains are an example of a protein-protein interaction interface where 
research has shown that most of the free energy of binding is due to a selection of a 
few residues contained within PDZ domain i.e. they contain the ‘hotspot’ regions 
described in [1.1]; thus, PDZ domains and the interactions they mediate have been 
deemed a suitable target for therapeutic intervention. 
 
 
 
Figure 1.3: An overview of the generic structure of the DLG subfamily of postsysnaptic density 
membrane-associated guanylate kinases (PSD-MAGUKs); the DLG family are an example of a 
family of proteins that contain numerous different protein-protein interaction domains. It can be seen 
that all proteins in the family contain three different PDZ domains, an L27 domain, an src homology 3 
(SH3) domain and an inactive C-terminal guanylate kinase (GUK). 
 
1.4 PDZ Domains 
A PDZ domain is a small, ~ 90 amino acid residue region of a protein that acts as a 
protein-protein interaction module. The name ‘PDZ domain’ is an acronym of the 
first three proteins that were found to share the domain: PSD-95 (postsynaptic 
L27 PDZ PDZ PDZ SH3 GUK 
N C 
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density-95 protein), Dlg (Drosophila disc large tumour suppressor) and ZO-1 (zona 
occludens-1). The predominant function of a PDZ domain is the recognition and 
binding of C-terminal motifs in partner proteins (Harris and Lim, 2001, Arkin and 
Wells, 2004). 
A PDZ domain consists of six β-strands (βA-βF) and two α-helices (αA and αB), 
which fold into a six stranded β-sandwich (Figure 1.4a) (Garner et al., 2000). The 
binding region of PDZ domains consist of a hydrophobic pocket formed by the 
GLGF motif (red, Figure 1.4b) and hydrophobic residues (blue, Figure 1.4b) and an 
extended groove between the βB strand and αB helix. PDZ ligands bind to the PDZ 
domain via a mechanism known as β-strand addition, with the PDZ ligand 
effectively forming an extra anti-parallel β-strand (Figure 1.4c) (Dev, 2004).  
 
Figure 1.4: a & b) The crystal structure of the Scrib1 PDZ1 domain (PDB ID = 2W4F). a) The 
protein in a cartoon representation; the six β-strands and two α-helices that comprise a conventional 
PDZ domain structure can be seen. b) A surface representation of the protein that highlights the 
hydrophobic pocket and extended groove of the PDZ domain binding region; the GLGF motif (red), 
hydrophobic pocket (blue), conserved His (green) and βB – βC loop (yellow) residues have been 
highlighted. c) The crystal structure of the SAP97 PDZ2 – APC complex (PDB ID = 4G69) with the 
PDZ domain in a cartoon representation and the PDZ ligand represented as both sticks and a cartoon; 
the PDZ ligand is shown to bind in the typical manner between the βB strand and αB helix and 
effectively forms an extra anti-parallel β-strand. 
  
The key PDZ binding motif is thought to rely on the three or four C-terminal 
residues, where the C-terminus residue of a PDZ domain ligand is conventionally 
labelled ‘0’ and the adjacent residues then labelled with increasingly negative values 
as the distance from the C-terminus increases (Kurakin et al., 2007). PDZ domains 
αB 
a) b) c) 
βB 
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are conventionally divided into one of three different classes depending on the 
specific C-terminal sequence of their target partner protein(s); there are a few PDZ 
domains that do not fall into any of these classes and so, remain unclassified, i.e. the 
Dishevelled PDZ domain (Lee et al., 2009b). Class I PDZ domains recognise the 
extreme four C-terminal residue sequence X-S/T-X-Ф* (where X = any amino acid, 
Ф = hydrophobic amino acid and * represents the C-terminus). The S/T residue 
forms an important hydrogen bond to the His residue (green, Figure 1.4b) contained 
within the B helix of the PDZ domain (Ponting et al., 1997, Cai et al., 2002); this 
interaction is known to be important, as if the S/T site becomes phosphorylated, then 
binding of the ligand to the PDZ domain does not occur in some examples (Cai et al., 
2002). Class II PDZ domains associate with ligands with the C-terminal sequence X-
Ф-X-Ф* and class III domains interact with the sequence X-X-C* (Harris and Lim, 
2001). 
The -1 and -3 residues of the PDZ domain ligand are thought to be involved in 
determining the particular PDZ domain binding specificity of the respective protein 
(Fujii et al., 2003); although recent research has indicated that residues further 
‘downstream’ of the conventional four C-terminal residues may contribute towards 
affinity and specificity (yellow, Figure 1.4b) (Zhang et al., 2007).  
There are currently 267 PDZ domain-containing proteins that have been identified in 
the human genome (Bouzidi et al., 2013); arguably the two most well-studied and 
important PDZ proteins are members of the previously described DLG subfamily of 
the PSD-MAGUKs: the postsynaptic density-95 protein (PSD-95) and the synapse-
associated protein-97 (SAP97) (Tao and Raja, 2004, Schlueter et al., 2006). 
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1.5 PDZ Proteins: PSD-95 and SAP97 
1.5.1 PDZ Domain Comparison 
As PSD-95 and SAP97 are both members of the DLG subfamily of PSD-MAGUKs 
they both contain three different PDZ domains, with the overall sequence similarity 
of the six PDZ in total domains being 27.59% (Figure 1.5a); the sequence similarity 
of the respective PSD-95 and SAP97 PDZ1, PDZ2 and PDZ3 domains was found to 
be 90.81%, 88.51% and 86.42% respectively. Phylogenetic analysis of the different 
PDZ domains of the PSD-95 and SAP97 gives an insight into the evolutionary 
relationship of the individual PDZ domains. From the phylogenetic tree, it can be 
seen that the PDZ3 domains of PSD-95 and SAP97 do not share the same common 
ancestor as the PDZ1 & 2 domains. The tree also indicates that the respective PDZ1 
domains were the last of the three different pairs of PDZ domains to diverge in their 
evolutionary history; this would account for the fact that they are the respective PDZ 
domain pair that showed the greatest sequence similarity (Figure 1.5b). 
There has been a wide range of research performed on the PDZ domains of the PSD-
95/SAP97 proteins and the interactions that they mediate; this has yielded some 
important and interesting information about the PDZ proteins PSD-95 and SAP97. 
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Figure 1.5: a) The sequence alignment (produced using www.uniprot.org) of the three different PDZ 
domains of the PSD-95 and SAP97 proteins. The overall sequence similarity of the six PDZ domains 
was 27.59%, with the sequence similarity of the respective PDZ1, PDZ2 and PDZ3 domains found to 
be 90.81%, 88.51% and 86.42% respectively. b) The phylogenetic tree (produced using 
www.uniprot.org) of the six different PDZ domains indicated that the PSD-95 and SAP97 PDZ3 
domains do not share the same common ancestor as the PDZ1 & 2 domains. The tree also indicates 
that the order of evolutionary divergence of the respective PDZ domain pairs (from earliest to the 
latest) was PDZ3, PDZ2, PDZ1; this explains the trend in sequence similarity between the respective 
PDZ domains observed. 
  
1.5.2 PSD-95 
1.5.2.1 General Overview 
PSD-95 was originally identified as a protein with a molecular weight of 90 – 95kDa 
that was highly homologous to the product of the Drosophila discs-large tumour 
suppressor gene (Dlg), during studies to identify synaptic components (Cho et al., 
1992, Kistner et al., 1993). As a result, PSD-95 can also be found referred to in the 
literature as synapse-associated protein-90 (SAP90) and discs-large homolog-4 
(Dlg4) (Hata and Takai, 1999); PSD-95 is almost exclusively found localised to the 
PSD of neuron synapses. Solution state NMR spectroscopy and X-ray 
crystallography have been utilised independently to determine the structure of the 
individual PSD-95 PDZ1 (Piserchio et al., 2002, Long et al., 2003), PDZ2 (Tochio et 
al., 2000) and PDZ3 domains (Doyle et al., 1996, Camara-Artigas et al., 2010); the 
a) 
b) 
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structure of the PSD-95 PDZ1 & 2 tandem domain has also been produced by these 
methods (Sainlos et al., 2011, Bach et al., 2012). 
The role of the PSD-95 PDZ domain-mediated interactions in glutamate receptor 
localisation and trafficking is discussed further in [1.5.4]; however, a number of 
other important PSD-95 PDZ-mediated interactions have been identified by previous 
research studies. 
1.5.2.2 PSD-95 PDZ-Mediated Interactions 
There have been a variety of different proteins found to interact with at least one of 
the PDZ domains of PSD-95; the majority of these proteins are summarised (Table 
1.1), with the respective PSD-95 PDZ domain(s) they interact with indicated. A 
PSD-95 PDZ domain-mediated interaction that is of particular relevance to the 
research described in this thesis is the PSD-95 PDZ – 5-hydroxytryptamine receptor 
interaction. 
5-Hydroxytryptamine (5-HT, Figure 1.6a), also known in the literature as serotonin, 
and its corresponding 5-hydroxytryptamine receptors (5-HTx) are found to have 
biological relevance in virtually all major organ systems (Berger et al., 2009). The 5-
HT/5-HTx system has been shown to have a role in essentially every major central 
nervous system (CNS) function (Roth, 1994); the system is also responsible for 
regulating a large number of diverse physiological processes such as platelet 
aggregation and gastrointestinal motility (Berger et al., 2009, Roth, 2011). 
There are currently 15 distinct 5-HTx identified in humans and these are divided into 
seven families (5-HT1-7) (Gavarini et al., 2004); all the 5-HTx are members of the G-
protein coupled receptor super-family with the exception of 5-HT3, which is a 
ligand-gated channel (Bockaert et al., 2006). A number of the interactions of the 5-
HTx have been studied previously (Figure 1.6b) (Marin et al., 2012, Wacker et al., 
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2013) and it has been shown that there are physiologically relevant interactions 
between members of the 5-HT2x family and the PSD-95 PDZ domains (Backstrom et 
al., 2000, Becamel et al., 2002, Xia et al., 2003, Becamel et al., 2004, Bockaert et al., 
2006, Allen et al., 2008, Abbas et al., 2009, Pichon et al., 2010, Anastasio et al., 
2010); the 5-HT2x family interact with the PSD-95 PDZ domains via a conserved 
class I C-terminal PDZ binding motif.  
Table 1.1: The different proteins that exhibit PSD-95 PDZ domain-mediated binding; the specific 
PSD-95 PDZ domain – protein interactions are indicated by a Y (= Yes), along with the 
corresponding reference. 
Protein PDZ1 PDZ2 PDZ1&2 PDZ3 Reference(s) 
5-HT2a   Y  (Xia et al., 2003) 
5-HT2c   Y  (Becamel et al., 2002) 
β1-AR   Y  (Kreienkamp, 2002) 
Citron  Y  Y (Lim et al., 2002) 
CRIPT    Y (Niethammer et al., 1998) 
Cypin   Y  (Firestein et al., 1999) 
DHHC5    Y (Li et al., 2010) 
Fz1,2,4&7 Y Y Y  (Hering and Sheng, 2002) 
Kir2.1/2.3  Y Y  (Cohen et al., 1996, Pegan 
et al., 2007) 
Kv1.4 Y Y Y  (Imamura et al., 2002) 
nNOS  Y Y  (Brenman et al., 1996) 
NR2A-D Y Y Y  (Hata and Takai, 1999) 
Sema4c/f     (Burkhardt et al., 2005) 
Slo2 Y    (Uchino et al., 2003) 
SSTR1&4 Y Y   (Christenn et al., 2007) 
 
There are three members of the 5-HT2x family; 5-HT2a, 5-HT2b and 5-HT2c with 5-
HT2a and 5-HT2c being widely distributed in the CNS, whereas 5-HT2b localisation in 
the CNS is sparse (Bockaert et al., 2006). 5-HT2a and 5-HT2c share about 50% 
sequence similarity, with 5-HT2a being predominantly found in brain regions such as 
the hippocampus, cerebral cortex and spinal cord. 5-HT2a can also be expressed in 
several peripheral tissues i.e. smooth and skeletal muscle, kidney, liver and platelets; 
5-HT2c are exclusively located in the brain regions such as the cerebral cortex and 
striatum (Marin et al., 2012). 5-HT2a and 5-HT2c have been shown to interact with 
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the PSD-95 PDZ domains (Becamel et al., 2004), whereas 5-HT2b has been found to 
bind to MUPP1 PDZ10 domain (Becamel et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: a) The chemical structure of the neurotransmitter 5-hydroxytryptamine (serotonin), the 
agonist of the 5-hydroxytryptamine receptor family. b) The crystal structure of the complex formed 
between the 5-HT2b receptor (shown in a cartoon representation) and the alkaloid, ergotamine 
(represented as sticks); this is an example of previous research into the interactions of 5-
hydroxytryptamine receptor family (PDB ID = 4IB4 (Wacker et al., 2013)). 
 
The interaction between the PSD-95 PDZ domains and 5-HT2a enhances 5-HT2a 
receptor-mediated signal transduction by inhibition of agonist-induced receptor 
internalisation (Xia et al., 2003); the interaction has also been shown to be essential 
for somatodendritic targeting of 5-HT2a in vitro and in vivo (Xia et al., 2003, Abbas 
et al., 2009). However, the PDZ domain-mediated interaction between PSD-95 and 
5-HT2a has been shown to contribute to induced analgesia in painful diabetic 
neuropathy (Roth, 2011); this is because inhibition of the interaction resulted in 
reduced hyperalgesia in neuropathic pain (Pichon et al., 2010).  
The interaction between the PSD-95 PDZ domains and 5-HT2c is important in the 
regulation, expression, synaptic localisation and organisation of 5-HT2c (Becamel et 
al., 2002, Anastasio et al., 2010). The PSD-95 PDZ – 5-HT2c interaction has also 
been found to increase desensitisation of the 5-HT2c receptor Ca
2+
 response, as well 
as constitutive and agonist-induced receptor internalisation (Backstrom et al., 2000, 
Gavarini et al., 2006).  
  
b) a) 
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1.5.3 SAP97 
1.5.3.1 General Overview 
SAP97 was identified as the human homologue of the Drosophila discs-large tumour 
suppressor protein, with a molecular weight of 97kDa; this has resulted in SAP97 
being referred to in the literature as human Dlg (hDlg) (Lue et al., 1994, Muller et 
al., 1995). Unlike PSD-95, SAP97 is ubiquitously expressed and has been isolated 
from the synapses and axons of the CNS, as well as the basal lateral membrane of 
epithelial cells and the cytoplasmic surface between adjacent cells in cultured T84 
cells (Muller et al., 1995). As with PSD-95, solution state NMR spectroscopy and X-
ray crystallography have been utilised independently to determine the structure of the 
individual SAP97 PDZ1 (Wang et al., 2005), PDZ2 (von Ossowski et al., 2006, Haq 
et al., 2010) and PDZ3 domains (Cabral et al., 1996). 
The role of the SAP97 PDZ domain-mediated interactions in glutamate receptor 
localisation and trafficking is discussed further in [1.5.4]; however, a number of 
other important SAP97 PDZ-mediated interactions have been identified by previous 
research studies. 
1.5.3.2 SAP97 PDZ-Mediated Interactions 
There have been a variety of different proteins found to interact with at least one of 
the PDZ domains of SAP97; almost all of these proteins have been summarised 
(Table 1.2), with the respective PDZ domain(s) they interact with indicated. A 
SAP97 PDZ domain-mediated interaction that is of particular relevance to the 
research described in this thesis is the SAP97 PDZ – human papillomavirus E6 
protein interaction. 
The human papillomavirus (HPV) is a virus from the papillomavirus family that is 
capable of infecting humans; papillomaviruses are small, double stranded DNA 
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viruses that can induce hyperproliferative lesions in both mucosal and cutaneous 
epithelial tissue (Liu et al., 2007, Zhang et al., 2007). HPVs have been strongly 
associated with the development of both benign and malignant lesions; they have 
been found to promote cervical cancer in over 95% of cases (Munoz et al., 2003). 
There are over 60 different HPVs and these are commonly divided into two distinct 
groups depending on their clinical associations (Werness et al., 1990, Scheffner et 
al., 1990); HPVs are classified as either ‘low risk’ or ‘high risk.’  
Low risk HPV types, such as HPV6 and HPV11, are generally associated with 
benign proliferative lesions that infrequently progress to malignancy; high risk HPV 
types such as HPV16 and HPV18 are associated with malignant lesions (Chi et al., 
2011). The oncogenic potential of high risk HPV types such as HPV16 and HPV18 
(HPV16/18) is due to their ability to encode two oncoproteins, E6 and E7 (Kiyono et 
al., 1997). Research has shown that the open reading frames (ORFs) of the E6 and 
E7 proteins produced by high risk HPVs have been found intact and actively 
transcribed in cervical carcinomas and derived cell lines (Schwarz et al., 1985); this 
is further evidence of the causal factor of high risk HPVs in associated cancers. The 
HPV E6 protein has previously been shown to play an active role in the development 
and pathogenesis of several types of cancer such as cervical, head and neck 
(Syrjanen, 2005, Marur et al., 2010).  
Extensive studies have indicated that this pathogenesis of high risk HPVs is achieved 
via the E6-mediated degradation of p53 tumour-suppressor protein, which prevents 
the cell apoptosis associated with viral infection and leads to uncontrolled cell 
growth. However, research has also shown evidence of p53-independent functions of 
E6 that are important and necessary for transformation; one such example is the 
binding of E6 to PDZ domain-containing tumour suppressor proteins such as SAP97, 
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hScrib, MUPP1 and MAGI, via a conserved C-terminal binding motif (Zhang et al., 
2007). In epithelial cells of vertebrates, SAP97 is associated with the adherens 
junction (AJ), which is responsible for cell-cell contacts; the PDZ domain-mediated 
interaction of E6 targets SAP97 for degradation (as with p53), which decreases the 
phosphorylation of E-cadherin by protein kinase CK2 and this induced down-
regulation is a common event in carcinogenesis. Interestingly, research has shown E6 
mutants that are incapable of SAP97 PDZ domain binding are no longer able to 
induce E6-dependent transformation of rodent cells; this indicates that the SAP97 
PDZ – HPV E6 interaction is an underlying mechanism in the development of 
cancers (Figure 1.7) (Kiyono et al., 1997). 
The HPV16 and HPV 18 E6 oncoproteins have been shown to bind to all three PDZ 
domains of SAP97 (Chi et al., 2011); with the NMR solution state structures of the 
SAP97 PDZ2 – HPV18 E6 (Liu et al., 2007, Zhang et al., 2007) and SAP97 PDZ3 – 
HPV18 E6 (Zhang et al., 2007) being determined previously.  
Figure 1.7: The effect of the two oncoproteins (E6 & E7) produced by high risk human 
papillomavirus (HPV) types on the malignant transformation of cells is characterised by targeting of 
substrates for degradation. The HPV infects keratinocytes that have exited the cell cycle, E7 interacts 
with proteasome machinery which results in cell proliferation; this proliferation results in a p53-
mediated response that is targeted by the E6-E6AP (E6 associated protein) complex. The p53-
independent process of MAGUK degradation (i.e. SAP97) occurs late on in the malignancy, which 
contributes to the subsequent metastasis. Image taken from (Banks et al., 2003). 
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Table 1.2: The different proteins that exhibit binding to the SAP97 PDZ domains; the specific SAP97 
PDZ domain – protein interactions are indicated by a Y (= Yes), along with the corresponding 
reference. 
Protein PDZ1 PDZ2 PDZ3 ND
a
 Reference(s) 
AKAP79    Y (Gardner et al., 2007) 
APC Y Y   (Zhang et al., 2011b) 
β1-AR    Y (Gardner et al., 2007) 
Fz4&7 Y Y   (Hering and Sheng, 2002) 
GluR1  Y   (von Ossowski et al., 2006) 
HPV16 E6 Y Y Y  (Chi et al., 2011) 
HPV18 E6 Y Y Y  (Liu et al., 2007) 
HTLV1 Tax    Y (Lee et al., 1997) 
Kv1.5    Y (Godreau et al., 2003) 
Kir2.1 Y Y   (Pegan et al., 2007, Goult et 
al., 2007) 
Kir2.2  Y   (Leonoudakis et al., 2001) 
NR2A/B Y Y   (Gardoni et al., 2003, Wang 
et al., 2005) 
TACE    Y (Peiretti et al., 2003) 
a
 ND = Not determined.  
 
1.5.4 Roles of PSD-95 and SAP97 in LTD, LTP and Synaptic Plasticity  
As discussed previously [1.2-4], PSD-95 and SAP97 are PSD-MAGUKs and 
therefore, are involved in the functional localisation and trafficking of receptors in 
the PSD, via PDZ domain-mediated interactions. PSD-95 has been shown to 
predominantly interact with the N-methyl-ᴅ-aspartate receptors (NMDARs) (El-
Hussein et al., 2000, Cui et al., 2007), whereas the most prominent PDZ domain-
mediated receptor interaction of SAP97 is with the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) (Waites et al., 2009a, Howard et al., 
2010);  research has shown the presence of PSD-95 – AMPAR and SAP97 – 
NMDAR interactions also (Xu et al., 2008, Li et al., 2011, Marcello et al., 2012, 
Opazo et al., 2012).  
NMDARs/AMPARs belong to the glutamate subset of the ionotropic 
neurotransmitter receptor family and so, share some structural similarities. NMDARs 
are glutamate- and glycine-gated cation channels that are formed by the 
heterotetrameric assembly of subunits belonging to three classes: NR1, NR2A-D and 
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NR3A/B (Figure 1.8) (Gottschalk et al., 2009). Two NR1 subunits are a compulsory 
component of NMDARs, along with two of the other subunits; NR2A and NR2B are 
the primary other subunits in most central neurons. The NR1 subunit has been found 
to bind glycine, whereas the NR2 subunit binds glutamate; the NR2 subunit also 
contains a C-terminal class I PDZ domain binding motif and so, it is this subunit that 
participates in the PDZ domain-mediated interactions with PSD-95/SAP97 (Sheng 
and Sala, 2001). 
 
Figure 1.8: A simplistic overview of the structure of the N-methyl-ᴅ-aspartate receptors (NMDARs). 
a) A front-on perspective showing an individual NRX subunit, along with the different binding sites 
of various ions/chemicals and the different ions the NMDAR is responsible for transporting. b) A plan 
view illustrating the tetrameric structure forming a transmembrane pore; the NR1 (red) glycine and 
NR2 (blue) glutamate binding sites are shown. Image a) taken from http://sunburst.usd.edu/. 
 
AMPARs comprise of four closely related subunits GluR1-4, each of which consists 
of four transmembrane domains (Figure 1.9a) and these subunits combine in 
different stoichiometries to form a tetramer ion channel (Figure 1.9b); these 
tetrameric channels usually consist of a pair of subunit dimers (Shepherd and 
Huganirl, 2007). The GluR1 subunit contains a C-terminal class I PDZ domain 
binding motif and so, it is this subunit that participates in the PDZ domain-mediated 
interactions with PSD-95/SAP97 (Sheng and Sala, 2001).  
Glutamate 
binding site 
Glycine 
binding site 
Transmembrane 
pore 
a) b) 
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Figure 1.9: A simplistic overview of the structure of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs). a) A front-on perspective showing an individual 
GluRX subunit. b) A front-on perspective illustrating how the tetrameric structure of individual 
subunits forms a transmembrane pore. Image taken from (Shepherd and Huganirl, 2007). 
  
Research has shown that the PDZ domain-mediated association of PSD-95 and 
SAP97 with the C-termini of the NMDARs/AMPARS occurs via the PDZ1 and 
PDZ2 domains of the PDZ proteins (Wang et al., 2005, Marcello et al., 2012); the 
solution state NMR structures of SAP97 PDZ2 bound independently to NR2B 
(Wang et al., 2005) and GluR1 (von Ossowski et al., 2006) have been previously 
determined. The PDZ domain mediated-interaction between PSD-95/SAP97 and the 
NMDARs/AMPARs are vital in facilitating the role of PSD-95/SAP97 in the 
localisation of the NMDARs/AMPARs at the postsynaptic membrane and their 
transport to/from the membrane; therefore, PSD-95 and SAP97 are believed to have 
an important role in synaptic plasticity (Craven and Bredt, 1998).   
Synaptic plasticity is defined as the ability of a synapse to change in strength and it is 
the most important foundation in learning and memory storage within the brain 
(Montgomery et al., 2004). Two of the key processes underlying synaptic plasticity 
are long-term potentiation (LTP) and long-term depression (LTD) (Shepherd and 
Huganirl, 2007); these processes act by causing changes in the efficacy of synaptic 
connections via the addition or removal of receptors to/from the postsynaptic 
membrane (Montgomery et al., 2004). 
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LTP is an activity-dependent enhancement in synaptic transmission, this is usually 
induced by brief high frequency stimulation and is long lasting (more than 1 hour) 
(Shepherd and Huganirl, 2007); LTP is widely believed to be a key cellular 
mechanism in learning and long-term memory (Waites et al., 2009b). NMDARs are 
postulated to function as a cellular trigger for the phosphorylation of the AMPAR 
GluR1 subunit by CAMKII (Lau and Zukin, 2007); this facilitates AMPAR insertion 
into the PSD or directly at the synapse, this process is known as exocytosis (Figure 
1.10a).  
   
Figure 1.10: Two of the key processes underlying synaptic plasticity: long-term potentiation (LTP) 
and long-term depression (LTD). a) An overview of the exocytosis on-going during LTP; AMPAR 
insertion due to phosphorylation by NMDAR-mediated CaMKII activity occurs either directly at the 
synapse or at extrasynaptic sites and subsequent diffusion into the synapse (red arrow). b) An 
overview of the endocytosis occurring during LTD; AMPARs are either recycled or degraded. Image 
taken from (Shepherd and Huganirl, 2007). 
  
LTD is a long-lasting suppression of synaptic strength and is typically dependent on 
NMDAR-activated dephosphorylation of the GluR1 AMPAR subunit (Xu et al., 
2008); this allows retrieval of the AMPARs from synaptic sites and causes the 
AMPARs to diffuse out of the PSD, via endocytosis (Figure 1.10b) (Shepherd and 
Huganirl, 2007, Lau and Zukin, 2007). LTD is widely believed to be an important 
means of information storage in the brain and is implicated in the process of 
removing old memories.  
The research to-date on the interaction between the PSD-MAGUKs PSD-95/SAP97 
and the glutamate receptors NMDAR/AMPAR suggests that this is an important and 
b) a) 
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beneficial set of PDZ domain-mediated interactions. However, there is evidence to 
suggest that the PDZ domain-mediated interaction between PSD-95 and NMDAR is 
a potential therapeutic target in the treatment of stroke (Aarts et al., 2002, Cook et 
al., 2012) and chronic pain (Florio et al., 2009, LeBlanc et al., 2010); this is 
discussed further in [1.6]. 
1.5.5 Summary  
The brief summary of the PSD-95/SAP97 PDZ-mediated interaction research 
detailed in sections [1.5.1 – 1.5.4], along with other examples found in the literature, 
indicates that inhibition of PSD-95 and/or SAP97 PDZ domain-mediated interactions 
are valid therapeutic research topics. This would be also be a novel way of 
elucidating the exact role of the PDZ proteins in different cellular processes and 
hence, controlling signal cascades in complex diseases (Dev, 2004).  
1.6 Previous PDZ Domain Inhibition Research 
The PDZ domain/PDZ domain-mediated interaction inhibitor research to-date has 
produced different chemical classes of inhibitor, with varying strategies employed in 
the development process. A comprehensive collection of PDZ domain inhibition 
research-to-date is given in this section; this has been subdivided into depending on 
the chemical nature of the particular PDZ domain inhibitor. 
1.6.1 Peptides 
The use of PDZ domain inhibitory peptides derived from the C-terminus of the 
respective native PDZ domain ligand has been applied to different PDZ-mediated 
interactions; one such example is the three successive investigations by Tymianski’s 
research group. This process involved the attempted inhibition of the interaction 
between the PSD-95 PDZ1/2 domains and the NMDA receptor subunit 2B (NR2B), 
by a peptide. The researchers believed that by inhibiting PSD-95 and hence, 
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uncoupling PSD-95 from neurotoxic signalling pathways, it was possible to treat, 
minimise or even prevent stroke damage without blocking synaptic activity or 
calcium influx.  
The investigations utilised a 20 residue cell permeable peptide (Tat–NR2B9c) that 
consisted of the nine C-terminal residues of the NR2B subunit (KLSSIESDV) was 
fused to the 11-mer HIV-1 Tat protein (YGRKKRRQRRR). The effects of Tat-
NR2B9c on stroke damage was assessed in rat brain (Aarts et al., 2002, Sun et al., 
2008) and subsequently in gyrencephalic primate brain (Cook et al., 2012). In both 
mammals, it was established that stroke damage can be prevented by administration 
of a peptide inhibitor of the PSD-95 PDZ domain after stroke onset; efforts are now 
being made to translate these findings to humans.  
Inhibition of Wnt signalling by a peptide inhibitor of the Dishevelled (Dvl) PDZ 
domain has been achieved (Zhang et al., 2009); this is favourable as Dvl regulates 
Wnt signalling pathways, many of which have been implicated in cancer 
progression. The inhibitory peptide development procedure involved a combination 
of peptide-phage display and shotgun alanine scanning; this process resulted in four 
peptides with low micromolar affinity. The inhibitory peptide developed (pen-N3, 
KD = 4.6µM) consisted of an internal peptide (EIVLWSDIP), with an antennapedia 
sequence and a 5-carboxyfluorescin fluorophore fused to the N-terminus; this 
enabled internalisation and visualisation in cells respectively (Derossi et al., 1998). 
The results obtained demonstrated that pen-N3 inhibited Wnt/β-catenin signalling in 
a specific and dose-dependent manner, upstream of β-catenin; thus, Dvl PDZ domain 
inhibition may be a viable therapeutic target for Wnt signalling in cancers that are 
dependent on Dvl function. In related research, a tripeptide (VWV) developed by a 
combination of NMR spectroscopy and computational methods has been shown to 
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bind to the Dvl PDZ domain with low micromolar affinity (KD = 2µM) (Lee et al., 
2009a); the effects of the tripeptide on Wnt were, however, not explored in vivo.  
There are a number of other examples of peptides being utilised to inhibit PDZ 
domain-mediated interactions in the literature, these involve peptide inhibitors of the 
PSD-95 (Sharma et al., 2009), GIPC (Muders et al., 2009) and CAL PDZ-mediated 
interactions (Roberts et al., 2012). 
A related area of PDZ domain inhibition research by peptides is the development of 
bivalent peptides, which are peptides that have been designed bind to two PDZ 
domains at the same time; these can either be adjacent to each other on the same 
protein or target the same PDZ domain on two separate protein molecules. The 
binding of bivalent peptides to PDZ domains has reported an increase in binding 
affinity of up to 1000-fold compared with the corresponding monomeric ligand 
(Bach et al., 2012). 
An important example of this PDZ domain inhibition research area is the high 
affinity, dimeric inhibitor of the PSD-95 PDZ1/2 domains (Bach et al., 2012); the 
reasons for targeting the PSD-95 PDZ1/2 - NMDAR interaction for inhibition have 
been previously discussed. The dimeric inhibitor (Tat-N-dimer, Figure 1.11a) of the 
PSD-95 PDZ1/2 domains was developed from the group’s previous monomeric and 
dimeric inhibitor research (Bach et al., 2008, Bach et al., 2009). The Tat-N-dimer 
bivalent peptide consisted of two pentapeptides (IETDV) linked by a chemically 
modified PEG-based linker (NPEG4); a Tat peptide [1.6.1] was attached to the linker 
nitrogen to improve cell permeability. Tat-N-dimer was found to bind the tandem 
PSD-95 PDZ1/2 with an unprecedented high affinity of 4.6nM; it was also found to 
have improved blood plasma stability compared to the related monomeric peptide 
version, Tat-NR2B9c. The obtained results illustrated that the Tat-N-dimer was a 
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highly efficacious neuroprotective agent and so, has therapeutic potential in stroke 
treatment.    
The interaction of bivalent peptides with the PSD-95 PDZ3 domain has been 
investigated (Klosi et al., 2007); the bivalent peptides were derived from the protein 
CRIPT as it had previously shown good affinity for the PSD-95 PDZ3 domain (KD = 
0.8μM) (Klosi et al., 2007). Five bivalent peptides ranging from five to nine residues 
in length were produced, with diacid succinate used as the N-termini linker (BP1, 
Figure 1.11b); all five bivalent peptides were found to bind bivalently and showed 
low to moderate micromolar binding affinity to PSD-95 PDZ3 (KD = 4.3μM – 
23.2μM). A bivalent PDZ domain ligand of the PDZ-RhoGEF and LARG PDZ 
domains has also been reported in the literature (Paduch et al., 2007); however, no 
details of any PDZ domain-mediated interaction inhibition effects of the bivalent 
peptide detailed in the previous two studies were given. 
Cyclic peptides that have an inhibitory effect on PSD-95 PDZ domain-mediated 
interactions have been developed (LeBlanc et al., 2010); the researchers 
hypothesised that inhibiting the PSD-95 PDZ domains would interfere with the 
physiological phenomena in the spinal cord related to central sensitisation. The 
design and synthesis of the nine residue cyclic peptide (CN2097, Figure 1.11c) was 
based on the previous cyclic peptide work performed by the research group 
(Piserchio et al., 2004); the cyclic peptide contained a poly-Arg tag to promote cell 
permeability of the peptide. The cyclic nature of the peptide was created by linking 
the -1 and -3 residue side-chains and this cyclic structure was found to impart 
stability to the peptide. The results obtained indicated that the cyclic peptide 
selectively bound to the PSD-95 PDZ domains; this PDZ domain inhibitory effect of 
the cyclic peptide was found to block central sensitisation and attenuated thermal 
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hyperalgesia. Cyclic peptide ligands of the MUPP1 PDZ10 domain have also been 
reported (Sharma et al., 2007). 
The research into cyclic peptides has also led to the development of ‘bridged peptide 
macrocycles’ that have been found to bind to the PSD-95 PDZ3 domain with 
reasonable micromolar affinities (Br1, KD = 3.76μM, Figure 1.11d) 
(Udugamasooriya et al., 2005); no inhibitory effects of these ‘bridged peptide 
macrocycles’ were detailed however. 
The final form of peptides that have been investigated in previous PDZ domain 
inhibition research is that of chemically modified peptides, such as the chemically 
modified peptide designed to target the GIPC PDZ domain (Patra et al., 2012). GIPC 
was seen as a suitable target for such intervention as the abnormal activation of GIPC 
PDZ-mediated interactions has been implicated in breast and pancreatic cancers. A 
series of chemically modified and unmodified PDZ domain targeting peptides were 
produced, using previous research as the basis for design (Udugamasooriya et al., 
2008). The most active modified peptide (CR1166) consisted of septapeptide 
(SNSKSKA) with a N-terminal myristate to allow cell permeability; the Lys -1 and -
3 side-chains were modified by adding halogenated organic modifications CR1166 
was found to target the GIPC PDZ domain both in vitro and in vivo, with pronounced 
down-regulation of EGFR/1GF-IR expression; thus, CR1166 was found to exhibit 
significant activity against breast and pancreatic cancer in both cellular and animal 
models. 
Research into chemically modified peptide inhibitors of the PSD-95 PDZ – NMDAR 
interaction has also been performed (Bach et al., 2008); the implications of this PDZ-
mediated interaction have been discussed previously in this section. In this study, the 
effect of N-methylation of the different residues of an NR2B C-terminal-related 
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tetrapeptide on its binding affinity to PSD-95 PDZ1 or PDZ2 was investigated, with 
N-methylation of the -3 residue being the only modification shown to improve PSD-
95 PDZ binding affinity. The effect of different N-alkyl chemical groups on the N-
terminal residue (-3) was then probed and yielded a potent tetrapeptide inhibitor of 
the PSD-95 PDZ – NMDAR interaction (CP1, Figure 1.11e) (Ki = 0.94µM for 
PDZ1, 0.48µM for PDZ2 and 11µM for PDZ3).  
One final example of the development of a chemically modified peptide in PDZ 
domain inhibition research is the hybrid organic-inorganic (metallopeptide) inhibitor 
of the CAL PDZ – CFTR interaction (Kundu et al., 2012). The interaction between 
the CAL PDZ domain and CFTR has been shown to lead to CAL-mediated CFTR 
degradation, this is an important process in cystic fibrosis; thus, the inhibition of this 
interaction was a desired therapeutic target for cystic fibrosis treatment. The 
metallopeptide (MP1, Figure 1.11f) consisted of a Rh(II) centre tetracarboxylate 
attached at the -6 residue of septapeptide (E
Rh
VQSTRL) identified by inverted 
peptide array screens. The inhibitory effects of the produced metallopeptide was 
investigated with a CFTR C-terminal peptide; the results showed that the 
metallopeptide was the first reported inhibitor with submicromolar affinity for the 
CAL PDZ domain (Ki = 0.56µM).  
1.6.2 Peptidomimetics 
The use of peptides has been shown to extremely advantageous in PDZ domain 
inhibition research to-date but the common problems of peptide use as drugs still 
persist i.e. lack of oral bioavailability. Therefore, research into peptide mimics 
(peptidomimetics) for PDZ domain inhibition has been performed. Peptidomimetics 
usually involves an attempt to retain the desirable properties of a particular peptide 
but increase the oral bioavailability, cell permeability etc by use of a suitable 
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chemical scaffold. There has been evidence of a rational design approach to develop 
β-strand peptidomimetic PDZ domain interaction inhibitors; this is due to the 
knowledge that PDZ domain ligands/peptides effectively form an anti-parallel β-
strand upon PDZ domain binding. Thus, the development of effective β-strand 
peptidomimetic scaffolds may represent an important area of PDZ domain inhibition 
research.  
Bartlett et al undertook a developmental procedure to develop β-strand 
peptidomimetics. The initial stage of the process involved the incorporation of amino 
acid surrogate ‘@-unit’ in an oligopeptide to give a β-strand peptidomimetics known 
as ‘@-tides’ (Phillips et al., 2005); this resulted in the oligopeptide showing a high 
propensity for the extended β-strand conformation. The ‘@-tides’ amino acid 
surrogates were then developed further, this involved the incorporation of an ‘aza-@-
unit’ into an oligopeptide instead of an ‘@-unit’ (Hammond et al., 2006); this 
retained the conformational advantages of the ‘@-unit’ but enabled facile 
incorporation of precursor amino acid side-chains. The developed peptidomimetic 
contained an acyl amidine linkage to stabilise the compound sufficiently to permit its 
used in biological applications and consisted of a peptide sequence (Ac-K@
E
SLV, 
Figure 1.11g) derived from a known ligand of the α1-syntrophin PDZ domain 
(Schultz et al., 1998); this PDZ domain was chosen to test the PDZ binding ability of 
the peptidomimetic as it was well-known to bind to short peptides with micromolar 
affinity.  
Results of the α1-syntrophin PDZ binding studies showed that the developed peptide 
bound to the α1-syntrophin PDZ domain with submicromolar affinity (KD = 
0.32μM); this was 20-fold stronger binding than the parent KESLV peptide and is 
even stronger than one of the native α1-syntrophin PDZ ligands, nNOS (KD = 
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0.61μM). Although no evidence of in vitro or in vivo PDZ domain–mediated 
interaction inhibition was detailed, this research indicates that @-tide oligomers may 
hold considerable promise in future PDZ domain inhibition research. 
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Fig 1.11: The chemical structures of a selection of the peptide and peptidomimetic compounds designed to inhibit PDZ domain/PDZ domain-mediated interactions. a) Tat-N-
dimer (Bach et al., 2012). b) Bridged peptide 1 (BP1), where R = GKNYKQTSV (Klosi et al., 2007). c) CN2097 (LeBlanc et al., 2010). d) Bridged macrocycle 1 (Br1) 
(Udugamasooriya et al., 2005). e) Chemical peptide 1 (CP1) (Bach et al., 2008). f) Metallopeptide 1 (MP1) (Kundu et al., 2012). g) Ac-K@
E
SLV (Hammond et al., 2006).   
c) a) 
e) d) b) 
g) f) 
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1.6.3 Small Molecule Inhibitors 
The development of a specific, reversible small molecule PDZ domain/PDZ domain-
mediated interaction inhibitor is an attractive therapeutic target in PDZ domain 
inhibition research. This is because small molecule inhibitor drugs are orally 
bioavailable unlike peptide drugs and the processes used to identify possible small 
molecule lead-drug candidates are much better established than peptidomimetic drug 
scaffolds. A wide range of structurally diverse small molecule compounds have been 
produced in PDZ domain inhibitor research to-date; this section has been sub-divided 
depending on the methodology utilised to obtain the particular small molecule 
inhibitor of the respective PDZ domain/PDZ domain-mediated interaction. 
1.6.3.1 Rational Design 
There are numerous examples of small molecule PDZ domain inhibitors that have 
been developed through a rational design procedure; this process is usually 
completed by attempting to mimic the interaction of the native PDZ ligand with the 
PDZ domain by a novel organic compound. The first ever published small molecule 
PDZ domain inhibitor was produced by a rational design methodology and this was a 
selective, irreversible inhibitor of the MAGI3 PDZ2 – PTEN interaction (SM1, 
Figure 1.12a) (Fujii et al., 2003); the small molecule was based on an indole 
chemical scaffold. MAGI3 is a member of the MAGI family, a subfamily of 
MAGUKs and binds to PTEN, a lipid/protein phosphatase via the MAGI3 PDZ2 
domain; the role of this interaction is controversial and so, inhibition of this 
interaction by a small molecule inhibitor was seen as a novel method of elucidating 
the cellular role of the interaction. The small molecule inhibitor was found to inhibit 
the binding of PTEN to the MAGI3 PDZ2 domain; however, the inhibition of this 
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PDZ-mediated interaction was shown to be irreversible, which was obviously 
undesirable. 
In an effort to develop this compound into a reversible inhibitor, computational 
experiments were performed and the structure of the irreversible inhibitor was 
modified accordingly (Fujii et al., 2007a); the resultant small molecule (SM2, Figure 
1.12b) was shown to cause no covalent modification of the MAGI3 PDZ2 domain 
and so, was proven to be a reversible inhibitor of the MAGI3 PDZ2 – PTEN 
interaction. This research led to the production of a general chemical scaffold for 
developing reversible PDZ domain inhibitors, based on the indole aromatic ring 
(Sc1, Figure 1.12c); where different chemical groups can be placed around the indole 
structure to effectively mimic the side-chain structures of the native PDZ domain 
ligand. This general PDZ domain inhibitor scaffold has since been utilised to 
produce inhibitors of Dvl (Fujii et al., 2007c, Mahindroo et al., 2008), NHERF1 
(Mayasundari et al., 2008) and NHERF2 (Zhang et al., 2011a) PDZ domain-
mediated interactions. The indole scaffold has also formed the basis of a class I PDZ 
domain selective chemical probe developed by the same research group (Fujii et al., 
2007b); this indicated how biotinylated probes could be used to differentially 
visualise the cellular proteome and identify PDZ proteins (P1, Figure 1.12d). 
A small molecule inhibitor of the PSD-95 PDZ2 – nNOS interaction has been 
developed using a rational design process (Zhou et al., 2011); the PSD-95 PDZ2-
nNOS interaction is known to be ischaemia-induced and thus, may be a strategy to 
treat stroke, which prevents ischemic damage without directly blocking NMDAR 
function or inhibiting nNOS activity. The small molecule design process focused on 
the mechanism of nNOS-PSD-95 PDZ2 dimer formation; a key intramolecular salt-
bridge between the residues of the nNOS PDZ domain β-finger was identified as 
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structurally necessary for the nNOS β-finger to interact with the PSD-95 PDZ2 
domain.  
This is a rare example of a PDZ domain-mediated interaction inhibition design 
process where the focus of inhibitor design was targeted at the PDZ domain ligand, 
not the PDZ domain. A range of small molecule compounds were designed and 
synthesised in an attempt to disrupt the intramolecular nNOS salt bridge. The most 
potent compound (ZL006, IC50 = 82nM, Figure 1.12e) was shown to selectively 
inhibit the ischemia-induced PSD-95 PDZ2 – nNOS interaction, had potent 
neuroprotective activity and reduced ischemic brain damage; ZL006 also had no 
effect on NMDAR function and nNOS activity. 
1.6.3.2 Virtual Library Screening/NMR Spectroscopy 
A combination of virtual library screening (VLS) and NMR spectroscopy has proved 
effective in research on PDZ domain/PDZ domain-mediated interaction inhibition by 
a small molecule; Zheng’s research group have developed a variety of different small 
molecule inhibitors of the Dvl – Frizzled receptor (Fz) interaction. The rationale for 
targeting the Dvl PDZ domain has been previously discussed [1.6.1]. 
A process of structure-based virtual ligand screening followed by NMR spectroscopy 
yielded the compound NSC668036 (Figure 1.12f) (Shan et al., 2005); this small 
molecule was identified to specifically bind to the Dvl PDZ domain with high 
micromolar affinity (KD = 237μM). NSC668036 was shown to inhibit the Wnt 
signalling pathway at Wnt3A not at β-catenin, which is downstream of Dvl and so, 
indicates that the NSC668036 was exhibiting the desired inhibitory effect. 
NSC668036 was then used as the basis for a pharmacophore model along with two 
other non-binding organic compounds in a ligand similarity screening (Shan and 
Zheng, 2009); this identified 15 structures that bound to the Dvl PDZ. By expanding 
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the chemical space used in their in silico search, the researchers were able to obtain 
nine more Dvl PDZ binding compounds; to give 24 small molecule structures in total 
and all 24 were based on one of two scaffolds (Sc2&3, Figure 1.12g) (Shan et al., 
2012). Dvl PDZ domain binding affinities in the low micromolar range were 
reported by the researchers, however, the methodology implemented to determine the 
affinity values does not seem extremely accurate or reliable; hence, the KD values 
quoted in their research may not be reliable and so, have not been detailed here. This 
is because the binding affinity determination utilised an NMR titration, where the 
values obtained were normalised based on the discrepancy in the Dvl PDZ binding 
affinity of NSC668036 obtained by both fluorescence and NMR spectroscopy 
techniques.  
The VLS and NMR spectroscopy methodology has also been utilised by the same 
research group to develop the compound 3289-6825 (Figure 1.12h) (Grandy et al., 
2009); this was found to bind to the Dvl PDZ domain with low micromolar affinity 
(KD = 10.6μM) and exerted an inhibitory effect on the native Dvl PDZ - Dapper 
interaction (Ki = 4.9μM). The group have recently published their overall VLS and 
NMR spectroscopy methodology to small molecule PDZ domain inhibitor 
development (Shan and Zheng, 2012). 
A related VLS, NMR screening and chemical synthesis approach has also been 
utilised to develop small molecule ligand of the ALL-1 fusion partner on 
chromosome 6 (AF6) PDZ domain (SM3, Figure 1.12i) (Joshi et al., 2006). Research 
detailed in this thesis has also implemented a VLS, NMR screening and chemical 
synthesis approach to development of small molecule inhibitors of PDZ domain-
mediated interactions (Bouzidi et al., 2013).  
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1.6.3.3 High-Throughput Screening 
High-throughput screening (HTS) drug discovery methodologies have been applied 
to PDZ domain/PDZ domain-mediated interaction research; the development of a 
small molecule inhibitor of the PICK1 PDZ domain is an example of this (Thorsen et 
al., 2010). PICK1 is known to bind to the AMPA receptors (AMPARs) through its 
PDZ domain; this interaction has recently been recognised as a putative target in 
neuropathic pain (Garry et al., 2003), excitotoxicity (Bell et al., 2009) and cocaine 
addiction (Bellone and Luscher, 2006) and so, inhibition of this PDZ domain-
mediated interaction could have important therapeutic potential.  
A high-throughput fluorescence polarisation assay screening of 44,000 small 
molecules in the Neurosearch A/S chemical library resulted in compound FSC231 
(Figure 1.12j); FSC231 was found to bind specifically to the PICK PDZ1 domain 
with low micromolar affinity (Ki = 10.1µM). The small molecule was shown to 
inhibit the PICK1 PDZ – AMPAR interaction and that this inhibition affected 
AMPAR trafficking; FSC231 was also shown to inhibit synaptic plasticity in 
hippocampal CA1 neurons. The structure-activity relationship of the PDZ domain 
binding of FSC231 was subsequently investigated (Bach et al., 2010); this has 
produced an analogue with improved PICK1 PDZ binding affinity (Ki = 7.2µM) c.f. 
FSC231. 
A small molecule inhibitor of the PSD-95 PDZ – nNOS interaction has also been 
developed using HTS methods (Florio et al., 2009); the therapeutic rationale behind 
targeting this interaction has been discussed previously [1.6.1]. A high-throughput in 
vitro assay screening of 150,000 small molecules in the ICOS chemical library 
yielded several PDZ interaction inhibitors; the most potent compound from the HTS 
was modified to improve stability to give IC87201 (IC50 = 31µM, Figure 1.12k). 
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IC87201 was found to inhibit in vitro binding of nNOS to PSD-95 without affecting 
nNOS catalytic activity; it was also shown to reverse mechanical allodynia by 
chronic constriction of the sciatic nerve. However, subsequent work in our laboratory 
showed that there was no interaction between IC87201 and either PSD-95 PDZ1, 
PDZ2 or nNOS PDZ observed by NMR spectroscopy; there was also no indication 
of any PDZ domain-mediated interaction inhibition by IC87201 observed by NMR 
spectroscopy or ITC (L Dorr, unpublished data). 
High-throughput screening has also been used to develop small molecule inhibitors 
of Mint1 (HTS1, Figure 1.12l) (Chen et al., 2007b) and Shank3 (HTS2, Figure 
1.12m) (Saupe et al., 2011) PDZ mediated–interactions. 
1.6.3.4 Re-purposing of Existing Drugs 
A common difficulty in the development of small molecule inhibitors is determining 
a rational starting point for drug design and therefore, there is a current effort to find 
‘new purposes for old drugs.’ This is a potentially useful strategy for PDZ domain-
related drug discovery as they can provide possible templates for future inhibitor 
design; an example of this is Sulindac (Lee et al., 2009b).  
Sulindac (Figure 1.12n) is from a class of drugs known as non-steroidal anti-
inflammatory drugs (NSAIDs); previous research had indicated that Sulindac could 
exhibit chemopreventive effects, possibly by targeting the Wnt signalling pathway 
(Han et al., 2008). Both Sulindac and its metabolite Sulindac sulfone (Figure 1.12o) 
were shown to specifically bind to the Dvl PDZ and inhibit Wnt signalling by 
disrupting the Dvl PDZ - Fz7 receptor interaction; this inhibition was revealed to be 
the Dvl PDZ-mediated not -catenin-mediated Wnt signalling, which as previously 
discussed is desired.  
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1.6.4 Summary of Previous PDZ Domain Inhibition Research 
The PDZ domain inhibition research to-date detailed in [1.6] has shown that there 
have been a wide range of different types of chemical compound produced in an 
effort to develop PDZ domain-mediated interaction inhibitors; the different 
development methodologies implemented to produce these compounds are just as 
numerous. Each of the three different types of inhibitor: peptides, peptidomimetics 
and small molecules, have exhibited good efficacy in PDZ domain interaction 
inhibition, mainly through in vitro analyses and there is even a large degree of 
differentiation between compounds in the same inhibitor type sub-category.  
The highest affinity PDZ domain inhibitor developed at the time of writing is the 
bivalent peptide inhibitor of PSD-95 PDZ1/2 domains in tandem (Tat-N-dimer, KD = 
4nM) (Bach et al., 2012). However, this is still a peptide-based drug and although the 
tandem inhibition of two PDZ domains has been shown to increase binding affinity 
significantly, if the second PDZ domain has no role in the targeted interaction the 
inhibitor may also affect unrelated PDZ domain-mediated interactions and have 
adverse effects. Arguably, the ‘dream’ PDZ domain-mediated inhibitor would be a 
high affinity and highly inhibiting small molecule; with research to-date producing a 
low micromolar affinity small molecule inhibitor of the PICK1 PDZ domain (Ki = 
7.2µM) (Bach et al., 2010), this dream may become a reality in the not too distant 
future. 
However, it has been detailed that some examples of reported PDZ domain binding 
and/or inhibition reported in the literature may be erroneous (Florio et al., 2009) or 
unreliable (Shan and Zheng, 2009, Shan et al., 2012); this highlights the importance 
of critically evaluating the binding affinity determination methodology utilised when 
assessing the reliability of the information reported. Such flaws in PDZ domain 
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binding affinity determination methodologies could suggest why there has been little 
success in translating in vivo results into potential drugs for PDZ domain-mediated 
interactions to-date. 
Thus, it would appear that determining the specific type of PDZ domain inhibitor and 
the methodology to implement to produce the inhibitor is a combination of different 
considerations such as: preferred drug administration method, desired length of 
development process, technology and expertise available, previous research and 
accuracy of in vitro/in vivo assays amongst other considerations. 
1.7 Conclusion 
The research detailed in this chapter has highlighted that the PDZ domain mediated 
interactions of the PSD-MAGUKs PSD-95 and SAP97 are valid research targets; 
there are a number of instances where inhibition PSD-95 and/or SAP97 PDZ 
domain-mediated interactions would be of therapeutic benefit. Although there has 
been a reasonably substantial amount of research on the PSD-95/SAP97 PDZ 
domains and the interactions they mediate up to the present, a lot of this work has 
been cell-based; with a disproportionately low amount of structural research 
performed to-date and so, little information on the exact nature of the PDZ domain-
mediated interactions is available. The previous PDZ domain inhibition research has 
shown that there are a wide range of suitable types of compounds and methodologies 
to utilise; the design of a potentially potent inhibitor could be determined with 
structural knowledge of the target PDZ domain-mediated interaction. Thus, a 
research project that combines PDZ domain binding investigation with PDZ domain 
inhibitor development could be potentially effective. 
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1.8 Research Aims 
The overriding goal of the research programme in the laboratory was to develop 
small molecule inhibitors against the PSD-95 and SAP97 PDZ domains. The specific 
aims of the research described in this thesis can be divided into three categories: 
 Investigate the binding of the 5-HT2a/c receptors to the PSD-95/SAP97 
PDZ1&2 domains and determine the structure of a PDZ – 5-HT2x complex 
(Chapter 4). 
 Investigate the specific interactions in the binding regions of the SAP97 
PDZ1&2 domains using biophysical techniques (Chapter 5). 
 Through a developmental process, develop small molecule inhibitors of the 
PSD-95/SAP97 PDZ1&2 domains and determine the resultant PDZ – small 
molecule inhibitor complex(es) (Chapter 6). 
The techniques required to satisfy these research aims were: 
1. Protein production – to produce the various unlabelled and (13C,) 15N-
isotopically labelled PDZ domains required for use in NMR spectroscopy 
and ITC. Site-directed ligase-independent mutagenesis was implemented to 
produce PDZ domain mutants. 
2. NMR spectroscopy – utilised to determine if the produced PDZ domains 
were folded, to see if there was any interaction of an individual PDZ domain 
with a native peptide/small molecule and for binding affinity and structure 
determination purposes also. 
3. Isothermal titration calorimetry (ITC) – to determine if any PDZ domain – 
peptide interaction occurred and if so, the resultant thermodynamic 
parameters, in the absence/presence of small molecule compounds. 
4. NMR solution state structure determination methods: 
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a. CYANA – for automated assignment of PDZ domain – peptide 
complex NOE NMR spectra. 
b. CNS – to determine the in vacuo and water-refined structures of a 
PDZ domain – peptide complex. 
5. NMR restraint-driven docking method, High ambiguity-driven docking 
(HADDOCK) – to determine the structure of PDZ domain – small molecule 
complexes, using inter- and intramolecular distance restraints determined by 
NMR spectroscopy.    
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Fig 1.12: Chemical structures of a selection of the small molecule compounds designed to inhibit PDZ domain/PDZ domain-mediated interactions. a) Small molecule 1 (SM1) 
(Fujii et al., 2003). b) SM2 (Fujii et al., 2007a). c) Scaffold 1 (Sc1) (Fujii et al., 2007a). d) Probe 1 (Pr1) (Fujii et al., 2007b). e) ZL006 (Zhou et al., 2011). f) NSC668036 
(Shan et al., 2005). g) Sc2&3 (Shan et al., 2012). h) 3289-6825 (Grandy et al., 2009). i) SM3 (Joshi et al., 2006). j) FSC231 (Thorsen et al., 2010). k) IC87201 (Florio et al., 
2009). l) High-throughput screening 1 (HTS1) (Chen et al., 2007b). m) HTS2 (Saupe et al., 2011). n) Sulindac (Lee et al., 2009b). o) Sulindac sulfone (Lee et al., 2009b). 
e) d) b) c) a) 
i) h) g) f) 
j) 
m) o) n) l) 
k) 
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2. INTRODUCTION TO BIOPHYSICAL TECHNIQUES 
2.1 General 
In the process of carrying out the research required to produce this thesis, there were 
two biophysical techniques employed; protein nuclear magnetic resonance (NMR) 
spectroscopy and isothermal titration calorimetry (ITC). An introduction to the 
theory, instruments, practical considerations and applications of these well-known 
techniques is detailed in this chapter. 
2.2 Protein Nuclear Magnetic Resonance (NMR) Spectroscopy  
(Keeler, 2005, Cavanagh, 2007, Levitt, 2008, Lian and Roberts, 2011) 
2.2.1 Introduction to NMR Spectroscopy 
The NMR spectroscopic methodology is one of the principal techniques used to 
obtain physical, chemical, electronic and three-dimensional (3-D) information about 
molecules in solution; these range from small molecules and nucleic acids to 
carbohydrates and proteins. NMR exploits the natural phenomenon that, when 
exposed to a very strong magnetic field (2 - 21.1 Tesla), certain atomic nuclei align 
to this field. 
The first published NMR spectrum of a biological macromolecule was the 40MHz 
1
H spectrum produced of pancreatic ribonuclease in 1957. Since this initial 
experiment, continuous development in the NMR spectrometer hardware/pulse 
sequence/data analysis/structure determination, molecular biology and NMR sample 
preparation fields has occurred. This has led to protein NMR spectroscopy becoming 
a mainstream biophysical technique and particularly useful in structural biology. 
2.2.2 Classical NMR Spectroscopy 
All forms of matter consist of atoms, which in turn are made up of nuclei and 
electrons. Each atomic nucleus has four important physical properties; mass, electric 
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charge, magnetism and spin. Nuclear spin is an intrinsic property of the particle 
itself, not produced by its rotation and is a form of angular momentum. Nuclear spin 
angular momentum is a quantum mechanical property that does not have a classical 
analogue and is characterised by the nuclear spin quantum number, I. NMR 
spectroscopy is made possible due to this property of nuclei and thus, the theory 
behind NMR spectroscopy is concerned mainly with the quantum mechanics of 
nuclear spin angular momentum. This section introduces the semi-classical vector 
model to describe the behaviour of non-interacting spin-half nuclei in a static 
magnetic field, formulated by Bloch. This may seem futile to detail here but most of 
the language used in pulsed NMR is derived from the vector model and many of the 
features of the vector model have direct counterparts in the quantum mechanical 
explanation of NMR spectroscopy theory. 
To be NMR active, I must be a non-zero value. Nuclei with I > ½ possess quadrupole 
moments arising from non-spherical nuclear charge distribution and this results in 
the lifetime for these nuclei in solution being much shorter c.f. I = ½. The NMR 
resonance lines for quadrupolar nuclei are also more broad and difficult to study than 
the corresponding lines for I = ½. Therefore, for use in protein NMR spectroscopy, 
the most important nuclei are the I = ½ nuclei of 
1
H, 
13
C and 
15
N and the important 
properties of these nuclei have been detailed (Table 2.1). The I = 1 nucleus of 
2
H is 
also frequently utilised in protein NMR spectroscopy and so, its properties have been 
included in the table too. 
Table 2.1: The properties of the nuclei of interest in protein NMR spectroscopy, where I is the nuclear 
spin angular momentum quantum number and γ is the gyromagnetic ratio – a characteristic constant 
for the corresponding nuclei. The natural isotopic abundance for each nuclei is also given. 
Nuclei Natural Abundance (%) I γ (T s)-1 
1
H 99.99 1/2 2.6752 x 10
8
 
2
H 0.012 1 4.107 x 10
7
 
13
C 1.07 1/2 6.728 x 10
7
 
15
N 0.37 1/2 -2.713 x 10
7
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Nuclear spin angular momentum is a vector quantity, where the z-component (Iz for 
axis notation, Figure 2.1) is specified by convention and this z-component has a 
discrete set of values as Equation 2.1 illustrates. As Iz has a discrete set of values and 
a constant magnitude, its orientation in space is quantised. In the absence of an 
external field, the spin angle vector does not have a preferred orientation. Nuclei 
where I ≠ 0 also possess nuclear magnetic moments, where the nuclear magnetic 
moment, µ, is collinear with I and is defined by Equations 2.2 & 2.3. 
          Equation [2.1] 
where, m = magnetic quantum number i.e. (-I…+I) , ħ = 
 
  
 and h = Planck’s constant 
       Equation [2.2] 
      Equation [2.3] 
 
 
 
Figure 2.1: The right-handed set of axis that will be used throughout this chapter. The axis is 
described as right-handed as if the z-axis were grasped with the right hand, with the thumb pointing 
along +z, then the fingers curl from x to y; this is a positive rotation and has been shown in the figure. 
Image based on a figure in (Keeler, 2005). 
 
When the nucleus is placed in a magnetic field (B0), there is an interaction between 
the nuclear magnetic moment and the applied field, with the energy of the interaction 
depending on the angle between the two properties (Figure 2.2a). There is an 
energetic preference for the individual magnetic moments to align with the field (i.e. 
θ = 0) but this is opposed by the random thermal motion of molecules; as a result, 
there is no magnetisation when the field is first applied. However, after a sufficient 
time, the orientations of magnetic moments aligned with the field become more 
populated. When this is summed over the sample, the net (or bulk) magnetisation is 
parallel to the field direction and it is said that equilibrium magnetisation has built up 
(Figure 2.2b). 
x 
z 
y 
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Figure 2.2: a) The energy of the interaction between a magnetic moment (small arrow) and an applied 
magnetic field (B0) depends on the angle between the two components; the lowest energy arrangement 
is found when the magnetic moment is parallel to the to field i.e. θ = 0. Conversely, the highest energy 
arrangement is when the moment is opposite the field i.e θ = π. b) After a sufficient time in the 
magnetic field, the magnetic moments aligned with the field become more populated; when averaged 
over the sample, this gives rise to a bulk magnetisation parallel to the field. This is termed equilibrium 
magnetisation and can be represented as a vector. Image based on a figure in (Keeler, 2005). 
 
Once formed, the equilibrium magnetisation vector is fixed in size and direction, 
does not vary over time and precesses about the main static field axis (z-axis, Figure 
2.3a). The precession frequency is exactly the same as the frequency at which an 
allowed transition between two energy levels (Larmor frequency) occurs and hence, 
the precession of magnetisation about the field is sometimes termed Larmor 
precession. For those nuclei with a positive gyromagnetic ratio, the Larmor 
frequency (ω0) is negative which corresponds to a negative rotation about the z-axis 
(Figure 2.3b); the opposite is true for those nuclei with a negative gyromagnetic 
ratio. 
The precession of the magnetic moment about the static magnetic field constitutes a 
time-varying magnetic field and hence, according to Faraday’s law of induction, 
should induce an electromotive force in a coil in close proximity. However, at 
thermal equilibrium, the bulk magnetisation vector is collinear with the static field 
and therefore, no signal is produced in the coil. To produce an NMR signal, the 
magnetisation has to be rotated away from its equilibrium position along the z-axis to 
the xy-plane and this precession in the transverse plane generates a detectable signal 
in the coil. It is impossible to switch the main magnetic field suddenly in this way as 
it is supplied by a powerful, superconducting magnet and so, this result is achieved 
θ 
B0 B0 
Lowest 
energy 
Highest 
energy 
Individual magnetic 
moments 
Summed over 
sample 
Bulk 
magnetisation 
a) b) 
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by the idea of resonance. 
 
 
 
 
 
 
 
 
 
Figure 2.3: a) An illustration of how the equilibrium magnetisation vector described in Figure 2b 
builds up. When there is no magnetic field, the magnetic moments are in random orientations and so, 
there is no net magnetisation. It takes time for orientations aligned with the field to become populated 
and so, when the magnetic field is first applied along the +z-axis, there is still no net magnetisation. 
However, after a sufficient time period, those populations aligned with the field are populated enough 
to produce net magnetisation along the field direction axis. b) The precession of the magnetisation 
vector occurs by rotation about the field direction at a constant angle to the z-axis, this is called 
precession. The precession direction shown in the figure is for a nucleus with a positive gyromagnetic 
ratio and hence, a negative Larmor frequency. Image based on a figure in (Keeler, 2005). 
 
The coil used to detect the precessing magnetisation can also be used to generate an 
oscillating magnetic field at or near the Larmor frequency by supplying 
radiofrequency (RF) electromagnetic radiation to the coil; this is termed the 
transmitter frequency (ωtx). To understand how a weak RF field can overcome B0 
even though B0 is much greater in size, it is easier to think of the oscillating field as 
two counter rotating fields about the z-axis (Figure 2.4). 
 
 
 
 
 
 
x 
z 
y x 
z 
y x 
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y 
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not at equilibrium 
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Figure 2.4: An examination of how two counter-rotating fields (  
 and   
 ) shown in a) add together 
to give a field that oscillates along the x-axis in b). The graph in c) indicates how the field along the x-
axis varies over time. Image based on a figure in (Keeler, 2005). 
 
Only the field rotating in the same sense as the magnetic moment interacts 
significantly with the magnetic moment (Figures 2.4 & 2.5); in this example, a 
nucleus with a positive gyromagnetic ratio i.e. negative rotation about the z-axis is 
considered and hence, it is the   
  field that interacts with the magnetic moment. The 
field rotating in the opposite sense to the magnetic moment (  
 ) has no significant 
interaction with the magnetisation and thus, can be ignored. 
A co-ordinate system is then employed where the field is rotated about the z-axis at 
the same rate and in the same direction as B1 i.e. at -ωtx; this is termed the rotating 
frame, as opposed to it being a static field (laboratory frame) (Figure 2.5). The 
rotating frame removes the time-dependence of the RF (or B1) field and thus, makes 
it easier to determine the effect the field has on the magnetisation. If the rotating 
frame rotates at the same frequency and in the same sense as the Larmor precession, 
then the apparent magnetic field (or reduced field, ∆B) in the rotating frame will be 
zero (this can be seen by following Equations 2.4 – 2.6). This allows the conclusion 
that if the rotating frame is at the Larmor frequency, the apparent field is zero and 
thus, B1 can exert an influence on the motion of magnetisation even though it is 
2B1 
-2B1 
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much smaller than the applied field, B0. 
 
 
 
 
 
 
 
Figure 2.5: The laboratory frame (top) illustrates the motion of the field   
  when viewed in a fixed 
axis system; the field is rotating at -ωtx i.e. in the negative sense (this is clockwise in this figure). The 
rotating frame is also shown (bottom), this is the same   
  field but this time viewed in an axis system 
that is rotating at -ωtx about the z-axis and hence, shows how the   
 field appears to be static. Image 
based on a figure in (Keeler, 2005). 
 
                Equation [2.4] 
where, Ω = the apparent precession frequency in the rotating frame 
      Equation [2.5] 
    
 
 
  Equation [2.6] 
This can be seen more clearly if the concept of the effective field (Beff) is introduced, 
taking into account the two magnetic fields in the rotating frame; the RF field (where 
ωrot. frame = -ωtx and thus, gives a static field along the x-axis) and the reduced field 
(∆B, along the z-axis). In the rotating frame, the reduced field and the B1 field add 
vectorially to give an effective field Beff, with the tilt angle (θ) defined as the angle 
between Beff and ∆B (Figure 2.6a). As the offset is small, the effective field will lie 
close to the x-axis and the equilibrium magnetisation will be rotated away from the 
z-axis as desired. In practical terms, it is more convenient to think of the construction 
of the effective field in terms of precession frequencies rather than magnetic fields 
(Figure 2.6b); the principle outcomes are the same regardless. 
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Figure 2.6: a) In the previously described rotating frame, the effective field Beff is the vector sum of 
the reduced field ∆B and the B1 field, with the angle between Beff and ∆B labelled the tilt angle, θ. The 
effective field (Beff) can also be defined in terms of frequencies instead of fields i.e. a). Image based 
on a figure in (Keeler, 2005). 
 
The experimental aspects of the NMR spectrometer and the various processes that 
are performed during protein NMR spectroscopy to obtain the desired spectra are 
described in [2.2.3]. However, at this stage, the final spectrum output from a simple 
1
H protein NMR spectroscopy experiment will discussed here to introduce a few key 
aspects of NMR spectra (Figure 2.7). 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: A 
1
H NMR experiment of a seven residue peptide acquired at 600MHz, at 298K. There 
are a number of lines (peaks) in the spectrum and these correspond to different proton environments 
present in the peptide, with the scale measuring these peaks given as parts per million (ppm) not Hz  
(s
-1
); this is due to the magnetic field strength dependence of the frequencies of NMR lines.  
 
Like all forms of spectroscopy, an NMR spectrum is a plot of the intensity of 
absorption (or emission) on the vertical axis against frequency on the horizontal axis. 
However, if the spectrum in Figure 2.7 is analysed, it is clear that the scale on the 
horizontal axis is not in Hz (or s
-1
); the horizontal axis scale is given in parts per 
million (ppm). This is because the frequencies of NMR lines are directly 
θ 
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proportional to magnetic field strength (Figure 2.8) and thus, this field dependence 
makes it difficult to compare absorption frequencies between spectrometers which 
operate at different field strengths. In order to specify the position of an NMR line 
independent of the applied field, the chemical shift scale is introduced to NMR 
spectroscopy. This is done by using a simple reference compound (TMS for 
1
H and 
13
C) to define zero on the chemical shift scale. The position of a peak in the spectrum 
is determined by measuring its frequency separation from the reference peak and 
then dividing by the reference peak frequency. As the ratio of two frequencies is 
being obtained, the field dependence is cancelled out and the ratio multiplied by 10
6
 
to make the numbers more manageable (Equation 2.7). This is where the term 
chemical shift (δ) originates to describe the peaks in NMR spectra and why the 
values are quoted in parts per million (ppm).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Two representative NMR spectra consisting of two peaks, to illustrate the magnetic field 
strength dependence of NMR lines. In a) the magnetic field is such that the two lines appear at 
200.0002 and 200.0004MHz respectively; with a separation of 200Hz. However, in b) the magnetic 
field strength has been doubled, the frequency of each peak has doubled and thus, so has the 
separation between the two lines (400Hz). Image based on a figure in (Keeler, 2005). 
 
  (   )     
      
    
  Equation [2.7] 
The traditional chemical shift lineshape seen in simple NMR experiments is the 
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absorption mode lineshape (Figure 2.9a), this is a peak centred at υ0, height h and 
linewidth W (width measured at half the peak height, h/2). In 
1
H NMR spectroscopy, 
the peak or multiplet integral i.e. the area under the respective peak is proportional to 
the number of hydrogen’s that the peak represents (Figure 2.9b). 
 
 
 
 
 
Figure 2.9: a) An example of an absorption mode lineshape seen in NMR experiments, where the 
peak is centred at ν0, with height h and linewidth W (measured at half the peak height i.e. h/2). b) An 
illustration of how the integral (area) of a peak that corresponds to a certain number of protons is 
fixed. The peak on the right hand side is twice as broad, but only half the height of the peak on the left 
hand side; thus, both peaks in the example contain the same number of protons, as shown by the 
integral (red). Image based on a figure in (Keeler, 2005). 
 
The term ‘multiplet’ was used previously and this is an example of a peak in NMR 
spectra where the chemical shift has been split into two or more lines due to scalar 
(or J) coupling between nuclei and is mediated by chemical bonds. This property of 
NMR spectra is very useful in determining which nuclei are close to one another in 
the bonding framework; an example of two coupled spin-half nuclei can be seen 
(Figure 2.10).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: The spectrum shown in a) contains two lines at frequencies ν1 and ν2 corresponding to 
two different spins; if there is scalar (J) coupling between the two spins, each line splits symmetrically 
into two giving two ‘doublets.’i.e. b). The splitting of the two lines is the coupling constant J12 and the 
two lines of the doublet can be thought of as either spin ‘up’ or ‘down states, indicated by the open 
headed arrows above the peaks. Image based on a figure in (Keeler, 2005). 
a) b) 
a) 
b) 
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2.2.3 Experimental Aspects of NMR Spectroscopy 
The previous section [2.2.2] discussed the some of the theory and terminology of 
NMR spectroscopy; this section will now outline the essential aspects of NMR 
spectroscopic experiments using some of the terms introduced previously. 
In the vast majority of protein NMR spectroscopy experiments, especially the more 
complex multi-dimensional experiments, an NMR sample of a protein with isotope 
labelling is required to enable 
13
C and 
15
N nuclei to be detected. This isotope 
labelling of proteins helps to circumvent the fundamental problems of protein NMR 
i.e. signal overlap and line broadening, as it allows more than just 
1
H nuclei to be 
used; hence, increasing the number of dimensions that can be used to acquire the 
data. The methods for uniform or selective labelling of a protein with either 
2
H, 
13
C 
and/or 
15
N isotopes have become well established in the past 20 years (Lian and 
Middleton, 2001). 
An NMR spectrometer consists of a number of components (Figure 2.11a) and the 
roles and effects of a number of these constituents are now discussed in this section 
in more detail. The intense, stable and homogenous magnetic field discussed 
previously is produced by a superconducting magnet system (Figure 2.11b). The 
magnet consists of a superconducting coil immersed in liquid helium, in a dewar 
surrounded by a thermal radiation shield, a vacuum space and an outer dewar filled 
with liquid nitrogen. Obviously it is not desirable for the sample under investigation 
by NMR spectroscopy to be placed at liquid helium temperature and so, a room-
temperature bore of the magnet is created; this is accessible to the outside world, 
centred on the z-axis of the coil and houses the room temperature shim coils and 
probe. 
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Figure 2.11: a) A block diagram of the NMR spectrometer, divided into four distinct components: the 
magnet, RF electronics, receiver and computer; the major subsystems of each components have been 
indicated. Image based on a figure in (Cavanagh, 2007). b) A cutaway diagram of a superconducting 
magnet illustrating how the probe, sample spinner and room-temperature shim coils are positioned 
coaxially in the room temperature bore of the magnet. The solenoid and cryoshim coils are immersed 
in liquid helium, with the helium dewar surrounded by a thermal radiation shield, vaccum space and 
liquid nitrogen dewar. Image taken from (Cavanagh, 2007), courtesy of Bruker Instruments, inc. 
 
The field-frequency lock is a feedback system designed to keep the magnetic field at 
a steady value, by compensating for any small drift in magnetic field. The lock 
circuitry is essentially a specifically tuned (usually to the 
2
H NMR signal in D2O for 
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biological samples) NMR spectrometer that operates in parallel to the main 
spectrometer. The probe is a cylindrical metal tube that is inserted into the bore of 
the magnet, with the coil used to both excite and detect the NMR signal, held in 
proximity to where the NMR sample will be placed. The coil is connected in parallel 
with a capacitor to form a ‘tuned circuit’ and to ensure the best sensitivity possible, it 
is important that the tuned circuit is resonant at the Larmor frequency i.e. ‘tune the 
probe.’ 
The RF transmitter is the part of the spectrometer responsible for producing pulses of 
highly monochromatic RF electromagnetic radiation with defined phases and 
amplitudes (Figure 2.12). The pulse programmer executes the explicit pulse 
programme for the given NMR experiment by controlling the timing, duration, 
amplitudes and phases of the RF pulses produced by the RF transmitter. 
  
 
 
 
 
Figure 2.12: An overview of a typical arrangement of the RF transmitter where the source of the RF, 
the synthesiser produces a low level output that is fed to an attenuator and then onto a high-power 
amplifier, via a gate. The gate is used to switch on the RF power when required, with the attenuator 
used to vary the input to the amplifier and all the components of the RF transmitter are under 
computer control. Image based on a figure in (Keeler, 2005). 
 
The NMR signal detected by the probe is very small and so, needs to be amplified 
with the minimum level of noise introduced; this process is performed by the pre-
amplifier of the receiver. The phase-sensitive detector then performs quadrature 
detection of the signal (Figure 2.13) and reduces the amount of noise aliased into the 
spectrum using audio filters; quadrature detection is the generation of two orthogonal 
components from the NMR signal. An analogue to digital converter (ADC) then 
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converts the amplified analogue signal to a binary number, which is recorded and can 
be stored in computer memory. The digitisation process carried out by the ADC 
involves the sampling of the signal at regular intervals to give a good approximation 
of the smoothly varying signal (Figures 2.14a & b). The orthogonal components 
produced by quadrature detection are digitised separately and become the real and 
imaginary parts of the complex time-domain signal. 
 
 
 
 
 
 
Figure 2.13: A schematic overview of the arrangement used in the quadrature detection process, 
where the receiver reference reaching one of the two mixers has been 90
o
 phase shifted and results in 
orthogonal components of transverse magnetisation. The respective low-frequency difference signal 
from the post-mixer filter is digitised and can be stored in computer memory as real and imaginary 
parts of the time domain. Image based on a figure in (Keeler, 2005). 
 
As the NMR signal is now represented as a discrete sampling sequence in digital 
form, powerful processing techniques can be applied to extract the information 
content of the signal. The most commonly used approach to convert from the time-
domain signal to a frequency-domain signal is by applying a Fourier transform 
(Figure 2.14c).  
The Fourier transform essentially works by multiplying the FID with a number of 
trial cosine functions of known frequency to give a product function. The NMR 
spectrum is then generated by plotting the area under the product function against the 
frequency of the corresponding trial cosine wave (Figure 2.15). Fourier transform of 
the exponentially decaying time-domain signal gives a complex frequency-domain 
signal, whose real and imaginary parts have absorption and desorption mode 
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Lorentzian lineshapes respectively (Figure 2.16). 
 
 
 
 
 
 
 
 
Figure 2.14: a) The amplitude of the free-induction decay (FID) varies smoothly as a function of time 
(top) and the subsequent digital version of the same FID (bottom). b) An illustration of the effect of 
the sampling rate on the representation of the FID; (top) the data points are a good representation of 
the signal (shown by the continuous line), whereas (bottom) the points are too widely separated and 
thus, are a poor representation of the signal. c) The conversion of a time-domain signal to a frequency-
domain signal by the mathematical process of Fourier transformation, to give the familiar NMR 
spectrum. Images based on figures in (Keeler, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: An overview of how the Fourier transformation process works. The FID is multiplied by 
trial cosine waves of known frequency to give a product function and the final spectrum is produced 
by plotting the area under the product function against the frequency of the corresponding trial cosine 
wave. In this example, the trial cosine wave of a) at 15Hz matches the oscillations of the FID exactly, 
as a result the product function area is always positive and the area under this frequency is a 
maximum. b) at 17Hz gives a positive area but not as large as a) due to negative excursions in its 
product function and c) at 30Hz oscillates rapidly so the area under the product function and hence, 
the intensity in the spectrum is essentially zero. Image based on a figure in (Keeler, 2005). 
a) b) c) 
a) b) c) 
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Figure 2.16: Fourier transformation of an exponentially decaying time-domain results in a complex 
frequency-domain signal, where the real and imaginary parts have adsorption (a) and desorption (b) 
lineshapes respectively; the width (W, at half height) has been indicated, where R is the decay 
constant. The dispersion lineshape is considerably broader (3.7 times) than the absorption lineshape 
and contains both positive and negative parts c.f. absorption lineshape which is always positive. 
Image based on a figure in (Keeler, 2005). 
 
Prior to Fourier transform, it is possible to perform mathematical manipulations of 
the FID to enhance the signal-to-noise ratio. These manipulations include the 
application of weighting functions, zero filling and many others, however due to 
space constraints, these will not be discussed in any further detail. There also 
alternative methods for FID processing to Fourier transformation i.e. linear 
prediction but these will not be elaborated upon further in this chapter either. 
A key experimental aspect of protein NMR spectroscopy is the different pulse 
techniques that can be employed and the specific ordering of the pulses (pulse 
sequence), to obtain the optimal results. A number of the basic pulse techniques are 
detailed in this section.  
The simplest pulse to deal with is when the transmitter frequency (ωtx) is the same as 
the Larmor frequency (ω0) and thus, gives rise to the precession frequency about the 
B1 field (ω1); this is called an on-resonance pulse. When an on-resonance pulse is 
applied, rotation of equilibrium magnetisation occurs about a specified axis and the 
amount of rotation is called flip angle of the pulse (β); with an on-resonant pulse, the 
nuclei will respond ideally i.e. as described in [2.2.2]. The most commonly used flip 
a) b) 
 Introduction to Biophysical Techniques 
58 
 
angles are 90
o
 and 180
o
 and different phases of pulse rotate the equilibrium 
magnetisation about different axis (x, -x, y or –y) (Figure 2.17).  
 
 
 
 
Figure 2.17: A three-dimensional representation of the motion of the magnetisation vector during an 
on-resonance pulse, the red line follows the tip of the vector from its assumed starting point on the +z-
axis. The effective field is the same as the B1 field and lies along the x-axis with the magnetisation 
therefore precessing in the yz-plane. The rotation of magnetisation is in a positive sense about x and 
so the magnetisation ends up along a) the –y-axis (90o pulse flip angle) or b) the –z-axis (180o pulse 
flip angle). Image based on figure in (Keeler, 2005). 
 
With several different resonances in the protein NMR sample, it is not possible to be 
on-resonance with all the lines in the spectrum. However, if a pulse is applied which 
allows ω1 >> Ω, the equilibrium magnetisation vector for a range of resonances will 
behave as if it were on-resonance; this type of pulse is called a hard pulse or non-
selective pulse. A non-selective pulse is employed in the simple pulse-acquire 
experiment and if the pulse sequence for this experiment is analysed, it illustrates 
that all they key components of an NMR experiment are now known (Figure 2.18a). 
The most famous NMR experiment, the ‘spin echo,’ is composed of two hard pulses 
(90
o
 (x) and 180
o
 (x)) and is a component of a large number of much more complex 
protein NMR experiments (Figure 2.18b). 
 
 
 
 
 
 
 
 
Figure 2.18: The timing diagram (pulse sequence) for the a) simple pulse-acquire NMR experiment 
and b) the ‘spin echo’ NMR experiment, where the line labelled ‘RF’ shows the location of the 
radiofrequency pulses and ‘acq’ shows when the signal is recorded (acquired). The different 90o and 
180
o
 pulses are indicated by yellow and green rectangles respectively. The pulse-acquire experiment 
can be divided into three sections, with the 180
o
 pulse in the spin echo experiment in the centre of a 2τ 
delay between the 90
o
 pulse and acquisition. Images based on figures in (Keeler, 2005). 
 
a) b) 
- y 
x 
   z 
- y 
   z 
x 
 B1  B1 
a) b) 
 Introduction to Biophysical Techniques 
59 
 
An example of an NMR experiment based on the ‘spin echo’ experiment is the 
insensitive nuclei enhanced by polarisation transfer (INEPT) NMR experiment 
(Figure 2.19a); this experiment enhances signals observed from a low gyromagnetic 
ratio nucleus by transferring it to the larger equilibrium magnetisation of a high 
gyromagnetic ratio nucleus. Typically, the high gyromagnetic ratio nucleus is 
hydrogen and this magnetisation is transferred to nuclei, such as 
13
C or 
15
N; thus, the 
INEPT experiment forms the basis of heteronuclear correlation experiments such as 
the heteronuclear single-quantum correlation (HSQC) experiment (Figure 2.19b). 
The HSQC is widely used for recording one-bond correlation spectra between 
1
H and 
15
N or 
13
C, it is arguably the most useful experiment in protein NMR spectroscopy 
and its pulse sequence is the building block on which numerous three-dimensional 
experiments are derived; the described NMR experiments will not be discussed in 
any more detail here however. 
To obtain the maximum intensity in NMR experiments, it is necessary to perform a 
preliminary pulse calibration; this process involves using a version of the simple 
pulse-acquire experiment i.e. contains a hard pulse (Figure 2.20). In this experiment, 
the flip angle (β) of the pulse is augmented by increasing the pulse length until it 
reaches zero; this flip angle is then 180
o
 and thus, a 90
o
 pulse is halve the length of 
the 180
o
 pulse. 
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Figure 2.19: a) and b) The pulse sequences of the INEPT and HSQC NMR experiments, where the 
90
o
 and 180
o
 pulses are denoted as yellow and green rectangles respectively; I and S denote the two 
different spins of the proton and heteronucleus i.e. 
15
N respectively. a) The INEPT experiment results 
in an observable signal on the S spin, with the size of this signal depending on the equilibrium 
magnetisation of the I spin. By choosing, the I spin to have a higher gyromagnetic ratio than the S 
spin, the signal observed on the S spin is larger than it would be for a simple pulse-acquire experiment 
on the same spin. In the experiment, an anti-phase state is generated on the I spin during period A, this 
is transferred to S during period B and during period C, the anti-phase state evolves into an in-phase 
state and is then observed. b) The HSQC starts with an INEPT-like sequence during periods A and B 
and then the S spin magnetisation evolves for t1, with the centrally placed I spin 180
o
 pulse refocusing 
the evolution of the coupling. The magnetisation is transferred back to the I spin, a spin echo period E 
allows the anti-phase signals to become in-phase and observed using broadband S spin decoupling 
(red rectangle). Images based on figures in (Keeler, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.20: A depiction of how pulse calibration is achieved by varying the flip angle of the pulse, β; 
as shown by the graph, the signal intensity in this experiment is proportional to sinβ. Above the graph 
are the expected signal intensities at various different flip angles, where a maximum is reached at a 
flip angle of 90
o
 and null at 180
o 
or 360
o
. Pulse calibration is achieved by increasing the duration of 
the pulse until the signal goes to a null i.e. 180
o 
or 360
o 
and dividing the resultant
 
pulse length by two 
or four to give the 90
o 
pulse length i.e. the
 
maximum. Image based on a figure in (Keeler, 2005). 
b) 
a) 
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The pulses described in this chapter so far have either been on-resonance or the RF 
field strength is large compared to the offset. However, there are cases in NMR 
spectroscopy where i.e. off-resonance effects occur i.e. when ω0 ≠ ωtx and the offset 
(Ω) becomes comparable in size to the RF field strength (ω1); this can both be a 
problem and advantageously exploited in protein NMR spectroscopy. This is 
problematic in NMR spectroscopy because as the offset becomes comparable with 
RF field strength, the effective field moves up from the x-axis towards the z-axis 
(assuming the offset is positive (Figure 2.21). The result of these off-resonance 
effects is that the observed signal in the experiment is much weaker as less transverse 
magnetisation is generated and because x-magnetisation is generated, spectra with 
phase errors are produced. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21: A three-dimensional representation of the path followed during an x pulse for various 
different resonance offsets. The different colour lines show the path followed by the tip of the 
magnetisation vector starting from +z-axis, with the duration chosen to give an on-resonance flip 
angle of 90
o
. Path a is the on-resonance case and b – d are for when the offset is 0.5 (i.e. Ω = ω1/2), 1 
and 1.5 times the RF field strength; the resultant effective field directions are indicated by the dashed 
line. Image based on a figure in (Keeler, 2005). 
 
However, this effect also leads to the development of a pulse designed to excite just a 
small portion of the spectrum, such pulses are termed selective pulse or soft pulses 
(Figure 2.22). This is achieved by making the transmitter on-resonance with the line 
(or middle of the multiplet) and then reducing the RF field strength until the degree 
of excitation of the rest of the spectrum is sufficiently small. A selective inversion 
pulse follows the same principle as a selective pulse but with the pulse lengthened to 
- y 
x 
   z 
 A 
B 
C 
D 
d 
c 
a b 
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ensure the flip angle is maintained. There are many other important pulse techniques 
i.e. adiabatic, shaped, phase-modulated and composite, however these will not be 
discussed in this chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.22: The selective excitation of just one line in an NMR spectrum using a selective or soft 
pulse. The top spectrum is the spectrum that would be expected from a hard pulse, however, if the 
transmitter is placed on-resonance with the desired line/region of spectrum (in this example, the 
central line), then the excitation pattern shown in the middle will result. This causes the other peaks to 
be attenuated and thus, the bottom spectrum will be obtained; the extent to which the off-resonance 
peaks are excited is dependent on the strength and duration of the pulse. Image based on a figure in 
(Keeler, 2005). 
 
As the majority of studies of biological macromolecules by high-resolution protein 
NMR spectroscopy take place in aqueous solutions, the 
1
H nuclei in water are in 
extreme excess to the macromolecules (~110M c.f. 0.1 – 2mM). Thus, detection of 
the macromolecule signal in the presence of the solvent signal is a difficult problem 
but one that can be overcome by water suppression techniques or by using D2O as 
the solvent. The incorporation of a water suppression technique in an NMR 
experiment is important to obtaining high quality spectra in protein NMR 
spectroscopy but the different techniques for this will not be discussed in this thesis. 
A final experimental aspect of NMR spectroscopy is the phenomenon of relaxation; 
this is the process of the bulk magnetisation returning to its equilibrium position over 
time. Relaxation is unusually slow (µs – s) in NMR spectroscopy, compared to other 
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energy levels and this rate is determined by molecular properties such as shape and 
motion. This slow relaxation can be advantageous as it allows the transverse 
magnetisation to survive for long enough to be observed and it means that the FID 
persists for long enough to obtain high resolution spectra i.e. narrow linewidths. The 
disadvantage of slow relaxation is that it sets a lower limit on the repetition rate of a 
pulse, as equilibrium magnetisation needs to be re-established between pulses. The 
effects of relaxation are reasonably straightforward but understanding its origins and 
motion-dependence is a lot more complicated; neither of these relaxation topics will 
be discussed further but the important application of relaxation phenomena in the 
nuclear Overhauser effect (NOE) is included. 
The NOE is due to a dipolar interaction between two spins in close proximity which 
causes relaxation-induced energy level transitions to occur, these transition leads to 
dipolar relaxation between the two spins and this effect is termed cross-relaxation. 
The differential equation of the rate of change of z-magnetisation (Equation 2.8) 
states that if the z-magnetisation of spin 1 is being affected by the z-magnetisation of 
spin 2, the cross-relaxation constant (σ12) will have a non-zero value and thus, cross-
relaxation must be occurring. As σ12 is proportional to b
2 
(Equation 2.9), the 
distance-dependence of the cross-relaxation rate goes as 1/r
6
 and hence, the distance 
between two spins must be <6Å to be observed experimentally. The NOE is used in 
protein nuclear Overhauser effect spectroscopy (NOESY) NMR experiments to 
determine protons that are close in space; these could be intra-protein, intra-ligand or 
intermolecular between protein and ligand. 
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2.2.4 Applications of NMR Spectroscopy 
Protein NMR spectroscopy has many useful standard applications in structural 
biology ranging from determining if a particular protein is folded to deducing if there 
is an interaction between a protein and ligand. Two of the most important 
applications of protein NMR spectroscopy in structural biology are discussed briefly 
in this section. 
2.2.4.1 Protein Structure Determination 
Protein NMR spectroscopy is used to deduce the structure of an unbound protein or a 
bound protein-ligand complex by determining the individual protein residue 
resonance assignments and the corresponding structural distance restraints i.e. NOE, 
hydrogen bond etc. These are determined by performing 2-D and 3-D NMR 
experiments to give the desired spectra and then, using a spectral analysis software 
programme to assign the obtained spectra. The resultant assignments and restraints 
are then exported to a structure calculation programme to determine the structure. 
This whole process is discussed in more detail in chapters 3 & 4. 
2.2.4.2 Characterisation of Intermolecular Interactions 
Protein NMR spectroscopy can be used to obtain important information about the 
interaction between a protein and a ligand, where this information is not limited to 
simply whether a ligand binds to a protein or not. The exact residues that the ligand 
interacts with in the protein sequence can be deduced and hence, the ligand binding 
can be classified as specific or non-specific, if the binding site is known. More 
importantly, the specific binding site of a ligand to a protein can be determined by 
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protein NMR spectroscopy, as well as the binding affinity (KD) of the ligand to the 
protein. As previously, the applications of protein NMR spectroscopy to the 
characterisation of intermolecular interactions are elaborated upon further in chapters 
3 – 6. 
2.3 Isothermal Titration Calorimetry (ITC)  
(Freyer and Lewis, 2008, Jelesarov and Bosshard, 1999, Ladbury and Chowdhry, 
1996, Leavitt and Freire, 2001, Sigurskjold, 2000) 
2.3.1 Introduction to ITC 
Calorimetry is the measurement of the heat change associated with a physical 
process i.e. chemical reaction, physical change. The instrument used to measure the 
heat change in this technique, the calorimeter, was one of the first scientific 
instruments reported in early literature. Black measured the heat capacity and latent 
heat of water in the 1760’s (Black, 1803) and Lavoisier designed and employed an 
ice calorimeter to measure the metabolic heat produced by a guinea pig in the 1780’s 
(Lavoisier and Laplace, 1780). It is interesting to note that the first calorimetric 
experiment performed was a biologically relevant measurement. 
Titration calorimetry was first described as a method for the simultaneous 
determination of the equilibrium constant (Keq) and enthalpy change (∆H) for a 
reaction in the mid 1960’s (Christen.Jj et al., 1968, Hansen et al., 1965). This method 
was originally applied to weak acid-base equilibria and metal ion complexation 
reactions; it wasn’t until the late 1970’s that titration calorimetry was used to study 
biological equilibria and until the late 1980’s that the first commercially-available 
titration calorimeter for biological systems was developed (by MicroCal in 1989).  
Isothermal titration calorimetry (ITC) employs a calorimeter where the temperature 
of both the sample of interest and the reference sample is kept at the same constant 
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value and hence, isothermal. ITC is a routinely used technique to directly 
characterise the thermodynamic and kinetic properties of a biological system; only 
the determination of thermodynamic parameters of binding between a protein 
(titrand) and ligand (titrant) is of relevance to this thesis and so, the introduction to 
ITC is tailored as such. 
2.3.2 Advantages of ITC 
ITC allows the direct measurement of the binding affinity and thermodynamic 
parameters i.e. enthalpy (∆H) and entropy (∆S) of a biological system. This is a 
label-free technique so spectroscopically silent materials, such as those with no 
chromophore/fluorophore/isotopic-labelling can still be utilised. ITC also facilitates 
the study of opaque/turbid solutions i.e. cell suspensions and can be carried out at a 
range of biologically relevant conditions i.e. different temperatures, pH values and 
salt concentrations. ITC is particularly advantageous over other spectroscopic 
techniques and equilibrium studies, where parameter values are indirectly obtained 
from the van’t Hoff relationship; they are also expensive in both time and material 
terms. A single ITC experiment is used to determine the binding parameters for an 
interaction including ∆G and KD and by repeating this same experiment at different 
temperatures it is possible to obtain the change in heat capacity of the binding (∆Cp) 
for that interaction. 
ITC can be used as a stand-alone biophysical technique or in conjunction with other 
biophysical techniques i.e. NMR spectroscopy, surface plasmon resonance (SPR) 
spectroscopy or analytical ultra-centrifugation (AUC), as a guide to binding affinity 
or as a comparison of reliability. ITC also has the possibility to validate structure-
based computational predictions of binding by analysing the theoretical enthalpic and 
entropic contributions to the experimentally-determined values [2.3.4].  
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A historic problem associated with ITC was that, ITC experiments have upper/lower 
limits of binding affinity of ~ 10nM and ~1mM respectively. However, the 
development of competition (or ligand displacement) ITC experiments has led to 
binding parameter determination for very strong (or weak) binders. Complex systems 
involving multiple interacting or non-equivalent binding sites initially presented a 
problem; this was overcome by statistical thermodynamic treatment of obtained data 
and now deconvolution of isotherms of complex systems is becoming standard.  
2.3.3 Instrumentation and Experimental Overview 
There are a wide range of ITC calorimeters commercially available and each of these 
employ different temperature change detection and/or mixing techniques in the ITC 
experiment. An iTC200 Microcalorimeter (GE Healthcare, Figure 2.23a) was the 
only calorimeter used in this thesis and so, for the purposes of this brief overview it 
will be the only calorimeter discussed. The simplistic representation of the 
calorimeter (Figure 2.23b) shows that it consists of two cells; a reference cell 
containing water or buffer and a sample cell containing the titrand, into which the 
titrant is added. The titrant is added to the sample cell in a series of injections by a 
precision syringe driven by a computer-controlled motor; this means that the solution 
is constantly stirred to ensure thorough and rapid mixing of titrand and titrant 
throughout the experiment. There is a specified time delay between sequential 
injections, which is manipulated to a sufficient length of time that it allows the 
incidental heat change of each injection to return to baseline before the next 
injection. The shown calorimeter is a power-compensation calorimeter, this means 
that it measures the amount of power required to be applied (or removed) to maintain 
the same temperature in the sample cell as that in the reference cell at each injection 
point. 
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Figure 2.23: a) The iTC200 Microcalorimeter (GE Healthcare) that all ITC related-research described 
in this thesis was performed on. Image courtesy of GE Healthcare. b) A simplistic overview of an 
isothermal titration calorimeter; this instrument consists of three parts: a reference cell containing 
buffer or water, a sample cell containing the titrand and into which the titrant is added. The final 
component is the computer-controlled syringe containing the titrant; the syringe titrates the titrant in a 
series of sequential injections with stirring throughout, to ensure good mixing. The calorimeter shown 
here is a power-compensation calorimeter, this means that it measures the amount of power required 
to be applied (or removed) to maintain the same temperature in the sample cell as that in the reference 
cell, at each injection point. Image taken from http://www.huck.psu.edu/. 
 
When planning an ITC experiment it is important to determine the optimum 
conditions in which to carry out the experiment, with possibly the most rational 
being the desired starting titrand and titrant concentrations. These concentrations 
must result in a heat change that is both measurable and that varies for subsequent 
injections, to produce a curved isotherm (Figure 2.24). The first condition is an 
obvious requirement but the second is more problematic and involves the calculation 
of Brandt’s parameter, c (Equation 2.10). 
  [ ]      Equation [2.10] 
where, [M] is the starting titrand concentration and K is the equilibrium constant. 
This relationship shows that some prior knowledge or an estimation of the possible 
equilibrium constant value is required when planning the ITC experiment; c should 
be between 10 and 100 to obtain accurate binding affinity (KD) values. The starting 
concentrations of the samples used in planning the ITC experiment is not the only 
consideration prior to performing an ITC experiment that should be taken into 
a) b) 
a) b) 
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account; there are also the effects that pH, temperature, buffer and salt concentration 
could have on the interaction being investigated. Finally, both starting samples 
should be thoroughly buffer exchanged and degassed prior to use to avoid artefact 
heat changes, such as mixing or dilution effects. 
2.3.4 Analysis of Experimental Data 
At the conclusion of an ITC experiment, raw data is obtained (top, Figure 2.24) and 
this data may need to be corrected because after saturation, some small non-specific 
effects may be seen i.e. ligand dilution, solute mismatch. However, if the initial 
samples are well dialysed, these effects are virtually negligible and can often be 
omitted. The raw data is then analysed using a curve fitting process in which a non-
linear regression procedure is used to fit a model to the data in an iterative process; 
the model is a mathematical description of the particular process (biological, 
chemical or physical) being studied. In terms of the protein-ligand binding 
experiments detailed in this thesis, the model is formed from equilibrium constant 
and mass balance equations. The output of this analysis is an isotherm (bottom, 
Figure 2.24) along with the ‘best-fit’ values of the binding parameters i.e. n, KD, ∆H 
and ∆S. The (derivation of and the actual) mathematical equations used in this data 
analysis methodology will not be discussed here but can be found elsewhere (Freyer 
and Lewis, 2008, Jelesarov and Bosshard, 1999); however, the implications of the 
obtained parameter values on the binding process will be discussed. 
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Figure 2.24: An example of the final ITC figure produced from the binding interaction between a 
protein (titrand) and a peptide (titrant) in 20mM phosphate, pH6.3, on an iTC200 Microcalorimeter 
(MicroCal) at 298K. The isotherm produced by the ITC binding experiment can be seen (top), this 
data was then fitted to a single set of sites curve-fitting model, using Origin7 to give the curve shown 
(bottom). It is from this curve that all the thermodynamic parameters of the binding interaction can be 
determined i.e. stoichiometry, affinity, change in enthalpy/entropy and Gibbs free energy. 
 
The values obtained from an individual ITC experiment of n and KD give 
quantitative information about a binding process but not much qualitative 
information. By analysing the values of the thermodynamic parameters (∆H and ∆S), 
it is possible to gain a more in-depth understanding of the processes that are on-going 
and hence, important to binding affinity of a particular interaction. 
 ∆H and ∆S are the enthalpy and entropy changes, respectively, between the free and 
bound forms of titrand and titrant. The formation or destruction of intermolecular 
interactions/bonds during binding is an important contribution to ∆H; ∆H is more 
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negative and hence, more favourable for an interaction as the ratio of interactions 
formed : interactions broken increases. On the other hand, the addition or removal of 
water from an apolar surface is a significant contributor to the ∆S value; ∆S is more 
positive and hence, more favourable for an interaction as the amount of water 
molecules displaced increases or when conformational entropy is lost upon binding. 
Solute-solute dispersion interactions (Homans, 2007) and changes in internal 
dynamics (Tzeng and Kalodimos, 2012) upon ligand binding are also important 
contributors to any change in enthalpy and/or entropy observed, especially if the 
binding pocket is suboptimally hydrated. The binding between a titrand and a titrant 
can be classified as enthalpically- or entropically-driven depending on the magnitude 
of the values obtained from the ITC experiment. The knowledge of whether a 
particular interaction is enthalpically- or entropically-driven is extremely important 
for a variety of reasons i.e. it can be used to guide inhibitor design.    
2.3.5 Applications of ITC 
ITC has been used in a wide variety of biological investigations ranging from 
determining the stability, stoichiometry and specificity of biological systems, to 
elucidating the effects of co-solvents and denaturants on biological systems. As a 
result, ITC is becoming extremely useful in the drug design process and as the 
sensitivity of the instrument increases further then ITC will become even more 
important. ITC has been used in fragment-based drug discovery approaches where 
lead compounds have been developed from ITC fragment-based binding screening 
experiments. ITC has also been employed to determine the effect of protonisation on 
binding, which has led to different ionisable groups being developed to increase 
bioavailability of drug compounds. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Water 
The methods described in this chapter required at least de-ionised, distilled quality 
water; this was provided by the Institute of Integrative Biology, University of 
Liverpool and is be termed as RO water in this chapter. For the molecular biology 
methods detailed in this chapter, ultra-pure quality water was required and this was 
obtained by use of a Synergy Water Purification System (Millipore) fitted with a 
SynergyPak®1 cartridge and a MilliPak-20 Express system; this water is termed as 
MilliQ in the methods discussed subsequently. 
3.1.2 General Solvents 
Ethanol: The Department of Chemistry Solvent Service, University of Liverpool 
Methanol: Fisher Scientific 
3.1.3 General Reagents 
Unless otherwise stated, all reagents used in the methods detailed in this were of 
laboratory grade and supplied by Sigma-Aldrich. 
3.1.4 General Equipment 
The experimental methods in this chapter desribe specific volumes of liquids but do 
not detail the corresponding tubes or flasks or tubes that contained these liquids to 
avoid repetition; Table 3.1 is a guide to the typical size of tube/flask that was used 
for a given volume of liquid: 
Table 3.1: The particular vessel chosen for a given volume of liquid in the experimental methods 
described in this chapter. 
Volume (mL) Tube/Flask 
<1.5 1.5mL Eppendorf® 
1.5 ≤ x ≥ 10 30mL Sterilin® 
10 ≤ x ≥ 60 250mL conical flask 
60 ≤ x ≥ 250 1L conical flask 
250 ≤ x ≥ 500 2L conical flask 
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3.1.5 General Experimental Considerations 
A number of the methods subsequently detailed involve the use of substances that 
are potentially harmful to health but these hazards are not discussed or elaborated 
upon in the actual method; precaution needs to be taken in the handling of: 
 Ethidium bromide – it is extremely mutagenic and carcinogenic and so, gloves and 
labcoat must be worn and used on/over an absorbent surface to capture any spills. 
 Liquid nitrogen – this can cause cryogenic burns and is an asphyxiant and so, thick 
gloves and labcoat must be worn; liquid nitrogen must not be used in a small, 
confined space with no outside ventilation. 
 Sodium azide – it is extremely toxic and so, gloves and labcoat must be worn.  
 Acrylamide – it is extremely toxic and so, gloves and labcoat must be worn and used 
on/over an absorbent surface to capture any spills. 
 Strong acids and bases – these can be very corrosive and give off noxious fumes and 
so, gloves and labcoat must be worn and work with strong acid or base must be 
conducted in a fume cupboard. 
 Antibiotics – these can be very toxic depending on the particular antibiotic and so, 
gloves and labcoat must be worn. 
3.1.6 Expression Vectors 
There were two different expression vectors used in the protein production process, 
pETM-11 and pOPINS and these are detailed in Figure 3.1. 
3.1.7 Bacterial Strains 
The two different strains of E.coli used in the protein production process were: 
- XL1 Blue Competent Cells (Agilent Technologies) 
- BL21 (DE3) Competent Cells (Novagen®) 
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Figure 3.1: The maps of the two different expression vectors used in the protein production process, 
created with SnapGene® Viewer from the respective sequences – Top = pETM-11, Bottom = 
pOPINS. The restriction enzymes used in the preparation of the PDZ domain constructs utilised in the 
research in this thesis have been indicated, along with the positions of the respective vector they will 
cut at; the cleavage sites of the TEV and SUMO proteases used in the preparation of proteins from the 
pETM-11 and pOPINS vectors respectively have also been detailed; the T7 terminator feature of the 
pOPINS vector (5834-5881bp) has been hidden from the pOPINS vector map for this purpose. It can 
be seen that both the pETM-11 and pOPINS vectors are resistant to the antibiotic kanamycin. 
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3.1.8 Proteases 
There were two different proteases used to cleave the hexahistidine Ni
2+
 affinity tag 
depending on the vector used, these were: 
-  Tobacco-etch virus (TEV) protease for proteins expressed in the pETM-11 vector 
- Small ubiquitin-like modifier (SUMO) protease for proteins expressed in the 
pOPINS vector   
3.1.9 Media Recipes 
The recipes for the different growth media utilised in the methods in this chapter are: 
Super Optimal Broth with Catabolite Repression (SOC) Medium 
 Tryptone (20g, Fluka)  
 Yeast extract (5g, Fluka) 
 NaCl (10mM, Fisher Scientific) 
 KCl (25mM, ProLabo) 
 MgCl2.6H2O (10mM, BDH) 
 pH to 7.0 in total volume of 200mL of RO water, autoclave and then add 
glucose (20mM, BDH)  
Lysogeny Broth (LB) 
 25g of LB broth ‘Miller’ (Merck) per 1L of RO water 
LB Agar 
 37g of LB agar ‘Miller’ (Merck) per 1L of RO water 
Kanamycin-Selective LB 
 LB containing kanamycin (32µg/mL, Melford) 
Kanamycin-Selective LB Agar 
 LB agar containing kanamycin (32µg/mL)  
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Minimal Medium Solution A (MM A) 
 Na2HPO4 (88mM, ProLabo) 
 KH2PO4 (55mM, Fisher Scientific) 
 pH to 7.2 in total volume of 1L of RO water and autoclave 
Minimal Medium Solution B (MM B) 
 Thiamine.HCl (30µM, Duchefa Biochemie) 
 CaCl2.2H2O (135µM) 
 MgSO4.7H2O (1mM, Acros Organics) 
 (15)NH4Cl (20mM) 
 (13C) Glucose (20mM) 
 In 10mL of MilliQ and syringe-filtered through a 0.22µM Millex® HA filter 
unit    
Kanamycin-selective M9 Medium 
 MM A 
 MM B 
 Kanamycin (32µg/mL)     
3.1.10 Buffer Solutions 
The components of the various different buffers included in the methods of this 
chapter are:  
D-Buffer 
 MgCl2.6H2O (20mM, BDH) 
 Tris/HCl (20mM, Melford) 
 DTT (5mM, Melford) 
 pH 8.0   
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H-Buffer 
 NaCl (150mM) 
 Tris/HCl (25mM) 
 EDTA (10mM)  
 pH 8.0 
50x TAE Buffer 
 Tris base (2M, Fisher Scientifc) 
 Glacial acetic acid (5.71% (v/v)) 
 EDTA (5mM) at pH 8.0 
4x Loading Buffer 
 Tris/HCl (200mM) 
 DTT (400mM) 
 SDS (8% (w/v), Fisher Scientific) 
 Bromophenol blue (0.4% (w/v)) 
 Glycerol (40% (v/v), Fisher Scientific) 
 pH 6.8  
His-Trap Buffer A 
 Tris/HCl (50mM) 
 NaCl (500mM) 
 pH 7.5 
 His-Trap Buffer B 
 Tris/HCl (50mM) 
 NaCl (500mM) 
 Imidazole (500mM, Fluka)  
 pH 7.5 
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Gel Filtration Buffer 
 Tris/HCl (50mM) 
 NaCl (150mM) 
 DTT (2mM)  
 pH 7.4 
15% Resolving Gel 
 30% Acrylamide (5mL) 
 MilliQ (2.4mL) 
 1.5M Tris/HCl pH 8.8 (2.5mL)  
 10% (w/v) SDS (100µL) 
 10% (w/v) APS (75µL, BDH) 
 TEMED (7.5µL)  
4% Stacking Gel 
 30% Acrylamide (1.3mL) 
 MilliQ (6.1mL) 
 0.5M Tris/HCl pH 6.8 (2.5mL)  
 10% (w/v) SDS (100µL) 
 10% (w/v) APS (75µL, BDH) 
 TEMED (7.5µL) 
2x Sample Buffer 
 Tris/HCl (0.12mM) 
 Glycerol (20% (v/v)) 
 SDS (4% (w/v)) 
 β-mercaptoethanol (10% (w/v)) 
 Bromophenol blue (0.004% (w/v)) and pH to 6.8  
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10x SDS-PAGE Running Buffer 
 Tris/HCl (250mM)  
 Glycine (1.92M, Fisher Scientific) 
 SDS (1% (w/v))  
 Coomassie G250 Stain Solution 
 Coomassie blue G250 (0.1% (w/v)) 
 MeOH (45% (v/v)) 
 MilliQ (44.9% (v/v)) 
 Acetic Acid (10% (v/v))  
De-stain Solution 
 MeOH (45% (v/v)) 
 MilliQ (45% (v/v)) 
 Acetic Acid (10% (v/v)) 
3.2 Methods 
3.2.1 Molecular Biology Methods 
3.2.1.1 Site-Directed Ligand Independent Mutagenesis (SLIM) of SAP97 PDZ2 WT 
to SAP97 PDZ2 H73G/T 
3.2.1.1.1 Primer Design 
SLIM is a novel PCR-mediated mutagenesis approach that utilised an inverse PCR 
amplification of the SAP97 PDZ2 template by two tailed long primers and two short 
primers in a single reaction (Figure 3.2) (Chiu et al., 2004). The tailed primers were 
designed to contain the desired mutation on complementary overhangs at the 
terminus of PCR products (Figure 3.3 & Table 3.2). The most naturally abundant 3-
base code for the desired His to Gly and Thr mutations were determined using the 
Codon Usage Database (http://www.kazusa.or.jp/codon/); the primers were designed, 
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the suitability of their properties ensured by using the Promega BioMath Calculator 
(http://www.promega.com/techserv/tools/biomath/calc11.htm) and then ordered 
(Sigma-Aldrich). 
3.2.1.1.2 Polymerase Chain Reaction (PCR) 
A single PCR was performed for each SAP97 PDZ2 modification (including the wild 
type control) and consisted of the subsequent components in a PCR tube: 2.5µL of 
10x Phusion® Reaction buffer (with 7.5mM MgCl2, New England Biolabs), 200µM 
dNTP, 100mM betaine, 200nM of each of the primers, 0.5µL of the pETM-11 
plasmid containing SAP97 PDZ2 WT template (final concentration of 1ng/µL), 2.5U 
of Phusion® Hot Start II High Fidelity DNA polymerase (New England Biolabs). 
The mixture was made up to a final volume of 25µL with MilliQ and the PCR tube 
transferred to a Mastercycler Personal (Eppendorf) for the PCR. The reactions were 
hot-started by heating to 95
o
C for two minutes and then subjected to a further 29 
cycles of 95
o
C for 25s, 55
o
C for 20s and 70
o
C for 1 minute, with a 3.5 minute step on 
the last cycle at 68
o
C for extension (Figure 3.2) (Chiu et al., 2004). 
3.2.1.1.3 DpnI Digest of PCR Products 
The PCR mixture was then subjected to a PCR clean up step using a GenElute
TM
 
PCR Clean-Up kit (Sigma-Aldrich) to remove the excess primers, nucleotides, DNA 
polymerase, salts etc from the PCR amplification products; this yielded 50µL of the 
mixture in elution buffer. This was diluted with 5µL of D-buffer [3.1.10] plus 0.5µL 
DpnI (New England Biolabs) and this mixture was incubated at 37
o
C for one hour. 
The DpnI digestion was terminated by the addition of 5µL of H-buffer [3.1.10]. The 
mixture was then denatured for three minutes at 99
o
C and hybridisation was 
performed using two cycles of 65
o
C for five minutes and 30
o
C for 15 minutes. To 
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ensure that the SLIM procedure had been successful, agarose gel electrophoresis was 
carried out to visualise that the intact plasmid was at the correct molecular weight. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: An overview of the SLIM procedure,where the specific designed primers are denoted by: 
Fl = forward long, Fs = forward short, Rl = reverse long and Rs = reverse short; the forward and 
reverse long contain the intended mutation. The designed primers used in the PCR reaction result in 
four different products possible and the subsequent denaturation and reannealing of these products 
forms hybrids of products 1 & 2 with complementary overhangs. These overhangs cause spontaneous 
circularisation to occur which results in the plasmid containing the desired mutation (blue and white 
stripes). 
 
atagtgcgattatatgtgaaaaggcggaagccagcctcagaaaaaatcatggaaataaaa 
I  V  R  L  Y  V  K  R  R  K  P  A  S  E  K  I  M  E  I  K 
cttattaaaggccctaaaggtcttgggttcagcattgctggaggtgttggaaaccagcac 
L  I  K  G  P  K  G  L  G  F  S  I  A  G  G  V  G  N  Q  H 
attcctggggataacagcatctatgtaaccaaaataattgaaggaggtgcagcacacaag 
I  P  G  D  N  S  I  Y  V  T  K  I  I  E  G  G  A  A  H  K 
gacggcaaacttcagattggagacaagcttctagcagtgaacagtgtctgtttagaagaa 
D  G  K  L  Q  I  G  D  K  L  L  A  V  N  S  V  C  L  E  E 
gttactcatgaagaagcagtgactgccttaaagaatacatctgattttgtttatttgaaa 
V  T  H  E  E  A  V  T  A  L  K  N  T  S  D  F  V  Y  L  K 
gtggcaaaaccaacaagtatgtatataaatgatggctatgcaccacccgacatcactaat 
V  A  K  P  T  S  M  Y  I  N  D  G  Y  A  P  P  D  I  T  N 
Figure 3.3: The Ile201 – Asn320 section of the DNA base/residue sequence of full-length SAP97 
with the residues of the SAP97 PDZ2 domain, Met217 – Ser306 highlighted (red). The desired His73 
residue to be mutated to Gly and Thr residues is indicated (blue). 
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Table 3.2: The designed primers (two forward and two reverse) required for the SLIM methodology 
are detailed, with the DNA bases corresponding to the H73G/T mutations highlighted (blue). The G : 
C content and annealing temperatures for each individual primer are included in the table also. 
SAP97 
PDZ2 H73X 
Mutant 
Primer 5' → 3' Sequence G : C 
Content 
(%) 
Annealing 
Temp (
o
C) 
H73G Forward 
long 
gaagttactggtgaagaagcagtgactg
ccttaaagaatac 
41.5 66 
H73G Forward 
short 
gtgactgccttaaagaatacatctg 40 54 
H73G Reverse 
long 
tgcttcttcaccagtaacttcttctaaaca
gacactgttcactgc 
42.2 67 
H73G Reverse 
short 
ttctaaacagacactgttcactgc 41.7 54 
H73T Forward 
long 
gaagttactactgaagaagcagtgactg
ccttaaagaatac 
39.0 65 
H73T Forward 
short 
gtgactgccttaaagaatacatctg 40 54 
H73T Reverse 
long 
tgcttcttcagtagtaacttcttctaaacag
acactgttcactgc 
40 66 
H73T Reverse 
short 
ttctaaacagacactgttcactgc 41.7 54 
 
3.2.1.1.4 Agarose Gel Electrophoresis 
Preparation of the gels for agarose gel electrophoresis (0.8% (w/v) for 0.6 – 8.5kb 
separation) requires 60mL of 1x TAE buffer; 0.48g of powdered agarose (Bioline) 
was added to this and the mixture was gradually heated with periodic swirling to 
ensure the agarose dissolved. The solution was allowed to cool to <35
o
C and the cast 
for the subsequent gel was created by sealing the ends of the agarose gel plate; 5µL 
of ethidium bromide (final concentration = 0.1µg/mL) was then added to the 
solution. The mixture was poured into the cast, with a sample well comb inserted and 
allowed to set. 5µL of each of the individual SLIM products were added to 5µL of 
loading buffer and the full volume was pipetted into individual wells. 1kb standard 
DNA marker (New England Biolabs) was loaded in a separate well and the gel 
subjected to an 80V gradient using a BioRad PowerPac 3000 for ~ 40 minutes. The 
gel was then viewed under trans UV light to determine if the SLIM procedure had 
been successful (Appendices, A.1a). 
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3.2.1.1.5 Plasmid Preparation 
2µL of each SLIM product was added to 50 μL of XL1 Blue competent E.coli cells, 
mixed and then incubated on ice for 30 minutes. The cells were incubated at 42
o
C for 
45 seconds before incubating at 0
oC for a further five minutes. 200μL of GS96 
medium (Fisher Scientific) was then added and this mixture was incubated at 37
o
C 
for an hour, with shaking at 180 rpm. 200μL of the transformed cells were then 
pipetted onto a kanamycin-selective LB agar plate, spread evenly and left at 20 - 
25
o
C room temperature for 30 minutes. The agar plate was then incubated at 37
o
C 
for 14 – 18 hours without shaking.  
7mL of kanamycin-selective LB was inoculated with a single colony from the 
respective transformed plate and incubated at 37
o
C for 14 – 18 hours, with shaking at 
180rpm. 1mL of each of the resultant cultures was added to 500µL of autoclaved 
glycerol (Fisher Scientific) and 500µL of MilliQ to produce a glycerol stock of the 
plasmid in XL1 Blue cells and this was immediately stored at -80
o
C. 1mL of the 
individual culture was aliquoted for sequencing analysis (outsourced to Source 
Bioscience) [3.2.3.8]; a further 3mL was pelleted by centrifugation, in order to 
extract the plasmid DNA using a QIAprep Spin Miniprep kit (QIAGEN), to yield a 
50µL stock of the plasmid; at concentrations of 10 – 100 ng/µL. 
3.2.1.2 Preparation of Chemically Competent Cells 
Commercial glycerol stocks of the BL21 (DE3) and XL1 Blue E. coli competent 
cells, were used to streak out an LB agar plate containing kanamycin (for BL21 
(DE3) cells) or tetracycline (for XL1 Blue cells). 200mL of SOC medium (+ 
tetracycline for XL1 Blue cells) was inoculated with a single colony from the desired 
plate. This culture was incubated at 37
o
C with shaking at 180rpm until the optical 
density at 600nm (OD600) measured between 0.3 – 0.4, using a Cary 300 Bio UV/Vis 
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photospectrometer. The culture was then centrifuged at 3,000g for 10 minutes at 4
o
C 
and the resultant pellet was gently resuspended in 60mL of CCMB80 buffer. This 
was then incubated at 0
o
C for 30 – 60 minutes before being centrifuged at 3,000g for 
10 minutes at 4
o
C and resuspended in 6mL of CCMB80. The OD600 of a 50µL cell 
resuspension diluted to 250µL with SOC medium was measured and the cell 
resuspension diluted with CCMB80 buffer until a final OD600 of between 1 – 1.5 was 
obtained. The cells were then incubated on ice for a further 30 minutes before being 
aliquoted into 50µL quantities in 1.5mL eppendorfs (these were autoclaved and pre-
chilled at -20
o
C before use). Finally, the cells were flash frozen using liquid Nitrogen 
and stored at -80
o
C for up to three years.  
3.2.1.3 Transformation of Chemically Competent E.coli 
2μL of the desired plasmid containing the specific PDZ domain prepared via the 
SLIM methodology or from existing stocks was added to 50μL of BL21 (DE3) 
competent cells, mixed well and incubated at 0
o
C for 30 minutes. The cells were then 
incubated at 42
o
C for 45 seconds before being incubated at 0
o
C for a further five 
minutes. 200μL of SOC medium was then added and this was incubated at 37oC for 
one hour with shaking at 180rpm. 200μL of the transformed cells was pipetted onto a 
kanamycin containing agar plate, spread evenly and left at 20 - 25
o
C for 30 minutes. 
The agar plate was then left to incubate at 37
o
C overnight, without shaking, after 
which it was removed and incubated at 20 - 25
o
C for a further 30 minutes. Finally, 
the agar plate was sealed with Parafilm® and stored at 4
o
C for up to two weeks. 
3.2.2 Protein Expression Methods 
3.2.2.1 PSD-95 PDZ1&2, SAP97 PDZ1, PDZ2 WT1&2, PDZ2 H73G, PDZ2 H73T, & 
Expression in LB Medium 
50mL of kanamycin selective LB was inoculated with a single colony from the 
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desired transformed plate and incubated at 37
o
C with shaking at 180rpm for 14 – 18 
hours. The cells were centrifuged at 3,000g for 14 minutes at 4
o
C and the resultant 
pellet was resuspended in 5mL of kanamycin-selective LB. This cell suspension was 
then added to 1L of kanamycin-selective LB and the OD600 measured (normally a 
value of between 0.05 - 0.1). The cells were incubated at 37
o
C with shaking at 
180rpm until the OD600 of the solution measured between 0.7 – 1 (approximately 2 – 
3 hours); the cells were then induced with IPTG (Apollo Scientific), to a final 
concentration of 1mM and incubated at 18
o
C for 14 – 18 hours, with shaking at 
180rpm. The induced cells were then pelleted by centrifugation at 3,000g for 20 
minutes at 4
o
C, with the resultant supernatant decanted and discarded. The pellet was 
resuspended in HisTrap A buffer and a cOmplete EDTA-free cocktail protease 
inhibitor tablet (Roche) dissolved in 1mL of HisTrap A buffer was added. The 
resuspended cell pellets were stored left at -80
o
C until purification (for up to 3 
months). 
3.2.2.2 PSD-95 PDZ1&2, SAP97 PDZ1, PDZ2 WT, PDZ2 H73G, PDZ2 H73T, & 
PDZ2 KI Expression in Minimal Medium 
1mL of kanamycin-selective LB was inoculated with a single colony from the 
transformed plate and incubated at 37
o
C with shaking at 180rpm, for seven hours. 
100μL of the resultant cells was added to 10mL of kanamycin-selective M9 medium 
and incubated overnight at 37
o
C, with shaking at 180rpm. This cell suspension was 
then added to the 1L of kanamycin-selective M9 medium and the OD600 measured 
(normally a value of between 0.03 - 0.07). The cells were incubated at 37
o
C until the 
OD600 measured between 0.8 – 1 (usually 5 – 6 hours), then induced with 1mM final 
concentration of IPTG and incubated at 18
o
C for 14 – 18 hours, with shaking at 
180rpm. The induced cells were pelleted by centrifugation at 1,300g for 20 minutes 
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at 4
o
C and the subsequent supernatant was discarded. The cell pellet was 
resuspended in HisTrap buffer A, a cOmplete EDTA-free cocktail protease inhibitor 
tablet (Roche) dissolved in 1mL of HisTrap A buffer was then added and the mixture 
was stored at -80
o
C until purification. 
3.2.3 Protein Purification Methods 
3.2.3.1 Cell Lysis 
The cell solutions stored at -80
o
C were gently thawed at 20 - 25
 o
C, with DNase1 
from bovine pancreas then added to a final concentration of 12.5µg/mL (Sigma-
Aldrich) and incubated at 0
o
C for 10 minutes. The cells were then mechanically 
lysed using a Stansted ‘Pressure Cell’ Homogeniser (SFP Ltd), at 1000 PSI. The cell 
debris in the crude cell lysate was pelleted by centrifugation at 37,000g for 30 
minutes at 4
o
C; the resultant supernatant contained the desired protein. The 
supernatant was decanted and sterile filtered through a 0.45μm Millex® HA syringe-
driven filter unit in preparation for purification by chromatographic techniques. 
3.2.3.2 Ni
2+
 Affinity Chromatography 
A 5mL HisTrap Fast Flow (FF) column (GE Healthcare) was used on an 
ÄKTApurifier10 FPLC system (GE Healthcare), with the column initially washed 
with MilliQ and then equilibrated with HisTrap A and B buffers, at 2.5mL/min. The 
filtered cell supernatant was then loaded onto the column at a flow rate of 
2.5mL/min. The bound contents of the column were then eluted with a gradient of 
increasing imidazole concentrations at 2.5mL/min and fractionated into 5mL 
fractions. The fractions were analysed by UV absorbance at 280nm (A280) and those 
fractions that showed absorption levels above the baseline were analysed using SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) [3.2.4.2]. The fractions that yielded 
the desired gel retardation band were combined, ready to be concentrated. 
 Materials and Methods 
88 
 
3.2.3.3 Concentration of Protein Sample 
Concentration of the combined protein fractions from the Ni
2+
 affinity 
chromatography was carried out using Amicon Ultra Centrifugal Filter units with a 
3kDa molecular weight cutoff and volume capacity of 15mL (Millipore). The 
concentration unit membrane was equilibrated by centrifugation at 3,500g with 
MilliQ then HisTrap A buffer. The protein was then applied to the unit and 
centrifuged at 3,500g until the desired final volume of sample was achieved. The 
solution that passed through the membrane (flow through) was analysed by SDS-
PAGE to ensure that there was no membrane failure and hence, that none of the 
protein of interest had passed through. After use, the concentration units were 
centrifuged at 3,500g with MilliQ, then 20% (v/v) EtOH and left at 20 - 25
o
C in 20% 
(v/v) EtOH for reuse (up to two months). 
3.2.3.4 Buffer Exchange of Protein Sample 
The concentrated fractions from the Ni
2+
 affinity chromatography were then buffer 
exchanged to remove any imidazole present using a Sephadex G-25 Medium 
Gravity-Flow PD-10 Column (GE Healthcare) and HisTrap A buffer. The PD-10 
column was initially washed with 25mL of MilliQ and then 25mL of HisTrap A 
buffer to equilibrate the column. 2.5mL of the protein sample was applied to the 
column, with the flow through discarded; the sample was eluted by addition of 
3.5mL of HisTrap A buffer. As the maximum volume of protein that can be loaded 
onto the PD-10 column was 2.5mL; the equilibration, sample addition and sample 
elution sequence was repeated as necessary. The PD-10 column was then washed 
with 25mL of MilliQ then 25mL of 20% (v/v) EtOH and stored at room temperature 
in 20% (v/v) EtOH until required again. 
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3.2.3.5 Hexahistidine-Tag Removal Using Tobacco Etch Virus (TEV) Protease for 
PSD-95 PDZ1, SAP97 PDZ1, PDZ2 WT, PDZ2 H73G, PDZ2 H73T & PDZ2 KI 
TEV protease was added to the buffer exchanged protein in a ratio of PDZ domain : 
TEV protease = 20:1 (protein concentration determined as detailed in [3.2.4.1]) and 
the solution incubated at 20 – 25oC for 14 – 18 hours, without shaking. The cleavage 
solution was then loaded back through the Ni
2+
 affinity column at 2mL/min and the 
flow through containing successfully cleaved protein collected. Any uncleaved 
protein, cleaved tags and tagged protease in the cleavage solution all bound to the 
column and so, were eluted off using 100% HisTrap B buffer i.e. 500mM imidazole. 
3.2.3.6 SUMO-Tag Cleavage Using SUMO Protease for PSD-95 PDZ2 
The protocol detailed in [3.2.3.5] was followed for the SUMO-tag cleavage of PSD-
95 PDZ2, except that SUMO protease was added to the buffer exchanged protein in a 
ratio of PDZ domain : SUMO protease = 100:1 (protein concentration determined as 
detailed in [3.2.4.1]), instead of TEV protease. 
3.2.3.7 Size Exclusion Chromatography 
A HiLoad 26/60 Superdex 75 column was connected on an ÄKTApurifier10 FPLC 
system, with the column initially washed with MilliQ and then equilibrated with gel 
filtration buffer. The affinity tag-cleaved protein was concentrated to less than 5mL 
[3.2.3.3], manually injected into a 10mL injection loop connected to the FPLC 
system and loaded onto the size exclusion column at a flow rate of 3mL/min. The 
protein was then eluted with increasing volume of gel filtration buffer; the fractions 
that showed A280 levels above the baseline were analysed using SDS PAGE. The 
fractions that showed the desired molecular weight of protein were pooled, 
concentrated [3.2.3.3] and buffer exchanged into the desired buffer for NMR 
spectroscopy or ITC [3.2.3.4]. The final protein solution was flash frozen with liquid 
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Nitrogen and stored at -80
o
C. 
3.2.3.8 PDZ Domain Construct Sequences 
The amino acid sequence of the different PDZ domain proteins produced for the 
research described in this thesis have been detailed in this sub-section. It can be seen 
that two different SAP97 PDZ2 WT constructs were produced and utilised (WT1 & 
WT2), with the only difference between the two SAP97 PDZ2 constructs being the 
presence of an extra two amino acids (KI, blue) at the N-terminus of SAP97 PDZ2 
WT1; this increased the theoretical isoelectric point (pI) from 7.09 to 8.05. This 
resulted in the protein production being more productive as no protein was lost by 
precipitation incurred to crossing the pI. Mutagenesis of the SAP97 PDZ2 domain 
was performed on the SAP97 PDZ2 WT2 construct and the residues mutated have 
been highlighted in red on the respective sequence: 
PSD95 PDZ1 
 
G A M E M E Y E E I T L E R G N S G L G F S I A G G T D N P H I G D D P S I F 
I T K I I P G G A A A Q D G R L R V N D S I L F V N E V D V R E V T H S A A 
V E A L K E A G S I V R L Y V M R R K P P A 
 
PSD95 PDZ2 
 
M K V M E I K L I K G P K G L G F S I A G G V G N Q H I P G D N S I Y V T K 
I I E G G A A H K D G R L Q I G D K I L A V S S V G L E D V M H E D A V A 
A L K N T Y D V V Y L K V A K P S N A 
 
SAP97 PDZ1 
 
G A M A D Y E Y E E I T L E R G N S G L G F S I A G G T D N P H I G D D S S 
I F I T K I I T G G A A A Q D G R L R V N D C I L R V N E A D V R D V T H S 
K A V E A L K E A G S I V R L Y V K R R K P A S 
 
SAP97 PDZ2 WT1 
 
G A M G K I M E I K L I K G P K G L G F S I A G G V G N Q H I P G D N S I Y 
V T K I I E G G A A H K D G K L Q I G D K L L A V N S V C L E E V T H E E A 
V T A L K N T S D F V Y L K V A K P T S 
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SAP97 PDZ2 WT2 
 
G A M E I K L I K G P K G L G F S I A G G V G N Q H I P G D N S I Y V T K I I 
E G G A A H K D G K L Q I G D K L L A V N S V C L E E V T H E E A V T A L 
K N T S D F V Y L K V A K P T S 
SAP97 PDZ2 H73G 
 
G A M E I K L I K G P K G L G F S I A G G V G N Q H I P G D N S I Y V T K I I 
E G G A A H K D G K L Q I G D K L L A V N S V C L E E V T G E E A V T A L 
K N T S D F V Y L K V A K P T S 
SAP97 PDZ2 H73T 
 
G A M E I K L I K G P K G L G F S I A G G V G N Q H I P G D N S I Y V T K I I 
E G G A A H K D G K L Q I G D K L L A V N S V C L E E V T T E E A V T A L 
K N T S D F V Y L K V A K P T S 
3.2.4 Analytical Methods 
3.2.4.1 Protein Concentration Determination 
All protein concentrations (c) were determined using Beers law (A=εcl), where the 
absorbance at 280nm (A280) was obtained using an ND-1000 Spectrophotometer 
(NanoDrop®); with a standard path length (l) = 10mm and the extinction coefficient 
of the particular protein calculated from the protein sequence using the ProtParam 
tool on the ExPASy bioinformatics resource portal (web.expasy.org/protparam/). 
3.2.4.2 SDS-PAGE Gel Electrophoresis 
To prepare the gels required for SDS-PAGE gel electrophoresis, 10mL of 15% 
resolving gel was prepared, gently mixed and pipetted into a 0.75mm glass cast; with 
between 250 – 500µL of butan-2-ol added after to create a level surface. 10mL of 
15% resolving gel is sufficient for two gels and the gels were left to polymerise for 
15 minutes at 20 – 25oC; the butan-2-ol was then decanted off. 10mL of a 4% 
stacking gel was prepared, gently mixed and pipetted on top of the polymerised 
resolving gel in the cast; a sample well comb was then inserted. 10mL of 4% 
stacking gel is sufficient for four gels and the gels were left to polymerise for 20 
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minutes at 20 - 25
o
C. 
To prepare the individual samples to run in the SDS-PAGE, protein samples were 
diluted up to 20μL with MilliQ, followed by addition of 20μL of 2x sample buffer; to 
give a final protein concentration in the range of 0.5 - 1mg/mL [3.2.4.1]. The 
samples were denatured at 100
oC for five minutes before 7.5μL of each sample was 
loaded using a Hamilton syringe into an individual gel lane, excepting one lane per 
gel which was loaded with with 5μL of low-range molecular marker (Sigma-
Aldrich). The gels were packed into a Protean II rack (BioRad), situated in a tank 
containing 1x gel running buffer and a gradient of 200V passed through the solution 
for ~ 45 minutes. 
3.2.4.3 Coomassie Brilliant Blue Staining 
The gels from the SDS-PAGE were carefully removed from the cast and washed 
with RO water, prior to staining for 10 minutes in a solution of Coomassie G250 
with gentle rocking at 20 – 25oC. The Coomassie G250 stain solution was decanted 
off; the gels were washed with RO water and then destained by incubation for 14 – 
18 hours at 20 – 25oC in destain solution, with gentle rocking. 
3.2.4.4 Gel Imaging 
All destained gels were visualised within 12 hours of destaining using an 
ImageScanner III machine (GE Healthcare). 
3.3 NMR Spectroscopy 
3.3.1 General 
Samples to be examined by NMR spectroscopy of volumes 550µL or greater were 
pipetted into Wilmad 5mm 7” 800MHz Precision Pyrex Glass NMR Tubes (Goss 
Scientific). Samples of limited volume were pipetted into Shigemi Advanced NMR 
Microtube Assembly – Matched with D2O, bottom L 8mm tubes (Sigma-Aldrich).  
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The NMR spectra were acquired at 25
o
C on either a Bruker AVANCE II+ 600MHz 
Ultrashield or 800MHz US
2
 spectrometer, equipped with triple resonance 
cryoprobes. The Bruker TopSpin programme version 3.1 was used to process the 
resultant NMR spectra and the Collaborative Computational Project for NMR 
(CCPN) Analysis software programme was used for interactive spectral analysis and 
assignment. 
3.3.2 Unbound PDZ Domain Sample Preparation 
A 0.5mM uniformly 
13
C, 
15
N-doubly-labelled sample of the required PDZ domain 
was prepared in 20mM phosphate, 0.1mM EDTA, 1mM DTT, 0.01% (w/v) NaN3, 
pH 6.3 buffer [3.2].  
3.3.3 PDZ Domain – Ligand Complex Sample Preparation 
A 0.5mM uniformly 
13
C, 
15
N-doubly-labelled sample of the required PDZ domain 
was prepared in 20mM phosphate, 0.1mM EDTA, 1mM DTT, 0.01% (w/v) NaN3, 
pH 6.3 buffer [3.2] with the required ligand stock added to yield a final PDZ domain 
: ligand ratio of 1:5. 
3.3.4 Ligand Binding Screening by NMR Spectroscopy 
A 450mM stock of the potential PDZ domain binder was prepared by dissolving the 
appropriate mass of the organic compound/peptide in the necessary amount of 
hexadeuterodimethyl sulfoxide (DMSO-d6). 
1
H 1-D and 2-D 
1
H-
15
N HSQC NMR 
experiments (Bodenhausen and Ruben, 1980) were performed using 0.1 - 0.2mM 
15
N-labelled PDZ domain in 20mM phosphate buffered to pH 6.3. The NMR sample 
contained the required volume of either organic compound stock solution added to 
give a protein : potential binder ratio of 1:10 or the equivalent volume of DMSO-d6 
(reference spectrum). This ensured that all solutions (reference and ligand present) 
contained the same DMSO-d6 concentration and thus, any observed perturbations 
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were not due to the effects of DMSO-d6. The concentration of DMSO-d6 in the NMR 
sample never exceeded 0.44% (v/v) throughout the course of the ligand binding 
screening by NMR spectroscopy investigation. 
The resultant spectra were then assigned by transfer of the previously determined 
unbound backbone assignments of each PDZ domain [3.5.2] and analysed to identify 
which residue(s) of the PDZ domain had been perturbed. The chemical shift sum 
perturbation value (∆dppm) for each residue was then calculated (Equation 3.1, 
(Tochio et al., 2000, Piserchio et al., 2002)): 
      √((    )  (      ) )   Equation [3.1] 
where,     = Scaling Factor of 0.17 
 
3.3.5 Binding Affinity Determination by NMR Spectroscopy 
To determine the binding affinity (KD) of the small molecule binders to the particular 
PDZ domain by NMR spectroscopy, a series of 
1
H 1-D and 
1
H-
15
N 2-D HSQC NMR 
experiments were performed.  
The NMR experiments were carried out using 
15
N-labelled PDZ domain in 20mM 
phosphate buffered at pH 6.3 and the previously described stock of the potential 
small molecule inhibitors [3.3.4]. Two different 
15
N PDZ domain NMR samples 
were prepared (Table 3.3), with NMR experiments first carried out on these samples 
to give a reference (no inhibitor i.e. 100% solution A) and potential endpoint (20-
fold excess of inhibitor i.e. 100% solution B). The same volume of sample was 
removed from solutions A and B, with the sample of solution A placed into solution 
B and vice-versa; the subsequent step-wise dilution of one solution with the other 
then allowed the formation of a number of intermediate points in the small molecule 
concentration titration series (Table 3.4). 
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Table 3.3: The composition of the initial two 550µL samples prepared for determination of 
dissociation constants using NMR spectroscopy. Concentrations of sample constituents are denoted by 
[ ] and are given in µM or volume/volume percentages. Both solutions contained a PDZ:DTT ratio of 
1:2 and solution B contained the small molecule inhibitor in 20-fold excess to the protein. As the 
small molecule binders are dissolved in DMSO-d6, the same final percentage of DMSO was added to 
solution A as was present in solution B. 
Constituent Solution A Solution B 
PDZ Domain [182] [182] 
Small Molecule / [3640] i.e.0.81% DMSO-d6 
DMSO-d6 0.81% / 
DTT [364] [364] 
D2O 8.25% 8.25% 
 
Table 3.4: The detailed series of sequential dilutions starting from solutions A and B and finishing 
with solution A
VII
B
VII
 for the binding affinity determination titration to create a total of nine titration 
points ranging from PDZ domain : ligand 1:0 – 1:20. 
Solution 
Number 
PDZ:Ligand 
Ratio 
Volume of B 
Added to A (µL) 
Volume of A 
Added to B (µL) 
Ligand 
Concentration (µM) 
A 1:0 0 / 0 
A
I 
10:1 2.75 / 18.2 
A
II 
5:1 2.75 / 36.4 
A
III 
2:1 8.25 / 91 
A
IV 
1:1 13.75 / 182 
A
V 
1:2 27.5 / 364 
A
VI 
1:5 82.5 / 910 
A
VII
B
VII 
1:10 137.5 137.5 1820 
B
VI 
 / 82.5  
B
V 
 / 27.5  
B
IV 
 / 13.75  
B
III 
 / 8.25  
B
II 
 / 2.75  
B
I 
 / 2.75  
B 1:20 / 0 3640 
 
To ensure that the complex reached saturation, additional small molecule stock was 
added to the A
VII
B
VII
 solution to achieve a protein : ligand ratio of 1:30 (5.46mM 
ligand). One final titration point of 1:25 (4.55mM ligand) was obtained by dilution of 
the 5.46mM ligand sample with protein, with the highest DMSO-d6 concentration 
achieved during the titration experiment being 1.21% (v/v). 
 Materials and Methods 
96 
 
The resultant spectra were then assigned by transfer of the previously determined 
assignments [3.5.2], the individual residue chemical shifts were tracked in sequential 
spectra and fitted (using Equation 3.2, (Morton et al., 1996)): 
   ((   )  √((   )    ))   Equation [3.2] 
where,   
[ ]
[ ]
         
 
 
               (
  
[ ]
) 
 
The KD of the particular PDZ – small molecule interaction under investigation was 
determined by averaging the KD value given by the 10 residues that fitted the 
function the best (Figure 3.4). 
 
 
Figure 3.4: An example of a fit curve produced for an individual residue over the course of a small 
molecule concentration titration (blue) and the corresponding fitting function (magenta). This 
particular residue shows very good agreement between the experimental and fitting function values 
and would hence, be used in the KD value determination process. 
  
3.4 Isothermal Titration Calorimetry (ITC) 
3.4.1 Basic Set-up of an ITC Experiment 
All isothermal titration calorimetry experiments were carried out at 25
o
C on an 
iTC200 Microcalorimeter (GE Healthcare) with a 200µL cell capacity and 40µL 
syringe volume. For each experiment, the PDZ domain in 20mM phosphate buffer, 
pH 6.3, was in the cell and a synthetic peptide derived from the C-terminus of the 
native PDZ ligand (GenicBio, China) was in the syringe. The lyophilised peptide was 
 
Protein : Ligand Ratio 
∆δ 
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directly resuspended into the identical buffer as the PDZ domain and minimal pH 
adjustments were made if required. All ITC titration experiments were carried out 
with 100µM PDZ domain and 750µM peptide concentrations and consisted of an 
initial injection of 0.5µL followed by fifteen 2.39µL injections and a final injection 
of 1.89µL. The ITC titration data collected was analysed using the Origin®7 
software programme. 
3.4.2 Native Protein – Ligand Interaction Experiment 
Before the native protein – peptide ITC experiments were carried out, control 
experiments were performed whereby the peptide was titrated into buffer and buffer 
titrated into protein. In both cases no heat exchange was detected, confirming that 
there was appropriate match of buffer conditions with no evidence of dilution effects. 
As successful control experiments had been performed, the ITC titration experiments 
with protein and peptide were carried out as described in [3.4.1]. 
3.4.3 Competition Experiment 
The ITC competition experiments were carried out in a similar manner to the direct 
binding experiments in [3.4.2]. In these experiments, both protein and peptide 
solutions contained the potential small molecule inhibitor obtained from the same 
stock of small molecule dissolved in DMSO-d6 described in [3.3.4]. In each 
experiment, the protein (in the cell) and peptide (in the syringe) contained the same 
concentration of small molecule ligand and hence, the same DMSO-d6 concentration.  
Control experiments were performed whereby the peptide (with ligand) was titrated 
into buffer containing the same DMSO-d6 concentration and conversely, buffer 
containing the same DMSO-d6 concentration titrated into protein (with ligand). Both 
of these control experiments exhibited undetectable heat exchange, confirming that 
there was appropriate match of DMSO-d6/buffer conditions with no evidence of 
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dilution effects.  
A control experiment was also carried out that involved a peptide-protein titration, 
where the protein and peptide were both in a buffer that contained 5% (v/v) DMSO-
d6 (Appendices, A.3). This showed that the presence of such a high level of DMSO-
d6 had no effect on the resultant KD value obtained from the protein-peptide binding 
experiment; although it is possible that the presence of DMSO-d6 may have had an 
effect on the ∆H and ∆S thermodynamic binding parameters obtained. Thus, this 
control experiment showed that any inhibitory effect observed in the competition 
experiments was due to the inhibition of the native interaction by the small molecule 
ligand and not caused by the presence of a small amount of DMSO-d6. The highest 
concentration of DMSO-d6 used in the competitive inhibition experiments was 1.34% 
(v/v), with the various competition experiments having slightly different % (v/v) 
DMSO-d6 concentrations; as a result, only the KD binding parameter values of the 
respective competition experiments were compared. 
The competition experiments were performed at several concentrations of each 
potential small molecule inhibitor to obtain a range of   
   
 values. The Ki value of 
the ligand was determined using Equation 3.3 (Bodenreider et al., 2009): 
  
         
  
  
 [ ]   Equation [3.3] 
where,  
   
 is the measured KD in the presence of inhibitor, KD the dissociation 
constant for the peptide (in the absence of inhibitor) and [L] is the concentration of 
the potential inhibitor present. The value of Ki is estimated from the   
   
 
determined at various [L]. 
3.5 Protein : Ligand Structure Determination 
3.5.1 Collection of a Suite of NMR Experiments 
NMR samples were prepared as described in [3.3.1], [3.3.2] and [3.3.3]; these 
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samples were then used to perform several NMR spectroscopic experiments (Table 
3.5). The aim of these experiments was either to determine the backbone NH 
assignment of an unbound PDZ domain or obtain the structure of the PDZ domain in 
complex with a peptide/small molecule. 
3.5.2 Assignment of 
1
H, 
13
C and 
15
N Resonances of a PDZ Domain 
To assign the 
1
H, 
13
C and 
15
N resonances of the desired PDZ domain (- ligand 
complex), the particular combination of 1-D, 2-D and 3-D NMR experiments shown 
in Table 3.5 were performed. 2-dimensional NMR experiments are based on the 
NMR theory described for the simple pulse-acquire experiment in chapter 2 (Figure 
3.5); however, the magnetisation is transferred from a hydrogen to another nuclei 
either covalently connected in the amino acid sequence or close in space. The 
magnetisation is usually evolved on this atom and then transferred back to the 
hydrogen for detection. 3-dimensional NMR experiments are generally based upon 
2-D experiments and so can be thought of as a 2-D experiment extended into a third 
dimension i.e. 
1
H, 
13
C or 
15
N (Figure 3.5).  
 
 
 
 
 
 
Figure 3.5: An overview of the relationship between one-dimensional (1-D), two-dimensional (2-D) 
and three-dimensional (3-D) NMR spectroscopic experiments. 2-D NMR experiments are based on 1-
D NMR experiments (the theory for a simple pulse-acquire 1-D NMR experiment is detailed in 
chapter 2), however, the magnetisation is transferred from the hydrogen to another nuclei (
15
N in the 
example given) either covalently connected in the amino acid sequence or close in space; the 
magnetisation is evolved on this nuclei and then usually transferred back to the hydrogen for 
detection. 3-D NMR experiments can be thought of as a 2-D experiment extended into a third-
dimension; 
13
C in the example given. 
 
The resonance assignment process of the PDZ domain began with the backbone 
resonance determination, using a sequential assignment methodology with 
1
H 
1
H 
1
H 
15
N 
15
N 
13
C 
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complementary pairs of NMR spectra i.e. CBCACONH and HNCACB. The 
HNCACB experiment correlated each NH group in the protein with its own 
13
Cα and 
13
Cβ chemical shifts and the respective 
13
Cα/β chemical shifts of the preceding 
residue; the CBCACONH correlated a particular NH group in the protein with the 
13
Cα and 
13
Cβ chemical shifts of the preceding residue (Figure 3.6a). The correlation 
observed in this complementary set of spectra allowed the sequential linking of one 
NH group to the next (Figure 3.6b).  This process was repeated with other related 
spectra, to allow the assignment of the PDZ domain 
13
C (carbonyl) and 
1
Hα/β 
chemical shifts; thus, definitive sequence-specific backbone assignment achieved. 
To assign the 
1
H-
15
N HSQC of the individual PDZ domains, the previously described 
procedure was sufficient since only the backbone resonances need to be specifically 
assigned. However, to determine the structure of a PDZ domain – ligand complex, 
the residue side-chain assignment of the PDZ domain was also required; this was so 
that the precise intra- and intermolecular interactions occurring in the complex could 
be definitively assigned. 
The residue side-chain assignment was accomplished using aromatic and aliphatic 
HCCH-TOCSY NMR experiments. By navigating to the 
1
Hα/β chemical shifts 
previously determined for a given residue, it is possible to observe the accompanying 
Hγ/δ chemical shifts and hence, determine the Cγ/δ/ε residue chemical shifts (if present 
in the amino acid structure, Figure 3.7). 
The intra- and intermolecular interactions present in a particular complex were 
detected by carrying out standard and intra-protein isotope filtered 3-D 
13
C (aliphatic 
and aromatic) and 
15
N NOESY experiments; the principles behind the NOE 
experiment are discussed in [2.2.3]. In the NMR solution state structure 
determination of the PSD-95 PDZ1 – 5-HT2c complex, the peaks present in the 
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NOESY spectra were manually picked and then assigned by an automated procedure 
using a software programme, CYANA [3.5.3]. The assignment of the NOE spectra in 
the HADDOCK structure determination of a PDZ domain – small molecule complex 
is described in [3.5.5].  
 
  
 
 
. 
  
 
 
 
  
 
 
 
  
 
 
 
Figure 3.6a: The sequential assignment methodology implemented to complete the assignment of the 
PDZ domain backbone resonances using a complementary pair of 3-D NMR spectroscopic 
experiments (CBCACONH/HNCACB). The Cα/Cβ peaks for a particular residue in the HNCACB 
spectrum were correlated to their respective peaks in the CBCACONH spectrum (1); this identified 
the residue in front of the residue in the amino acid sequence i.e. i+1. The Cα/Cβ peaks of the i+1 
residue were used to determine the corresponding NH group in the CBCACONH experiment (2); this 
assignment was transferred to the HNCACB experiment, which enabled the Cα/Cβ peaks for the i+1 
residue to be determined (3). The process was then repeated to determine the peaks corresponding to 
the i+2, i+3 residues etc. 
 N Cα C’  N Cα C’  N Cα C’  N Cα C’ 
 H  H  H  H 
Cβ Cβ Cβ Cβ 
HNCACB 
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Figure 3.6b: An example of the residue backbone assignment performed on PSD-95 PDZ1 by 
sequential assignment; the Cα/Cβ peaks of the CBCACONH spectrum are shown in blue, with the 
Cα/Cβ peaks of the HNCACB spectrum are shown in red and green respectively. It can be seen how 
the Ser22 – Gly25 length of the PSD-95 PDZ1 domain sequence could be assigned from the 
complementary pair of NMR experiments. The figure also indicates how most Cα are found between 
40 – 70ppm, whereas, the majority of Cβ peaks are have chemical shifts of 10 – 40ppm; this is not true 
for Ser/Thr Cβ peaks however (60 – 75ppm). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: An example of the completed side-chain assignment of the Val67 residue of the PSD-95 
PDZ1 domain using a 3-D HCCH-TOCSY NMR experiment. The four different Carbon and hydrogen 
environments of the Val67 residue can be seen in each respective slice of the NMR experiment.      
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Table 3.5 (continues onto page 33): The different NMR spectroscopic experiments that have been performed in the process of carrying out the research described in this 
thesis. The table indicates the different areas of NMR spectroscopy-related research that the particular experiment was used in; selected NMR experiment acquisition 
parameter values (number of scans and FID resolution) is detailed for each individual experiment. For all experiments with different proteins, typical offset values (ppm) were 
13
C (aliphatic) = 27 – 45, 13C (aromatic) = 124 – 126, 13C carbonyl = 176 and 15N = 117 - 119; for the NOESY and TOCSY experiments, the mixing times were 300ms and 
45ms respectively. For a selection of the NMR experiments, the references for the pulse sequences implemented are given. 
NMR Experiment 
For PDZ Backbone 
Assignment 
For NMR 
Structure 
Determination 
For HADDOCK 
Structure 
Determination 
No. of 
Scans 
FID Resolution (Hz) 
F1 F2 F3 
1-D 
1
H
a
 Yes Yes Yes 32 1.761 / / 
13
C 
15
N-filtered 1-D 
1
H No Yes Yes 32 1.612 / / 
1-D Excitation Sculpting No Yes No 32 0.587 / / 
1-D Saturation-Transfer Difference No Yes No 32 1200.266 0.587 / 
2-D 
1
H-
15
N HSQC
b
 Yes Yes Yes 4 22.807 8.174 / 
2-D 
1
H-
12
C HSQC (Aliphatic) No Yes No 32 82.528 10.016 / 
2-D 
1
H-
13
C HSQC (Aliphatic)
c
 Yes Yes Yes 4 84.424 10.016 / 
2-D 
1
H-
13
C HSQC (Aromatic)
 
 Yes Yes Yes 4 75.843 13.951 / 
2-D 
1
H-
13
C HSQC (HβCβCγCδHδ)
d
 Yes Yes No 96 75.483 12.520 / 
2-D 
13
C TROSY
e
 Yes Yes Yes 4 115.006 18.780 / 
13
C, 
15
N F1-filtered 2-D NOESY-HSQC No Yes Yes 64 37.508 11.161 / 
13
C, 
15
N F1-filtered 2-D TOCSY No Yes No 64 37.578 14.085 / 
3-D HNCO
f
 Yes Yes No 4 58.704 81.103 10.899 
3-D HNCACO
g
 Yes Yes No 8 100.636 133.482 10.899 
3-D CBCACONH
h
 Yes Yes Yes 8 272.519 81.103 10.899 
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NMR Experiment 
Apo PDZ Backbone 
Assignment 
NMR Structure 
Determination 
HADDOCK Structure 
Determination 
No. of 
Scans 
FID Resolution (Hz) 
F1 F2 F3 
3-D HNCACB
i
 Yes Yes Yes 8 272.519 81.103 10.899 
3-D HBHACONH
j
 Yes Yes No 4 100.038 81.103 10.899 
3-D HBHANH
j
 Yes Yes No 4 64.024 81.103 10.899 
3-D HCCH-TOCSY (Aliphatic)
k
 No Yes No 8 48.010 97.853 8.22 
3-D HCCH-TOCSY (Aromatic)
k
 No Yes No 4 75.028 180.295 21.798 
3-D 
13
C NOESY-HSQC (Aliphatic) No Yes No 4 64.024 156.520 18.780 
3-D 
13
C NOESY-HSQC (Aromatic) No Yes No 8 99.776 180.295 9.354 
3-D 
15
N NOESY-HSQC
l
 No Yes No 4 64.024 87.862 16.711 
13
C, 
15
N F1-filtered 
13
C F3-edited 3-D NOESY-
HSQC (Aliphatic) 
No Yes No 16 102.166 204.386 12.019 
13
C, 
15
N F1-filtered 
13
C F3-edited 3-D NOESY-
HSQC (Aromatic) 
No Yes Yes 8 100.038 180.295 16.711 
13
C, 
15
N F1-filtered 
15
N F3-edited Filtered 3-D 
NOESY-HSQC 
No Yes No 8 64.024 87.862 15.964 
a
 (Piotto et al., 1992, Sklenar et al., 1993) 
b
 (Bodenhausen and Ruben, 1980, Piotto et al., 1992, Sklenar et al., 1993) 
c
 (Vuister and Bax, 1992) 
d
 (Yamazaki et al., 1993) 
e
 
(Meissner and Sorensen, 1999) 
f
 (Grzesiek and Bax, 1992c, Schleucher et al., 1993, Kay et al., 1994) 
g
 (Clubb et al., 1992, Kay et al., 1994) 
h
 (Grzesiek and Bax, 1992a, 
Grzesiek and Bax, 1993, Muhandiram and Kay, 1994) 
i
 (Grzesiek and Bax, 1992b, Wittekind and Mueller, 1993)  
j
 (Grzesiek and Bax, 1993, Muhandiram and Kay, 1994) 
k
 
(Bax et al., 1990, Kay et al., 1993) 
l
 (Sklenar et al., 1993). 
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3.5.3 Assignment of NOESY’s and Preliminary Structure Determination Using 
CYANA 
The initial stage of the automated NMR solution state structure determination of the 
PSD-95 PDZ1 – 5-HT2c complex structure involved the use of the CYANA version 
2.1 programme (Guntert, 2004). Automated NOESY assignment with CYANA has 
been found to be as effective as the conventional, interactive ‘manual’ approach but 
is a lot faster and more objective. The amino acid (AA) sequences, sequence-specific 
assignments and NOESY cross-peak positions and volumes previously determined 
[3.5.2] were used as inputs for in CYANA (Figure 3.8); the individual PSD-95 PDZ1 
and 5-HT2c component parts of the complex were treated as one single protein in 
CYANA, separated by a 50 Gly residue linker.  
  CANDID Algorithm 
 
 
 
 
 
 
Figure 3.8: An overview of the automated combined NOESY assignment and structure calculation 
carried out by CYANA. The experimental input data (sequences, assignments and NOESY cross-
peaks) is read as part of the CANDID algorithm which is a cycle of seven stages, at the end of which 
an ensemble of 3-D complex structures is produced and the cycle starts again with the previous 
structural information taken into account. At the end of seven cycles, the outputs from the CYANA 
methodology (NOESY assignments and final 3-D complex ensemble) are obtained. 
  
In CYANA, the automated NOESY assignment is performed by the CANDID 
algorithm (Herrmann et al., 2002) and proceeds in seven iterative cycles of NOE 
assignment and subsequent structure calculation using torsion angle dynamics (TAD, 
Figure 3.9). The TAD algorithm uses a ‘geometric’ force field consisting of the 
short-range repulsive potential of non-bonded interactions and replaces the Lennard-
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Jones and electrostatic interactions. 
 
Figure 3.9: A plot at the five stages of the torsion angle dynamics (TAD) algorithm that forms the 
structure calculation part of the CANDID algorithm in CYANA (Figure 6); where, 1 = Initial 
minimisation (100 conjugate gradient minimisation steps), 2 = High temperature phase (10,000K, 1/5 
of TAD steps, 2fs), 3= Slow cooling (close to 0K, 4/5 of TAD steps), 4 = Low temperature phase (0K, 
100 conjugate gradient minimisation steps then 200 TAD steps) and 5 = Final minimisation (1000 
conjugate gradient minimisation steps). The total number of TAD steps used in the CYANA process 
was 10,000; therefore 2,000 and 8,000 TAD steps were used at stages two and four respectively. 
 
The structure calculation starts from a conformation with all torsion angles treated as 
independent, uniformly distributed random variables. In the first cycle, the structure-
independent NOE self-consistency check (network anchoring) has a dominant impact 
because structure-based criteria cannot be applied yet. The second and subsequent 
cycles use the 3-D structures obtained from the previous cycle to guide NOESY 
assignment. In a single cycle, only cross-peaks with at least one assignment and a 
network anchoring score above a user-defined threshold are retained; a conventional 
distance restraint is created for those cross-peaks with a single assignment, with 
ambiguous distance restraints created for cross-peaks with multiple assignments. The 
final cycle has an additional filtering step to ensure that all NOE’s have either a 
unique assignment to a single H-H interaction or are eliminated; those NOESY 
cross-peaks with ambiguous distance constraints are treated as a superposition of 
degenerate signals in this filtering step and so, the cross-peak is divided into fractions 
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based on the resultant structures generated. 
The CYANA input file (CALC.cya) was amended so that the structure calculation 
contained 10,000 TAD steps, structural restraints (distance, hydrogen bond 
(determined by D2O exchange NMR experiments, Appendices, A.4) and dihedral 
restraints (predicted by DANGLE in CCPN Analysis) [4.6.2.3]) and to ensure that 
the assigned intermolecular NOE’s were kept throughout the structure determination 
process [4.6.2.3]. The output of the automated NMR solution state structure 
determination of the PSD-95 PDZ1 – 5-HT2c complex by CYANA consists of 3-D 
structure as an ensemble of the 20 lowest energy complexes as well as lists of cross-
peak assignments and potential artefacts/mis-assigned peaks. A value termed the 
‘average target function value’ is also given for each cycle of the structure 
calculation; this would be zero if all experimental distance and torsion angle 
constraints are fulfilled and hence, should be as close to zero as possible.  
3.5.4 Structure Determination & Water Refinement Using CNS 
3.5.4.1 PSD-95 PDZ1 - 5-HT2c Structure Refinement 
The structure of the PSD-95 PDZ1 – 5-HT2c complex determined by CYANA [3.5.3] 
was refined using CNS version 1.2, first in vacuo and then water-refined (Brunger, 
2007). The list of cross-peak assignments outputted from CYANA was imported into 
the previous CCPN Analysis project [3.5.3] and exported as NOE-distance restraints 
in CNS format (Appendices, A.5). The template Protein DataBank (PDB) files for 
each component of the complex (PSD-95 PDZ1, segment ID A and 5-HT2c, segment 
ID B) were generated from their sequence. The individual PDZ domain and ligand 
PDB’s were used to create PDB and molecular topology files (mtf) of the complex 
and used as inputs in CNS. The hydrogen bond restraints used in CYANA were 
converted into CNS format (Appendices, A.6) and used as restraint inputs along with 
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the NOE-distance restraints in the CNS refinement methodology (Figure 3.10). 
 
 
 
 
 
Figure 3.10: An overview of the CNS refinement protocol of the PSD-95 PDZ1 – 5-HT2c structure 
determined by CYANA. The different non-bonded parameter force-field used in the different stages 
of the protocol is given in brackets. The input data (NOE-distance and hydrogen bond restraints and 
individual PDB’s of the bound conformations of PSD-95 PDZ1 and 5-HT2c) are used in 4 different 
Cartesian space molecular dynamics (MD) experiments – random coil generation followed by 
simulated annealing and in vacuo refinement and final explicit solvent refinement in water. The output 
from the CNS refinement methodology is an ensemble of the 20 lowest energy water-refined PSD-95 
PDZ1 – 5-HT2c complex structures. 
 
The initial CNS in vacuo refinement protocol began with the generation of 100 
random coil structures which were then subjected to two Cartesian space molecular 
dynamics (MD) simulated annealing stages: (i) a high-temperature phase in at 
2,000K (4000 steps of 3fs integration time steps), (ii) cooling from 2000K to 100K in 
50K temperature steps with 750 MD steps of 3s per temperature. At the end of the 
simulated annealing stage there was a final energy minimisation (400 steps). 
The 100 structures were then refined in vacuo using a Cartesian space MD protocol 
consisting of: (i) a high temperature phase at 2,000K (20,000 steps of 5fs), (ii) 
Cartesian cooling phase from 2000K to 1000K (30,000 steps of 1fs) and (iii) 
Cartesian cooling phase from 1000K to 100K (12,000 steps of 1fs). At the end of the 
in vacuo refinement there was a final energy minimisation (500 steps). 
The 20 lowest energy structures of the 100 obtained were water-refined using the 
final explicit solvent refinement protocol of the recalculated co-ordinate 
(RECOORD) database (Nederveen et al., 2005). This process involved: (i) 
immersion in a 7Å shell of water and energy minimisation, (ii) slow heating from 
100K to 500K in 100K temperature steps with 200 MD steps of 3fs at each 
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temperature step, (iii) refinement at 500K with 2,000 MD steps of 4fs, (iv) slow 
cooling from 500K to 25K in 25K temperature steps with 200 MD steps of 4fs per 
temperature step and (v) final energy minimisation (200 steps). The output of this 
process was 20 water-refined structures of the PSD-95 PDZ1 – 5-HT2c complex. 
3.5.5 Rigid Body Semi-Flexible Restraint Driven Docking using HADDOCK 
The HADDOCK webserver on the e-NMR GRID 
(http://haddock.science.uu.nl/enmr/services/HADDOCK/haddock.php) was utilised 
to determine the structure of the particular bound PDZ domain - small molecule 
complex. The HADDOCK webserver uses version 2.0 of HADDOCK, which is a 
docking method driven by experimental knowledge of the interface region between 
the molecular components. Unlike other docking programmes, HADDOCK allows 
for conformational change of the backbone and side chains of the molecules involved 
during complex formation. HADDOCK makes use of CNS version 1.2 as its 
‘structure calculation engine’ but this is modified to use an optimised potential for 
liquid simulation X (OPLSX) force field and allow definition of additional docking 
restraints. 
The HADDOCK webserver implements the full set of parameters supported by the 
HADDOCK programme and has access to the resources of the e-NMR GRID 
infrastructure (*). As a result, a typical docking run takes only a couple of minutes to 
prepare and a few hours to complete (Figure 3.11). 
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Figure 3.11: An overview of the different aspects of the HADDOCK webserver methodology used to 
determine the structure of the PDZ domain - small molecule inhibitor complexes. The PDB’s of the 
protein and ligand were generated and inputted into the webserver. The most suitable parameters 
(including the NOE distance restraints) were selected and the HADDOCK webserver docking run 
started. The output from the webserver had the non-polar ligand protons added using CNS and the 
final structure quality validated by scoring energies and validation software including PROCHECK. 
 
The HADDOCK webserver required both the initial protein and ligand information 
to be submitted as individual PDB files. The first PDZ domain component of the 
PSD-95 PDZ1&2 double domain crystal structure (PDB accession code: 3GSL, 
(Sainlos et al., 2011)) was used as the input for the PSD-95 PDZ1 domain. The 
lowest energy conformation structure of the small molecules were generated using 
ChemBio3D Ultra 12.0, saved as PDB files and used as the ligand input in the 
respective docking experiments. 
On the HADDOCK webserver, there are a number of different possible interface 
selections, each of increasing complexity and allows greater user control over the 
docking procedure, on the HADDOCK webserver; for all docking runs the ‘guru’ 
interface was the chosen interface. This level of interface allows full control over 
most of the aspects of the docking procedure and supports a wide-range of 
experimental restraints including distance restraints determined by NMR 
spectroscopy. 
The intermolecular and intra-ligand distance restraints were obtained as described in 
[3.5.1]; the protein side-chain atoms responsible for the NOE interactions observed 
were assigned by transfer of residue side-chain assignments from unbound 
assignments to the bound spectra. The specific atoms of the small molecule 
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inhibitors that showed NOE interactions to the particular PDZ domain were assigned 
by transfer of atom assignments from the unbound 
1
H spectrum to the bound 
13
C, 
15
N 
F1-filtered 
1
H spectrum. The cross-peak heights in the 2-D 
13
C, 
15
N F1-filtered 
NOESY experiment were used to calculate the distance restraints between atoms in 
the PDZ domain – small molecule inhibitor complex (Appendices, A.7 & A.8); the 
calculations were based on the proportional relationship between NOE intensity and 
interatomic distance described in chapter 2.  
The HADDOCK docking process proceeds via several stages (Figures 3.12a & 
3.12b); the initial step is the generation of CNS topologies of the molecules to be 
docked from the input PDB files. The actual docking protocol consists of three 
stages, with the first stage being a two temperature-step rigid body minimisation 
stage. The docked interface is then subjected to a two temperature-step semi-flexible 
simulated annealing stage, which minimizes clashing contacts. The final docking 
stage is a three temperature-step explicit solvent refinement process, where the 
presence of water in the molecular dynamics simulation provides a more realistic 
docked complex, both in side-chain orientation and surface polarity terms. The 
output structures from the HADDOCK webserver are subjected to clustering analysis 
and scored based on energy terms.  
There are a number of different docking parameters that can be enabled or disabled 
in the docking procedure; the effect of each of these parameters on the output of the 
docking process was systematically investigated and the most suitable combination 
of these parameters for PDZ domain – small molecule complex determination was 
deduced (Table 3.6). It is possible to select PDZ domain residues that were thought 
to be involved in the small molecule binding to artificially direct the docking process 
i.e. the GLGF motif and conserved His residue; this would be biasing the docking 
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process based on no experimental evidence, which is obviously not ideal and so, this 
parameter was not used in the final docking conditions. Incorporating the 
intermolecular distance restraints determined by NMR spectroscopy as unambiguous 
restraints (where all NOE restraints are retained) rather than ambiguous restraints, 
(where 50% of NOE restraints are randomly discarded) gave less NOE violations and 
lower energy structures; thus, the NOE distance restraints were included as 
unambiguous restraints in the final docking parameter set. The structures obtained 
from docking runs where solvated docking was performed and all non-polar protons 
were kept, gave more realistic complex structures and so were included in the final 
docking conditions. The most suitable RMSD clustering cut-off was determined to 
be 1Å, as this gave the best balance between cluster size and overall structural 
similarity of the cluster. A range of various hydrogen bond restraints between the 
different residues of the GLGF motif and the 6-CO2H group were investigated and, 
interestingly, were found to have little effect on the structure produced; this was also 
biasing the docking process with no experimental evidence to corroborate and so, 
hydrogen bond restraints were omitted from the final docking conditions used on the 
HADDOCK webserver. 
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b)  
Process No. of 
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Temp (K) 
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Temp (K) 
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a
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b
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(1b) 
1000 2000 500 500 
Cooling Stage with Flexible 
Side Chain (2a) 
200 1000 50 1000 
Cooling Stage with Fully 
Flexible Interface (2b) 
200 500 50 1000 
Final Solvated Refinement 
Heating Phase (3a) 
200 100 300 300 
Final Solvated Refinement 
300K Phase (3b) 
200 300 300 1250 
Final Solvated Refinement 
Cooling Phase (3c) 
200 300 100 1500 
Figure 3.12: a) An overview of the different stages in the docking process carried out by the 
HADDOCK webserver. The HADDOCK webserver automatically generates the topology and energy 
parameters for the inputted PDZ domain and small molecule to be docked from the GlycoBioChem 
PRODRG2 server (http://davapc1.bioch.dundee.ac.uk/prodrg/). The docking protocol then consists of 
a rigid body minimization, followed by a semi-flexible refinement in torsion angle space and a final 
explicit solvent refinement in water. The docked complexes are then outputted as PDB files. b) 
a
 MD 
= Molecular dynamics The key parameters i.e. number of structures, starting and final temperature 
and the number of MD steps at the various different stages of the HADDOCK docking protocol.  
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Table 3.6: The various different parameters available to the user of the ‘guru level’ interface of the HADDOCK webserver. Each of these were trialled in order to obtain the 
best possible of the PDZ domain - inhibitor complexes. Active residues are residues of the PDZ domain that were selected as they were thought to be involved in small 
molecule binding and so, artificially direct the docking process. The distance restraints determined by NMR could either be included in the docking process as ‘ambiguous 
restraints’ (50% randomly removed) or ‘unambiguous restraints’ (all retained). The non-polar proton removal option removes non-polar protons at the beginning of the 
docking protocol and does not replace them. Solvated docking allows for the presence of water molecules in all the docking stages, not solely the final refinement stage in 
non-solvated docking. The RMSD clustering cut-off refers to the maximum allowed distance deviation in corresponding complex structures to be clustered together in the 
analysis stage of the HADDOCK webserver process. Similarly to the active residues option, hydrogen bonds that were believed to occur in the complex could be specified. 
The highlighted row at the bottom of the table indicates the optimal conditions used for all PDZ domain – inhibitor complexes. 
Active Residues Ambiguous 
Restraints 
Unambiguous 
Restraints 
Non-Polar Proton 
Removal 
Solvated Docking RMSD Clustering 
Cut-Off 
Hydrogen Bonds 
18
GLGF
21
, 74H No No Yes No No No 
18
GLGF
21
, 74H Yes No Yes No No No 
No Yes No Yes No No No 
No Yes Yes Yes No No No 
No No Yes Yes No No No 
No No Yes Yes No 3Å No 
No No Yes Yes No 1Å No 
No No Yes Yes No 0.5Å No 
No No Yes Yes No 1Å 19L or 20G 
No No Yes Yes No 1Å 20G or 21F 
No No Yes Yes No 1Å 19L or 20G or 21F 
No No Yes Yes Yes 1Å No 
No No Yes No Yes 1Å No 
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As the desired docking parameter set for the HADDOCK webserver ‘guru’ interface 
had been established, the restraint-driven docking process was then initiated; the 
output of the docking procedure is ranked based on a fully flexible scoring system 
termed the ‘HADDOCK score.’ This is a weighted sum of all the different energy 
terms calculated during the run; the individual weighting for an energy term can be 
manually altered if required. The cluster with the lowest average sum of energy 
terms (HADDOCK score) is ranked first and hence, it is the lowest energy cluster 
obtained from the docking run. The 20 lowest energy structures of the lowest energy 
cluster were selected and analysed externally of the HADDOCK webserver, using 
the WHAT IF web interface (Vriend, 1990); this was to ensure that all the structures 
obtained were viable. The structures obtained from the HADDOCK webserver had 
all the protein protons present but only the polar protons present on the small 
molecule inhibitors. Thus, the process of re-protonation and geometry optimisation 
was performed outside the HADDOCK webserver using CNS version 1.2; this 
process was conducted on the lowest energy structure in the lowest energy cluster i.e. 
the representative structure.  
To complete the protonation of the complex, the PDB file of the representative 
structure was split into its individual components and saved as two separate PDB 
files (PDZ domain and small molecule). The individual PDZ domain and ligand 
PDB’s were used to create PDB and molecular topology files (mtf) of the complex 
[3.5.4] using the standard CNS generate hydrogen’s protocol (Appendices, A.1b); the 
resultant PDB file of the complex was fully protonated. Finally, the quality of the 
final PDZ domain – small molecule complex structure was verified externally of 
HADDOCK or CNS, using PROCHECK (Laskowski et al., 1993). 
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4. THE BIOPHYSICAL CHARACTERISATION OF PDZ INTERACTIONS 
INVOLVING THE 5-HYDROXYTRYPTAMINE  
RECEPTOR 2A AND 2C VARIANTS 
4.1 Introduction 
As detailed in [1.5.2.2], the 5-hydroxytryptamine receptor 2a and 2c variants (5-HT2a 
and 5-HT2c respectively) are known to interact with the PSD-95 PDZ domains; the 5-
HT2a/c receptors are able to interact with the PSD-95 PDZ domains via their C-
terminal class I PDZ domain binding motif i.e. X-S/T-X-Ω (VSCV and ISSV 
respectively). 
The PSD-95 PDZ 5-HT2a interaction has been found to enhance 5-HT2a receptor-
mediated signal transduction (Xia et al., 2003) and to be essential for 
somatodendritic targeting of 5-HT2a, both in vitro and in vivo (Xia et al., 2003, 
Abbas et al., 2009). The PSD-95 PDZ domain-mediated interaction with 5-HT2c is 
extremely important in the regulation, expression, synaptic localisation and 
organisation of 5-HT2c (Becamel et al., 2002, Anastasio et al., 2010). However, the 
PDZ domain-mediated interactions between PSD-95 and 5-HT2a/c have recently been 
implicated in a variety of pathological conditions, such as induced analgesia in 
painful diabetic neuropathy (Roth, 2011); this is because inhibition of the interaction 
resulted in reduced hyperalgesia in neuropathic pain (Pichon et al., 2010). This has 
led to the conclusion that disruption of the PDZ domain-mediated interaction 
between the 5-HT2a/c receptors and PSD-95, as well as the related PSD-MAGUK 
protein SAP97, are valid therapeutic targets.   
However, there have been no studies to date that have used a combination of NMR 
spectroscopy and ITC to qualitatively and quantitatively characterise the binding of 
5-HT2a/c to the PSD-95 and SAP97 PDZ domains. Furthermore, there are no 
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structures of the complex formed between a PSD-95/SAP97 PDZ domain and 5-
HT2a/c currently available in the PDB; these are the aims of the research discussed in 
this chapter. 
The results of the transformation, expression and purification of the PSD-95 and 
SAP97 PDZ1 & PDZ2 domains are summarised in this chapter. NMR spectroscopy 
was used to determine the individual residue chemical shift assignments of three of 
the four (
13
C,) 
15
N-isotopically labelled PDZ domains. NMR spectroscopy was also 
employed to determine if there was any binding observed between a particular PDZ 
domain and a C-terminal nonapeptide of the 5-HT2a or 5-HT2c receptors; the binding 
observed was then quantified using ITC. Finally, the NMR spectroscopy solution 
state structure of the complex formed between the PSD-95 PDZ1 domain and the C-
terminal peptide of 5-HT2c was determined. 
4.2 Purification of the PSD-95 and SAP97 PDZ1 & PDZ2 Domains 
The transformation, expression and purification of unlabelled and (
13
C,) 
15
N-
isotopically labelled PSD-95 and SAP97 PDZ1 & PDZ2 domains were carried out as 
detailed in [3.2.1.3], [3.2.2] and [3.2.3] respectively. 
The chromatograms produced from size exclusion chromatography, the final 
purification stage of the four different PDZ domains, can be seen as a chromatogram 
overlay (Figure 4.1a). The size exclusion column had been previously calibrated 
(Appendices A.2) and so, the respective PDZ domain elution volumes in the size 
exclusion chromatography indicate the oligomeric states of the four different PDZ 
domains. As an elution volume of ~ 220mL was determined to correspond to a 
molecular weight of ~10kDa, all four PDZ domains were deduced to be monomeric. 
Samples of each of the four PDZ domains obtained at the end of the protein 
purification process were analysed by SDS-PAGE gel electrophoresis to ensure their 
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purity (Figure 4.1b); the SDS-PAGE gel showed each of the four different PDZ 
domains to be pure.  
NMR spectroscopy was then utilised to ensure that the four PDZ domains were 
folded and then subsequently, in an attempt to determine the individual backbone 
residue chemical shift assignments of each individual PDZ domain.  
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Figure 4.1: The chromatograms obtained from size exclusion chromatography using a HiLoad 26/60 
Superdex 75 in 50mM Tris/HCl, 150mM NaCl, 2mM DTT buffer, pH 7.4; this was the final stage of 
the PDZ domain purification process. The size exclusion chromatograms for PSD-95 PDZ1 (pink), 
PSD-95 PDZ2 (green), SAP97 PDZ1 (blue) and SAP97 PDZ2 (red) are shown. The elution volume 
for each of the four PDZ domain chromatograms has been detailed; the column equilibration 
(Appendices, A.2) indicated that an elution volume of ~220mL corresponds to ~10kDa protein and 
thus, all four PDZ domains are shown to be within acceptable limit values for monomeric proteins. 
The corresponding SDS-PAGE gel (inset) of the obtained proteins shown that each final PDZ domain 
samples obtained was pure; 1 = marker, 2 = PSD-95 PDZ1, 3 = PSD-95 PDZ2, 4 = SAP97 PDZ1, 5 = 
SAP97 PDZ2. 
 
4.3 Characterisation of the PDZ Domains by NMR Spectroscopy 
Unlabelled and 
15
N-labelled PDZ domain samples were prepared as described in 
[3.3.1] and both 1-D 
1
H and 2-D 
1
H – 15N HSQC NMR spectroscopic experiments 
were performed. The resultant NMR spectra showed that all four PDZ domains were 
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definitely folded (Figure 4.2 – 4.6); this is shown by the well-defined and dispersed 
peaks present in the obtained NMR spectra for each PDZ individual domain. The 
assignment of the residue backbone NH chemical shifts present in the 
1
H – 15N 
HSQC spectra of the four different PDZ domains was then attempted. To do this, 
13
C, 
15
N-doubly labelled PDZ domain NMR samples were prepared [3.3.1 & 3.3.2], a 
suite of NMR spectroscopic experiments collected [3.5.1] and assigned using the 
methodology described in [3.5.2].  
This process resulted in the complete residue backbone NH assignments for PSD-95 
PDZ1, SAP97 PDZ1 & PDZ2 (Figures 4.3, 4.5 & 4.6 respectively). Unfortunately it 
was not possible to collect sufficient quality NMR spectra to facilitate a full 
assignment of the PSD-95 PDZ2; this was due to the limited stability of the protein. 
However, a limited assignment of the PSD-95 PDZ2 residue backbone NH chemical 
shifts was achieved by a combination of NMR spectroscopy and sequence 
comparison with PSD-95 PDZ1 (Figure 4.4).  
As the four PDZ domains were shown to be folded, monomeric and the backbone 
NH chemical shifts assigned, NMR spectroscopy was then utilised to determine if 
there were any observable interactions between the four individual PDZ domains and 
the different 5-HT2a/c nonapeptides; the residue assignments could be used to 
determine if any binding observed was specific or not. 
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Figure 4.2: The 1-D 
1
H NMR spectra of the PSD-95 and SAP97 PDZ1&2 domains acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3. a) 
PSD-95 PDZ1. b) PSD-95 PDZ2. c) SAP97 PDZ1. d) SAP97 PDZ2 (red, bottom). All four NMR spectra shown indicate that the four PDZ domains produced were folded as 
the peaks are well defined and there is evidence of peak dispersion around the extreme upfield methyl (0ppm) region.   
c) 
b) d) 
a) 
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Figure 4.3: The 2-D 
1
H – 15N HSQC spectrum of PSD-95 PDZ1 acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; the individual residue 
chemical shift assignments for the PSD-95 PDZ1 domain construct were completed using a suite of NMR experiments [3.5.1], on a prepared NMR sample [3.3.1 & 3.3.2] and 
then, following the assignment methodology described in [3.5.2] . The given spectrum shows that the PSD-95 PDZ1 domain is folded, as the peaks are well dispersed and that 
almost all of the peaks present were able to be definitively assigned.  
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Figure 4.4: The 2-D 
1
H – 15N HSQC spectrum of PSD-95 PDZ2 acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; the individual residue 
chemical shift assignments for the PSD-95 PDZ2 domain construct were attempted by collecting a suite of NMR experiments [3.5.1], on a prepared NMR sample [3.3.1 & 
3.3.2] and then, following the assignment methodology described in [3.5.2]. The given spectrum shows that the PSD-95 PDZ2 domain is folded, as the peaks are well 
dispersed; however, the PSD-95 PDZ2 NMR sample proved unsuitable for full NMR data collection, possibly due to aggregation and so, a complete backbone NH assignment 
was not possible. A partial assignment of the PSD-95 PDZ2 
1
H – 15N HSQC spectrum has been performed using the NMR data that was successfully obtained and sequence 
similarity comparison with the PSD-95 PDZ1 domain.   
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Figure 4.5: The 2-D 
1
H – 15N HSQC spectrum of SAP97 PDZ1 acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; the individual residue 
chemical shift assignments for the SAP97 PDZ1 domain construct were completed using a suite of NMR experiments [3.5.1], on a prepared NMR sample [3.3.1 & 3.3.2] and 
then, following the assignment methodology described in [3.5.2] . The given spectrum shows that the SAP97 PDZ1 domain is folded, as the peaks are well dispersed and that 
almost all of the peaks present were able to be definitively assigned.  
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Figure 4.6: The 2-D 
1
H – 15N HSQC spectrum of SAP97 PDZ2 acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; the individual residue 
chemical shift assignments for the SAP97 PDZ2 domain construct were completed using a suite of NMR experiments [3.5.1], on a prepared NMR sample [3.3.1 & 3.3.2] and 
then, following the assignment methodology described in [3.5.2]. The given spectrum shows that the SAP97 PDZ2 domain is folded, as the peaks are well dispersed and that 
almost all of the peaks present were able to be definitively assigned.  
 Biophysical Characterisation of PDZ Interactions Involving the 5-HT Receptor 2a and 2c Variants 
127 
 
4.4 PDZ Domain Binding Screening of 5-HT2x Receptors by NMR Spectroscopy 
4.4.1 General 
The sample preparation and experimental conditions employed in the binding 
screening of the 5-HT2a/c peptides to the four different PDZ domains, by NMR 
spectroscopy, are described in [3.3.1 & 3.3.4]. The nine residue C-terminal peptides 
of 5-HT2a (GVNEKVSCV) and 5-HT2c (VVSERISSV) were purchased from 
Innobiochips, France and GenicBio, China respectively.  
4.4.2 PDZ Domain-Mediated Interactions of 5-HT2a 
The binding of a 5-HT2a nonapeptide to the four different PDZ domains was 
investigated by NMR spectroscopy (Figures 4.7 – 4.10); this process indicated that 
the 5-HT2a nonapeptide bound to all four of the PDZ domains. This conclusion was 
made as a result of the large number and/or magnitude of the residue chemical shift 
perturbations observed in the 
1
H – 15N HSQC spectra in the presence of the peptide 
c.f. the free PDZ domain spectra. The binding of the 5-HT2a nonapeptide to each 
individual PDZ domain was determined to be specific as the residues perturbed in 
each experiment were those of the respective PDZ domain ligand binding region that 
showed perturbations i.e. GLGF motif, hydrophobic binding pocket, conserved His 
residue, βB – βC loop etc. 
4.4.3 PDZ Domain-Mediated Interactions of 5-HT2c 
The binding of the 5-HT2c nonapeptide to the four different PDZ domains was 
investigated by NMR spectroscopy (Figures 4.11 – 4.14); this process indicated that 
the 5-HT2c nonapeptide bound to all four of the PDZ domains with reasonable 
affinity. This conclusion was made as a result of the large number and/or magnitude 
of the residue chemical shift perturbations observed in the 
1
H – 15N HSQC spectra in 
the presence of the peptide c.f. the free PDZ domain spectra. The binding of the 5-
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HT2c nonapeptide to each individual PDZ domain was determined to be specific as it 
was the residues of the respective PDZ domain binding region that showed 
perturbations i.e. GLGF motif, hydrophobic binding pocket, conserved His residue, 
βB – βC loop etc. 
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Figure 4.7: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of PSD-95 PDZ1 in the free form (blue) and in the presence of 5-HT2a nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif, hydrophobic pocket and 
the conserved His have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo PSD-95 PDZ1 spectrum shift in the presence of 5-HT2a; 
this indicates that there is specific binding occurring between the PSD-95 PDZ1 domain and 5-HT2a nonapeptide and that this binding is of reasonable affinity. 
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Figure 4.8: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of PSD-95 PDZ2 in the free form (blue) and in the presence of 5-HT2a nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif and surrounding binding 
region have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo PSD-95 PDZ2 spectrum shift in the presence of 5-HT2a; this 
indicates that there is specific binding occurring between the PSD-95 PDZ2 domain and 5-HT2a nonapeptide and that this binding is of reasonable affinity. 
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Figure 4.9: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ1 in the free form (blue) and in the presence of 5-HT2a nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif, hydrophobic pocket and 
the conserved His have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo SAP97 PDZ1 spectrum shift in the presence of 5-HT2a; 
this indicates that there is specific binding occurring between the SAP97 PDZ1 domain and 5-HT2a nonapeptide and that this binding is of reasonable affinity. 
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Figure 4.10: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ2 in the free form (blue) and in the presence of 5-HT2a nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif, hydrophobic pocket and 
the conserved His have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo SAP97 PDZ2 spectrum shift in the presence of 5-HT2a; 
this indicates that there is specific binding occurring between the SAP97 PDZ2 domain and 5-HT2a nonapeptide and that this binding is of reasonable affinity.  
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Figure 4.11: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of PSD-95 PDZ1 in the free form (blue) and in the presence of 5-HT2c nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif, hydrophobic pocket and 
the conserved His have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo PSD-95 PDZ1 spectrum shift in the presence of 5-HT2c; 
this indicates that there is specific binding occurring between the PSD-95 PDZ1 domain and 5-HT2c nonapeptide and that this binding is of reasonable affinity. 
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Figure 4.12: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of PSD-95 PDZ2 in the free form (blue) and in the presence of 5-HT2c nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif and surrounding binding 
region have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo PSD-95 PDZ2 spectrum shift in the presence of 5-HT2c; this 
indicates that there is specific binding occurring between the PSD-95 PDZ2 domain and 5-HT2c nonapeptide and that this binding is of reasonable affinity. 
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Figure 4.13: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ1 in the free form (blue) and in the presence of 5-HT2c nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif, hydrophobic pocket and 
the conserved His have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo SAP97 PDZ1 spectrum shift in the presence of 5-HT2c; 
this indicates that there is specific binding occurring between the SAP97 PDZ1 domain and 5-HT2c nonapeptide and that this binding is of reasonable affinity. 
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Figure 4.14: A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ2 in the free form (blue) and in the presence of 5-HT2c nonapeptide (P:L = 1:10, red), 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; a number of the key peaks from residues in the GLGF motif, hydrophobic pocket and 
the conserved His have been labelled. It can be clearly seen that these peaks and many other peaks present in the apo SAP97 PDZ2 spectrum shift in the presence of 5-HT2c; 
this indicates that there is specific binding occurring between the SAP97 PDZ2 domain and 5-HT2c nonapeptide and that this binding is of reasonable affinity. 
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4.4.4 Discussion 
The binding screening utilising NMR spectroscopy showed that both the 5-HT2a and 
5-HT2c nonapeptides bound specifically to all four of the PDZ domains investigated. 
The screening indicated that regardless of the particular peptide or PDZ domain 
involved, the pattern and strength of perturbations shown in the subsequent spectra 
were reasonably similar. 
The binding of the 5-HT2a/c nonapeptides to the four different PDZ domains was 
determined to be specific as the residues perturbed from the respective free spectra 
upon binding, were those of the known PDZ domain binding regions. The residue 
chemical shift perturbations induced in the PSD-95 PDZ1 domain upon binding of 
the 5-HT2c nonapeptide were then quantified. This was achieved by performing an 
NMR titration, where the ligand concentration was varied [3.3.5]; related examples 
of this titration methodology are given in [6.3] and so, the resultant spectra will not 
be given here. The individual residue chemical shifts were tracked from P:L = 1:0 to 
1:10 (i.e. the ligand binding screening ratio) to allow the assignment of the 5-HT2c 
bound PSD-95 PDZ1 spectrum; the assigned NMR spectra of the PSD-95 PDZ1 – 5-
HT2c complex are given in [4.6.2] and so, will not be shown here. The difference in 
the individual residue chemical shifts between the nonapeptide free and the binding 
screening PSD-95 PDZ1 bound forms was then calculated [3.3.4] and plotted (Figure 
4.15). The histogram indicates that the residues most significantly perturbed in the 
PSD-95 PDZ1 domain upon binding of the 5-HT2c nonapeptide are those of the 
expected PDZ binding region and the surrounding flexible regions i.e. the GLGF 
motif (red), hydrophobic pocket (dark blue), conserved His (green) and the BB-BC 
loop (yellow); this definitively confirmed the binding was specific. 
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As the NMR binding experiments of 5-HT2a/c to the four different PDZ domains had 
shown that interactions were present in all experiments, ITC was then used to 
quantify the actual strength of the individual PDZ domain – 5-HT2a/c binding 
interactions. 
 
 
Figure 4.15: A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 
and bound to a C-terminal peptide of the 5-HT2c receptor (VVSERISSV, P:L = 1:10), using the 
equation       √((    )  (      ) ) where,    = Scaling Factor of 0.17. The different 
areas of the PSD-95 PDZ1 domain thought to be important in determining binding affinity indicated: 
GLGF motif (red), hydrophobic pocket (dark blue), conserved His (green) and βB-βC loop (yellow). 
The histogram shows that the 5-HT2c nonapeptide binds to the PSD-95 PDZ1 domain, as the number 
and strength of individual residue chemical shifts perturbed in PSD-95 PDZ1 is considerable. This 
binding can be defined as specific as those residues significantly perturbed are the residues of the 
PSD-95 PDZ1 domain binding region and the surrounding flexible regions i.e. the residues 
highlighted in the graph. 
 
4.5 Binding Affinity Determination by ITC 
4.5.1 General 
The experimental conditions and procedure employed in each of the ITC binding 
experiments conducted in this section are described in [3.4.1] and [3.4.2]. The 
nonapeptides utilised were the same as those described in [4.4] and the initial protein 
and peptide concentrations were kept constant throughout to avoid any concentration 
effects biasing one experiment over another. As discussed in [2.3], ITC allows the 
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determination of the thermodynamic parameters, ∆H and ∆S for a particular binding 
interaction; ∆H and ∆S. These thermodynamic parameters can be used to calculate 
the Gibbs free energy (∆G) for a particular interaction between two macromolecules 
(Equation 4.1), where a negative value indicates that non-covalent association is 
occurring. ∆G can then be used to determine the binding affinity of an interaction 
(Equation 4.2); hence, ITC is an extremely useful biophysical technique for 
determination and comparison of the interactions of 5-HT2a/c nonapeptides with the 
four different PDZ domains. 
           Equation [4.1] 
             Equation [4.2] 
4.5.2 Quantification of PDZ Domain Binding Strength of 5-HT2a 
The binding between the 5-HT2a nonapeptide and the four different PDZ domains 
was investigated using ITC; the individual isotherms can be seen (Figures 4.18 – 
4.21) and the resultant data obtained has been summarised together (Table 4.1 and 
Figure 4.16). 
The obtained data shows that the 5-HT2a nonapeptide bound to the SAP97 PDZ2 
domain most strongly of the four PDZ domains investigated, with the SAP97 PDZ1 
– 5-HT2a interaction being the weakest observed; analysis of the thermodynamic 
parameters obtained from the PDZ domain – 5-HT2a ITC binding experiments is 
discussed in [4.5.4].  
The ITC curve obtained for the PSD-95 PDZ1 – 5-HT2a interaction (Figure 4.18), 
can be described as a ‘shallow ITC curve,’ as it does not exactly resemble the 
‘typical ITC curve;’ this is due to the reasonably low affinity binding interaction 
being observed. The resultant errors in the binding parameters (KD, ∆H, ∆S and ∆G) 
obtained from ‘shallow ITC curves’ such as Figure 4.18 are typically slightly larger 
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than those obtained from ITC experiments that result in ‘perfect ITC curves;’ to 
improve this ‘shallow curve’ a higher concentration of both titrand and titrant could 
have been employed. However, it was a balance between achieving the best possible 
quality data and protein and/or ligand availability/solubility; as the PSD-95 PDZ1 – 
5-HT2a interaction was performed in triplicate and gave concordant results, it was 
decided that the detailed conditions were suitably sufficient to yield accurate data. 
Table 4.1: The different PDZ domains used in the 5-HT2a binding experiment by ITC and the 
respective binding parameters obtained. The errors in the binding parameters were calculated from a 
PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table. 
PDZ Domain KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
PSD-95 PDZ1 94.34 ± 
10.87 
-5.371 ± 0.200 0.238 ± 0.009 -5.133 ± 0.191 
PSD-95 PDZ2 30.03 ± 
3.46 
-9.617 ± 0.358 3.457 ± 0.128 -6.160 ± 0.229 
SAP97 PDZ1 112.11 ± 
12.92 
-5.269 ± 0.196 -0.123 ± 0.005 -5.392 ± 0.201 
SAP97 PDZ2 12.38 ± 
1.43 
-8.551 ± 0.318 1.857 ± 0.069 -6.694 ± 0.249 
 
 
 
Figure 4.16: The thermodynamic parameters (dH = ∆H (blue), -TdS = -T∆S (red) and dG = ∆G 
(green)) obtained from the binding interaction between the 5-HT2a nonapeptide and each of the four 
different PDZ domains. ∆H is the dominant thermodynamic parameter in ∆G determination and 
hence, binding affinity; this is because ∆H is a moderate to large negative value in each ITC binding 
experiment, with -T∆S being a small negative or positive value and so, contributes much less 
significantly to ∆G. 
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4.5.3 Quantification of PDZ Domain Binding Strength of 5-HT2c 
The binding between the 5-HT2c nonapeptide and the four different PDZ domains 
was investigated using ITC; the individual isotherms can be seen (Figures 4.22 – 
4.25) and the resultant data obtained has been summarised together (Table 4.2 and 
Figure 17).  
The obtained data shows that the 5-HT2c nonapeptide bound to the PSD-95 and 
SAP97 PDZ2 domains most strongly of the four PDZ domains investigated, with the 
SAP97 PDZ1 – 5-HT2c interaction being the weakest observed; analysis of the 
thermodynamic parameters obtained from the PDZ domain – 5-HT2c ITC binding 
experiments is located in [4.5.4]. 
Table 4.2: The different PDZ domains used in the 5-HT2c binding experiment by ITC and the 
respective binding parameters obtained. The errors in the binding parameters were calculated from a 
PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table.  
PDZ Domain KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
PSD-95 PDZ1 19.65 ± 
2.26 
-7.089 ± 0.264 0.668 ± 0.025 -6.421 ± 0.239 
PSD-95 PDZ2 10.01 ± 
1.15 
-8.121 ± 0.302 1.299 ± 0.048 -6.822 ± 0.254 
SAP97 PDZ1 43.86 ± 
5.05 
-6.687 ± 0.249 0.739 ± 0.027 -5.948 ± 0.221 
SAP97 PDZ2 10.49 ± 
1.21 
-9.64 ± 0.359 2.843 ± 0.106 -6.797 ± 0.253 
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Figure 4.17: The thermodynamic parameters (dH = ∆H (blue), -TdS = -T∆S (red) and dG = ∆G 
(green)) obtained from the binding interaction between the 5-HT2c nonapeptide and each of the four 
different PDZ domains. ∆H is the dominant thermodynamic parameter in ∆G determination and 
hence, binding affinity; this is because ∆H is a moderate to large negative value in each ITC binding 
experiment, with -T∆S being a small negative or positive value and so, contributes much less 
significantly to ∆G. 
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Figure 4.18: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM PSD-95 PDZ1 (cell) and 750µM 5-HT2a nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 94.34µM for 5-HT2a to the PSD-95 PDZ1 domain. 
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Figure 4.19: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM PSD-95 PDZ2 (cell) and 750µM 5-HT2a nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 30.03µM for 5-HT2a to the PSD-95 PDZ2 domain. 
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Figure 4.20: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ1 (cell) and 750µM 5-HT2a nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 112.11µM for 5-HT2a to the SAP97 PDZ1 domain. 
 
 
 
 
 
 
 
 
 
 Biophysical Characterisation of PDZ Interactions Involving the 5-HT Receptor 2a and 2c Variants 
146 
 
 
Figure 4.21: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM 5-HT2a nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 12.38µM for 5-HT2a to the SAP97 PDZ2 domain.  
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Figure 4.22: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM PSD-95 PDZ1 (cell) and 750µM 5-HT2c nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 19.65µM for 5-HT2c to the PSD-95 PDZ1 domain. 
 
 
 
 
 
 
 
 
 
 Biophysical Characterisation of PDZ Interactions Involving the 5-HT Receptor 2a and 2c Variants 
148 
 
 
Figure 4.23: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM PSD-95 PDZ2 (cell) and 750µM 5-HT2c nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 10.01µM for 5-HT2c to the PSD-95 PDZ2 domain. 
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Figure 4.24: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ1 (cell) and 750µM 5-HT2c nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 43.86µM for 5-HT2c to the SAP97 PDZ1 domain. 
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Figure 4.25: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM 5-HT2c nonapeptide (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 10.49µM for 5-HT2c to the SAP97 PDZ2 domain.  
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4.5.4 Comparison of 5-HT2a/c PDZ Domain Binding 
If the binding of the 5-HT2a and 5-HT2c to the four different PDZ domains is 
analysed there are a number of similarities. In all experiments, the enthalpy change 
upon PDZ domain binding of the nonapeptide was the dominant contribution to the 
binding affinity; this is evident because ∆H was a moderate to large negative value, 
whereas, -T∆S was a small positive or negative value and so, could be considered 
insignificant. As discussed in [2.3.4], ∆H is dependent on the strength and number of 
interactions formed/broken upon binding, whereas, -T∆S is a measure of the amount 
of water displaced from buried surfaces and loss of conformational entropy by the 
act of binding. This observation therefore corresponds well with previously reported 
PDZ domain-mediated interactions with peptides (Liu et al., 2007). The observation 
that both nonapeptides exhibited stronger binding to the PSD-95 and SAP97 PDZ2 
domains than the PDZ1 domains can be rationalised to the decrease in enthalpic 
change upon PDZ1 domain binding of the nonapeptides. However, this is a 
somewhat simplistic view of the binding interactions being observed and presumes 
that all the PDZ binding pockets are optimally hydrated. The vast number of residue 
chemical shift perturbations observed upon PDZ domain binding of the nonapeptides 
in the NMR binding screening experiments (Figures 4.7 – 4.14), indicates that there 
may be another important consideration to take into account; this is the change in 
entropic distribution of the particular PDZ domain from the unbound state to the 
peptide-bound state. It is possible that the PSD-95 and SAP97 PDZ2 domains are 
less affected by the change in internal dynamics upon binding of the nonapeptides 
than the PDZ1 domains and hence, account for the stronger nonapeptide binding 
observed for the PSD-95 and SAP97 PDZ2 domains c.f. PDZ1. It is possible to 
investigate if there was any change in rigidity/flexibility of the individual PDZ 
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domains upon nonapeptide binding, by utilising NMR spectroscopy relaxation 
experiments; however, this falls outside the scope of this particular investigation and 
thus, was will not be elaborated upon further. 
All four PDZ domains exhibited stronger binding with the 5-HT2c nonapeptide than 
the 5-HT2a nonapeptide; with PSD-95 PDZ1 there was as much as a 4.5-fold stronger 
binding affinity for 5-HT2c than 5-HT2a. This was again due to a decrease in 
enthalpic change upon binding of the 5-HT2a nonapeptide c.f. 5-HT2c; this finding 
was interesting as, by convention, the 0 and -2 residues of a PDZ domain ligand are 
considered the most important in facilitating PDZ domain binding. Given that both 
5-HT2a (GVNEKVSCV) and 5-HT2c (VVSERISSV) nonapeptides share the same 0 
and -2 residues (Val and Ser respectively), the results obtained in this section suggest 
that other residues of the 5-HT2x ligand are affecting the PDZ domain binding ability. 
This could be due to residues of 5-HT2a, such as Val6 or Cys8, forming more 
unfavourable steric or electrostatic interactions with the PDZ domains than the 
corresponding 5-HT2c residues of Ile6 or Ser8 
A more likely conclusion for the observed difference in PDZ domain binding ability 
between the 5-HT2a and 5-HT2c nonapeptides is that residues outside of the 
conventional four C-terminal sequence are important to PDZ domain binding 
affinity. The 5-HT2c (VVSERISSV) Arg5 or Ile6 residues may be able to form 
favourable hydrophobic or electrostatic interactions with residues of the PDZ 
domains more effectively than the 5-HT2a (GVNEKVSCV) Lys5 or Val6 residues; 
this will increase the PDZ domain binding ability of 5-HT2c c.f. 5-HT2a. 
As the binding between the 5-HT2a and 5-HT2c nonapeptides and the four different 
PDZ domains had been proven to be specific by NMR spectroscopy and quantified 
using ITC, the logical final step in the investigation into the interactions of the 5-
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HT2x receptors was to determine the structure of one of the PDZ – peptide 
complexes. The determination of the structure of the complex formed between a 
PDZ domain and a 5-HT2x receptor was believed to be an extremely important 
achievement as it would highlight the important interactions for PDZ binding; this 
knowledge would then be able to be used to guide drug design for future therapeutic 
applications. The chosen interaction was the PSD-95 PDZ1 – 5-HT2c complex as this 
had been shown to be physiologically relevant, there had been shown to be 
therapeutic requirements, there was no previously existing structure and ITC had 
shown that the affinity of the interaction would be suitable for structure 
determination. The chosen method for the structure determination process was 
solution state NMR spectroscopy, as this would give an atomic resolution PSD-95 
PDZ1 – 5-HT2c complex structure; attempts were made in parallel to produce a 
crystal structure of the complex by a colleague but these proved unsuccessful. 
4.6 PSD-95 PDZ1 – 5-HT2c NMR Solution State Structure Determination 
4.6.1 Overview 
An overview of the process implemented in the NMR solution state structure 
determination of the PSD-95 PDZ1 – 5-HT2c complex has been detailed (Figure 
4.26). The initial stage of the process was the preparation of an NMR sample of the 
PSD-95 PDZ1 – 5-HT2c complex [3.3.1 & 3.3.3] and collection of a suite of NMR 
experiments [3.5.1]. 
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Figure 4.26: An overview of the different stages of the process performed to determine the NMR 
solution state structure of the PSD-95 PDZ1 – 5-HT2c complex. The initial stages of the procedure 
were the preparation of the NMR sample [3.3.1 & 3.3.3], followed by the collection of the NMR 
experiments [3.5.1]. The backbone and side-chain atoms were assigned manually [3.5.2], with the 
observed NOE’s assigned in an automated manner using CYANA [3.5.3]. The resultant assignments 
were then utilised in an in vacuo structure calculation [3.5.4] and the subsequent structures produced 
analysed for any errors/erroneous assignments; with the necessary adjustments made manually and the 
in vacuo structure calculation performed again in an iterative process. When no errors remained 
following the in vacuo structure calculation, the top 20 structures obtained were then water-refined 
[3.5.4] to give the final PSD-95 PDZ1 – 5-HT2c NMR solution state structural ensemble. 
 
4.6.2 Assignment of NMR Spectra 
4.6.2.1 Bound Protein Backbone and Side-Chain Assignment 
The collected NMR spectra corresponding to the backbone and side-chain atoms of 
the PSD-95 PDZ1 domain in the 5-HT2c bound complex form were assigned as 
described in [3.5.2]. This process resulted in 97.3% backbone atom assignment and 
85.59% side-chain assignment to give an overall assignment value of 91.54%; the 
missing resonance assignments have been mapped onto the PSD-95 PDZ1 sequence 
Preparation of NMR sample 
Collection of a suite of NMR experiments 
Manual assignment of backbone/sidechain atoms 
Automated NOE assignment 
In vacuo structure calculation 
Water-refinement of top 20 structure ensemble 
FINAL ENSEMBLE/STRUCTURE 
Iterative analysis 
and manual 
intervention 
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(Figure 4.27). It can be seen that the vast majority of the residues with incomplete 
backbone or side-chain assignments are in highly flexible, surface exposed regions of 
the PDZ domain and/or are the extreme side-chain atoms of residues with long 
and/or flexible side-chains; the assignment of these type of protein residues is often 
problematic. The final assigned versions of the 2-D HSQC spectra are also shown 
(Figures 4.28 & 4.29). 
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Figure 4.27: The sequence of the PSD-95 PDZ1 domain present in the PSD-95 PDZ1 – 5-HT2c 
complex sample, with the secondary structure given above. Below the sequence, residues for which a 
full backbone (b) or side-chain (s) assignment has not been possible have been indicated; the majority 
of these residues are in highly flexible regions of the protein and/or have long flexible side-chains that 
make assignment more difficult.  
 
4.6.2.2 Bound Peptide Assignment 
4.6.2.2.1 Introduction 
In the free form, it was possible to definitively assign the Ser3 – Val9 residues of the 
5-HT2c nonapeptide (Figure 4.30). 
13
C, 
15
N-filtered NMR experiments were carried 
out on the PSD-95 PDZ1 – 5-HT2c complex sample so that the peptide could be 
assigned in the bound form; however, these NMR experiments indicated that the 
peptide was in intermediate-exchange between the unbound and bound complex 
forms (Figures 4.31 & 4.32). This phenomenon can be seen by analysing the overlaid 
αA 
αB 
βA βB 
βC βD 
βF 
βE 
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unbound (and bound 
13
C, 
15
N filtered-) 1-D 
1
H and 2-D TOCSY NMR spectra 
(Figures 4.31 & 4.32 respectively); there is an obvious reduction in the number, 
intensity and form of the peaks present in the bound complex spectra c.f. unbound 
spectra, which is indicative of an intermediate-exchange process occurring. Of 
particular importance is the NMR spectra overlays of the extreme upfield methyl 
region (Figure 4.31d), which corresponds to the three different Val Hγ and Ile residue 
Hδ. The figure shows how, in the bound form of 5-HT2c, one of the residue peaks is 
attenuated completely and the intensity and form of the peak of another is severely 
affected by intermediate-exchange. 
As the 5-HT2c nonapeptide was shown to be in intermediate-exchange between free 
and bound states, the process of definitively assigning the bound peptide was much 
more difficult; thus, only a few residues could be definitively assigned (Figures 
4.32b and d), with no peaks assigned for the Ile6 and Val9 residues. However, there 
were two peaks present in the filtered-TOCSY spectrum of the PSD-95 PDZ1 – 5-
HT2c complex filtered-TOCSY spectra that could have corresponded to either/or both 
of the residues (circled in red, Figure 32d). It was important to conclusively assign 
peaks corresponding to Ile6 and/or Val9 before the NOE assignment and structure 
calculation processes were initiated as they were believed to be important residues in 
the binding of 5-HT2c. It was also imperative that all assignments could be validated 
so the obtained complex structures were reliable and representative of the data. 
Therefore, an NMR titration of 
13
C, 
15
N PSD-95 PDZ1 into 5-HT2c was performed; 
the aim of this experiment set was to track each individual peak from the free 5-HT2c 
form to the bound complex form, in an attempt to conclusively assign peaks 
corresponding to Ile6 and/or Val9. 
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4.6.2.2.2 NMR Titration  
An initial NMR sample of free 5-HT2c nonapeptide (909µM) was prepared, with 1-D 
1
H, excitation sculpting (ES) and saturation transfer difference (STD) and 2-D 
NOESY and TOCSY NMR experiments carried out on the sample. A series of 1-D 
1
H, ES and STD, 
13
C, 
15
N-filtered-1-D 
1
H, 
13
C, 
15
N-filtered 2-D NOESY and 
TOCSY NMR experiments were then performed at different 5-HT2c : PSD-95 PDZ1 
ratios; this NMR titration series was achieved by adding an appropriate amount of 
13
C, 
15
N-labelled PSD-95 PDZ1 (1mM) to the sample to give the desired 
peptide:protein ratio. A range of different peptide:protein ratios were investigated so 
that individual peaks could be tracked from unbound to the bound complex positions 
(Table 4.3). 
Table 4.3: The concentrations of the 5-HT2c nonapeptide and 
13
C,
15
N-labelled PSD-95 PDZ1 present 
in the respective sample of the NMR titration series. 
[5-HT2c] (µM) [PSD-95 PDZ1] (µM) 5-HT2c : PSD-95 PDZ1 
909 / 1:0 
889 18 50:1 
851 43 20:1 
825 55 15:1 
800 80 10:1 
727 145 5:1 
667 267 2.5:1 
  
By performing the NMR titration and tracking the movement of each signal (Figure 
4.33), it was possible to definitively show that the peak in the bound TOCSY 
spectrum at 4 ppm (ω1), 2 ppm (ω2) (circled in red, Figure 4.33c) corresponded to 
the Val9 Hβ atom; in addition, several other atoms could be assigned and the 
previous assignments were validated (Figure 4.34). The confirmed assignments were 
then transferred onto the bound peptide (Figure 4.35) and complex NOESY spectra, 
in preparation for the subsequent automated NOESY assignment by CYANA process 
[4.6.2.3].  
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The NMR titration series also provided some useful information about the binding of 
the 5-HT2c nonapeptide to the PSD-95 PDZ1 domain, by analysis of the different 1-
D NMR experiments performed at each titration point (Figures 4.36 – 4.38). The 1H 
1-D spectra (Figure 4.36) show that there is evidence of free peptide signals at a ratio 
as low as peptide:protein = 2.5:1 (Figure 4.36a) and bound peptide signals can be 
observed up to peptide:protein = 15:1; this indicates the difficulty of intermediate-
exchange that can be encountered when trying to determine a PDZ domain – peptide 
complex structure. The ES experiments exhibit how the free peptide signals decrease 
(Figure 4.37a) and the bound peptide signals increase (Figure 4.37b), as the 
concentration of PSD-95 PDZ1 in the NMR sample increases. The STD experiments 
(Figure 4.38) indicated the different protein – peptide interactions that occur at the 
various L:P ratios; this experiment seems more susceptible to interference from 
protein signal than the ES experiment and so, only the free 5-HT2c (blue) and L:P = 
50:1 (red) spectra have been shown for clarity. Figure 4.38 shows a prominent peak 
in the L:P = 50:1 spectrum; the figure highlights that this peak corresponds to an 
intermolecular interaction and is not due to interference from protein signal by 
comparison with the unbound PSD-95 PDZ1 spectrum (black). However, the specific 
residue chemical group of the 5-HT2c nonapeptide that is responsible for the 
predominant interaction with PSD-95 PDZ1 can only be ambiguously assigned to 
either Ile6Hδ or Val9Hγ1/2 by comparison with the free and bound spectra of 5-HT2c 
(magenta and green respectively). 
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Figure 4.28: NMR spectra acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3. a) The 2-D 
1
H – 15N HSQC spectrum of the 
PSD-95 PDZ1 – 5-HT2c complex (P:L = 1:5); the individual protein residue corresponding to the backbone NH peak present in the spectrum has been labelled (90 out of 94 
possible, 95.7%). b) The 2-D 
1
H – 13C aliphatic HSQC spectrum of the PSD-95 PDZ1 – 5-HT2c complex (P:L = 1:5); with both positive (i.e. Thr Cα-Hα, blue) and negative 
(i.e. Thr Cβ-Hβ, red) levels shown every ‘X’ corresponds to a peak that has been assigned to an individual Carbon-bound Hx atom of PSD-95 PDZ1, the individual assignment 
has not shown on the spectrum for clarity, however. 
a) b) a) 
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Figure 4.29: NMR spectra acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 
0.1mM EDTA buffer, pH6.3. a) The 2-D 
1
H – 13C HβCβCγCδHδ HSQC spectrum of the PSD-95 PDZ1 
– 5-HT2c complex (P:L = 1:5); the individual Carbon-bound Hx atom responsible for the specific peak 
present in the spectrum has been labelled. b) The 2-D 
1
H – 13C aromatic TROSY spectrum of the 
PSD-95 PDZ1 – 5-HT2c complex (P:L = 1:5); the individual Carbon-bound Hx atom responsible for 
the specific peak present in the spectrum has been labelled. 
 
b) 
a) Aliphatic 
b) Aromatic 
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Figure 4.30: NMR spectra collected of free 5-HT2c nonapeptide (VVSERISSV) acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA 
buffer, pH6.3; it can be seen that all spectra show numerous, well-defined peaks. a) The 1-D 
1
H spectrum of free 5-HT2c. b) The aliphatic-amide region (ω1-ω2) region of the 
2-D TOCSY spectrum of free 5-HT2c (mixing time = 100ms); the peaks corresponding to Ser3 – Val9 have been indicated, it was not possible to locate any peaks 
corresponding to Val1 or Val2 due to exchange with the solvent water. c) The aliphatic-aliphatic region (ω1-ω2) of the 2-D TOCSY spectrum of free 5-HT2c; the peaks 
corresponding to Ser3 – Val9 have been indicated, it was not possible to definitively assign Val1 or Val2, although they could ambiguously identified as Val residues. 
E4 
b) 
R5 a) b) 
c) 
I6 S8 
E4 S7 S3 
S8 
I6 
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V9 
V1/2 
R5 
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Figure 4.31: A selection of different views of the 1-D 
1
H NMR spectrum of free 5-HT2c (blue) overlaid with the 1-D 
1
H spectrum of PSD-95 PDZ1 bound 5-HT2c (red) 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3. a) The full 
1
H spectra. b) The amide region. c) An expansion of a 
section of the aliphatic region. d) The Val Hγ/Ile Hδ region of the 
1
H spectra with the corresponding peaks in the respective spectra labelled in the spectrum colour; this 
indicates that the Ile6 and Val9 residues are in intermediate-exchange in the PSD-95 PDZ1 – 5-HT2c complex. It is clear that there are a lot fewer and less well-defined peaks 
present in the spectrum of bound 5-HT2c, due to intermediate-exchange between the free and bound 5-HT2c forms occurring. 
c) 
a) b) d) Val1/2Hγ1/2 Val9Hγ1/2 
Ile6Hδ 
Ile6Hδ 
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Figure 4.32: Expansions of the 
13
C, 
15
N-filtered 2-D TOCSY NMR spectra of free and PSD-95 PDZ1 bound 5-HT2c acquired at 298K, with a field strength of 600MHz, in 
20mM phosphate 0.1mM EDTA buffer, pH6.3.  a) The assigned aliphatic-amide region (ω1-ω2) of free 5-HT2c. b) The assigned aliphatic-amide (ω1-ω2) region of PSD-95 
PDZ1 bound 5-HT2c. c) The overlaid aliphatic-aliphatic (ω1-ω2) region of the free (blue) and PSD-95 PDZ1 bound (red) forms of 5-HT2c. d) The assigned aliphatic-aliphatic 
region (ω1-ω2) of PSD-95 PDZ1 bound 5-HT2c. In b) & d), the peaks that were able to be definitively or ambiguously assigned prior to the NMR titration have been indicated, 
with the two possible peaks that could have corresponded to Ile6/Val9 circled in red. It is clear that there are a lot fewer and less well-defined peaks present in the spectrum of 
bound 5-HT2c, this is due to intermediate-exchange between the free and bound 5-HT2c forms occurring. 
a) b) 
c) 
d) 
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S3 
E4 
S3 
E4 S7 S3 
S8 R5 
I6 
V9 
V1/2 
E4 
R5 
S7/8 
V1/2 
S3 
  
 
 
Biophysical Characterisation of PDZ Interactions Involving the 5-HT Receptor 2a and 2c Variants 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33: A selection of different regions of the overlaid 
13
C, 
15
N-filtered 2-D TOCSY spectra produced at the different 5-HT2c : PSD-95 PDZ1 ratios during the NMR 
titration series, acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3; a titration key is given on the right hand side. a) The 
aliphatic-amide region (ω1-ω2); at lower peptide:protein ratios there are more peaks observed, these correspond to exchange peaks between free and PSD-95 PDZ1 bound 
forms of 5-HT2c. b) The aliphatic-aliphatic region (ω1-ω2). c) An expanded view of the methyl region of the aliphatic-aliphatic (ω1-ω2) section of the spectrum highlighted 
by the dashed rectangle in b); the Val9 Hβ has been tracked from the free peptide form (dashed black arrow) and can be assigned to the peak at 2, 4ppm (circled in red), which 
is also shown in Figure 4.32d. 
5-HT2c:PDZ       Colour 
 
         1:0        Blue 
        50:1        Red 
        20:1        Green 
        10:1        Purple 
          5:1        Maroon 
       2.5:1        Magenta 
a) b) 
c) 
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Figure 4.34: The final assignment of the 2-D 
13
C, 
15
N-filtered TOCSY NMR spectrum of the 
13
C, 
15
N PSD-95 PDZ1 bound form of the 5-HT2c peptide acquired at 298K, with 
a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3; the definitive assignments of the peaks in this spectrum had been possible due to the tracking of 
the peaks from the free peptide form in the NMR titration series previously described. The peaks corresponding to Val1/2 individually, have been assigned to a single Val 
residue in the spectra shown here but the resultant peak file produced was adapted to introduce the desired ambiguity to ensure no bias or inaccuracies in the structure 
calculation; the same is also true for the Ser7/8 residues. 
a) b) 
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Figure 4.35: The final assignment of the 2-D 
13
C,
15
N-filtered NOESY NMR spectrum of the 
13
C, 
15
N PSD-95 PDZ1 bound form of the 5-HT2c peptide acquired at 298K, with 
a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3; the definitive assignments of the peaks in this spectrum had been possible due to the tracking of 
the peaks from the free peptide form in the NMR titration series previously described. The peaks corresponding to Val1/2 individually, have been assigned to a single Val 
residue in the spectra shown here but the resultant peak file produced was adapted to introduce the desired ambiguity to ensure no bias or inaccuracies in the structure 
calculation; the same is also true for the Ser7/8 residues. 
a) b) 
c) 
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Figure 4.36: The spectra produced by the 
13
C, 
15
N-filtered 1-D NMR experiments performed throughout the course of the NMR titration of 
13
C, 
15
N PSD-95 PDZ1 into the 5-
HT2c nonapeptide, acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3. a) An expansion of a section of the amide region; the 
peaks present in the spectrum of the free peptide lose definition and intensity as the P:L ratio increases, with free peptide signals still seen as low as L:P = 2.5:1. b) An 
expansion of a different section of the amide region; as the P:L ratio increases, the presence of bound 5-HT2c forms can be seen up to L:P = 15:1. This spectrum has been 
aligned with a selection of the titration TOCSY spectra to highlight that these peaks correspond to bound peaks in the TOCSY spectra. 
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Figure 4.37: The spectra produced by the 1-D excitation sculpting (ES) NMR experiment throughout the course of the titration of 
13
C, 
15
N PSD-95 PDZ1 into the 5-HT2c 
nonapeptide, acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3. a) An expansion of a section of the amide region; this 
shows how the peaks present in the spectrum of the free peptide lose definition and intensity as the P:L ratio increases. b) An expansion of a different section of the amide 
region; this shows that as the P:L ratio increases, the presence of bound 5-HT2c forms can be seen. This spectrum has been aligned with a selection of the titration TOCSY 
spectra to highlight that these peaks correspond to bound peaks in the TOCSY spectra. 
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Figure 4.38: A 1-D saturation transfer difference (STD) NMR experiment was performed at each concentration titration point in attempt to evaluate the mode of binding of 5-
HT2c to the PSD-95 PDZ1 domain, acquired at 298K, with a field strength of 600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3. The figure shows an overlay of the 
STD experiments of free 5-HT2c (blue) and 5-HT2c:PSD-95 PDZ1 = 50:1 (red); it can be seen that there is a peak at ~0.78ppm. Interference from protein signal cannot account 
for this peak after comparison with the 
1
H spectrum of the unbound PSD-95 PDZ1 (black) and the peak is due to the 5-HT2c residue side-chain group that shows the most 
prominent interaction with PSD-95 PDZ1.The peaks in this spectral region of both the free (magenta) and PSD-95 PDZ1 bound (green) 5-HT2c forms have been assigned 
(un)ambiguously but do not aid in the unambiguous assignment of the peak in the 50:1 (L:P) STD spectrum. Thus, it can be concluded that the 5-HT2c residue chemical group 
participating in the most prominent intermolecular interaction with PSD-95 PDZ1 is either Ile6Hδ or Val9Hγ1/2. 
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ω1 (ppm) 
Key: 
Blue = Free 5-HT2c STD 
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4.6.2.3 NOESY Assignment 
The assignment of the respective 3-D NOESY spectra [Table 3.5, 3.5.1] of the PSD-
95 PDZ1 – 5-HT2c complex was carried out in an automated manner using the 
CYANA programme as described in [3.5.3]; the results of the process are detailed 
(Table 4.4). The final cycle statistics of the automated NOE assignment process were 
deemed acceptable due to comparison with the documented validation criteria in the 
CYANA manual: 
 There were nearly 1600 NOE distance restraints assigned; this represented on 
average over 16 NOE restraints per residue which is a reasonably large number of 
restraints and thus, should enable an accurate structure to be calculated. 
 The backbone and heavy atom RMSD were below 0.5Å and 1Å respectively; which 
suggests that the NOE’s assigned have produced structures with convergent structure 
and so, it is possible to have more confidence that the assignments are correct. 
 The average target function value (ATFV) was a reasonably low value (11); as 
discussed in [3.5.3], this value should be as close to zero as possible but as a 50xGly 
linker was used to connect the protein and peptide chains, achieving an ATFV of 
lower than ~20 may, in this instance, be considered a desirable result.  
Table 4.4: The statistics obtained from the different cycles of the CYANA programme during the 
automated NOE assignment process for the PSD-95 PDZ1 –  5-HT2c complex spectra. 
Cycle 1 2 3 4 5 6 7 Final 
Peaks:         
            Selected 2642 2642 2642 2642 2642 2642 2642  
            Assigned 2505 2517 2478 2491 2468 2446 2432  
            Unassigned 137 125 164 151 174 196 210  
Upper Distance Limits:         
     Total 1698 1615 1548 1538 1491 1495 1495 1581 
     Short Range ((i-j) = 1) 1021 937 884 854 808 790 731 778 
     Medium Range (1< (i-j) < 5) 516 397 230 233 227 212 239 250 
     Long Range ((i-j) > 5) 161 281 434 451 456 442 525 553 
     Ave Assignment / Constraint 4.61 2.43 1.53 1.49 1.39 1.32 1.00 1.00 
Average Target Function Value 72.10 38.22 77.23 21.59 17.87 14.79 10.71 11.01 
Average RMSD to mean 
(residues 20 – 80): 
        
            Backbone 1.82 1.27 0.52 0.55 0.46 0.52 0.52 0.45 
            Heavy Atom 2.28 1.78 1.04 1.04 0.99 1.01 1.00 0.95 
  
a) 
1
H 
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The NOE assignments obtained from the automated assignment process using 
CYANA were then converted into a CNS suitable format [3.5.3], in preparation for 
use in structure calculation using CNS. 
4.6.3 Structure Calculation 
4.6.3.1 In Vacuo 
The initial in vacuo structure calculation of the PSD-95 PDZ1 – 5-HT2c complex was 
conducted as detailed in [3.5.4]; the statistical details of the 20 lowest energy 
complex structures obtained from the in vacuo structure calculation process were 
analysed (Table 4.5). The 20 lowest energy structures did not violate any NOE 
restraints over 0.5Å; this was a good indication that the NOE’s assigned were non-
contradictory. The structures also had comparable overall energy values, which 
suggests that they were thermodynamically and hence, structurally similar to each 
other. 
Table 4.5: The relevant statistics of the 20 lowest energy PSD-95 PDZ1 – 5-HT2c complex ensemble 
obtained from the in vacuo structure calculation using CNS; the standard deviation from the average 
values of the 20 structure ensemble have been indicated by a ± value. 
NOE 
Violations 
Bond 
Energy 
Angle 
Energy 
Improper 
Energy 
Van der 
Waals
 
Energy 
NOE 
Energy 
Dihedral 
Energy 
Overall 
Energy 
0 
3.70 ± 
0.33 
40.51 ± 
3.23 
4.84 ± 
0.82 
69.58  
± 3.66  
52.26 ± 
4.48 
490.10 ± 
4.20 
673.50 
± 9.48 
  
To give a more accurate and therefore, physiologically relevant NMR solution state 
structure of the PSD-95 PDZ1 – 5-HT2c complex, the 20 lowest energy structures 
from the in vacuo structure calculation were subjected to an explicit water-
refinement protocol in CNS. 
4.6.3.2 Water-Refinement 
The refinement of the top 20 PSD-95 PDZ1 – 5-HT2c complex structures from the in 
vacuo structure calculation [4.6.3.1], in the presence of water, was performed using 
the procedure described in [3.5.4]. The relevant statistics for the structures obtained 
from the water-refinement protocol are given (Table 4.6), the structures had 
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comparable overall energy values, which again suggested that they were 
thermodynamically and hence, structurally similar to each other. The ensemble 
showed a small number of NOE restraint violations above the 0.5Å threshold, after 
the water refinement process (average of 2.45 NOE violations per structure); it was 
not possible to achieve a water-refined ensemble of the PSD-95 PDZ1 – 5-HT2c 
complex with no NOE violations over the 0.5Å threshold. However, as those NOE 
violations observed were mostly small (less 0.7Å) and there were no consistent 
distance restraint violations in the ensemble, it was decided that this ensemble was 
sufficient to determine the representative structure of the PSD-95 PDZ1 – 5-HT2c 
complex from. 
Table 4.6: The relevant average value statistics of the top 20 lowest energy PSD-95 PDZ1 – 5-HT2c 
complex ensemble obtained from the water refinement in CNS of the in vacuo structure calculation; 
the standard deviation from the average values of the 20 structure ensemble have been indicated by a 
± value. 
NOE 
Violations 
Bond 
Energy 
Angle 
Energy 
Improper 
Energy 
Van der 
Waals
 
Energy 
NOE 
Energy 
Dihedral 
Energy 
Overall 
Energy 
2.45 ± 
1.10 
1139.11 
± 13.63 
1070.04 
± 51.68 
141.85 ± 
13.52 
2541.17  
± 23.22 
10.08 ± 
2.77 
517.89 ± 
6.46 
5441.91 
± 84.77 
 
4.6.4 Characterisation and Validation of Water-Refined NMR Solution State 
Structure of the PSD-95 PDZ1 – 5-HT2c Complex 
The ensemble of the PSD-95 PDZ1 – 5-HT2c complex obtained from the NMR 
solution state structure determination process was characterised and validated using a 
number of different NMR structure analysis methodologies. These included the 
structure identification (Stride) web interface (Heinig and Frishman, 2004), 
PDBsum (http://www.ebi.ac.uk/pdbsum/), MultiProt (Shatsky et al., 2004), 
MOLMOL (Koradi et al., 1996) and the interactive common interface for NMR 
structure generation iCING (http://nmr.cmbi.ru.nl/cing/iCing.html) (Table 4.7). 
Stride showed that the ensemble of 20 complex structures exhibited the desired 
secondary structure of the PSD-95 PDZ1 domain, with six β-strands and two α-
helices present in the bound complex form (Figures 4.36 & 4.37). MultiProt and 
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MOLMOL were used in tandem to determine the backbone and heavy atom root 
mean square deviation (RMSD) of the individual components and the overall PSD-
95 PDZ1 – 5-HT2c complex structure ensemble (Table 4.7): PSD-95 PDZ1 (residues 
5 – 14 & 18 - 96, RMSD = 0.401Å and 1.181Å), 5-HT2c (residues 4 – 9, RMSD = 
0.348Å and 1.277Å) and PSD-95 – 5-HT2c complex (RMSD = 0.439Å and 1.226Å). 
The RMSD values obtained for the ensemble suggests that the techniques used in the 
NOE assignment and structure calculation process were sufficient to result in 
consistent structures of the PSD-95 PDZ1 – 5-HT2c complex.  
iCING carried out a plethora of NMR structure validation processes including 
Ramachandran analysis on the complex structure ensemble (Table 4.7 & 
Appendices, A.9a) and indicated that over 80% of the residues of the ensemble are in 
favoured regions (80.4%), with less than 2% of residues in disallowed regions 
(1.6%). The majority of the 1.6% of residues of the 20 structures in disallowed 
regions corresponded to Leu19 and Asn65, which are both residues in highly flexible 
regions of the PSD-95 PDZ1 domain and so, could be forming non-favoured 
orientations as a result. Although these values are not as optimal as desired i.e. ideal 
values being >90% and <1% for residues in favoured and disallowed regions 
respectively, they compare well with the Ramachandran statistics of the only other 
ligand-bound PSD-95 PDZ1  bound NMR solution state structure in the protein 
database (PDB ID = 2KA9 (Wang et al., 2009), favoured = 70.2%, additionally 
allowed = 25.1%, generously allowed = 3.4% and disallowed 1.3%); Leu19 and 
Asn65 were again found to be prominent disallowed residues in this NMR solution 
state structure ensemble indicating that these residues are endemic of unfavourable 
orinetations. The crystal structure of the tandem PSD-95 PDZ1 & PDZ2 domain 
(PDB ID = 3GSL), also shows 2.6% of residues in disallowed regions. This 
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information collated suggests that the less than optimal Ramachandran statistics 
obtained for the PSD-95 PDZ1 – 5-HT2c complex ensemble could be due to the 
inherent differences in the bound structure of the PSD-95 PDZ1 domain, than that of 
those structures used as references in the Ramachandran analysis procedures. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36: The secondary structure of PSD-95 PDZ1 – 5-HT2c complex as predicted by: a) Stride 
(Heinig and Frishman, 2004) with a legend that details the different secondary structure icons given, 
b) PDBsum (http://www.ebi.ac.uk/pdbsum/) where β-strands are indicated by pink arrows, α-helices 
indicated by red cylinders and random coil regions denoted by blue connecting lines. The N and C 
termini have been labelled, with the numbers inside the secondary structure elements denoting the 
residue range for the particular feture. Both secondary structure prediction methodologies determine 
that the bound complex form of PSD-95 PDZ1 has the standard PDZ domain secondary structure with 
six β-strands and two α-helices. However, both Stride and PDBsum did not determine that the bound 
5-HT2c nonapeptide had any notable secondary structure. 
 
 
 
 
 
 
 
a) 
b) 
αB 
αA 
βA                        βC 
  βD 
  βF 
βE          βB 
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Table 4.7: Summary of the structure calculation statistics and the relevant statistics for the resultant 
water-refined ensemble of 20 NMR solution state structures of the PSD-95 PDZ1 – 5-HT2c complex. 
  
Number of Structures 20 
  
NOE Distance Restraints  
        Total 1581 
        Short Range ((i-j) = 1) 778 
        Medium Range (1< (i-j) < 5) 250 
        Long Range ((i-j) > 5) 553 
        Intermolecular 52 
        Hydrogen Bonds 20 
  
Root Mean Square Deviation (RMSD, Å):  
        Overall Complex Backbone 0.439 
        Overall Complex Heavy atom 1.226 
        PSD-95 PDZ1 (5 – 14, 18 – 96)a Backbone 0.401 
        PSD-95 PDZ1 (5 – 14, 18 – 96)a Heavy Atom 1.181 
        5-HT2c (4 – 9)
a
 Backbone 0.396 
        5-HT2c (4 – 9)
a
 Heavy Atom 1.277 
  
Ramachandran Assessment
b 
(%):  
     Most Favoured 80.4 
     Additionally Allowed  12.8 
     Generously Allowed 5.2 
     Disallowed 1.6 
  
Buried Surface Area (BSA, Å
2
) 628 
a
 Residues 5-14 and 18-96 of PSD-95 PDZ1 and 4-9 of 5-HT2c were defined as structured regions of 
the respective components of the complex from the NOE’s observed using MultiProt (Shatsky et al., 
2004). 
b
 Determined by using the PROCHECK (Laskowski et al., 1993) analysis function in iCING 
(http://nmr.cmbi.ru.nl/cing/iCing.html) to check structure viability. 
 
The 20 water-refined complex structures were used to determine a representative 
NMR solution state structure of the PSD-95 PDZ1 – 5-HT2c complex; this was done 
by creating an average co-ordinate structure for the ensemble using MOLMOL and 
selecting the PSD-95 PDZ1 – 5-HT2c water-refined complex structure with the 
closest heavy atom RMSD to this average structure i.e. a closest-to-mean structure 
(Figures 4.38A & 4.39). The representative NMR solution state structure of the PSD-
95 PDZ1 – 5-HT2c complex shows that 5-HT2c binds to PSD-95 PDZ1 in the classic 
PDZ domain ligand manner, in the hydrophobic pocket and extended groove 
between the βB strand and the αB helix. Both Stride and iCING were not able to 
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ascertain that any secondary structure was present in the 5-HT2c nonapeptide when 
bound to PSD-95 PDZ1. This was not unexpected as it reflects the difficulties 
encountered in the peptide assignment process previously described and hence, 
demonstrates that the determined structure is fully representative of the data 
obtained. The use of a 
13
C, 
15
N-labelled 5-HT2c peptide was considered and may 
have facilitated the determination of dihedral constraints to restrain the bound 
peptide further; however, there were obvious problems such as cost to acquire or 
cost/difficulty of recombinant production and time constraints. 
Detailed analysis of the protein – peptide interaction interface of the representative 
PSD-95 PDZ1 – 5-HT2c complex structure was performed utilising NACCESS 
(http://www.bioinf.manchester.ac.uk/naccess/), PDBsum, the protein interactions 
calculator (PIC, (Tina et al., 2007)) and PDB ePISA (http://www.ebi.ac.uk/msd-
srv/prot_int/cgi-bin/piserver). Analysis of the interaction interface shows that 21 
residues of PSD-95 PDZ1 (21.2%) and all 9 residues of the 5-HT2c peptide (100%) 
participate in intermolecular interactions in the complex. The buried surface area 
(BSA, Å
2
) of the PSD-95 PDZ1 and 5-HT2c interaction interfaces are 492.8 and 
685.9Å
2
 respectively, which indicates that the interactions formed upon PSD-95 
PDZ1 binding of 5-HT2c occur over a relatively large area of the protein (6.4%). It 
was interesting to observed that Ramachandran analysis of the representative 
structure on its own showed 82% of residues were in favoured regions, 12.4% of 
residues in additionally regions, 5.6% in generously allowed regions and 0 residues 
in unfavoured regions; this suggests that the representative structure is an appropriate 
representation of the data (Appendices, A.9b). 
The representative structure highlights the presence of a number of important 
intermolecular interactions which enable binding, stabilise the complex and account 
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for the moderate micromolar binding affinity. The subsequent described interactions 
of the Arg5 → Val9 residues of the 5-HT2c nonapeptide were probed across the 20 
complex structures and were found to be regular features in at least 90% of the 
ensemble.  
The Ile6 and Val9 residues of the 5-HT2c peptide are over 90% buried in the 
complex, forming hydrophobic interactions with the surrounding residues. The 5-
HT2c C-terminal Val9 side-chain forms hydrophobic interactions with the side-chains 
of residues that constitute the hydrophobic pocket of the PSD-95 PDZ1 domain 
binding region i.e. Leu19, Phe21, Val78 and Leu81 (Figure 4.39b); with Ile6 residue 
interacting with the side-chains of the residues in the βB strand i.e. Ser22 and Ala24 
(Figure 4.39c). These hydrophobic interactions of Val9 and Ile6 are most likely the 
reason why the corresponding bound peaks were so difficult to detect in NMR 
experiments. The representative structure indicates the formation of the expected 
hydrogen bond between the 5-HT2c C-terminal Val9 carboxyl group and PSD-95 
PDZ1 Phe21 carbonyl in the obtained structure (Figure 4.39a). 
The 5-HT2c Ser8 residue is over 50% buried in the determined complex structure, 
interacting with the Phe21, Ser22, Ile23 and Val78 surrounding residues of the 
hydrophobic pocket (Figure 4.38b). As PSD-95 PDZ1 is a class I PDZ domain, it 
was expected that there would be evidence for a hydrogen bond formed between the 
PSD-95 PDZ1 His74 residue and the 5-HT2c Ser7 (i.e. -2) residue; however, this was 
not observed in the representative structure nor any member of the ensemble, with 
the distance between the two atoms measuring between 5Å and 8Å across the 
ensemble. This is not surprising however, as all the previous examples of class I PDZ 
domain – ligand NMR solution state structures, where the ligand contains a Ser (-2) 
residue (PDB ID’s = 2KA9 (Wang et al., 2009), 2PDZ (Schultz et al., 1998) and 
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2K2O) do not show this proposed hydrogen bond either. There are also examples of 
PDZ domain – peptide NMR solution state structures where the peptide contains a 
Thr (-2) and there is no evidence of an intermolecular hydrogen bond with the PDZ 
conserved His residue (PDB ID = 2OQS, (Liu et al., 2007)). This suggests that this 
electrostatic interaction between class I PDZ domains and the -2 residue of PDZ 
ligands in solution is more transient than previously thought and so is more difficult 
to model in NMR solution state structures than it is in compactly packed proteins in a 
crystal lattice. This over representation of an interaction by a crystal structure that is 
not observed in solution should serve as a cautionary note for future research.  
The Arg5 residue side-chain methylene groups were found to interact with the PSD-
95 PDZ1 His74 side-chain imidazole ring, with the Arg5 side-chain NηH2 groups 
forming a hydrogen bond with the Asn29 amide carbonyl (Figures 4.38b & 4.39d); 
the importance of Arg5 (-5) interactions in improving binding affinity has been 
alluded to previously in the literature (Zhang et al., 2007).  
The four N-terminal residues of the 5-HT2c peptide (Val1 → Glu4) exhibit a greater 
degree of flexibilty in their bound conformation and so, display an array of different 
minor interactions with the residues of the βB – βC loop across the ensemble of 
structures; this was to be expected as this region of the peptide was less constrained 
by intermolecular distance restraints. In the representative structure, the N-terminal 
residues show interactions with Pro30, His31 and Ile32 residues and so, this indicates 
the importance of residues further adjacent to the C-terminus to PSD-95 PDZ1 
domain binding; rather than just the accepted canonical C-terminal sequence of X-
S/T-X-Ω for class I PDZ domains only; this extended binding motif is investigated 
further in Chapter 5.  
The representative structure/ensemble of structures of the PSD-95 PDZ1 – 5-HT2c 
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complex could have important future uses in PDZ domain/PDZ domain-mediated 
interaction inhibition research and will be deposited into the PDB in the near future, 
if proven to be of sufficient quality. Furthermore, the over-reliance on crystal 
structures and their more rigid conformations in this case has led to what could be a 
mistaken belief that the PDZ His – PDZ ligand S/T hydrogen bond interaction is 
conserved in solution. 
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Figure 4.37: The final 20 water-refined NMR solution state structure ensemble of the PSD-95 PDZ1 – 5-HT2c complex obtained from the structure calculation process with 
both PSD-95 PDZ1 and 5-HT2c: a) in the cartoon representation, b) backbone atoms represented as sticks. The 20 aligned complex structures all show the expected secondary 
structure of the 5-HT2c bound form of the PSD-95 PDZ1 domain of six β-strands and two α-helices, with high structural similarity (Overall complex backbone and heavy atom 
RMSD = 0.439Å and 1.226Å respectively), with only the highly flexible regions of PSD-95 PDZ1 i.e. N/C termini and GLGF motif showing any slight structural deviation 
(PSD-95 PDZ1 backbone and heavy atom RMSD = 0.401Å and 1.181Å respectively); there is little difference in the bound conformation of the 5-HT2c peptide across the 
ensemble but no inherent secondary structure was identifed by Stride (5-HT2c nonapeptide backbone and heavy atom RMSD = 0.348Å and 1.277Å respectively).  
a) b) 
b) a) 
N-terminus 
C-terminus 
5-HT2c 
GLGF Motif 
αB βB 
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Figure 4.38: a) The representative structure of the PSD-95 PDZ1 – 5-HT2c complex determined by NMR solution state spectroscopy, where PSD-95 PDZ1 is shown as a 
surface representation (grey) with the 5-HT2c nonapeptide represented as sticks; the representative structure was obtained by creating an average co-ordinate structure of the 
20 water-refined structure ensemble and selecting the ensemble structure with the lowest heavy atom RMSD to the average structure i.e. it is a closest to mean structure. The 
representative structure shows that 5-HT2c binds to PSD-95 PDZ1 in the hydrophobic pocket and extended binding groove between the βB-strand and αB-helix i.e. the 
classical manner. b) A LigPlot representation created using PDBsum (http://www.ebi.ac.uk/pdbsum/) showing most of the important intermolecular interactions occurring in 
the representative structure of the PSD-95 PDZ1 – 5-HT2c complex, such as hydrophobic interactions of Val9 with Leu19, Phe21 and Val78. The presence of interactions of 
ligand residues further away from the C-terminus i.e. Ile6 →Val1, suggests that residues further up from the C-terminus than the conventional X-S/T-X-Ω of a PDZ ligand 
may be important in PSD-95 PDZ1 binding. 
b) a) 
αB βB 
Val9 
Val1 
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Figure 4.39: Expansions of different keyareas of the interaction interface in the representative structure of the PSD-95 PDZ1 – 5-HT2c complex, with the PSD-95 PDZ1 
domain in cartoon representation (grey) with the residues involved in intermolecular interactions and the 5-HT2c nonapeptide represented as sticks. All non-polar protons have 
been removed for clarity, except those involved in the intermolecular interactions; interactions have been indicated with yellow dashed lines, with hydrogen bonds 
differentiated from hydrophobic interactions by the addition of distance values (Å). a) The hydrogen bond formed between the C-terminal Val9 carboxyl group of 5-HT2c and 
the backbone carbonyl of Phe21 of PSD-95 PDZ1 (orange). b) The 5-HT2c Val9 interacts with residues of the PSD-95 PDZ1 hydrophobic pocket (cyan); these residues 
include Leu19, Phe21, Val78 and Leu81. c) The 5-HT2c Ile6 residue with the Ser22 and Ala24 residues of the PSD-95 PDZ1 βB-strand (light pink). d) The 5-HT2c Arg5 
interacts with the His74 and Asn29 side-chains of PSD-95 PDZ1 (magenta). 
a) b) 
c) d) 
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4.7 Conclusion 
Through a process that encompassed protein expression, purification, NMR 
spectroscopy and ITC, the binding of 5-HT2a and 5-HT2c nonapeptides to the 
PDZ1&2 domains of PSD-95 and SAP97 were investigated in detail. The PDZ 
binding affinity of 5-HT2c was found to be stronger than that of 5-HT2a for each PDZ 
domain, even though they share the same 0 and -2 residues; this suggests the 
importance in other residues of the PDZ ligand in determining PDZ domain binding 
affinity. 
The most important aspect of the research detailed in this chapter is the 
determination of the NMR solution state structure ensemble of the PSD-95 PDZ1 – 
5-HT2c complex; this is a structure that has not been solved previously and is 
currently in the process of deposition into the protein databank (PDB). The 
representative structure showed that all the 5-HT2c nonapeptide residues exhibited 
interactions with residues of the PSD-95 PDZ1 domain; this corroborated the finding 
by ITC that PDZ ligand residues other than the 0 and -2 residues form important 
interactions with the PSD-95 PDZ1 domain and contribute to binding affinity. There 
are few previous examples of PDZ domain – peptide complex structures determined 
by NMR solution state spectroscopy, only 39 out of a total of 367 PDZ domain/PDZ 
domain complex structures in the PDB. This comparison highlights that other 
researchers may have experienced similar problems to those described in this chapter 
i.e. ligand residues being in intermediate-exchange between unbound and bound 
forms. This assignment difficulty was overcome by performing an NMR titration 
series of doubly-labelled PSD-95 PDZ1 into free 5-HT2c; the titration series also 
helped to further elucidate the PSD-95 PDZ1 binding mode of 5-HT2c via ES and 
STD NMR experiments.  
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By close analysis of the structure of the determined PSD-95 PDZ1 – 5-HT2c 
complex, it is possible to determine the key interactions required for developing 
potent and selective PSD-95 PDZ1 binders/inhibitors. Therefore, it is hoped that the 
NMR solution state ensemble of the PSD-95 PDZ1 – 5-HT2c complex provides 
valuable insight and direction for not just future PSD-95 PDZ1 – 5-HT2c inhibition 
research but for PSD-95 PDZ1-mediated interaction and PSD-95 PDZ1 domain 
inhibition research in general. 
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5. THE BIOPHYSICAL INVESTIGATION INTO THE INTERACTION 
BETWEEN THE SAP97 PDZ2 DOMAIN AND THE HUMAN 
PAPILLOMAVIRUS TYPE 16/18 E6 PROTEINS 
5.1 Introduction 
As discussed in [1.5.3.2], the SAP97 PDZ domains are known to interact with the 
human papillomavirus (HPV) E6 oncoprotein produced by ‘high-risk’ HPV types, 
such as HPV16 and HPV18 (Lee et al., 1997); this interaction occurs via PDZ 
domain binding motif at the C-terminus of the HPV16/18 E6 proteins (Chi et al., 
2009). This PDZ domain-mediated interaction causes SAP97 to be targeted for 
degradation and leads to p53-independent HPV E6-induced pathogenesis (Kiyono et 
al., 1997, Mantovani and Banks, 2003, Latorre et al., 2005, Zhang et al., 2007). It has 
therefore been concluded that the PDZ domain-mediated interaction between SAP97 
and the HPV16/18 E6 oncoproteins is a viable research/therapeutic target.   
The binding affinity of the SAP97 PDZ2 - HPV16/18 E6 oncoproteins interaction 
has been previously determined using N-acetylated hexaresidue C-terminal peptides 
of the HPV16 (Ac-RRETQL) and HPV18 (Ac-RRETQV) E6 oncoproteins in ITC 
experiments (SAP97 PDZ2 – HPV16/18 E6 KD = 1.33µM and 6.49µM respectively) 
(Liu et al., 2007). The solution-state NMR and crystal structures of SAP97 PDZ2 in 
complex with a C-terminal peptide of the HPV18 E6 peptide have also been 
determined (Liu et al., 2007, Zhang et al., 2007); the structures obtained showed the 
presence of important interactions between the SAP97 PDZ2 domain and residues of 
the HPV18 E6 peptide further away from the C-terminus than was previously 
thought important. This observation was also confirmed when recombinant full-
length HPV16 and HPV16L151V mutant (a mimic of HPV18) E6 protein was 
produced and its binding to the three individual SAP97 PDZ domains quantified by 
 Investigation into the Interaction Between the SAP97 PDZ2 Domain and the HPV E6 Proteins 
187 
 
ITC (Chi et al., 2011); the determined binding affinity to SAP97 PDZ2 was higher 
than that given by the hexaresidue peptides (SAP97 PDZ2 – HPV16L151V E6 KD = 
0.34µM). 
The previous research into the interaction between the SAP97 PDZ domains and the 
HPV E6 oncoproteins has given useful information about the interaction, although 
the main factors that contribute to binding affinities have not been investigated in a 
systematic manner. There are a number of factors that are considered to contribute to 
the binding of the SAP97 PDZ – HPV E6 interaction, yet these have not been 
investigated in detail to determine the relative importance of each to the overall 
binding affinity (Figure 5.1). The contributing factors to binding are: 
 The hydrogen bond interaction between the carboxyl group of the C-terminal 
amino acid and the amide backbone of the GLGF motif (Figure 5.1, red). 
 The hydrophobic interaction between the side-chain of the C-terminal ligand 
residue (0) and the residues that form the hydrophobic pocket of the SAP97 
PDZ domain (Figure 5.1a, blue). 
 The hydrogen bond between the S/T (-2) ligand residue and the conserved 
His residue in the class I PDZ domains of SAP97 (Figure 5.1a, green). 
 The interaction between residues further away from the C-terminus of the 
ligand than the conventional four C-terminal residues and the binding region 
of the SAP97 PDZ domains (Figure 5.1a, yellow). 
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Figure 5.1: a) The crystal structure of the SAP97 PDZ2 domain in complex with a C-terminal peptide 
of HPV18 E6 (PDB ID = 2I0L, (Zhang et al., 2007)) in a cartoon and surface representation, with the 
peptide ligand removed. The different contributing factors to binding affinity highlighted; the GLGF 
motif (red), hydrophobic interactions of the binding pocket (blue), the electrostatic interaction 
involving the conserved His residue (green) and the further downfield interactions with the residues of 
the βB – βC loop (yellow). b) A LIGPLOT representation of the hydrophobic and electrostatic 
interactions that occur in the SAP97 PDZ2 – HPV18 E6 crystal structure; it is evident that there are 
important intermolecular interactions between the C-terminal Val (0 or 2006 in this figure) to the Arg 
(-5 or 2001) of HPV18 E6 and the regions of the SAP97 PDZ2 domain highlighted in a): Val (0) – 
Leu328/Phe330 (GLGF motif, red), Val (0) – Leu390 (hydrophobic pocket, blue), Thr (-2) – His383 
(conserved His, green) and Arg (-4/-5) – Asn338 (βB-βC loop, yellow). 
  
Data that characterised the relative importance of each of the above contributions to 
SAP97 PDZ binding would be extremely useful in the design of potential inhibitors 
of the SAP97 PDZ domains. The investigation detailed in this chapter attempts to 
explore the contributions to SAP97 PDZ2 binding of the different factors.  
The research described in this chapter is a systematic investigation into the 
interaction between the SAP97 PDZ2 domain and the HPV18 E6 protein. The 
methodology described in this chapter employs standard protein production 
procedure to produce wild-type SAP97 PDZ2, with site-directed ligase-independent 
mutagenesis (SLIM) employed to produce mutant forms of the SAP97 PDZ2 
domain. ITC was utilised to detect the resultant binding (or lack thereof) between the 
particular SAP97 PDZ2 domain and commercially acquired peptides of the HPV18 
a) a) b) 
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E6 C-terminus (Table 6.1) and quantify the dissociation constants. The peptides 
investigated had varying lengths and amino acids at the 0/-2 ligand positions; a 
couple of peptides of the HPV16 E6 protein C-terminus were included in the 
investigation to see if there were any common binding trends between the two 
different E6 proteins (Table 6.1). ITC was the chosen biophysical technique for this 
investigation as not only is it able to quantify the binding affinity of the particular 
protein-peptide interaction, it is able to provide qualitative thermodynamic parameter 
information about the binding process; the change in enthalpy and entropy induced 
by binding is measured and this can be used to evaluate the interactions occurring 
during the binding process.   
The investigation was also carried out on the SAP97 PDZ1 – HPV18 E6 interaction 
but will not be discussed here due to the space constraints of this thesis. 
Table 6.1: The sequences of the different peptides (GenicBio, China) utilised in the SAP97 PDZ – 
HPV18 E6 binding investigation by ITC; the peptides corresponding to the HPV16 E6 sequence have 
been highlighted in red. 
Tripeptide Pentapeptide Pentapeptide Nonapeptide Nonapeptide 
TQV RETQV RETQαa LQRRRETQV LQRRREGQV 
TQA RETQL RETQβb SRTRRETQL  
 RETQI REγQVc LQRRRETQF  
 RETQG REδQVd LQRRRESQV  
a
 α = norvaline. b β = norleucine. c γ = allothreonine. d δ = betahydroxynorvaline. 
 
5.2 Purification of SAP97 PDZ2 Mutants 
By mutating His73 of the SAP97 PDZ2 domain, it was possible to investigate the 
effect of removing the potential to form a hydrogen bond interaction between the 
PDZ domain and the ligand. The His73 residue was mutated to both Gly and Thr 
residues; Gly was chosen as this would definitely eliminate the ability to form a 
hydrogen bond between the mutant PDZ domain and peptide ligand and so the effect 
on binding affinity of the electrostatic interaction could be deduced. On the other 
hand, Thr was selected to determine if it was still possible to form an alternative 
hydrogen bond between the SAP97 PDZ2 mutant domain and the HPV18 E6 
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peptide. Both mutant forms enabled comparison of the resultant binding affinity to 
that of the wild-type domain, in the absence or possible presence of an electrostatic 
interaction. The mutation of the His73 residue of wild-type SAP97 PDZ2 to Gly and 
Thr was carried out using SLIM as detailed in [3.2.1.1] and was shown to be 
successful (Appendices, A.1a).  
The subsequent transformation, expression and purification of unlabelled and 
15
N-
isotopically labelled SAP97 PDZ2 wild-type, H73G and H73T mutant domains was 
carried out as detailed in [3.2.1.3], [3.2.2] and [3.2.3] respectively. The 
chromatograms produced from size exclusion chromatography, the final purification 
stage of the three different SAP97 PDZ2 domains, can be seen as a chromatogram 
overlay (Figure 5.2a). As mentioned in [4.2], the size exclusion column had been 
previously calibrated and so, the three PDZ domains were deduced to be monomeric. 
Samples of each of the SAP97 PDZ2 domains obtained at the end of the protein 
purification process were analysed by SDS-PAGE gel electrophoresis to ensure their 
purity (Figure 5.2b); the SDS-PAGE gel showed each of the three different PDZ 
domains to be pure. 
The three SAP97 PDZ2 domains were then characterised by NMR spectroscopy to 
determine if the mutant forms of the SAP97 PDZ2 domain were folded like the wild-
type form and to ensure that the His73 residue had been mutated successfully. 
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Figure 5.2: a) The chromatograms obtained from size exclusion chromatography using a HiLoad 
26/60 Superdex 75 in a 50mM Tris/HCl, 150mM NaCl, 2mM DTT buffer, pH 7.4; this was the final 
stage of the PDZ domain purification process. The size exclusion chromatograms for SAP97 PDZ2 
wild-type (blue) and the SAP97 PDZ2 H73G (red) and H73T mutants (green) are shown. The elution 
volume for each of the three PDZ domain chromatograms has been detailed; the column equilibration 
(Appendices, A.2) indicated that an elution volume of ~220mL corresponds to ~10kDa protein and 
thus, all three PDZ domains are shown to be within acceptable limit values for monomeric proteins. b) 
The corresponding SDS-PAGE gel of the obtained proteins shown that each final PDZ domain 
samples obtained was pure; 1 = marker, 2 = SAP97 PDZ2 wild-type, 3 = SAP97 PDZ2 H73G, 4 = 
SAP97 PDZ2 H73T. 
  
5.3 Characterisation of SAP97 PDZ2 Mutants by NMR Spectroscopy 
15
N-labelled SAP97 PDZ2 domain mutant samples were prepared [3.3.2] and 
1
H 1-D 
and 
1
H-
15
N 2-D HSQC NMR spectroscopic experiments were carried out. The 
resultant NMR spectra showed that all three forms of the SAP97 PDZ2 domain were 
folded and that the His73 residue of the wild-type SAP97 PDZ2 had been 
successfully mutated in both proteins (Figures 5.3 – 5.5). This was concluded as the 
peak corresponding to the His residue in the wild-type (circled red in Figure 5.3) was 
not present in either spectra of the mutant forms (Figures 5.4 & 5.5). There were also 
49 
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extra peaks present in the spectra of the mutant SAP97 PDZ2 proteins corresponding 
to the Gly and Thr residue mutations; hence the mutagenesis was deemed successful. 
As expected, there are a number of peaks shifted in the mutant SA97 PDZ2 forms 
c.f. wild-type SAP97 PDZ2. A number of the residues in the binding region that have 
been shown to be shifted in the SAP97 PDZ2 mutant forms c.f. wild-type, have been 
mapped onto the SAP97 PDZ2 wild-type structure (solid rectangles, Figure 5.6). The 
residues of the SAP97 PDZ2 mutants shown to be affected by the His73 mutation are 
in structured or flexible regions close in space to the wild-type His73 residue; this 
suggests that the binding region of the SAP97 PDZ2 H73G/T mutants could be 
structurally different to that of the wild-type SAP97 PDZ2 domain. 
As the SAP97 PDZ2 mutants were shown to be monomeric, pure and folded they 
were ready for use, along with the SAP97 PDZ2 wild-type domain, in the SAP97 
PDZ2 – HPV18 E6 interaction binding investigation by ITC. 
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Figure 5.3: The 2-D 
1
H – 15N HSQC spectrum of SAP97 PDZ2 wild-type acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3. The 
spectrum shows that the SAP97 PDZ2 wild-type domain is folded as the peaks are well dispersed and the conserved His73 residue that is mutated in the SAP97 PDZ2 mutants 
has been circled.  
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Figure 5.4: The 2-D 
1
H – 15N HSQC spectrum of the SAP97 PDZ2 H73G mutant acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3. The 
spectrum shows that the SAP97 PDZ2 H73G mutant is folded as the peaks are well dispersed, with the region corresponding to the conserved His73 and mutant Gly73 
residues circled in black and red respectively.  
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Figure 5.5: The 2-D 
1
H – 15N HSQC spectrum of the SAP97 PDZ2 H73T mutant acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3. The 
spectrum shows that the SAP97 PDZ2 H73T mutant is folded as the peaks are well dispersed, with the region corresponding to the conserved His73 and mutant Thr73 
residues circled in black and red respectively.  
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Figure 5.6: An overlay of the 2-D 
1
H – 15N HSQC NMR spectroscopic experiments of SAP97 PDZ2 WT (blue), SAP97 PDZ2 H73G (red) and SAP97 PDZ2 H73T (green) 
acquired at 298K, with a field strength of 600MHz, in 20mM phosphate buffer, pH6.3; the peaks corresponding to the His73, Gly73 and Thr73 residue residues in the 
respective spectra have been circled in blue, red and green respectively. The peaks corresponding to Glu44 and Asn64 (dashed rectangles) overlay perfectly in all three spectra 
and so, are not affected by the mutation of the wild-type His73 residue; this is not surprising as these residues are in structured regions of the SAP97 PDZ2 domain away from 
the mutagenesis site. However, Gly24, Gly25, His30 and Thr 72 (solid rectangle) are residues affected by the His73 mutation as they are in structured or flexible regions close 
to the His73 residue in the wild-type form and hence, suggests that that the binding region of the SAP97 PDZ2 H73G/T mutants might be could be affected.  
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5.4 SAP97 PDZ2 – HPV E6 Interaction Binding Investigation 
5.4.1 General 
The experimental conditions and procedure employed in each of the ITC 
experiments conducted in this chapter are described in [3.4.1] and [3.4.2]. In two of 
the experiments performed, the protein and peptide were in 20mM phosphate, pH 7.4 
buffer, instead of pH 6.3; this was to compare the effect of pH on the binding affinity 
and thermodynamic parameters of the SAP97 PDZ2 – HPV18 E6 interaction. The 
initial protein and peptide concentrations in the cell and syringe respectively, were 
kept constant throughout to avoid any concentration effects biasing one experiment 
over another; therefore, the highest KD values that could be obtained reliably under 
the experimental concentrations was ~250µM. The results of the binding 
investigation by ITC of the SAP97 PDZ2 – HPV18 E6 interaction has been divided 
into four areas; the investigation into the contribution to binding of pH, peptide 
length, the hydrophobic interaction and that of the electrostatic interaction.   
5.4.2 pH Investigation 
The effect of pH on SAP97 PDZ2 binding affinity was probed by performing two 
separate ITC binding experiments with the HPV18 E6 nonapeptide (LQRRRETQV), 
in the same buffer but at either pH 6.3 or 7.4 (Table 5.2 and Figures 5.7 – 5.9). The 
SAP97 PDZ2 – LQRRRETQV interaction was found to be stronger at pH 6.3, than 
the more physiologically relevant pH 7.4. The enthalpy change (∆H) upon SAP97 
PDZ2 binding was shown to be the driving force in both experiments, with the 
change in entropy (∆S, -T∆S) due to binding unfavourable; the less negative ∆H 
value for SAP97 PDZ2 binding at pH 7.4 results in the weaker binding affinity 
observed. At pH 6.3 it is likely that the majority of populations of the conserved 
SAP97 PDZ2 His residue will be protonated, which increases the strength of the 
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intermolecular hydrogen bond formed between the His and Thr (-2), relative to pH 
7.4. As ∆H is dependent on the strength/number of interactions formed/broken upon 
binding, this accounts for the more favourable ∆H value at pH 6.3 and hence, 
stronger binding affinity observed for the SAP97 PDZ2 – LQRRRETQV interaction, 
than at pH 7.4.   
Table 5.2: The different pH values used in the SAP97 PDZ2 – LQRRRETQV binding experiment by 
ITC and the respective binding parameters obtained. The errors in the binding parameters were 
calculated from a PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with 
the standard deviation in calculated KD and ∆G values used to determine the errors for the KD and 
thermodynamic parameter values respectively in the binding experiments shown in the table. 
pH KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
6.3 0.61 ± 
0.07 
-14.430 ± 0.537 5.960 ± 0.222 -8.470 ± 0.315 
7.4 1.08 ± 
0.12 
-11.790 ± 0.439 3.636 ± 0.135 -8.154 ± 0.303 
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Figure 5.7: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM LQRRRETQV (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 0.61µM for LQRRRETQV to the SAP97 PDZ2 domain.  
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Figure 5.8: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM LQRRRETQV (syringe) in 20mM 
phosphate, pH7.4, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 1.08µM for LQRRRETQV to the SAP97 PDZ2 domain. 
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Figure 5.9: The thermodynamic parameters (∆H = blue, -T∆S = red and ∆G = green) obtained from the binding interaction between the HPV18 E6 nonapeptide 
(LQRRRETQV) and the SAP97 PDZ2 domain at both pH 6.3 and pH 7.4. ∆H is the dominant thermodynamic parameter in ∆G determination and hence, binding affinity; this 
is because ∆H is a moderate to large negative value in both ITC binding experiments, with -T∆S being a small positive value in comparison and so, contributes much less 
significantly to ∆G. The ∆G value for the SAP97 PDZ2 – LQRRRETQV interaction at pH 6.3 is more favourable than at pH 7.4 i.e. more negative and hence, the interaction 
was shown to be stronger at the lower pH value. The difference in ∆G value between the two pH values is due to the less favourable ∆H value at pH 7.4 c.f. pH 6.3; this is due 
to a weaker intermolecular hydrogen bond formed between the SAP97 PDZ2 His and Thr (-2) at pH 7.4 as the populations of the His residue in the protonated state are much 
less than those at pH 6.3. The more favourable -T∆S value at pH 7.4 is not sufficient to compensate for this decrease in enthalpy and hence, leads to weaker SAP97 PDZ2 
binding of LQRRRETQV, than at pH 6.3.  
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5.4.3 Peptide Length Investigation 
The effect of peptide length on SAP97 PDZ2 binding affinity was then investigated 
by performing ITC binding experiments with three, five and nine residue peptides of 
the C-terminus of HPV18 E6 (Table 5.3 and Figures 5.7, 5.10 – 12 ). 
Table 5.3: The peptide ligands used in the SAP97 PDZ2 domain binding experiment by ITC and the 
respective binding parameters obtained. The errors in the binding parameters were calculated from a 
PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table. 
Ligand KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
TQV 57.14 ± 
6.58 
-5.623 ± 0.209 -0.163 ± 0.006 -5.786 ± 0.215 
RETQV 1.08 ± 
0.12 
-5.077 ± 0.189 -3.069 ± 0.114 -8.146 ± 0.303 
LQRRRETQV 0.61 ± 
0.07 
-14.430 ± 0.537 5.960 ± 0.222 -8.470 ± 0.315 
 
Extension of the C-terminal HPV18 E6 peptide from three to five and five to nine 
residues was shown to increase binding affinity; with all three interactions shown to 
be enthalpy driven, as the entropy change upon binding is small in comparison. The 
tripeptide (TQV) was able to bind to SAP97 PDZ2 with moderate micromolar 
affinity, indicating that SAP97 PDZ2 domain binding is possible with a small 
organic molecule capable of forming effective hydrophobic and electrostatic 
interactions.  
The difference in SAP97 PDZ2 binding affinity of the tri- and pentapeptide 
(RETQV) is due to the more favourable change in binding entropy of RETQV c.f. 
TQV; this indicates that the extension in peptide length increases the ability of the 
peptide to remove bound water molecules from the SAP97 PDZ2 binding region. 
This shows that the residues preceding the 0 and -2 ligand residues are important to 
SAP97 PDZ2 domain binding affinity; this corroborates previous research where Arg 
(-4) has been shown to form extended interactions with the SAP97 PDZ2 conserved 
His residue and residues of the βB – βC loop (Liu et al., 2007, Zhang et al., 2007).  
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Extending the pentapeptide to a nonapeptide (LQRRRETQV) increased the ∆H value 
for SAP97 PDZ2 binding by over 9 kcal mol
-1
 but decreased the -T∆S value by 
almost the same amount. This is because the extension of the peptide length to nine 
residues extends the number of intermolecular interactions possible with the SAP97 
PDZ2 domain; however, this also multiplies the loss of conformational entropy 
leading to the unfavourable -T∆S and hence, only results in the modest increase in 
binding affinity by extension from five to nine residue peptide length observed. It is 
not possible to determine if the nonapeptide is the optimal length for SAP97 PDZ2 
binding from the data obtained, as it is plausible that the intervening length peptides 
i.e. 6- to 8-mers may balance ∆H and -T∆S binding factors more favourably and 
hence, produce stronger SAP97 PDZ2 binding. This is an area of important future 
research as knowledge of the optimal peptide length would be extremely useful in 
guiding future SAP97 PDZ2 domain inhibition research.  
Penta- (RETQL) and nonapeptides (SRTRRETQL) of the C-terminus of the HPV16 
E6 protein were also used in ITC experiments to determine the effect of peptide 
length on SAP97 PDZ2 binding affinity (Table 5.4).  
Table 5.4: The peptide ligands used in the SAP97 PDZ2 domain binding experiment by ITC and the 
respective binding parameters obtained. The errors in the binding parameters were calculated from a 
PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table. 
Ligand KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
RETQL 24.94 ± 
2.87 
-3.109 ± 0.116 -3.159 ± 0.118 -6.268 ± 0.233 
SRTRRETQL 9.35 ± 
1.08 
-5.444 ±0.203 -1.416 ±0.053 -6.860 ± 0.255 
 
As with HPV18 E6, increasing the peptide length was shown to increase the SAP97 
PDZ2 binding affinity of HPV16 E6. The SAP97 PDZ2 binding of RETQL is 
equally dependent on both enthalpy and entropy factors; by extending to the 
nonapeptide, the binding enthalpy becomes the determining factor and is able to 
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compensate for the less favourable entropy change and yield tighter binding. The 
relative binding affinities of the HPV16/18 E6 pentapeptides is discussed in the next 
section [5.4.4]. 
 
Figure 5.10: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM TQV (syringe) in 20mM phosphate, 
pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the ITC 
experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding affinity 
(KD) of 57.14µM for TQV to the SAP97 PDZ2 domain.  
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Figure 5.11: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM RETQV (syringe) in 20mM phosphate, 
pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the ITC 
experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding affinity 
(KD) of 1.08µM for RETQV to the SAP97 PDZ2 domain. 
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Figure 5.12: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM RETQL (syringe) in 20mM phosphate, 
pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the ITC 
experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding affinity 
(KD) of 24.94µM for RETQL to the SAP97 PDZ2 domain. 
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Figure 5.13: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM SRTRRETQL (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 9.35µM for SRTRRETQL to the SAP97 PDZ2 domain. 
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Figure 5.14: The thermodynamic parameters (∆H = blue, -T∆S = red and ∆G = green) obtained from the binding interaction between various length peptides of the a) HPV18 
E6 and b) HPV16 E6 C-termini to the SAP97 PDZ2 domain, in the investigation of the effect of peptide length on SAP97 PDZ2 binding affinity. With the exception of 
RETQL, ∆H is the dominant thermodynamic parameter in ∆G determination and hence, binding affinity; this is because ∆H is a moderate to large negative value in all ITC 
binding experiments, with -T∆S being a small to moderate negative/positive value in comparison and so contributes much less significantly to ∆G. The tripeptide (TQV) was 
able to bind to SAP97 PDZ2 with moderate micromolar affinity, indicating that SAP97 PDZ2 domain binding is possible with a small organic molecule capable of forming 
the hydrophobic and electrostatic interactions as effectively as the native ligand. The difference in SAP97 PDZ2 binding affinity of the tri- and pentapeptide (RETQV) is due 
to the more favourable change in binding entropy of RETQV c.f. TQV; this indicates that the extension in peptide length increases the ability of the peptide to remove bound 
water molecules from the SAP97 PDZ2 binding region. Extending the pentapeptide to a nonapeptide (LQRRRETQV) increased the ∆H value for SAP97 PDZ2 by over 9 kcal 
mol
-1
 but decreased ∆S by almost the same value; this results in the modest increase in binding affinity shown. The extension of the peptide length to nine residues extends the 
number of intermolecular interactions possible with the SAP97 PDZ2 domain; however, this also multiplies the loss of conformational entropy by the act of PDZ domain 
leading to the unfavourable ∆S observed. As with HPV18 E6, increasing the peptide length was shown to increase the SAP97 PDZ2  binding affinity of HPV16 E6. The 
binding of RETQL is equally dependent on both enthalpy and entropy factors; by extending to the nonapeptide, the binding enthalpy becomes the determining factor and is 
able to compensate for the less favourable entropy change and yield tighter binding.  
a) b) 
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5.4.4 Hydrophobic Interaction Investigation 
This section of the investigation involved the substitution of the C-terminal Val 
residue of HPV18 E6 peptides of various lengths, with a range of natural and non-
natural amino acids (Tables 5.5 – 5.7, Figures 5.7, 5.10 – 5.12 and 5.15 – 5.21). 
Table 5.5: The tripeptide ligands used in the SAP97 PDZ2 domain binding experiment by ITC and 
the respective binding parameters obtained. The errors in the binding parameters were calculated from 
a PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table. 
a
 DNB = Did not bind.  
Ligand KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
TQV 57.14 ± 
6.58 
-5.623 ± 0.209 -0.163 ± 0.006 -5.786 ± 0.215 
TQA DNB
a
 DNB DNB DNB 
 
Table 5.6: The pentapeptide ligands used in the SAP97 PDZ2 domain binding experiment by ITC and 
the respective binding parameters obtained. The errors in the binding parameters were calculated from 
a PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table. 
a
 DNB = Did not bind, 
b
 
α = Norvaline, c β = Norleucine. 
Ligand KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
RETQV 1.08 ± 
0.12 
-5.077 ± 0.189 -3.069 ± 0.114 -8.146 ± 0.303 
RETQL 24.94 ± 
2.87 
-3.109 ± 0.116 -3.159 ± 0.118 -6.268 ± 0.233 
RETQI 4.51 ± 
0.52 
-5.737 ± 0.213 -1.556 ± 0.058 -7.293 ± 0.271 
RETQG DNB
a
 DNB DNB DNB 
RETQαb 2.58 ± 
0.30 
-7.129 ± 0.265 -0.498 ± 0.019 -7.627 ± 0.284 
RETQβc 5.92 ± 
0.68 
-6.468 ± 0.241 -0.665 ± 0.025 -7.133 ± 0.265 
 
Table 5.7: The nonapeptide ligands used in the SAP97 PDZ2 domain binding experiment by ITC and 
the respective binding parameters obtained. The errors in the binding parameters were calculated from 
a PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table.  
Ligand KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
LQRRRETQV 0.61 ± 
0.07 
-14.430 ± 0.537 5.960 ± 0.222 -8.470 ± 0.315 
LQRRRETQF 20.37 ± 
2.35 
-9.824 ± 0.365 3.427 ± 0.127 -6.397 ± 0.238 
 
With the exception of RETQL, the individual peptide binding interactions with the 
SAP97 PDZ2 were shown to be enthalpy driven, with the entropy change upon 
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binding shown to be a much smaller negative or positive values than that of ∆H. 
Removal of the ability of the C-terminal residue to form effective hydrophobic 
interactions with the SAP97 PDZ2 domain by substitution of Val with Ala or Gly 
eradicated binding completely (Table 5.5 & 5.6), indicating that the electrostatic 
interaction alone was not enough to facilitate binding of the peptides. Substitution of 
the C-terminal Val of HPV18 E6 led to a decrease in binding affinity in all cases 
(Tables 5.6 & 5.7); this was due to the less favourable entropy change of the 
interactions i.e. -T∆S was less negative. The exception to this rule was RETQL, 
where the -T∆S was comparable with RETQV but ∆H upon SAP97 PDZ2 binding of 
RETQL was reduced; the reduction in ∆H indicates that the Leu side-chain is not 
able to form as effective hydrophobic interactions with the hydrophobic pocket as 
Val and hence, ∆G and KD values are reduced for the HPV16 c.f. HPV18 E6 protein. 
The obtained data corroborates the previously described disparity in SAP97 PDZ2 
binding of the HPV16/18 E6 proteins (Liu et al., 2007). 
As -T∆S is dependent upon dynamic changes such as displacement of bound water 
molecules and conformational entropy loss by a binding interaction, this indicates 
that the Val side-chain is the optimal side-chain for the SAP97 PDZ2 domain, both 
in terms of size and rigidity. The peptides with C-terminal Ile and non-natural amino 
acids norvaline (NorV, isomeric with Val) and norleucine (NorL) show increased 
enthalpy change which indicates that their side-chains interact more effectively with 
SAP97 PDZ2 than the native HPV18 E6 Val; however, the reduction in ∆S upon 
binding is not sufficiently compensated by the increase in ∆H and so, the binding is 
comparable but still weaker than the native peptide. 
The obtained data suggests that the side-chains of Leu and Phe are much less suitable 
for SAP97 PDZ2 domain binding than the other C-terminal residues investigated. 
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This indicates that either the conformation and/or bulk of their side-chains prevents 
them from effectively interacting with the hydrophobic binding pocket or that the 
Phe and Leu side-chains are forming unfavourable interactions with the residues of 
the SAP97 PDZ2 binding pocket, which will obviously affect the binding affinity. 
The information obtained about the residue side-chain size and shape preferences of 
the SAP97 PDZ2 hydrophobic binding pocket could be extremely useful in guiding 
future SAP97 PDZ2 inhibitor design. 
 
 
 
 
 
Figure 5.15: The side-chains of a) Val and b) Ala, the C-terminal amino acids of the respective 
tripeptides described in the text. The Val side-chain has two extra Cγ attached to Cβ and thus, is able to 
interact much more effectively with the residues of the binding pocket than the smaller side-chain of 
Ala; this results in no observable SAP97 PDZ2 binding of the TQA tripeptide. 
 
5.4.5 Hydrophobic Interaction Investigation Summary 
The investigation into the hydrophobic interaction contribution to the binding affinity 
of the SAP97 PDZ2 – HPV18 E6 interaction has led to the following conclusions: 
 The Val side-chain is the amino acid side-chain structure that results in the 
strongest binding affinity of the C-terminal residues investigated. 
 When the hydrophobic interaction is removed, the contribution of the 
electrostatic interaction to binding is not sufficient enough to facilitate 
binding, even in pentapeptide forms. 
 The binding of peptides containing non-natural amino acid isomers of natural 
amino acids at the C-terminal residue position showed comparable or even 
stronger than their isomeric natural amino acid counter-parts. 
  
α α 
β 
γ 
β 
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Figure 5.16: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM RETQI (syringe) in 20mM phosphate, 
pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the ITC 
experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding affinity 
(KD) of 4.51µM for RETQI to the SAP97 PDZ2 domain.  
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Figure 5.17: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM RETQα (syringe) in 20mM phosphate, 
pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the ITC 
experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding affinity 
(KD) of 2.58µM for RETQα to the SAP97 PDZ2 domain.  
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Figure 5.18: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM RETQβ (syringe) in 20mM phosphate, 
pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the ITC 
experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding affinity 
(KD) of 5.92µM for RETQβ to the SAP97 PDZ2 domain.  
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Figure 5.19: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM LQRRRETQF (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 20.37µM for LQRRRETQF to the SAP97 PDZ2 domain. 
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Figure 5.20: a) The thermodynamic parameters (∆H = blue, -T∆S = red and ∆G = green) obtained from the binding interaction between the HPV18 E6 pentapeptide 
(RETQV) and pentapeptides with substituted C-terminal residues to the SAP97 PDZ2 domain, in the investigation of the effect of the hydrophobic interaction on SAP97 
PDZ2 binding affinity. With the exception of RETQL, ∆H is the dominant thermodynamic parameter in ∆G determination and hence, binding affinity; this is because ∆H is a 
moderate to large negative value in all ITC binding experiments, with -T∆S being a small to moderate negative/positive value in comparison and so, contributes much less 
significantly to ∆G. The removal of the ability of the C-terminal residue to effectively form hydrophobic interactions with the SAP97 PDZ2 domain by substitution of Val 
with Gly eradicated binding completely; indicating that the electrostatic interaction alone was not enough to facilitate binding of the peptides. Substitution of the C-terminal 
Val of HPV18 E6 led to a decrease in binding affinity in all cases (Tables 5.6 & 5.7); this was due to the less favourable entropy change of the interactions i.e. -T∆S was less 
negative. The exception to this rule was RETQL, where the -T∆S values were comparable with RETQV but the enthalpy change upon SAP97 PDZ2 binding of RETQL was 
reduced, compared to RETQV. The data indicates that the Val side-chain is the optimal side-chain for the SAP97 PDZ2 domain of the residues investigated. b) The structure 
of the side-chains of the native C-terminal HPV18 E6 residue Val and the five other residues substituted in the hydrophobic interaction investigation; the Val side-chain was 
shown to be the optimal for SAP97 PDZ2 binding, with the Leu side-chain having most detrimental effect on SAP97 PDZ2 binding affinity of the six C-terminal residues.  
a) b) 
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Figure 5.21: a) The thermodynamic parameters (∆H = blue, -T∆S = red and ∆G = green) obtained from the binding interaction between the HPV18 E6 nonapeptide 
(LQRRRETQV) and a nonapeptide with a Phe C-terminal residue to the SAP97 PDZ2 domain, in the investigation of the effect of the hydrophobic interaction on SAP97 
PDZ2 binding affinity. ∆H is the dominant thermodynamic parameter in ∆G determination and hence, binding affinity; this is because ∆H is a large negative value in both 
ITC binding experiments, with -T∆S being a small to moderate positive value in comparison and so, contributes much less significantly to ∆G. The substitution of the C-
terminal Val of HPV18 E6 with Phe led to a decrease in binding affinity; this was due to the less favourable enthalpy change of the interaction i.e. ∆H was less negative,  
indicating that the bulk of the Phe side-chain prevents effective interaction with the SAP97 PDZ2 hydrophobic binding pocket. b) The structure of the side-chains of the native 
C-terminal HPV18 E6 residue Val and the Phe residues substituted in the hydrophobic interaction investigation; it can be seen that the side-chain of Phe is much bulkier than 
that of Val and hence, is not suitable to effectively interact with the SAP97 PDZ2 domain.  
a) b) 
α α 
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5.4.6 Electrostatic Interaction Investigation 
This section investigates the contribution of the electrostatic interaction between the 
His residue of the SAP97 PDZ2 domain and the Thr (-2) residue of the HPV18 E6 
protein. This is investigated from both the ligand (by substitution of the -2 Thr 
residue) and PDZ domain (by mutation of the His residue) perspectives.  
5.4.6.1 Ligand Perspective  
The contribution of the electrostatic interaction to binding affinity, from the ligand 
perspective, was examined by substitution of the Thr (-2) residue of HPV18 E6 
peptides of differing lengths, with a variety of natural and non-natural amino acids 
(Tables 5.8 & 5.9, Figures 5.7, 5.10&11 and 5.22 – 5.25). 
Table 5.8: The peptide ligands used in the SAP97 PDZ2 domain binding experiment by ITC and the 
respective binding parameters obtained. The errors in the binding parameters were calculated from a 
PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table. 
a
 γ = Allothreonine, b 
DNB = Did not bind, 
c δ = Betahydroxynorvaline. 
Ligand KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
RETQV 1.08 ± 
0.12 
-5.077 ± 0.189 -3.069 ± 0.114 -8.146 ± 0.303 
REγQVa DNB DNB DNB DNB 
REδQVc 13.04 ± 
1.50 
-3.671 ± 0.137 -2.980 ± 0.111 -6.651 ± 0.247 
 
Table 5.9: The peptide ligands used in the SAP97 PDZ2 domain binding experiment by ITC and the 
respective binding parameters obtained. The errors in the binding parameters were calculated from a 
PSD-95 PDZ1 – 5-HT2a binding experiment that was performed in triplicate, with the standard 
deviation in calculated KD and ∆G values used to determine the errors for the KD and thermodynamic 
parameter values respectively in the binding experiments shown in the table. 
a
 DNB = Did not bind.  
Ligand KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
LQRRRETQV 0.61 ± 
0.07 
-14.430 ± 0.537 5.960 ± 0.222 -8.470 ± 0.315 
LQRRREGQV DNB DNB DNB DNB 
LQRRRESQV 4.02 ± 
0.46 
-8.240 ± 0.307 0.879 ± 0.033 -7.361 ± 0.274 
 
As with the hydrophobic interaction investigation, the binding interactions are driven 
by enthalpic factors, although the SAP97 PDZ2 binding of REδQV is much more 
dependent on entropic factors, compared with the binding of the other peptides. 
Substitution of the -2 Thr of HPV18 E6 led to a decrease in binding affinity in all 
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cases, due to the less favourable enthalpy change of the non-native peptide 
interactions i.e. ∆H was less negative c.f. HPV18 E6. This indicates that the 
substituted residues have formed a weaker hydrogen bond with the SAP97 PDZ2 
domain conserved His than the native Thr residue, as ∆H is dependent upon the 
number/strength of interactions formed/broken in the act of binding. Allothreonine 
(AThr) is a non-natural amino acid and diastereoisomer of Thr (Figure 5.24b), where 
the hydroxyl group is pointing in the opposite direction in space c.f. Thr and so, is 
too far away in space from the His residue. The removal of the ability to form the 
electrostatic interaction with the SAP97 PDZ2 His residue by substitution with AThr 
and Gly obliterated binding; suggesting that the hydrophobic interaction involving 
the hydrophobic C-terminal residue alone is not sufficient to facilitate SAP97 PDZ2 
binding. 
The substitution of Thr (-2) with the non-natural amino acid betahydroxynorvaline 
(BVal) or Ser indicated that the addition/removal of a methyl group from the Thr 
side-chain structure of Thr respectively, had a detrimental effect on binding affinity. 
The extra residue side-chain methylene of BVal leads to less favourable ∆H and -
T∆S parameters, suggesting that either the extra methylene group causes 
unfavourable side-chain steric clashes with the residues of the SAP97 PDZ2 binding 
region or that it places the methyl group in a less optimal position c.f. Thr side-chain; 
this will affect the ability of the methyl group to form hydrophobic interactions with 
the surrounding residues. The position of the methyl group of Thr in space has been 
shown to be important as it forms hydrophobic interactions with the surrounding 
residues of the SAP97 PDZ2 binding region and constrain the hydroxyl group 
orientation in space; the Ser side-chain does not have this methyl group present 
(Figure 5.25b). The less favourable ∆H value of LQRRRESQV binding to SAP97 
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PDZ2 can therefore be attributed to a weaker hydrogen bond formed in the absence 
of the methyl group and hence, results in weaker SAP97 PDZ2 binding, compared to 
LQRRRETQV.  
The contribution of the electrostatic interaction to the binding affinity of the SAP97 
PDZ2 – HPV18 E6 interaction was then investigated from the protein perspective. 
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Figure 5.22: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM REδQV (syringe) in 20mM phosphate, 
pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the ITC 
experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding affinity 
(KD) of 13.04µM for REδQV to the SAP97 PDZ2 domain.  
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Figure 5.23: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 (cell) and 750µM LQRRRESQV (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 4.02µM for LQRRRESQV to the SAP97 PDZ2 domain. 
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Figure 5.24: a) The thermodynamic parameters (∆H = blue, -T∆S = red and ∆G = green) obtained from the binding interaction between the HPV18 E6 pentapeptide 
(RETQV) and pentapeptides with substituted non-natural amino acid -2 residues to the SAP97 PDZ2 domain, in the investigation of the effect of the electrostatic interaction 
on SAP97 PDZ2 binding affinity. ∆H is the dominant thermodynamic parameter in ∆G determination and hence, binding affinity; this is because ∆H is a moderate to large 
negative value in both ITC binding experiments but -T∆S is also a moderate negative value in comparison and so, contributes more significantly to ∆G than previous 
interactions. The removal of the peptides ability to form an electrostatic interaction with the SAP97 PDZ2 His by substitution of Thr with AThr eradicated binding 
completely; indicating that the hydrophobic interaction alone was not enough to facilitate peptide binding. Substitution of the -2 Thr of HPV18 E6 with BVal led to a decrease 
in binding affinity; this was due to the less favourable enthalpy change of the interaction i.e. -∆H was less negative, due to a weaker hydrogen bond formed with the His. b) 
The side-chain structure of the native HPV18 E6 -2 residue Thr and the two non-natural amino acids substituted in the electrostatic interaction investigation; the Thr side-
chain was shown to be the optimal side-chain for SAP97 PDZ2 domain binding as this was able to maximise the electrostatic interaction with the conserved His residue, as the 
hydroxyl group of AThr side-chain is oriented in the wrong direction in space and the absence of the methyl group in the Ser side-chain has a detrimental effect.  
a) b) 
α α α 
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Figure 5.25: a) The thermodynamic parameters (∆H = blue, -T∆S = red and ∆G = green) obtained from the binding interaction between the HPV18 E6 nonapeptide 
(LQRRRETQV) and nonapeptides with substituted -2 residues to the SAP97 PDZ2 domain, in the investigation of the effect of the electrostatic interaction on SAP97 PDZ2 
binding affinity. ∆H is the dominant thermodynamic parameter in ∆G determination and hence, binding affinity; this is because ∆H is a moderate to large negative value in the 
ITC binding experiments, with -T∆S being a small to moderate positive value in comparison and so, contributes much less significantly to ∆G. The removal of the ability of 
the peptide to form an electrostatic interaction with the SAP97 PDZ2 domain His by substitution of Thr with Gly eradicated binding completely, as seen previously with ATr 
(Figure 5.24). Substitution of the -2 Thr of HPV18 E6 with Ser led to a decrease in binding; this was due to the less favourable enthalpy change of the interactions i.e. -∆H 
was less negative, due to a weaker hydrogen bond formed with the SAP97 PDZ2 His caused the lack of a methyl group on the side-chain of Ser c.f. Thr (Figure 5.25b). b) The 
structure of the side-chains of the native HPV18 E6 -2 residue Thr and the two other residues substituted in the electrostatic interaction investigation; the Thr side-chain was 
shown to be the optimal side-chain for SAP97 PDZ2 domain binding as this was able to maximise the electrostatic interaction with the conserved His residue, substitution 
with Gly eradicated SAP97 PDZ2 binding and the absence of the methyl group in the Ser side-chain has a detrimental effect on the binding interaction and hence, affinity.  
a) b) 
 α α α 
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5.4.6.2 PDZ Domain Perspective  
To investigate the contribution of the electrostatic interaction to the binding affinity 
of the SAP97 PDZ2 – HPV18 E6 interaction from the protein perspective, the 
SAP97 PDZ2 H73G/T mutants [5.2 & 5.3] were utilised in ITC binding experiments 
with the HPV 18 E6 (LQRRRETQV) and LQRRRESQV nonapeptides (Tables 
5.11&12 and Figures 7 and 26 – 29). 
Table 5.11: The different forms of the SAP97 PDZ domain used with the HPV18 E6 nonapeptide 
(LQRRRETQV) ligand in the binding experiment by ITC and the respective binding parameters 
obtained. The errors in the binding parameters were calculated from a PSD-95 PDZ1 – 5-HT2a 
binding experiment that was performed in triplicate, with the standard deviation in calculated KD and 
∆G values used to determine the errors for the KD and thermodynamic parameter values respectively 
in the binding experiments shown in the table. 
Protein KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
WT 0.61 ± 
0.07 
-14.430 ± 0.537 5.960 ± 0.222 -8.470 ± 0.315 
H73G 62.11 ± 
7.16 
-7.788 ± 0.290 2.047 ± 0.076 -5.741 ± 0.214 
H73T 79.37 ± 
9.14 
-10.070 ± 0.375 4.470 ± 0.166 -5.600 ± 0.208 
 
Table 5.12: The different forms of the SAP97 PDZ domain used with the Ser nonapeptide 
(LQRRRESQV) ligand in the binding experiment by ITC and the respective binding parameters 
obtained. The errors in the binding parameters were calculated from a PSD-95 PDZ1 – 5-HT2a 
binding experiment that was performed in triplicate, with the standard deviation in calculated KD and 
∆G values used to determine the errors for the KD and thermodynamic parameter values respectively 
in the binding experiments shown in the table. 
Protein KD (µM) ∆H (kcal mol
-1
) -T∆S (kcal mol-1) ∆G (kcal mol-1) 
WT 4.02 ± 
0.46 
-8.240 ± 0.307 0.879 ± 0.033 -7.361 ± 0.274 
H73G DNB DNB DNB DNB 
H73T 166.7 ± 
19.20 
-4.468 ± 0.166 -0.685 ± 0.025 -5.153 ± 0.192 
 
The binding of the nonapeptides to the SAP97 PDZ2 H73G/T mutant forms was 
again shown to be dependent on enthalpic factors; with the decrease in binding 
affinity of the nonapeptides to the mutant SAP97 PDZ2 domains due to a decrease in 
enthalpy. This is in agreement with the related investigation into the effect of the 
electrostatic interaction from the ligand perspective in the previous section, where 
perturbation of the SAP97 PDZ2 – HPV18 E6 hydrogen bond decreased the ∆H 
parameter and hence, weakened binding. However, removal of the ability to form an 
 Investigation into the Interaction Between the SAP97 PDZ2 Domain and the HPV E6 Proteins 
226 
 
electrostatic interaction in [5.4.4.1] eradicated binding, whereas, the SAP97 PDZ2 
mutants were both found to bind the HPV18 E6 nonapeptide. As the H73G mutant 
shows better affinity for LQRRRETQV than H73T, this cannot be rationalised by the 
formation of a hydrogen bond with the -2 Thr residue of the nonapeptide and thus, 
facilitate binding. It is possible that the single point mutation of the SAP97 PDZ2 
His73 residue to Gly and Thr respectively has induced a structural change in the 
SAP97 PDZ2 mutants, relative to the wild-type structure; this was alluded to 
previously when comparing the HSQC spectra of the SAP97 PDZ2 wild-type and 
H73G/T domains (Figure 5.6). The binding region of the SAP97 PDZ2 H73G/T 
mutants may therefore be able to bind in an unconventional manner that is not 
accessible to the wild-type domain and hence, explain the unexpected observed 
binding of the HPV18 E6 nonapeptide to both SAP97 PDZ2 mutant forms (and 
LQRRRESQV to the H73T mutant). 
5.4.7 Electrostatic Interaction Investigation Summary 
The investigation into the electrostatic interaction contribution to the binding affinity 
of the SAP97 PDZ2 – HPV18 E6 interaction has led to the following deductions: 
 The Thr side-chain is the amino acid side-chain structure that results in the 
strongest binding affinity out of the -2 residues investigated. 
 When the electrostatic interaction is removed, the contribution of the 
electrostatic interaction to binding is not sufficient enough to facilitate 
binding, even in longer peptide forms. 
 The binding of peptides containing non-natural amino acid isomers of natural 
amino acids at the ligand -2 position showed no binding or weaker binding 
than the natural amino acid peptide variants. 
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 PDZ domain mutant forms were still able to bind to the nonapeptides despite 
the reduced or lack of ability to form an electrostatic interaction; this could 
have been due to structural changes of the PDZ domain binding region 
induced by the residue mutation. 
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Figure 5.26: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 H73G (cell) and 750µM LQRRRETQV (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 62.11µM for LQRRRETQV to the SAP97 PDZ2 H73G domain.  
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Figure 5.27: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 H73T (cell) and 750µM LQRRRETQV (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 79.37µM for LQRRRETQV to the SAP97 PDZ2 H73T domain.  
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Figure 5.28: The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding 
experiment between 100µM SAP97 PDZ2 H73T (cell) and 750µM LQRRRESQV (syringe) in 20mM 
phosphate, pH6.3, on an iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced 
by the ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in a binding 
affinity (KD) of 166.67µM for LQRRRESQV to the SAP97 PDZ2 H73T domain. 
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Figure 5.29: The thermodynamic parameters (∆H = blue, -T∆S = red and ∆G = green) obtained from the binding interaction between the SAP97 PDZ2 wild-type, H73G and 
HT3T domains with a) HPV18 E6 nonapeptide (LQRRRETQV) and b) LQRRRESQV, in the investigation of the effect of the electrostatic interaction on SAP97 PDZ2 
binding affinity, from the protein perspective. ∆H is the dominant thermodynamic parameter in ∆G determination and hence, binding affinity; this is because ∆H is a moderate 
to large negative value in both ITC binding experiments, with -T∆S being a small to moderate negative/positive value in comparison and so, contributes much less 
significantly to ∆G. The decrease in binding affinity of the nonapeptides to the mutant SAP97 PDZ2 domains was due to a decrease in enthalpy. This is in agreement with the 
related investigation into the effect of the electrostatic interaction from the ligand perspective in the previous section, where perturbation of the SAP97 PDZ2 – HPV18 E6 
hydrogen bond decreased the ∆H parameter and hence, weakened binding. However, removal of the ability to form an electrostatic interaction in [5.4.4.1] eradicated binding, 
whereas, the SAP97 PDZ2 mutants were both found to bind the HPV18 E6 nonapeptide. As the H73G mutant showing better affinity for LQRRRETQV than H73T, this 
cannot be rationalised by the formation of a hydrogen bond with the -2 Thr residue of the nonapeptide and thus, facilitate binding. It is possible that the single point mutation 
of the SAP97 PDZ2 His73 residue to Gly and Thr respectively has induced a structural change in the SAP97 PDZ2 mutants, relative to the wild-type structure; this was 
alluded to previously when comparing the HSQC spectra of the SAP97 PDZ2 wild-type and H73G/T domains (Figure 5.6). The binding region of the SAP97 PDZ2 H73G/T 
mutants may therefore be able to bind in an unconventional manner that is not accessible to the wild-type domain and hence, explain the unexpected observed binding of the 
HPV18 E6 nonapeptide to both SAP97 PDZ2 mutant forms (and LQRRRESQV to the H73T mutant). 
  
a) b) 
 Investigation into the Interaction Between the SAP97 PDZ2 Domain and the HPV E6 Proteins 
232 
 
5.5 General Discussion 
The systematic investigation into the factors that determine SAP97 PDZ2 binding 
affinity has yielded a number of extremely important points that will guide future 
SAP97 PDZ2 domain inhibitor design consideration: 
 The residue side-chain structure that interacts most effectively with the 
SAP97 PDZ2 hydrophobic binding pocket is the isopropyl group of Val. 
 To maximise the electrostatic interaction with the conserved SAP97 PDZ2 
His residue, the Thr side-chain is the optimal conformation and orientation of 
constituent chemical groups. 
 To bind to the SAP97 PDZ2 domain with an affinity < 250µM, both 
hydrophobic and electrostatic interactions must be formed with the PDZ 
binding region. 
 Formation of the minimal hydrophobic and electrostatic interactions will 
result in moderate micromolar affinity (KD of TQV = 57.14µM); the presence 
of a more extensive network of interactions with the SAP97 PDZ2 domain 
binding region is required to achieve low micromolar/high nanomolar 
affinity. 
 The HPV18 E6 peptide length that maximises SAP97 PDZ2 binding was 
found to be greater than five residues, up to and including nine residues.   
The knowledge obtained from the research detailed in this chapter will be invaluable 
in guiding an SAP97 PDZ2 domain inhibition research. Critical analysis of the 
resultant information obtained from this research could lead to the hypothesis that, 
given the expansive area and number of interactions required for effective SAP97 
PDZ2 domain binding, the development of a high affinity small molecule inhibitor of 
the SAP97 PDZ2 domain may not be a feasible target. Therefore, the development of 
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native SAP97 PDZ2 ligand peptidomimetic scaffolds may be a more suitable starting 
point, from which to design reversible inhibitors of SAP97 PDZ2 domain-mediated 
interaction inhibitors. 
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6. THE DEVELOPMENT OF NOVEL SMALL MOLECULE INHIBITORS 
OF THE PSD-95 AND SAP97 PDZ DOMAINS BY BIOPHYSICAL 
TECHNIQUES 
6.1 Introduction 
As detailed in [1.6], there are a number of PDZ domain-mediated interactions where 
reversible inhibition of the interaction by a small organic molecule would be 
favourable for therapeutic reasons. As a result, there have been a variety of strategies 
employed by different research groups/organisations in an effort to develop 
inhibitors of PDZ domain-mediated interactions; with varying degrees of success 
[1.6]. As a brief summary, these strategies have either involved the use of peptides, 
rational non-peptide small molecule design, screening of virtual libraries, high-
throughput screening or the ‘re-purposing of existing drugs.’ 
The two particular PDZ domain-containing proteins of interest to this thesis are PSD-
95 and SAP97. There are no examples of any SAP97 PDZ domain inhibition 
research to-date and a reasonably limited amount of previous research into 
developing inhibitors of the PSD-95 PDZ domains; these research efforts have 
focussed almost exclusively on the development of inhibitory peptides (Piserchio et 
al., 2004, Pichon et al., 2010, Sainlos et al., 2011, Bach et al., 2012, Cook et al., 
2012). There are also two examples of PSD-95 PDZ domain-mediated interaction by 
a small molecule compound, although this inhibitor targets the ligand protein rather 
than the PDZ domain itself. Thus, to date, there are no examples in the literature 
where an attempt has been made to develop a novel, reversible small molecule 
inhibitor of the PSD-95/SAP97 PDZ domains by a rational design and development 
procedure; this was the aim of the research detailed in this chapter. 
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This chapter describes the screening of potential small molecule inhibitors for 
binding to the PSD-95 PDZ1 domain by NMR spectroscopy and then investigates 
their effect on PSD-95 PDZ1 – 5-HT2c receptor interaction; the investigation was 
carried out with all four PDZ domains of interest but was limited solely to the above 
described interaction due to the space constraints of the thesis. 
The initial starting compounds in the binding screening were designed using 
computational docking by the group of our collaborators (Professor Sylvie Ducki et 
al, Clermont Université), with a number of the compounds adapted from the 
previously described Fujii indole scaffold [1.6.3.1] (Figure 6.1) (Fujii et al., 2007a) 
and were synthesised via well-known synthetic routes to PDZ domain ligands 
(Mayasundari et al., 2008, Vogrig et al., 2011). NMR samples of the particular PDZ 
domain under investigation, in the absence and presence of the potential inhibitor, 
were prepared and the resultant NMR spectra analysed. Specific binding was 
identified and binding efficacy quantified by comparison to the chemical shift 
perturbations induced by the binding of the native ligand of the respective PDZ 
domain. Designs for the possible structure of future compounds that were thought to 
enhance binding affinity were then relayed to our collaborators, in an iterative 
manner, to develop subsequent generations of compounds. The potential inhibitors 
initially started as relatively simple organic compounds and became progressively 
more substituted and complex as the inhibitor development process advanced. 
Those compounds that showed the best PDZ domain binding (i.e. most numerous 
and/or largest chemical shift perturbations of the key residues in the binding 
pocket/extended groove) had their binding affinity (KD) for the specific PDZ domain 
quantified by NMR spectroscopy. To see if these compounds then exhibited any 
inhibitory effects of the respective native PDZ domain – ligand interaction, ITC 
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competitive inhibition experiments were performed. This led to the determination of 
the quantitative inhibitory constant (Ki) of that small molecule compound for that 
specific interaction. 
Finally, the structure of the bound complexes formed between a number of different 
PDZ domains and small molecule inhibitors were solved by a combination of NMR 
spectroscopy and NOE distance restraint-driven docking. These are the first 
examples of HADDOCK being used to determine the structure of PDZ domain – 
small molecule inhibitor complexes. 
 
 
 
 
 
 
Figure 6.1: The structure of the indole chemical scaffold developed by Fujii et al to target class I PDZ 
domains such as PSD-95 PDZ1 (Fujii et al., 2007a); the chemical numbering used conventionally to 
describe the different positions around the indole scaffold has been labelled. The scaffold was 
developed to mimic the interactions of the native PDZ domain ligand by substitution of appropriate 
chemical groups around the indole scaffold i.e. the 6-carboxyl group represents the C-terminus 
carboxylic acid group, which is known to form a hydrogen bond with the GLGF motif. This scaffold 
was modified by our collaborators using docking studies in an attempt to be specific for PSD-95 
PDZ1. 
 
6.2 Ligand Binding Screening by NMR Spectroscopy 
6.2.1 General 
The experimental conditions and the procedure employed to analyse the resultant 
data obtained from the binding screening of potential small molecule binders to the 
PSD-95 PDZ1 domain by NMR spectroscopy, discussed in this section are described 
in [3.3.1] and [3.3.4]. The chemical shift perturbations induced in the residues of the 
PSD-95 PDZ1 domain upon binding of a nine residue peptide of the C-terminus of 
the 5-HT2c receptor (VVSERISSV) i.e. the native ligand, was used as a reference for 
the PSD-95 PDZ1 domain inhibitor development process (Figures 6.2a & 6.2b).  
Those residues significantly perturbed in the PSD-95 PDZ1 domain, upon binding of 
the 5-HT2c receptor (Table 6.1), were used to determine if any binding by potential 
C-terminus 
X (-3) 
S/T (-2) 
X (-1) 
Ω (0) 
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inhibitor was specific. A residue was considered significantly perturbed if it was 
known to be a key residue in the PSD-95 PDZ1 binding region and/or the shift sum 
value was greater than the average shift sum i.e. the shift sum threshold. The shifts 
perturbed above the threshold are therefore an indication of the binding mode of the 
ligand. 
Table 6.1: The significant residue chemical shift perturbations induced by the binding of the nine 
residue C-terminal peptide of the 5-HT2c receptor to different regions of the PSD-95 PDZ1 domain, 
along with the corresponding shift sum threshold value. 
Ligand Shift Sum 
Threshold
a
 
(ppm) 
GLGF 
Motif & βB 
Strand
b
 
βB - βC 
Loop
b
 
αB Helixb Othersb 
5-HT2c 0.30 15G, 18G, 
20G, 21F, 
22S, 23I, 
24A, 25G 
26G, 27T, 
31H 
74H, 78V, 
81L 
43I, 44I, 
49A, 50A, 
88V, 90L  
a
 The equation used to determine the individual residue chemical shift perturbation sum value was 
      √((    )  (      ) ) where,    = Scaling Factor of 0.17. 
b
 Residues were 
considered significantly perturbed if they were known to be in PSD-95 PDZ1 binding region and/or 
the chemical perturbation shift sum value upon binding was greater than the shift sum threshold. 
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Figure 6.2: a) A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 and bound to a C-terminal peptide of the 5-HT2c receptor (VVSERISSV), 
with the shift sum threshold value indicated by the horizontal dashed line. The secondary structure of the PSD-95 PDZ1 domain (blue arrow = β-strand, red cylinder = α-
helix) is given below the plot. (* = residue not able to assign in unbound PSD-95 PDZ1, # = residue not able to assign in bound PSD-95 PDZ1 and P = Proline; these residues 
are absent from the chemical shift perturbation sum graph here and subsequently) b) A surface representation (grey) of the PSD-95 PDZ1 domain structure (PDB ID: 3GSL 
(Sainlos et al., 2011)) with the residues that produced the most pronounced chemical shifts mapped onto the structure (cyan). Overall the figure shows how the residues of the 
GLGF motif and the βB strand (18 – 24) and those residues in flexible regions of the PDZ domain are the most affected by binding of the C-terminal 5-HT2c receptor peptide. 
a) b) 
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6.2.2 First Generation Compounds 
The first generation of potential PDZ domain binders consisted of four compounds 
(Figure 6.3), with three based on an indole chemical scaffold (compounds 1a-c) and 
one based on a quinoline chemical scaffold (compound 1d); the numbering used to 
describe the different positions around the indole scaffold in this chapter is also 
shown in the figure. As mentioned previously, these compounds were the result of 
preliminary computational docking attempts of small molecule structures into the 
PSD-95 PDZ1 domain by our collaborators. 
 
 
 
1a: R1 = OMe; R2 = OH 
1b: R1 = Me; R2 = NHCH2CH2NH2 
1c: R1 = Me; R2 = NHCH2CO2H 
 
 
 
Figure 6.3: The structures of the first generation of potential PSD-95 PDZ1 domain binders, where 
1a-c are small molecule compounds based on the Fujii indole scaffold with chemical group variations 
at R1 and R2; 1d is a more divergent potential binder based on a quinolone scaffold. (Me = methyl i.e. 
CH3) 
 
The NMR binding screening showed that three of the four first generation 
compounds exhibited binding to the PSD-95 PDZ1 domain, albeit quite weak, when 
compared to that of the native ligand (Table 6.2 & Figure 6.4). 
Table 6.2: The significant residue chemical shift perturbations induced by the binding of the small 
molecule compounds 1a-d to different regions of the PSD-95 PDZ1 domain, along with the 
corresponding shift sum threshold value. 
Ligand Shift Sum 
Threshold
a
 
(ppm) 
GLGF 
Motif & 
βC Strand 
βB - βC 
Loop 
αB Helix Others Binding 
Efficacy
b
 
1a 0.03 20G, 21F, 
22S 
32I 74H, 
78V 
49A Weak 
1b / / / / / DNB
c
 
1c 0.01 20G / / / VV Weak
d
 
1d 0.02 20G 32I 74H / V Weak
d
 
a
 The equation used to determine the individual residue chemical shift perturbation sum value was 
      √((    )  (      ) ) where,     = Scaling Factor of 0.17. 
b
 Binding efficacy was 
classified using the shift sum threshold value: <0.01 = DNB, 0.01 – 0.019 = VV Weak, 0.02 – 0.024 = 
V Weak, 0.025 – 0.039 = Weak, 0.04 – 0.044 = Weak – Moderate, 0.045 – 0.059 = Moderate, 0.06 – 
0.074 = Moderate – Good, 0.075 – 0.139 = Good, 0.14 – 0.199 = Good – V Good, 0.2 – 0.299 = V 
Good, 0.30< = Excellent.
  c
 DNB = Did Not Bind. 
d
 V = Very.  
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From Table 6.2 and Figure 6.3, it is apparent that 1a binds better than 1c and 1d, 
with 1b showing no detectable binding to the PSD-95 PDZ1 domain; this was 
concluded as 1a showed the most numerous and substantial perturbations of the four 
first generation compounds. The binding was believed to be specific because those 
residues that showed chemical shift perturbations were the same as those affected by 
the binding of the native PSD-95 PDZ1 ligand, 5-HT2c. 
The reason why 1a showed the most numerous and substantial perturbations of the 
four first generation compounds may have been due to the carboxylic acid group at 
the 6-position forming a hydrogen bond with the residues in the GLGF motif, with 
the alkyl chain of the 5-methoxy (5-OMe) group extending into the hydrophobic 
pocket to give tighter binding; as the indole chemical scaffold had been shown to 
previously (Figure 6.1) (Fujii et al., 2007a). There is also the possibility that this 
hydrogen bond could have been formed between the GLGF motif and the 2-carboxyl 
group; however, this would not explain why 1a is shown to bind better to the PSD-95 
PDZ1 domain than 1c. The fact that no binding between 1b and PSD-95 PDZ1 is 
observed (or any of the other PDZ domains investigated) could have been as a result 
of the group at the 2-position being too large in terms of length or bulk, resulting in 
an unfavourable steric clash; which would also explain the very weak binding of 1c 
to the PSD-95 PDZ1 domain. 
Interestingly, the quinoline-based inhibitor 1d showed only very weak binding to the 
PSD-95 PDZ1 domain, whereas with the other three PDZ domains (PSD-95 PDZ2, 
SAP97 PDZ1&2), it showed reasonably good binding (Appendices, A.10 - A.12). 
This finding suggests that the actual binding pocket and extended groove of PSD-95 
PDZ1 may have a different shape to that of the other PDZ domains and hence, not be 
a suitable fit for the quinoline chemical scaffold. The exhibited PDZ domain 
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specificity of the quinoline scaffold of 1d may be useful for future research into 
novel, reversible, specific small molecule PDZ domain inhibitors. 
It was decided that the most logical next step would be to design and synthesise a 
number of inhibitors that have a longer and/or bulkier alkyl chain at the indole 5-
position. The rationale for this decision was to probe further into the hydrophobic 
pocket of the PSD-95 PDZ1 domain to see if this substitution has any effect on 
binding affinity. It was also believed that extension of the hydrophobic interactions 
between PSD-95 PDZ1 and the potential binders would ensure that the small 
molecule would bind in the desired orientation i.e. hydrogen bond formed between 
GLGF – 6-CO2H rather than GLGF – 2-CO2H. In addition to extending the alkyl 
chain at the 5-position, a couple of more novel and less rigid chemical scaffolds were 
designed; the aim was to investigate the suitability of other non-indole structure 
based scaffolds.  
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Figure 6.4: A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 domain and in the presence of the respective first generation potential PDZ 
domain binders, with the shift sum threshold values for the individual potential binder has been indicated by a horizontal dashed line in the corresponding colour of the data in 
the plot. The secondary structure of the PSD-95 PDZ1 domain (blue arrow = β-strand and red cylinder = α-helix) is given below the plot. The plot shows that small molecules 
1a, 1c and 1d bound to the PSD-95 PDZ1 domain with 1a being the potential PDZ binder that induced the strongest and most numerous chemical shift perturbations of the 
first generation compounds; 1b did not produce any significant chemical shift perturbations and so, was concluded to not to bind to PSD-95 PDZ1.    
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6.2.3 Second Generation Compounds 
Our collaborators synthesised a second generation of compounds (Figure 6.5), based 
on the analysis of the results from the first generation.  
 
 
 
 
 
2a: R1 = Et 
2b: R1 = CH2Ph 
 
 
 
Figure 6.5: The structures of the second generation of potential PSD-95 PDZ1 domain binders, where 
2a&b are small molecule compounds based on the Fujii indole scaffold with chemical group 
variations at R1. The structure of compounds 2c and 2d are based on more novel and extended organic 
scaffolds. (Et = ethyl i.e. C2H5 and Ph = phenyl i.e. C6H5) 
 
The binding screening of the second generation of compounds showed that two 
indole scaffold-based compounds (2a & 2b) specifically bound to the PSD-95 PDZ1 
domain (Table 6.3 & Figure 6.6). The binding of these two compounds was deemed 
to be better than the first generation as they perturbed a greater number of residues 
and with greater magnitude of chemical shift perturbations than those of the first 
generation. Whereas the remaining two compounds, with the more novel organic 
scaffolds (2c & 2d), showed no evidence of binding to the PSD-95 PDZ1 domain 
whatsoever. 
The only difference between first generation 1a and second generation compounds 
2a & 2b is the alkyl chain attached to the 5-O atom (OMe c.f. OEt and OCH2Ph 
respectively). 2a and 2b were shown to induce greater and more substantial chemical 
shift perturbations in the PSD-95 PDZ1 domain then 1a, this suggests that the 
previous hypothesis of adding a larger 5-alkyl chain would increase strength of 
binding may have been correct. This is most likely due to the ability of the small 
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molecule to interact more effectively with the hydrophobic pocket. The 5-ethoxy (5-
OEt) group of 2a has a small effect on increasing the chemical shift perturbations of 
the PSD-95 PDZ1 domain c.f. 1a but this is only a minor improvement. This could 
be due to the ethyl chain not being long enough or orientated sufficiently well 
enough to interact effectively enough with the hydrophobic pocket. 
Based on the number and magnitude of chemical shift perturbations, 2b was shown 
to be the best PSD-95 PDZ1 domain binder of the second generation compounds and 
this is most likely due to the large phenyl (Ph) ring being able to form more 
extensive hydrophobic interactions with the hydrophobic pocket. The inherent 
rotation possible around the 5-benzyloxy (5-O-CH2-Ph) side chain means that the 
phenyl ring is able to maximise the hydrophobic interaction with the pocket and yet 
still maintain the important 6-CO2H – GLGF motif hydrogen bond. 
It was disappointing that compounds 2c and 2d that contained the reasonably novel 
organic scaffolds, proved to be unsuccessful binders to the PSD-95 PDZ1 domain; 
2d did not show binding to any of the other three PDZ domains investigated either. 
2c showed some binding to the other three PDZ domains but the residues perturbed 
were far away from the canonical PDZ domain binding site and so the binding was 
believed to be non-specific (Appendices, A.13 – A.15). The size/length of 2c and 2d 
was probably too great to fit effectively in the PDZ binding region of the 
hydrophobic pocket and extended groove; this removed the potential for formation of 
favourable interactions and hence, resulted in no binding. 
The second generation of NMR binding screening experiments led to the conclusion 
that the indole chemical scaffold was the most suitable scaffold upon which to 
develop a PDZ domain inhibitor. Therefore, efforts were made to develop more 
extensive interactions between the designed potential inhibitors and those residues in 
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the binding region. As a result, a number of potential binders with alternative groups 
placed at various positions around the indole chemical scaffold were designed in an 
attempt to determine the importance of these positions to PDZ domain binding 
affinity and specificity. 
Table 6.3: The significant residue chemical shift perturbations induced by the binding of the small 
molecule compounds 2a-d to different regions of the PSD-95 PDZ1 domain, along with the 
corresponding shift sum threshold value. 
Ligand Shift Sum 
Threshold
a
 
(ppm) 
GLGF 
Motif & 
βC 
Strand 
βB - βC 
Loop 
αB Helix Others Binding 
Efficacy
b
 
2a 0.04 20G, 21F, 
22S 
32I, 78V 49A Weak 
2b 0.07 15G, 17S, 
20G, 21F, 
22S 
32I 74H, 
78V, 
81L 
44I, 49A Moderate 
- Good 
2c / / / / / DNB
c
 
2d / / / / / DNB
c
 
a
 The equation used to determine the individual residue chemical shift perturbation sum value was 
      √((    )  (      ) ) where,     = Scaling Factor of 0.17. 
b
 Binding efficacy was 
classified using the shift sum threshold value: <0.01 = DNB, 0.01 – 0.019 = VV Weak, 0.02 – 0.024 = 
V Weak, 0.025 – 0.039 = Weak, 0.04 – 0.044 = Weak – Moderate, 0.045 – 0.059 = Moderate, 0.06 – 
0.074 = Moderate – Good, 0.075 – 0.139 = Good, 0.14 – 0.199 = Good – V Good, 0.2 – 0.299 = V 
Good, 0.30< = Excellent.
  c
 DNB = Did Not Bind.  
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Figure 6.6: A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 domain and in the presence of the respective second generation potential 
PDZ domain binders, with the shift sum threshold values for the individual potential binder has been indicated by a horizontal dashed line in the corresponding colour of the 
data in the plot. The secondary structure of the PSD-95 PDZ1 domain (blue arrow = β-strand and red cylinder = α-helix) is given below the plot. The plot shows that small 
molecules 2a and 2b bound to the PSD-95 PDZ1 domain with 2b being the potential PDZ binder that induced the strongest and most numerous chemical shift perturbations of 
the second generation compounds; 2c and 2d did not produce any significant chemical shift perturbations and so, were concluded to not to bind to PSD-95 PDZ1.  
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6.2.4 Third Generation Compounds 
The structures of the resultant five indole scaffold-based third generation potential 
PDZ domain binders synthesised are shown below (Figure 6.7): 
3a: R1 = CH2Ph; R2 =  NHCH2CH2NHCH3; R3 = H 
3b: R1 = CH2Ph; R2 = OH; R3 = CH2CH2CO2H 
3c: R1 = CH2Ph; R2 = OH; R3 = CH2CH2CH2CO2H 
3d: R1 = OMe; R2 = NHCH2CH2NH2; R3 = H 
3e: R1 = OH; R2 = OH; R3 = H 
 
Figure 6.7: The structures of the third generation of potential PSD-95 PDZ1 domain binders, where 
3a-e are small molecule compounds based on the Fujii indole scaffold with chemical group variations 
of different length/bulk at R1, R2 and/or R3. (Me = methyl i.e. CH3 and Ph = phenyl i.e. C6H5) 
 
The binding screening investigation showed that four of the five compounds bound 
to PSD-95 PDZ1 (3a, 3b, 3c and 3e, Table 6.4), with 3d being the only potential 
inhibitor not to bind to the PDZ domain under investigation (Figure 6.8). 
Table 6.4: The significant residue chemical shift perturbations induced by the binding of the small 
molecule compounds 3a-e to different regions of the PSD-95 PDZ1 domain, along with the 
corresponding shift sum threshold value. 
Ligand Shift Sum 
Threshold
a
 
(ppm) 
GLGF 
Motif & 
βC 
Strand 
βB - βC 
Loop 
αB Helix Others Binding 
Efficacy
b
 
3a 0.06 15G, 20G, 
21F 
32I / 44I, 47G, 
50A, 90L 
Moderate 
- Good 
3b 0.075 15G, 17S, 
18G, 20G, 
21F, 22S 
/ 78V, 
81L 
44I, 46G, 
47G, 49A, 
50A, 90L 
Good 
3c 0.1 15G, 17S, 
18G, 20G, 
21F, 22S 
/ 78V, 
81L 
44I, 46G, 
47G, 49A, 
50A, 88V, 
90L 
Good 
3d / / / / / DNB
c
 
3e 0.1 20G, 21F, 
22S 
31H, 32I 74H, 
78V, 
81L 
49A, 72V Good 
a
 The equation used to determine the indivual residue chemical shift perturbation sum value was 
      √((    )  (      ) ) where,     = Scaling Factor of 0.17. 
b
 Binding efficacy was 
classified using the shift sum threshold value: <0.01 = DNB, 0.01 – 0.019 = VV Weak, 0.02 – 0.024 = 
V Weak, 0.025 – 0.039 = Weak, 0.04 – 0.044 = Weak – Moderate, 0.045 – 0.059 = Moderate, 0.06 – 
0.074 = Moderate – Good, 0.075 – 0.139 = Good, 0.14 – 0.199 = Good – V Good, 0.2 – 0.299 = V 
Good, 0.30< = Excellent.
  c
 DNB = Did Not Bind. 
 
The four PSD-95 PDZ1 binders from the third generation all showed more 
significant and better defined chemical shift perturbations than the compounds 
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produced in the second generation. 3a-c are, in structural terms, reasonably similar to 
each other with 3b and 3c differing only in the length of the alkyl chain prior to the 
carboxyl group at the 1-position; 3c has an extra CH2 c.f. 3b. The screening by NMR 
showed that 3b and 3c perturbed more residues (and more strongly) upon binding to 
the PSD-95 PDZ1 domain than 3a. 3a-c are also structurally similar to 2b; 3a has an 
alternative group substituted at the 2-position c.f. 2b; whereas, 3b and 3c have an 
alkylcarboxyl group at the 1-position c.f. 2b. This shows that substitution of 2b with 
a reasonably large amide side chain at the 2-position is not as effective as 
substitution with an alkylcarboxyl group at the 1-position; this can be concluded as 
3b and 3c are found to perturb the chemical shifts of PSD-95 PDZ1 residues in 
greater number and magnitude than 3a. These results may indicate that substitution 
at the 1-position of the indole scaffold enables different, potentially more favourable 
interactions to be formed with other residues in the binding area c.f. the 2-position. It 
is also possible that the 2-position is a suitable indole position to substitute at with 
various chemical groups but that the long amide-based side-chain (R2) of 3a forms 
undesirable interactions with surrounding residues; this will obviously reduce the 
binding potential of 3a c.f. 3b & 3c. 
The reason why 3b has a closer shift sum threshold to 3a than 3c may be due to the 
synthetic route utilised in its production. Our collaborators found it difficult to 
completely separate the 1-N-unsubstituted form i.e. 2b from the 1-N-substituted form 
i.e. 3b when producing 3b and so, some of the free NH form (2b) was detected in the 
3b sample; this will have meant that the actual PSD-95 PDZ1 : 3b ratio in the NMR 
sample was lower than intended. This problem was not encountered in the synthesis 
of 3c and so, is a possible explanation for the discrepancy in the chemical shift 
perturbations induced by 3b and 3c upon binding to PSD-95 PDZ1. 
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3d & 3e are structurally much simpler than 3a-c, with 3e in particular having no 
large chains at any position of the indole scaffold. 3d, in addition to no observable 
PSD-95 PDZ1 binding, also showed no binding to the SAP97 & PSD-95 PDZ2 
domains and only weak binding to the SAP97 PDZ1 domain (Appendices, A.16 – 
A.18). 3d is structurally similar to 1a, with the exception that 3d has an amide side 
chain at the 2-position, instead of the 2-carboxyl group of 1a. The lack of observable 
binding of 3d to three of the four PDZ domains is interesting as 1a bound, albeit 
weakly, to all four of the PDZ domains under investigation. This suggests that the 
large amide substitution (R2) has a detrimental effect on the binding of 3d to PDZ 
domains, possibly due to steric clashes or unfavourable interactions. 
The structure of 3d is very similar to 3a also, although 3d has a 5-methoxy group 
rather than the 5-benyzloxy group of 3a. As 3a bound satisfactorily to all four PDZ 
domains, this highlights the importance of the 5-benzyloxy group in ‘anchoring’ the 
small molecule into the binding pocket; probably by the formation of extensive 
interactions with the hydrophobic residues of the PSD-95 PDZ1 domain. The 5-
methoxy group is not able to form these hydrophobic interactions as successfully and 
hence, this combined with the bulky amine group at the 2-position possibly results in 
the inability of 3d to bind to the PSD-95 PDZ1 domain. 
3e was shown to exhibit good levels of chemical shift perturbations in the PSD-95 
PDZ1 domain, which is reasonably surprising given its simplicity i.e. it is identical to 
1a except for a 5-hydroxy group present in 3e (1a = 5-methoxy group). The observed 
levels of chemical shift perturbations could be due to 3e binding to the PSD-95 
PDZ1 domain in a number of different orientations in the high small molecule 
concentrations (10-fold excess) implemented in the binding screening by NMR 
process. This is a valid hypothesis as 3e does not have an alkyl chain at the 5-
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position and so, has no potential to form hydrophobic interactions with the 
hydrophobic pocket of the PDZ domain binding region to confer rigidity for a 
particular bound conformation; it also has four hydrogen bond acceptor/donor groups 
present (two carboxylic acid groups, one hydroxyl group and one amine group). A 
combination of these factors could possibly lead to 3e binding in a number of 
different orientations and hence, explain the surprising levels of perturbations 
observed. 
The 5- and 1-positions of the indole scaffold had been shown, by the effects of a 
range of substitutions in the binding screening by NMR of the third generation 
compounds, to be the regions of greatest impact to binding potential. Hence, the 
design of the next generation of potential binders focussed on substituting alternative 
groups at these positions. 
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Figure 6.8: A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 domain and in the presence of the respective third generation potential PDZ 
domain binders, with the shift sum threshold values for the individual potential binder has been indicated by a horizontal dashed line in the corresponding colour of the data in 
the plot. The secondary structure of the PSD-95 PDZ1 domain (blue arrow = β-strand and red cylinder = α-helix) is given below the plot. The plot shows that small molecules 
3a-c and 3e bound to the PSD-95 PDZ1 domain with 3c and 3e being the potential PDZ binders that induced the strongest and most numerous chemical shift perturbations of 
the third generation compounds; 3d did not produce any significant chemical shift perturbations and so, was concluded to not to bind to PSD-95 PDZ1. 
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6.2.5 Fourth Generation Compounds 
The PDZ domain inhibitor design process then led to the production of three more 
potential small molecule PDZ domain inhibitors (Figure 6.9). 
 
4a: R1 = CH2Ph; R2 =  CH2CH2CH2OH 
4b: R1 = 
Cy
Pe; R2 = CH2CH2CH2CO2H 
4c: R1 = OH; R2 = CH2CH2CH2CO2H 
 
 
Figure 6.9: The structures of the fourth generation of potential PSD-95 PDZ1 domain binders, where 
4a-c are small molecule compounds based on the Fujii indole scaffold with chemical group variations 
of different length/bulk at R1. (Ph = phenyl i.e. C6H5 and 
Cy
Pe = cyclopentyl i.e. C5H9) 
 
All three of the fourth generation compounds bound to the PSD-95 PDZ1 domain, 
with 4c showing promising levels of residue chemical shift perturbations of the PDZ 
domain upon binding (Table 6.5 & Figure 6.10). 
Table 6.5: The significant residue chemical shift perturbations induced by the binding of the small 
molecule compounds 4a-c to different regions of the PSD-95 PDZ1 domain, along with the 
corresponding shift sum threshold value. 
Ligand Shift Sum 
Threshold
a
 
(ppm) 
GLGF 
Motif & 
βC 
Strand 
βB - βC 
Loop 
αB Helix Others Binding 
Efficacy
b
 
4a 0.025 20G, 21F / / / Weak 
4b 0.08 15G, 18G, 
20G, 21F, 
22S 
26G, 
31H 
74H, 
78V, 
81L 
43I, 44I, 
49A, 50A, 
90L  
Good 
4c 0.20 15G, 18G, 
20G, 21F, 
22S, 23I, 
24A, 25G 
26G, 
27T, 
31H 
74H, 
78V, 
81L 
43I, 44I, 
49A, 50A, 
88V, 90L  
V Good
c
 
a
 The equation used to determine the individual residue chemical shift perturbation sum value was 
      √((    )  (      ) ) where,     = Scaling Factor of 0.17. 
b
 Binding efficacy was 
classified using the shift sum threshold value: <0.01 = DNB, 0.01 – 0.019 = VV Weak, 0.02 – 0.024 = 
V Weak, 0.025 – 0.039 = Weak, 0.04 – 0.044 = Weak – Moderate, 0.045 – 0.059 = Moderate, 0.06 – 
0.074 = Moderate – Good, 0.075 – 0.139 = Good, 0.14 – 0.199 = Good – V Good, 0.2 – 0.299 = V 
Good, 0.30< = Excellent.
  c
 V = Very. 
 
4a was designed to see if an 1-alkylhydroxyl group could form a better (or indeed 
any) interaction with the conserved His residue in the class I PDZ domain of PSD-95 
PDZ1 c.f. a 1-alkylcarboxyl group in 3c. However, this substitution made the 
compound extremely insoluble in aqueous buffer and sparingly soluble in DMSO-d6; 
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the maximum solubility in the aqueous NMR sample in the presence of 0.44% (v/v) 
DMSO-d6 was ~ 100µM. As a result, even though the binding screening showed that 
4a bound to the PSD-95 PDZ1 domain, the actual concentration of 4a present in the 
NMR sample was not the desired 10-fold excess, instead PSD-95 PDZ1 was in slight 
excess. Thus, it is not possible to directly compare, based on chemical shift 
perturbations, how well 4a binds to PSD-95 PDZ1 relative to the other ligands due to 
the solubility issue incurred. To investigate the effects of the 1-alkylhydroxyl group 
on PDZ domain binding, alterations would have to be made to the structure of 4a or 
of 4a-like compounds to make them more soluble in aqueous solutions. 
4b and 4c are structurally similar, differing only by the incorporation of 5-
cyclopentoxy (5-O
Cy
Pe) and 5-hydroxy (5-OH) groups respectively. Of the two 
compounds, 4c appeared to bind better; the binding of 4c to PSD-95 PDZ1 is 
reminiscent of the native ligand binding, as virtually every residue of the PSD-95 
PDZ1 domain is perturbed upon binding (Figure 13). 4c is an evolution of 3e with a 
1-alkylcarboxyl group added instead of an unsubstituted 1-NH group and the binding 
screening shows that this addition results in much more extensive chemical shift 
perturbations of the PSD-95 PDZ1 domain. This implies that substitution of an 
alkylcarboxyl group at the 1-position of the indole scaffold enables more interactions 
to be formed between the small molecule and PSD-95 PDZ1 and hence, more 
chemical shift perturbations produced upon binding. However, as with 3e, it cannot 
be ruled out that the lack of an alkyl chain at the 5-position may allow 4c to bind to 
the PSD-95 PDZ1 domain in a number of different orientations in the binding region. 
The multiple binding modes possible could therefore account for the extensive and 
native ligand-like chemical shift perturbations exhibited by 4c upon binding to the 
PSD-95 PDZ1 domain. 
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4b shows that substitution of the 5-benzyloxy group in 3c with 5-cyclopentoxy group 
results in slightly weaker binding to the PSD-95 PDZ1 domain compared to 3c, 
suggesting that the cyclopentyl ring of 4b is not able to form as numerous and/or as 
strong hydrophobic interactions with the PDZ domain binding pocket than the benzyl 
group. This could be because the cyclopentyl ring structure is a less suitable structure 
to fit in the hydrophobic pocket of PSD-95 PDZ1 than the phenyl ring and hence, 
does not maximise the possible interactions with the surrounding residues as 
effectively. 
The final stage of the binding screening by NMR spectroscopy investigation was to 
determine the importance of the 6-carboxyl and 3-methyl groups to the binding of 
the PSD-95 PDZ1 domain; therefore a final generation of inhibitors was designed 
and synthesised accordingly. 
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Figure 6.10: A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 domain and in the presence of the respective fourth generation potential 
PDZ domain binders, with the shift sum threshold values for the individual potential binder has been indicated by a horizontal dashed line in the corresponding colour of the 
data in the plot. The secondary structure of the PSD-95 PDZ1 domain (blue arrow = β-strand and red cylinder = α-helix) is given below the plot. The plot shows that small 
molecules 4a-c all bound to the PSD-95 PDZ1 domain with 4c being the potential PDZ binders that induced the strongest and most numerous chemical shift perturbations of 
the fourth generation compounds. The limited solubility in aqueous buffer of 4a meant that, although it was shown to bind to PSD-95 PDZ1, it was not an accurate indication 
of the actual strength of binding of 4a relative to that of the other fourth generation compounds.   
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6.2.6 Fifth Generation Compounds 
Three final potential small molecule PDZ domain inhibitors were designed, 
synthesised and screened for binding to the PSD-95 PDZ1 domain (Figure 6.11). 
 
5a: R1 = O CH2Ph; R2 = H; R3 = CH2CH2CH2CO2H; R4 = 
CO2H 
5b: R1 = O CH2Ph; R2 = H; R3 = CH2CH2CO2H; R4 = H 
5c: R1 = O CH2Ph; R2 = Me; R3 = CH2CH2CH2CO2H; R4 = H 
 
 
Figure 6.11: The structures of the fifth generation of potential PSD-95 PDZ1 domain binders, where 
5a-c are small molecule compounds based on the Fujii indole scaffold with chemical group variations 
of different length/bulk at R2 and/or R4. (Ph = phenyl i.e. C6H5) 
 
The binding screening by NMR spectroscopy showed that all three compounds 
bound to the PSD-95 PDZ1 domain, although there was a marked difference between 
the perturbations induced upon binding of 5a and those of 5b & 5c (Table 6.6 & 
Figure 6.12); where 5a was found to bind to PSD-95 PDZ1 much better than 5b and 
5c. 
Table 6.6: The significant residue chemical shift perturbations induced by the binding of the small 
molecule compounds 5a-c to different regions of the PSD-95 PDZ1 domain, along with the 
corresponding shift sum threshold value. 
Ligand Shift Sum 
Threshold
a
 
(ppm) 
GLGF 
Motif & 
βC 
Strand 
βB - βC 
Loop 
αB Helix Others Binding 
Efficacy
b
 
5a 0.15 15G, 18G, 
20G, 21F, 
22S, 23I, 
25G 
26G, 
27T, 
31H 
72V, 
74H, 
78V 
42K, 44I, 
49A, 88V, 
90L  
Good – 
V Good
c
 
5b 0.04 / 31H, 32I 74H, 
78V, 
81L 
90L Weak - 
Moderate 
5c 0.03 / 31H, 32I 74H / Weak 
a
 The equation used to determine the indivual residue chemical shift perturbation sum value was 
      √((    )  (      ) ) where,     = Scaling Factor of 0.17. 
b
 Binding efficacy was 
classified using the shift sum threshold value: <0.01 = DNB, 0.01 – 0.019 = VV Weak, 0.02 – 0.024 = 
V Weak, 0.025 – 0.039 = Weak, 0.04 – 0.044 = Weak – Moderate, 0.045 – 0.059 = Moderate, 0.06 – 
0.074 = Moderate – Good, 0.075 – 0.139 = Good, 0.14 – 0.199 = Good – V Good, 0.2 – 0.299 = V 
Good, 0.30< = Excellent.
  c
 V = Very. 
 
The structure of 5a is very similar to 3c, but with the 3-methyl group removed; this 
alteration indicates that removal is preferential for binding strength as 5a showed 
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more extensive chemical shift perturbations than 3c. Interestingly, this indicates that 
the presence of the 3-methyl group in 3c either leads to slightly unfavourable steric 
clashes or prevents the molecule from interacting as effectively with neighbouring 
residues in the binding site. 
5b has the same structure as 5a but with the 6-carboxyl group removed. This has a 
pronounced effect on the residue chemical shift perturbations induced upon binding 
to the PSD-95 PDZ1 domain and hence, the binding affinity of 5b; based on 
chemical shift perturbations, the PSD-95 PDZ1 binding of 5b is much weaker 5a. 
This was as expected because as the ability to form a 6-CO2H – GLGF hydrogen 
bond has been removed and so, the binding of 5b to the PSD-95 PDZ1 domain relies 
mainly upon the hydrophobic interactions between the 5-benzyloxy group and the 
residues of the binding pocket; thus, less PSD-95 PDZ1 residues will be perturbed. It 
is possible that the molecule could ‘flip’ its binding orientation and form a 2-CO2H – 
GLGF hydrogen bond but this is likely to be more unfavourable due to steric clashes 
of the 1-alkylcarboxyl group with the surrounding residues of the PSD-95 PDZ1 
domain.  
5c is a variation on the structure of 5b with an additional 3-methyl group and 5c and 
was shown to bind to PSD-95 PDZ1 less effectively than 5b as 5c induced less 
chemical shift perturbations in the PSD-95 PDZ1 domain c.f. 5b. This again suggests 
that the presence of a 3-methyl group has a detrimental effect on binding, which is 
consistent with the trend in binding affinity observed between 3c and 5a. This can 
again be attributed to the same reasons described previously. 
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Figure 6.12: A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 domain and in the presence of the respective fifth generation potential PDZ 
domain binders, with the shift sum threshold values for the individual potential binder has been indicated by a horizontal dashed line in the corresponding colour of the data in 
the plot. The secondary structure of the PSD-95 PDZ1 domain (blue arrow = β-strand and red cylinder = α-helix) is given below the plot. The plot shows that small molecules 
5a-c all bound to the PSD-95 PDZ1 domain with 5a being the potential PDZ binders that induced the strongest and most numerous chemical shift perturbations of the fifth 
generation compounds. The reduced perturbations of 5b and 5c upon binding c.f.5a indicate the importance of the 6-CO2H group to PSD-95 PDZ1 binding affinity.   
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6.2.7 Summary of Ligand Binding Screening by NMR Spectroscopy 
A number of different small organic molecules have been designed and synthesised. 
These compounds started from relatively simple organic molecules and got 
increasingly more complex and substituted as the inhibitor development process 
progressed (Figure 6.13).  
 
 
 
 
 
 
 
 
 
 
Figure 6.13: The figure shows the evolution of the potential PSD-95 PDZ1 domain binders from the 
initial lead compound from the first generation of compounds – 1a. It can be seen that 2b and 3c were 
the structures in their respective binder design iteration that were used as templates for the subsequent 
generation of potential binders. It is interesting to note that the two strongest PSD-95 PDZ1 binders 
(4c and 5a) do not share similar development processes and this is reflected in the relative complexity 
of their structures. 
 
The binding affinity, as assessed by the number and magnitude of chemical shift 
perturbations induced, of the small molecule compounds to the PSD-95 PDZ1 
domain was shown to increase substantially from the early to late development 
stages (Figure 6.14). A large number of the synthesised potential inhibitors showed 
binding to the PSD-95 PDZ1 domain, with 4c and 5a showing levels of residue 
chemical shift perturbations approaching that of the native PSD-95 PDZ1 ligand, the 
5-HT2c receptor. 
There was a number of important PDZ domain inhibitor design points discovered 
during the ligand binding screening by NMR spectroscopy process: 
- The most suitable organic scaffold to build a PDZ domain inhibitor upon 
was found to be an indole structure. 
- An indole 6-carboxyl group is extremely important for binding. 
1a 2b 
2a 
3b 
3a 
3c
a 
3e
 
 2b 
4c 
4b 
4a 
5a
a 
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- An extended alkyl chain at the indole 5-position helps to confine the 
small molecule inhibitor to bind in the desired orientation/conformation. 
- The indole 1-position is a more effective position to substitute at than the 
indole 2-position to improve binding affinity. 
- Any chemical group substitution at the indole 3-position other than a 
hydrogen may be detrimental to binding affinity. 
The next stage in the development of novel small molecule inhibitors of the PSD-95 
PDZ1 – 5-HT2c interaction was to determine the actual strength of binding of a 
number of the small molecules to PSD-95 PDZ1. This was done using two different 
biophysical methods – NMR Spectroscopy and isothermal titration calorimetry 
(ITC). 
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Figure 6.14: A plot of the chemical shift perturbation sum differences between free PSD-95 PDZ1 domain and in the presence of the best binder in each of the five 
generations of compounds tested in the PSD-95 PDZ1 domain inhibitor development process and the C-terminal peptide of the 5-HT2c receptor, with the shift sum threshold 
values for the individual potential binder has been indicated by a horizontal dashed line in the corresponding colour of the data in the plot. The secondary structure of the 
PSD-95 PDZ1 domain (blue arrow = β-strand and red cylinder = α-helix) is given below the plot. The plot and the threshold values show how the binding affinity has 
progressed from the initial low values of the lead compound 1a to the high levels of chemical shift perturbations produced by binders 4c and 5a. It can be seen that binding of 
the 4c to the PSD-95 PDZ1 domain induces perturbations of practically all the PSD-95 PDZ1 domain residues in a similar manner that the 5-HT2c peptide does and that 5a 
binding shows a similar profile of individual residue perturbations to the native ligand, although to a lesser extent in terms of magnitude.    
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6.3 Binding Affinity Determination by NMR Spectroscopy 
6.3.1 General 
The experimental conditions and the procedure employed to analyse the resultant 
data from the binding affinity determination of 3c and 4c to the PSD-95 PDZ1 
domain by NMR spectroscopy discussed in this chapter are described in [3.3.5].   
6.3.2 PSD-95 PDZ1 – 3c KD Determination 
The NMR experiments were first carried out on 
15
N PSD-95 PDZ1 in the absence 
and presence of up-to 30-fold excess of 3c (Figure 6.16); the data obtained was used 
to determine how strongly 3c bound to the PSD-95 PDZ1 domain. Analysis of this 
data yielded a PSD-95 PDZ1 KD of 2.355mM (Table 6.7 & Figure 6.15) and 
indicates that 3c binds to the PSD-95 PDZ1 domain with an affinity of over two 
orders of magnitude weaker than the 5-HT2c receptor (KD (determined by ITC 
[4.5.3]) = 19.95µM); the native PSD-95 PDZ1 ligand. This difference in the 3c PSD-
95 PDZ1 KD value to the native ligand was not unexpected as the binding screening 
had indicated that compared to native ligand binding, the extent and magnitude of the 
chemical shift perturbations induced by 3c in the PSD-95 PDZ1 domain were both 
fewer and of weaker magnitude.  
As well as being able to calculate the binding affinity of 3c to the PSD-95 PDZ1 
domain using this NMR experimental methodology, it is also possible to gain an 
insight into how 3c binds to the PDZ domain. This is achieved by analysing the 
residue chemical shifts perturbed at each concentration point compared to the 
reference spectrum and how strongly these residues are perturbed overall (Table 6.8). 
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Figure 6.15: The fit curve produced for Val88 of PSD-95 PDZ1 over the course of the 3c 
concentration titration (blue) and the corresponding fitting function (magenta). This particular residue 
shows very good agreement between the experimental and fitting function values and hence, was used 
in the KD value determination process. 
 
Table 6.7: The KD measured for the ten residues of the PSD-95 PDZ1 domain that best fitted the 
fitting function during the NMR titration with 3c and hence, were used in the determination of the 
binding affinity of 3c to PSD-95 PDZ1.  
Residue KD (mM) 
15Gly 2.498 
21Phe 2.38 
49Ala 2.495 
50Ala 2.712 
53Gly 2.342 
71Glu 2.899 
80Ala 1.693 
82Lys 2.497 
86Ser 2.191 
88Val 1.841 
Average = 2.355mM 
 
 
  
Protein : Ligand Ratio 
∆δ 
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Figure 6.16: a) An overlay of the 
1
H-
15
N HSQC experiments of 
15
N PSD-95 PDZ1 in the presence of 3c (P:L = 1:0-1:30, acquired at 298K, with a field strength of 600MHz, 
in 20mM phosphate 0.1mM EDTA buffer, pH6.3); where the colour of the spectrum corresponding to each titration point is given in the table to the right. A number of the 
important residues and/or largest perturbations have been labelled, along with the direction of the shift over the course of the titration. b) An enlarged view of the peak 
corresponding to Gly20 over the titration; it can be seen how the peak intensity shifts and decreases from P:L = 1:0 – 2:1 and then disappears from 1:1 onwards. c) An 
enlarged view of the peaks corresponding to the 31His and 74His in the titration.   
 
 
a) b) 
c) 
31H 
74H 
20G 
49A 
82K 
22S 
23I 
32I 
21F 
78V 
80A 
44I 
11T 
P:L         Colour 
 
1:0              Blue 
10:1             Red 
5:1            Green 
2:1           Purple 
1:1          Orange 
1:2             Cyan 
1:5        Midpink 
1:10          Black 
1:20     Sky Blue 
1:25       Maroon 
1:30      Magenta    
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Table 6.8: The individual residues of the PSD-95 PDZ1 domain that are perturbed at the different 3c 
concentrations. Those residues highlighted in red are those that showed the most pronounced shift 
perturbations over the series of titrations. 
PSD-95 PDZ1 – 3c Ratio Residue(s) Perturbed 
1:0 / 
10:1 20G 
5:1 / 
2:1 21F, 49A, 80A, 82K 
1:1 15G, 22S, 23I, 44I, 78V, 
81L 
1:2 18G, 46G, 47G, 71E, 86S 
1:5 11T, 16N, 26G, 31H, 32I, 
48A, 50A, 74H, 77A, 84A, 
88V, 90L 
1:10 24A, 25G, 27T, 41T, 61I, 
64V, 75S, 89R, 92V, 94R 
1:20 25G, 29N, 38I, 40I, 53G, 
65N, 76A, 84A 
 
The titration indicates that even at a 10-fold excess of protein, 3c appears to target 
the GLGF motif (Gly20 indicated in bold) as desired and is able to show a 
perturbation in the chemical shift of Gly20. A number of residues in the binding 
region of the PSD-95 PDZ1 domain show perturbations at 3c concentrations of 
equimolar or less; suggesting that the compound binds in a conformation and 
orientation to form numerous interactions with surrounding residues. The Gly20 
peak disappears from the spectrum from equimolar concentrations onwards, which 
suggests the residue is in intermediate exchange between unbound and 3c bound 
states; this has caused attenuation of the peak to occur. By 10-fold excess of 3c, all 
the key residues in the binding domain showed perturbations and by 20-fold excess, 
over 50% of the PSD-95 PDZ1 domain residues showed perturbations. At 30-fold 
excess, the residue perturbations had ceased, suggesting that the PSD-95 PDZ1 
domain had reached saturation level of 3c.  
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6.3.3 PSD-95 PDZ1 – 4c KD Determination 
A second series of NMR experiments were carried out on 
15
N PSD-95 PDZ1 in the 
absence and presence of up-to 30-fold excess of 4c (Figure 6.19). This data was used 
to determine how strongly 4c bound to the PSD-95 PDZ1 domain and yielded a KD 
of 1.177mM (Table 6.9 & Figure 6.17). Therefore, 4c apparently binds to the PSD-
95 PDZ1 domain with an affinity of under 1.5 orders of magnitude weaker than the 
5-HT2c receptor. Given that the NMR binding screening results displayed that 4c 
showed similar residue chemical shift perturbations to 5-HT2c, this KD value is 
somewhat surprising. It is possible that 4c binds heterogeneously to the PSD-95 
PDZ1 domain, via a number of different orientations and conformations at higher 4c 
concentrations or that determination of KD by NMR spectroscopy may not be the 
most suitable or accurate method; this could be due to solubility effects or limited 
accessibility of the saturated state. 
 
 
Figure 6.17: The fit curve produced for Gly85 of PSD-95 PDZ1 over the course of the 4c 
concentration titration (blue) and the corresponding fitting function (magenta). This particular residue 
shows very good agreement between the experimental and fitting function values and hence, was used 
in the KD value determination process. 
 
4c was calculated to have a KD of 348µM to SAP97 PDZ1 (Figure 6.18) by the same 
NMR methodology and this appears to be a better approximation of the PDZ domain 
binding ability of 4c, given the binding screening results. This result indicates a level 
 
Protein : Ligand Ratio 
∆δ 
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of PDZ domain specificity of 4c, this had been initially indicated in the NMR 
binding screening as 4c had shown more substantial chemical shift perturbations 
when binding to the SAP97 PDZ1 domain c.f. PSD-95 PDZ1 (Appendices, A.19). 
 
 
Figure 6.18: The fit curve produced for Lys43 of SAP97 PDZ1 over the course of the 4c 
concentration titration (blue) and the corresponding fitting function (magenta). This particular residue 
shows very good agreement between the experimental and fitting function values and hence, was used 
in the KD value determination process. 
 
Table 6.9: The KD of the 10 residues of the PSD-95 PDZ1 domain that best fitted the fitting function 
best during the NMR titration with 4c and hence, were used in the determination of the binding 
affinity of 4c to PSD-95 PDZ1.  
Residue KD (mM) 
20Gly 1.191 
24Ala 1.341 
42Lys 1.454 
43Ile 1.129 
46Gly 0.935 
48Ala 0.846 
49Ala 1.346 
80Ala 1.124 
85Gly 1.178 
86Ser 1.222 
Average = 1.177mM 
  
Analysis of the residues perturbed at low concentration of 4c i.e. 5-fold excess of 
PSD-95 PDZ1 indicates that 4c binds in the binding region as desired (Table 6.10). 
However, unlike 3c, it does not perturb residues of the GLGF motif until equimolar 
 
Protein : Ligand Ratio 
∆δ 
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concentrations and the Gly20 peak, although shifted, remains unattenuated 
throughout the titration. This means that 20Gly is not going into intermediate 
exchange upon binding to 4c unlike 3c, suggestive of a difference in the binding 
nature of the two molecules. By 5-fold of excess of 4c, 50% of the PSD-95 PDZ1 
domain residues showed perturbations and by 10-fold excess, there was uniform 
residue perturbation. 
Table 6.10: The individual residues of the PSD-95 PDZ1 domain that are perturbed at the different 4c 
concentrations. Those residues highlighted in red are those that showed the most pronounced shift 
perturbations over the series of titrations. 
PSD-95 PDZ1 – 3c Ratio Residue(s) Perturbed 
1:0 / 
10:1 / 
5:1 22S, 23I, 80A, 81L, 82K 
2:1 24A, 31H, 49A, 78V, 82K, 
84A 
1:1 15G, 16N, 20G, 32I, 84A 
1:2 21F, 41T, 42K, 43I, 44I, 
48A, 83E, 85G 
1:5 12L, 14R,18G, 27T, 38I, 
39F, 40I, 46G, 47G, 61I, 
64V, 72V, 74H, 75S, 76A, 
88V, 89R, 90L 
1:10 All other residues 
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Figure 6.19: a) An overlay of the 
1
H-
15
N HSQC experiments of 
15
N PSD-95 PDZ1 in the presence of 4c (P:L = 1:0 =1:30, acquired at 298K, with a field strength of 600MHz, 
in 20mM phosphate 0.1mM EDTA buffer, pH6.3); where the colour of the spectrum corresponding to each titration point is given in the table to the right. A number of the 
important residues and/or largest perturbations have been labelled, along with the direction of the shift over the course of the titration. b) An enlarged view of the peak 
corresponding to Gly20 over the titration; it can be seen how the peak shifts across the course of the titration but in the opposite direction and does not disappear c.f. 3c 
(Figure 6.16). c) An enlarged view of the peaks corresponding to the 31His and 74His in the titration.   
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6.3.4 Discussion 
Determination of the binding affinity of 3c and 4c to the PSD-95 PDZ1 domain by 
NMR spectroscopy shows that 4c binds the PDZ domain more strongly than 3c, 
which is consistent with the initial NMR chemical shift perturbation data. The 
determined PSD-95 PDZ1 KD values with the various small molecules were slightly 
weaker than expected, especially in the case of 4c; this was based upon initial 
docking statistics and the levels of chemical shift perturbations induced in the NMR 
binding screening. Therefore, it was important to verify the binding constant of 3c 
and 4c to PSD-95 PDZ1 using another biophysical technique, such as isothermal 
titration calorimetry (ITC). 
6.4 Binding Affinity Determination by Isothermal Titration Calorimetry   
6.4.1 General 
Determination of a direct binding affinity value (KD) between the PSD-95 PDZ1 
domain and either 3c or 4c by ITC was unsuccessful, due to the weak binding of the 
small molecule binders; therefore, an indirect measurement was used. This was done 
by determining the inhibitory constant value (Ki). To determine the Ki value for 3c or 
4c, titrations of the native PSD-95 PDZ1 interaction were required in the absence and 
presence of (and thus, in competition with), the potential inhibitor under 
investigation. This process also indicated if (and to what extent) the PDZ domain 
binders were able to disrupt the native PSD-95 PDZ1 – 5-HT2c interaction. 
The experimental conditions and the procedure employed to analyse the resultant 
data obtained from the inhibitory constant determination of 3c and 4c for the PSD-95 
PDZ1 - 5-HT2c interaction by ITC discussed in this chapter are described in [3.4.1] 
and [3.4.3]. 
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6.4.2 Competition Experiments with 3c 
Two ITC experiments were carried out between 100µM PSD-95 PDZ1 and 750µM 
5-HT2c with 3c present in both samples at a protein : 3c ratio of 1:10 and 1:25 (1mM 
or 2.5mM ligand respectively, Appendices, A.20). The resultant ITC curves were 
overlaid with the native interaction ITC curve (Figure 6.20a) and the resultant   
   
, 
along with the native KD, values were plotted against ligand concentration to 
determine Ki (Figure 6.20b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.20: (a) Overlay of PSD-95 PDZ1 – 5HT2c ITC titration curves in the absence (black) and 
presence of 3c at PDZ : 3c ratio of 1:10 (red) and 1:25 (blue). As the concentration of 3c increases, the 
binding curve gradient becomes shallower indicating weaker binding i.e. an inhibitory effect. (b) The 
plot of resultant KD/  
   
 values used in the equation   
         
  
  
 [ ], to give a Ki for 3c of 
932µM.  
 
The competition experiments carried out by ITC with 3c resulted in a Ki value of 
932µM for the PSD-95 PDZ1 – 5-HT2c interaction. This shows that 3c is able to 
exert an inhibitory effect on the native interaction of the PSD-95 PDZ1 domain albeit 
reasonably weakly, by reversibly binding to PSD-95 PDZ1. 
6.4.3 Competition Experiments with 4c 
Three ITC experiments were carried out between 100µM PSD-95 PDZ1 and 750µM 
5-HT2c with 4c present in both samples at either a protein : 4c ratio of 1:2.5, 1:5 or 
K
D
/ 
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1:7.5 (250µM, 500µM or 750µM ligand respectively, Appendices, A.21). The 
resultant ITC curves were overlaid with the native interaction ITC curve (Figure 
6.21a) and the resultant   
   
, along with the native KD, values were plotted against 
ligand concentration to determine Ki (Figure 6.21b).  
 
Figure 6.17: (a) Overlay of PSD-95 PDZ1 – 5HT2c ITC titration curves in the absence (black) and 
presence of 4c at PDZ : 4c ratio of 1:2.5 (red), 1:5 (blue) and 1:7.5 (green). As the concentration of 4c 
increases, the binding curve gradient becomes shallower indicating weaker binding i.e. an inhibitory 
effect. (b) The plot of resultant KD/  
   
 values used in equation   
         
  
  
 [ ], to give a Ki 
for 4c of 353µM.  
 
The competition experiments carried out by ITC with 4c resulted in an inhibitory 
constant value of 353µM for the PSD-95 PDZ1 – 5-HT2c interaction. This shows that 
4c, like 3c, is able to exert a reasonably satisfactory inhibitory effect on the native 
interaction of the PSD-95 PDZ1 domain, by reversibly binding to PSD-95 PDZ1. 
The lower Ki value for 4c than 3c indicates that 4c has more of an inhibitory effect 
on the PSD-95 PDZ1 – 5-HT2c interaction than 3c; which is again consistent with the 
previous results of the NMR binding screening and KD determination by NMR 
spectroscopy. 
6.5 Comparison of KD and Ki  
Comparison of the KD and Ki values for 3c and 4c shows that the two values differ, 
with Ki being consistently lower than KD (Table 6.11); however, both methods 
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consistently indicate that 3c binds more weakly to PSD-95 PDZ1 than 4c. The reason 
for these observed differences could be due to the inherent differences in the two 
biophysical techniques. 
Table 6.11: A comparison of the binding affinities of the small molecule binders 3c and 4c with the 
PSD-95 PDZ1 domain determined by NMR spectroscopy and ITC  
Inhibitor KD Ki 
3c 2.355mM 930µM 
4c 1.177mM 353µM 
 
For the NMR titration to yield reliable KD values, the system should be in a very fast 
exchange regime; deviation from this leads to errors in the determination of KD 
values. Furthermore, the KD value determined by NMR spectroscopy is specific for 
the PSD-95 PDZ1 domain itself regardless of the various different ligands that it may 
interact with naturally; it is a measure of how strongly 3c or 4c bind to the PDZ 
domain. Whereas, the Ki value is specific solely to the PSD-95 PDZ1 – 5-HT2c 
interaction; it is a measure of how strongly 3c or 4c disrupts this particular 
interaction and hence, could vary reasonably significantly from one PSD-95 PDZ1 
domain interaction to the next. 
In terms of the respective experimental procedures, the determination of binding 
affinity by NMR uses higher protein and ligand concentrations than the ITC 
methodology. In addition, the process of tracking individual residue chemical shifts 
quantitatively and then using these in a fitting function has a number of sources of 
possible of error and inaccuracy. The ITC titrations themselves have been shown to 
be more precise; thus, a combination of the described technical differences could 
have led to the variation in constant values determined for 3c and 4c. It can be 
concluded that although, the constants KD and Ki values are not directly comparable, 
they can be used in conjunction with each other to give an idea of the binding 
efficacy of small molecule inhibitor 3c and 4c to the PSD-95 PDZ1 domain. 
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It was important to determine the structure of the PSD-95 PDZ1 domain bound 
separately to both 3c and 4c, to get an accurate idea of the various intermolecular 
interactions that were occurring in each PDZ domain – small molecule complex. 
This information could then be used to direct future research in PSD-95 PDZ1 
domain inhibition or even PDZ domain inhibition research in general. 
6.6 PDZ Domain – Small Molecule Complex Structure Determination by NMR 
Restraint-Driven Docking 
6.6.1 General 
Due to the weak binding of the small molecules, it was not possible to obtain a 
structure of the PSD-95 PDZ1 domain bound to either 3c or 4c by crystallographic or 
NMR spectroscopy methods, the High Ambiguity Driven DOCKing program 
webserver (HADDOCK) (Dominguez et al., 2003, van Dijk et al., 2006, De Vries et 
al., 2010) on the e-NMR grid (*) was utilised. HADDOCK was the chosen docking 
methodology as it has performed extremely well in the critical assessment of 
predicted interactions (CAPRI) experiments (van Dijk et al., 2005, De Vries et al., 
2007) and because this docking methodology allows the incorporation of 
experimentally-derived parameters, such as distance restraints determined by NMR 
spectroscopic experiments, to drive the docking protocol. 
To determine the distance restraints for the particular PSD-95 PDZ1 – small 
molecule complex by NMR spectroscopy, the desired NMR sample was prepared 
and the experimental procedure carried out as described in [3.3.3] and [3.3.5] 
respectively. The HADDOCK methodology utilised for the restraint-driven docking 
of the PSD-95 PDZ1 domain in complex with the particular small molecule inhibitor 
is detailed in [3.5.5]. 
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6.6.2 PSD-95 PDZ1 – 3c Complex Structure Determination 
The NMR experiments were performed on the prepared PSD-95 PDZ1 – 3c complex 
sample and the resultant intra-ligand and intermolecular interactions obtained were 
assigned to the respective protein and ligand atoms, as previously described [3.5.5] 
(Figure 6.22 & Appendices, A.7).  
The intra-ligand and intermolecular distance restraints were incorporated into the 
HADDOCK docking procedure, along with the docking options that were found to 
be the most suitable [Table 3.6, 3.5.5]. The output of the distance restraint-driven 
docking gave seven different possible clusters of structures of the PSD-95 PDZ1 
domain in a bound complex with 3c (Figure 6.23a & b). An ensemble of the 20 
lowest HADDOCK scoring structures from the lowest HADDOCK scoring cluster 
was created (Figure 6.23c) and the structure with the lowest HADDOCK score of 
these was taken as the representative structure of the PSD-95 PDZ1 – 3c complex 
(Figure 6.23d-f). It can be seen that the complexes from the top three clusters 
produced from the HADDOCK docking process are very similar structurally and 
these account for over 180 of the 200 final solvent refined structures. There is some 
deviation observed in the docked conformation of 3c in the other four clusters c.f. the 
representative cluster; however these are of limited number and are a consequence of 
the cluster analysis method. The calculated structure of the complex formed between 
PSD-95 PDZ1 and 3c highlights a number of important details that could explain: 
a) Why 3c is able to bind to the PSD-95 PDZ1 domain 
b) Why 3c is not able to bind with greater affinity to the PSD-95 PDZ1 domain 
The obtained structure shows that the 6-carboxyl group of 3c forms a hydrogen bond 
with the backbone NH of the 19L residue of the GLGF motif, as the native ligand 
does. Such is the power of the rigid body docking algorithm, that the HADDOCK 
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webserver was able to model this interaction even without any hydrogen bond 
restraints being placed in the docking parameter set. As mentioned in [3.5.5], when 
hydrogen bond restraints were added to the run parameters, there was very little 
difference in the resultant structures obtained; as there was no need to artificially bias 
the docking process, the hydrogen bond restraints were not included in the docking 
protocol. There are also hydrophobic interactions present in the representative 
structure between the 5-benzyloxy group and the residues that form the hydrophobic 
binding pocket including Val78 and Leu81. These hydrophobic interactions were 
thought to be crucial in allowing 3c to bind to the PSD-95 PDZ1 domain in the NMR 
binding screening process and this has been corroborated by the representative 
structure obtained from the HADDOCK webserver. 
Conversely, the bound complex structure indicates that the presence of a 3-methyl 
group on 3c could be causing unfavourable steric clashes with the Gly20 and Phe21 
residues in the GLGF motif of PSD-95 PDZ1; this indicates that the rationale behind 
the description as to why 5a binds to the PSD-95 PDZ1 domain more tightly than 3c, 
may have been correct. Also, from the representative structure, there is no evidence 
of the 1-alkylcarboxyl group forming any intermolecular interactions with the PSD-
95 PDZ1 domain and so, may in fact, be detrimental to binding affinity by causing 
unfavourable steric clashes or electrostatic repulsion (Figure 6.23d-f). 
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Figure 6.22: The obtained 2-D 
13
C, 
15
N-filtered NOESY spectrum of 
13
C 
15
N PSD-95 PDZ1 domain : 3c complex (P:L = 1:5, acquired at 298K, with a field strength of 
600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3 and with an NOE mixing time of 300ms); the structure of 3c is inset into the spectrum with the different proton 
environments in the structure labelled. The peaks on the right-hand side of the diagonal correspond to intra-ligand and intermolecular interactions observed; the protein and 
ligand contributions to the interaction can be seen on the x- and y-axis respectively and a number of these inter/intramolecular interactions have been assigned.  
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Figure 6.23: In this figure, PSD-95 PDZ1 is depicted as a cartoon representation (grey), with 3c represented by sticks; for clarity the hydrogen’s have been omitted from some 
structures. a) The representative structures of the first (green), second (blue) and third (magenta) lowest energy clusters of the seven total clusters. b) The representative 
structures of the lowest (green) and highest energy (purple) clusters. c) The top 20 lowest energy structures of the lowest energy cluster. d) The representative structure of the 
PSD-95 PDZ1 – 3c complex, with the residues that showed intermolecular NOE’S highlighted. e) Enlarged view of the PSD-95 PDZ1 domain binding region with the protein 
surface shown. f) Enlarged view of the PSD-95 PDZ1 domain binding region with the protein surface shown and 3c in a space-filling representation. 
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The relevant parameters, clustering and validation analysis for the restraint-driven 
docking process are displayed in Table 6.12. 34 distance restraints for the PSD-95 
PDZ1 – 3c complex were obtained from the NMR spectroscopic experiments and 
only two of these restraints were slightly violated in the obtained representative 
structures obtained. It would have been desirable to have produced a representative 
structure of the complex with no distance restraint violations but given the nature of 
the NOESY NMR experiment, it was possible to observe a range of NOE 
interactions. Therefore, distance restraints can be derived from minor populations of 
3c bound to PSD-95 PDZ1, as well as the major population; the two distance 
restraints violated may have been from a minor population of 3c and hence, this 
could be why HADDOCK has not been able to satisfy them in the representative 
structure.  
As mentioned in [3.5.5], the output of the HADDOCK docking procedure is given as 
a ‘HADDOCK score;’ this is a weighted sum of all the energy terms calculated 
during the docking process, with a more negative value indicating the more 
energetically favourable the subsequent complex is. The value of the root mean 
square deviation (RMSD) of the structures in the representative cluster is 0.479Å; 
this low value shows that the 105 structures in the representative cluster show little 
deviation in the overall bound structure.  
As the HADDOCK score for the representative structure of the PSD-95 PDZ1 – 3c 
complex is an extremely negative value of -76.04, this indicates that the 
representative structure obtained is energetically favourable. The average 
HADDOCK score of the 20 lowest energy structures is -58.51, which is also a large 
negative value; this demonstrates that the top 20 representative structures cluster are 
similarly energetically favoured. The average buried surface area (BSA) value of 
 Development of Novel Small Molecule Inhibitors of the PSD-95 and SAP97 PDZ Domains 
281 
  
570.44Å
2
 is a quantification of the change in solvent accessible area from the free 
PSD-95 PDZ1 domain to the PSD-95 PDZ1 – 3c complex; this shows the ability of 
3c to interact with a substantial surface area of the PSD-95 PDZ1 domain binding 
region.   
Table 6.12: The statistical characteristics of the HADDOCK structural determination process for the 
complex between PSD-95 PDZ1 and 3c. 
  
Unambiguous restraints  
        Intermolecular NOEs
a
 26 
        Intramolecular NOEs
b
 8 
  
RMSD of lowest energy cluster (105 structures) (Å) 0.479 
  
HADDOCK score of lowest energy structure -76.04 
Average HADDOCK score of 20 lowest energy 
structures in the lowest energy cluster 
-58.51 
Average buried surface area of 20 lowest energy 
structures in the lowest energy cluster (Å
2
) 
570.44 
  
Number of unambiguous distance restraint violations 2 
Number of bad contacts 0 
  
Ramachandran plot (%)
c
  
        Residues in most favoured regions 76.6 
        Residues in additional allowed regions 20.8 
        Residues in generously allowed regions 0 
        Residues in disallowed regions 2.6
d
 
  
a
 Obtained from 3-D [
13
C, 
15
N]-filtered NOE Experiment (mixing time = 300 ms, 25
o
C, pH 6.3). 
b
 2-
Dimensional [
13
C, 
15
N]-filtered NOE Experiment (mixing time = 300 ms, 25
o
C, pH 6.3). 
c
 Determined 
by using PROCHECK (Laskowski et al., 1993) analysis to check structure viability. 
d
 Consistent with 
the residues in disallowed regions of the initial crystal structure used in the docking process (PDB ID 
= 3GSL (Sainlos et al., 2011)). 
  
6.6.3 PSD-95 PDZ1 – 4c Complex Structure Determination 
As with 3c, the NMR experiments were carried out on the prepared PSD-95 PDZ1 – 
4c complex (Figure 6.24), the resultant intra-ligand and intermolecular interactions 
were assigned (Appendices, A.8) and incorporated along with the other parameters 
highlighted in the experimental procedure in the HADDOCK docking method.  
It is clear that 4c showed less intra-ligand and intermolecular interactions with the 
PSD-95 PDZ1 domain than 3c. This was not unexpected as the structure of 4c is 
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much simpler and less-substituted; hence, it contains fewer atoms to form NOE’s 
with the PSD-95 PDZ1 domain, than 3c. The output of the distance restraint-driven 
docking gave four different possible structures of the PSD-95 PDZ1 domain in 
complex with 4c (Figure 6.25a & b). An ensemble of the 20 lowest energy structures 
from the lowest energy cluster was created (Figure 6.25c) and the structure with the 
lowest energy of these was taken as the representative structure of the PSD-95 PDZ1 
– 4c complex structure (Figure 6.25d-f). It can be seen that the lowest energy 
complexes from the top three low energy clusters generated from the HADDOCK 
docking process are very similar structurally and these account for over 190 of the 
200 final solvent refined structures. However, there is some deviation between the 
representative complex structure and the fourth cluster but this is due to the ability of 
the HADDOCK webserver to explore all local minima in the energy landscape. The 
structure shows that the 5-hydroxy group of 4c forms a hydrogen bond with the 
backbone NH of Ile23 and this bound conformation is stabilised by polar interactions 
between the 1-alkylcarboxyl and 2-carboxyl groups of 4c and the side chains of 
residues Lys82 and Arg14 respectively in the PSD-95 PDZ1 domain. The 3-methyl 
group shows hydrophobic interactions with those residues of the hydrophobic 
binding pocket including Leu81. 
Given the simple and little-substituted nature of 4c, the structure does not indicate 
any areas of the molecule that could be detrimental to its PSD-95 PDZ1 binding 
affinity. After careful analysis of the bound orientation, it may be possible to 
increase the binding affinity of 4c by substitution with a 2-alkylhydroxyl group to 
interact with His74 or a larger alkyl group than 3-methyl to interact with the 
hydrophobic pocket more effectively of the PSD-95 PDZ1 domain. 
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Figure 6.24: a) The obtained 2-D 
13
C, 
15
N-filtered NOESY spectrum of 
13
C 
15
N PSD-95 PDZ1 domain : 4c complex (P:L = 1:5, acquired at 298K, with a field strength of 
600MHz, in 20mM phosphate 0.1mM EDTA buffer, pH6.3 and with an NOE mixing time of 300ms); the structure of 4c is inset into the spectrum with the different proton 
environments in the structure labelled. The peaks on the right-hand side of the diagonal correspond to intra-ligand and intermolecular interactions observed; the protein and 
ligand contributions to the interaction can be seen on the x- and y-axis respectively and a number of these inter/intramolecular interactions have been assigned. 
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Figure 6.25: In this figure, PSD-95 PDZ1 is depicted as a cartoon representation (grey), with 4c represented by sticks; for clarity the hydrogen’s have been omitted from most 
structures. a) The representative structures of the first (green), second (blue) and third (magenta) lowest energy clusters of the four total clusters. b) The representative 
structures of the lowest (green) and highest energy (yellow) clusters. c) The top 20 lowest energy structures of the lowest energy cluster. d) The representative structure of the 
PSD-95 PDZ1 – 4c complex, with the residues that showed intermolecular NOE’S highlighted. e) Enlarged view of the PSD-95 PDZ1 domain binding region with the protein 
surface shown. f) Enlarged view of the PSD-95 PDZ1 domain binding region with the protein surface shown and 4c in a space-filling representation.   
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The relevant parameters, clustering and validation analysis for the restraint-driven 
docking process are displayed in Table 6.13. 25 distance restraints for the PSD-95 
PDZ1 – 4c complex were obtained from the NMR spectroscopic experiments and 
only one of these restraints was slightly violated in the obtained representative 
structure. As with the PSD-95 PDZ1 – 3c complex, it would have been desirable to 
obtain a representative structure of the complex that had no distance restraint 
violations but the reasons as to possibly why this is not the case were discussed in 
[6.6.2]. As only one NOE is violated out of the 25 distance restraints, this would 
suggest that the NOE’s assigned were either for one predominant bound orientation 
of 4c or that the NOE’s observed were an average of the different bound orientations 
at a 5-fold excess of 4c. It is difficult to distinguish between these two possibilities 
but the HADDOCK process has produced the most likely structure of the PSD-95 
PDZ1 – 4c complex in solution, at the given concentration.  
The RMSD value of the structures in the representative cluster is 0.448Å; this low 
value shows that the 167 structures in the cluster show little total deviation in the 
overall bound structure. As the HADDOCK score for the representative structure of 
the PSD-95 PDZ1 – 4c complex is an extremely negative value of -77.88, and so, 
indicates that the representative structure obtained is energetically favourable. The 
average HADDOCK score of the 20 lowest energy structures is -64.78, which is also 
a very large negative value; this demonstrates that the top 20 representative 
structures cluster are similarly energetically favoured. As with the PSD-95 PDZ1 – 
3c structure, the average BSA value of 471.63Å
2
 quantifies the change in solvent 
accessible area from the free PSD-95 PDZ1 domain to the PSD-95 PDZ1 – 4c 
complex and again, shows the ability of 4c to interact with a substantial surface area 
of the PSD-95 PDZ1 domain binding region. 
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Table 6.13: The statistical characteristics of the HADDOCK structural determination process for the 
complex between PSD-95 PDZ1 and 4c. 
  
Unambiguous restraints  
        Intermolecular NOEs
a
 16 
        Intramolecular NOEs
b
 9 
  
RMSD of lowest energy cluster (167 structures) (Å) 0.448 
  
HADDOCK score of lowest energy structure -77.88 
Average HADDOCK score of 20 lowest energy 
structures in the lowest energy cluster 
-64.78 
Average buried surface area of 20 lowest energy 
structures in the lowest energy cluster (Å
2
) 
471.63 
  
Number of unambiguous distance restraint violations 1 
Number of bad contacts 0 
  
Ramachandran plot (%)
c
  
        Residues in most favoured regions 81.8 
        Residues in additional allowed regions 15.6 
        Residues in generously allowed regions 0 
        Residues in disallowed regions 2.6
d
 
 
a
 Obtained from 3-D [
13
C, 
15
N]-filtered NOE Experiment (mixing time = 300 ms, 25
o
C, pH 6.3). 
b
 2-
Dimensional [
13
C, 
15
N]-filtered NOE Experiment (mixing time = 300 ms, 25
o
C, pH 6.3). 
c
 Determined 
by using PROCHECK (Laskowski et al., 1993) analysis to check structure viability. 
d
 Consistent with 
the residues in disallowed regions of the initial crystal structure used in the docking process (PDB ID 
= 3GSL (Sainlos et al., 2011)). 
  
6.6.4 HADDOCK Structure Comparison 
It is clear to see that the representative structures of small molecule inhibitors 3c and 
4c bound to the PSD-95 PDZ1 domain indicates that the two inhibitors bind in 
completely different orientations. The indole scaffold of 3c is orientated almost 
perpendicular to αB helix and the βB strand, whereas the indole scaffold of 4c is in a 
more parallel orientation to αB helix and the βB strand (Figure 6.26). This shows the 
importance of the large alkyl group attached to the 5-O atom in ‘anchoring’ in the 
binding pocket and hence, restricting the bound orientation of the small molecule. As 
solvated docking is employed in the HADDOCK protocol, the docking methodology 
is able to account for the presence and influence of water molecules in the PSD-95 
PDZ1 – 3c/4c complexes; however, HADDOCK is not able to model the presence of 
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any key bridging water molecules in the resultant PSD-95 PDZ1 – small molecule 
complexes. As a result, it is not possible to interpret the relative enthalpic and 
entropic contributions of the 3c and 4c small molecules to PSD-95 PDZ1 binding 
from the HADDOCK structures, as it would be from a reasonable resolution crystal 
structure. 
Figure 6.26: In this figure, the PSD-95 PDZ1 crystal structure (PDB ID = 3GSL (Sainlos et al., 
2011)) is depicted as a cartoon representation (grey), with the representative structures of 3c (green) 
and 4c (blue) represented by sticks. a) A comparison of the different PSD-95 PDZ1 bound 
conformations of the two small molecule inhibitors; it can be seen that the indole scaffold of 3c is 
oriented almost perpendicular to the αB helix, c.f. the indole scaffold of 4c is almost parallel. b) A 
close-up view of the representative structures, this view shows more clearly how the 5-benzyloxy and 
3-methyl groups of 3c and 4c respectively, interact with the binding pocket. 
  
It is interesting to observe that the less-substituted compound 4c forms fewer clusters 
(4) i.e. exists in fewer possible PSD-95 PDZ1 bound orientations, than 3c (7) and 
that 4c also has more structures in its representative cluster (167) than 3c (105). 
These observations could either be due to the ability of the more-substituted structure 
of 3c to explore more of the slight variations in the local minima in the energy 
landscape than the less-substituted 4c. Alternatively, as alluded to in [6.6.3], it is 
possible that the assigned NOE’s of the PSD-95 PDZ1 – 4c complex may have been 
a) b) 
βB 
αB 
αB 
βB 
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due to either a sole, major population of 4c bound to PSD-95 PDZ1 or an average of 
all the bound populations; either of these possibilities will result in more cluster 
analysis variation of 3c c.f. 4c.  
Direct comparison of the HADDOCK scores obtained from the representative 
structures of the PSD-95 PDZ1 complexes with 3c and 4c is not possible as the 
HADDOCK score output is a relevant value only for the individual protein and 
ligand set in the docking process; it is not a comparable value. However, both 
HADDOCK scores for the representative structures of the PSD-95 PDZ1 – 3c/4c 
complexes are large negative values; this suggests that the structures obtained are 
energetically favourable and thus, are an accurate representation of the actual bound 
orientations of the respective small molecule inhibitor. 
The BSA of the representative PSD-95 PDZ1 – 3c/4c structures indicates that upon 
binding, 3c is able to induce the greater change in buried surface area than 4c; this 
was to be expected as 3c is a larger and more-substituted small molecule c.f. 4c and 
so, is able to occupy more surface area of the PSD-95 PDZ1 domain binding region 
upon binding. The Ramachandran plot analysis performed by PROCHECK 
(Laskowski et al., 1993) shows that both the PSD-95 PDZ1 – small molecule 
inhibitor complexes have the majority of residues in favoured or additionally allowed 
regions; those residues that are in the disallowed regions are consistent with the 
initial PSD-95 PDZ1 crystal structure utilised (PDB ID = 3GSL (Sainlos et al., 
2011)). As a result, both the obtained representative structures can be concluded to 
viable representations of the PSD-95 PDZ1 domain in complex with either small 
molecule inhibitor 3c or 4c.  
Analysis of the bound structures and the subsequent clustering and validation 
analysis of both of the PSD-95 PDZ1 inhibitors have led to the identification of key 
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moieties of ligand binding to PSD-95 PDZ1, as well as how to reduce unwanted 
clashes/repulsions with the PSD-95 PDZ1 domain. As a result, the obtained PSD-95 
PDZ1 – small molecule complex structures can provide an essential insight for use in 
future small molecule inhibitor development of the PSD-95 PDZ1 domain and 
possibly, even PDZ domains in general. 
6.7 Conclusion 
Through a developmental process encompassing a number of different biophysical 
techniques, a large number of novel, reversible small molecule binders of the PSD-
95 PDZ1 domain have been rationally synthesised and tested for binding. The 
binding affinity to PSD-95 PDZ1 of two of these compounds has been determined 
and both of these compounds have been shown to have a reversible inhibitory effect 
on the native interaction. A selection of the small molecule binders developed by the 
research process detailed in this chapter have been shown to corroborate the in vitro 
results shown and have been found to exert PSD-95 PDZ domain inhibitory effects 
in vivo ((Bouzidi et al., 2013, Vogrig et al., 2013)). This may be seen as surprising 
as, in order to exert an observable effect in the rat models, the developed small 
organic molecules are required to cross the blood-brain barrier; molecules that 
achieve this are often quite hydrophobic. Given the presence of a number of 
carboxylic acid groups on the detailed organic molecules, these compounds are not 
particularly hydrophobic. Thus, this suggests that the small molecules are still able to 
pass the blood-brain barrier or that they are able to exert an inhibitory effect, via an 
alternate pathway, that does not require blood-brain barrier passage. 
Arguably, the most important aspect of the research detailed in this chapter is the 
determination of the representative structure of the PSD-95 PDZ1 domain bound 
individually to small molecule inhibitors 3c and 4c, using the HADDOCK 
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webserver. These are the first examples of the HADDOCK webserver being utilised 
to determine a PDZ domain – small molecule inhibitor complex and has a wide-
range of possible applications for future PDZ domain research. Given how well 
HADDOCK has performed in the CAPRI experiments; the reliability, validity and 
accuracy of the obtained PSD-95 PDZ1 – small molecule complexes can be 
substantiated. As a result, this illustrates how HADDOCK can be an extremely 
important tool for future PDZ domain research, by determining the structure of PDZ 
– small molecule inhibitor complexes when it is not possible to obtain a 
crystallographic or NMR structure. It is hoped that the research detailed in the latter 
part of this chapter illustrates how determination of PDZ – small molecule inhibitor 
structure by HADDOCK, can facilitate a much quicker and easier method to 
enhancing PDZ domain binding affinity; this technique should drive future PDZ 
domain inhibition by small molecules research forward at a more accelerated rate. 
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7. GENERAL DISCUSSION AND FUTURE RESEARCH 
7.1 Conclusions 
If the original aims of the research are reviewed, it can be seen that these have been 
satisfied: 
 The interactions of the 5-HT2a/c receptors with PSD-95/SAP97 PDZ1&2 
have been proven by NMR spectroscopy and quantified by ITC; the structure 
of the PSD-95 PDZ1 – 5-HT2c complex has been determined for the first time 
using NMR solution state spectroscopy and is in the process of being 
deposited onto the PDB. 
 Using ITC, a thorough and systematic biophysical investigation of the SAP97 
PDZ1&2 binding regions using peptides containing natural and non-natural 
amino acids has been performed; the effect of peptide length, 0 and -2 residue 
substitutions, pH and functional group orientation was probed. 
 A variety of moderate to high micromolar affinity small molecule PSD-
95/SAP97 PDZ1&2 binders have been developed through an NMR 
spectroscopy-based screening process; a number of these small molecules 
have shown PDZ domain-mediated inhibitory effects in vitro and in vivo 
(Bouzidi et al., 2013, Vogrig et al., 2013). PSD-95 PDZ1/SAP97 PDZ2 – 
small molecule complexes has been determined using NMR restraint-driven 
docking with HADDOCK; this is the first example of HADDOCK being 
used to determine a PDZ – small molecule complex.  
After reviewing the research presented in this thesis and the accompanying 
appendices, it can be concluded that the production of indole scaffold-based small 
molecule inhibitors of the PSD-95/SAP97 PDZ domains may not be an achievable 
target; this may even be extended to PSD-95/SAP97 PDZ domain-mediated 
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interaction by small molecule compounds in general. This has been proposed for the 
following reasons: 
 Although the presence of ‘hotspots’ within the PDZ domain had been 
identified by previous research, the research detailed in this thesis has shown 
the interactions that a small molecule needs to mimic, are spread out over a 
reasonably large area of over 490Å
2
; (area of the PSD-95 PDZ1 domain that 
interacts with the 5-HT2c nonapeptide in the representative structure). This 
may mean that small molecule inhibition of the PSD-95/SAP97 PDZ 
domains is not feasible (Figure 7.1): 
o The PSD-95 PDZ1 – 5-HT2c complex structure showed the presence 
of interactions of 5-HT2c with the residues of the βB – βC loop. 
o The biophysical characterisation of the SAP97 PDZ1/2 binding 
regions showed the importance of interactions outside the canonical 
class I C-terminal PDZ binding sequence (X-S/T-X-Ω).   
 The produced indole scaffold-based binders of the PSD-95/SAP97 PDZ1&2 
domains showed only a moderate to high micromolar binding affinity despite 
five stages of the development process. 
 The examples of low micromolar/nanomolar affinity small molecule PSD-95 
PDZ – nNOS interaction inhibitors in vivo were designed to bind target the 
PDZ domain ligand, nNOS, not the PSD-95 PDZ domain itself. Subsequent 
research in our laboratory has indicated that one of these small molecule 
compounds, IC87021, has no observable inhibitory effect on the PSD-95 
PDZ – nNOS interaction by NMR spectroscopy and ITC; this possibly raises 
questions over the validity of other reported small molecule compounds as 
PDZ domain inhibitors.   
 General Discussion and Future Research 
294 
 
Therefore, the future inhibition of PSD-95/SAP97 PDZ domain-mediated 
interactions research has a variety of different directions in which to progress. 
 
Figure 7.1: The ‘hotspot’ binding regions of typical PDZ domains in a surface representation: GLGF 
motif (red), hydrophobic pocket (blue), conserved His (green) and βB – βC loop (yellow). a) The 
crystal structure of the Scrib1 PDZ1 domain (PDB ID = 2W4F). b) The representative structure of the 
PSD-95 PDZ1 – 5-HT2c complex structure determined by solution state NMR spectroscopy (grey) 
with the 5-HT2c ligand removed; the PSD-95 PDZ1 bound conformations of small molecules 3c 
(green) and 4c (magenta) determined by restraint-driven docking using HADDOCK have been 
aligned with the representative structure, with the non-polar protons have been removed for clarity in 
the small molecule compounds. The figure shows how difficult it is to develop a small molecule 
inhibitor of the PSD-95 PDZ1 domain that is able to effectively interact with the four different hotspot 
regions indicated and hence, produce sufficient binding affinity; it is possible that this difficulty may 
apply to all PSD-95 PDZ1 inhibition by small molecule research, regardless of the chemical scaffold 
utilised. 
  
7.2 Future PDZ Domain Inhibition Research 
After analysing the previous PDZ domain inhibition research and the research 
detailed in this thesis, the future research into the development of inhibitors of PSD-
95/SAP97 PDZ domain-mediated interactions can be divided into two different 
areas: 
 Development of a more effective chemical scaffold on which to base a small 
molecule PDZ domain inhibitor. 
 Production of a β-strand peptidomimetic as a PDZ domain inhibitor. 
 
 
a) b) 
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7.2.1 New Small Molecule Scaffold 
The development of a new chemical scaffold for small molecule inhibition of PDZ 
domains could proceed in a variety of methodologies; one such example is a 
fragment-based screening approach. This drug discovery approach has been used for 
a variety different protein targets (Congreve et al., 2008); this methodology would 
entail screening of PSD-95/SAP97 PDZ domain binding of fragments by a 
biophysical technique i.e. ITC or surface plasmon resonance (SPR), determining the 
PDZ – fragment bound structures by X-ray crystallography or NMR restraint-driven 
docking and finally, chemical knowledge or in-silico methods to produce a suitable 
chemical scaffold capable of positioning the fragments as desired (Figure 7.2) (Rees 
et al., 2004, Jhoti et al., 2007). 
 
Figure 7.2: A comparison of the potential advantages of using a fragment-based screening rather than 
a high-throughput drug discovery methodology. a) A poor HTS hit of a molecule that contains four 
different functional fragments; two of these functional fragments have the potential to bind to the 
target well but are unable to in the molecule screened. b) & c) By adopting a fragment-based 
screening approach to drug discovery it is possible to identify the two fragments that bind to the target 
well and then connect these using a suitable chemical scaffold/linker to produce a potentially strong 
binder. Images taken and adapted from (Rees et al., 2004). 
  
The design of an alternative small molecule chemical scaffold could also be achieved 
by implementing one of the previously described methodologies utilised in PDZ 
domain inhibition research [1.6]: virtual library screening (VLS), high-throughput 
screening (HTS) or the re-purposing of existing drugs. 
7.2.2 β-strand Peptidomimetics 
As discussed in [1.4 & 1.6], PDZ domain ligands form an antiparallel β-strand upon 
PDZ domain binding and so, a β-strand peptidomimetic could be an effective non-
a) b) c) 
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peptidic PDZ domain inhibitor; a couple of β-strand peptidomimetic binders of PDZ 
domains have already been designed (Figure 7.3a) (Hammond et al., 2006). These 
compounds showed promising levels of α1-syntrophin PDZ domain binding affinity 
(KD = 0.32µM) and so, the fact that there have been no further examples of PDZ 
domain peptidomimetic inhibitor investigations is surprising; this could be as a result 
of unforeseen problems with the particular peptidomimetic design i.e. solubility, 
stability issues etc. Adaptation of this previous PDZ domain research to overcome 
such issues and result in the particular PSD-95/SAP97 PDZ domain specificity may 
yield a potent peptidomimetic inhibitor of a PDZ domain-mediated interaction. 
There is also evidence in the literature of other examples of β-strand 
(peptido)mimetics developed for non-PDZ domain-containing protein targets (Figure 
7.3b) (Smith et al., 1992, Smith et al., 1994, Kang et al., 2012, Sutherell et al., 2012); 
these could possibly be adapted for PSD-95/SAP97 PDZ domain-targeting and 
hence, be important in future PDZ domain inhibition research. 
 
 
 
 
Figure 7.3: a) The structure of the β-strand peptidomimetic developed to bind to the α1-syntrophin 
PDZ domain; the aza-@-unit has been highlighted (red) and this peptidomimetic showed low 
micromolar/high nanomolar PDZ domain (KD = 0.32µM) (Hammond et al., 2006). b) The aryl-linked 
imidazolidin-2-one developed as a non-peptidic β-strand mimic; this and/or related compounds could 
have important applications in future PDZ domain inhibition research  (Sutherell et al., 2012). 
 
     
  
b) a) 
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APPENDIX 
A.1. a) Agarose gel visualisation under trans UV light of the products from the site-directed ligase-
independent mutagenesis (SLIM) procedure on the SAP97 PDZ2 domain; the agarose gel shows that 
the SLIM methodology resulted in the desired PCR products, indicated by the bright white bands 
visible: 1 = Marker, 2 = SAP97 PDZ2 H73G and 3 = SAP97 PDZ2 H73T.  b) The standard ‘generate 
protons using CNS’ protocol implemented to add non-polar hydrogens to the small molecules in the 
PSD-95 PDZ1 – 3c/4c complex HADDOCK structures.  
 
 
 
 
 
 
 
 
 
1. Split the pdb file of the representative structure into two separate pdb files, where 
one contains the individual PSD-95 PDZ1 component of the complex and the other 
contains the small molecule component. Alter the segment ID (SEGID) of the small 
molecule pdb so that ‘SEGID’ = ‘B’ and save accordingly. 
2. Ensure that the mtf file contains the relevant topology (.top) and parameter (.par) 
files for the small molecule. 
3. Adapt the gen.inp file as necessary for the respective input parameters and output 
files. 
4. Initiate the process and check that the outputted files contain the desired addition of 
non-polar hydrogens. 
 
 
 
 
 
 
 
a) 
b) 
 1  2   3 
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A.2. The calibration process of the HiLoad 26/60 Superdex 75 size exclusion chromatography column 
carried out by a colleague, where Vo = void volume, Ve = elution volume i.e. retention time, Vc = 
column volume and      
     
     
 . Thus, knowledge of the retention time of the protein of interest 
leads to determination of the Log Mr value and hence, molecular weight (Mr). 
  
 
 
 
  log Mr Mr Vo Ve Ve-Vo Vc-Vo Kav 
Blue Dextran   113    
 Conalbumin 1.875 75   142.42 29.42 207 0.142 
Ovalbumin 1.633 43   158.97 45.97 207 0.222 
Carbonic 
anhydrase 1.462 29   182.01 69.01 207 0.333 
Ribonuclease 1.137 13.7   209.94 96.94 207 0.468 
Aprotinin 0.792 6.5   243.65 130.65 207 0.631 
 
 
 
 
 
 
y = -0.4589x + 0.9927 
R² = 0.9955 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.5 0.7 0.9 1.1 1.3 1.5 1.7 1.9 2.1
Kav 
Log Mr 
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A.3. The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding experiment between 100µM SAP97 PDZ2 (cell) and 750µM RETQV (syringe) in a) 
20mM phosphate, pH7.4 and b) 20mM phosphate, 5% (v/v) DMSO pH7.4, on an iTC200 Microcalorimeter (MicroCal) at 298K. c) A table summarising the binding affinity 
and Gibbs free energy parameters obtained from the respective ITC experiments; fitting of the curve produced by the individual ITC experiment to a single set of sites curve-
fitting model, using Origin7, resulted in a binding affinity (KD) of 1.639 and 1.140µM for RETQV to the SAP97 PDZ2 domain, in the absence or presence of 5% (v/v) DMSO 
respectively. The difference in the obtained binding parameters between the respective ITC binding experiments is small and within experimental error; as the concentration 
of DMSO present in the ITC competition experiments is 10-fold less than in the experiments shown here, it can be concluded that the presence of DMSO in the samples of the 
ITC competition experiments will have no or negligible effect on the subsequent results obtained and thus, any conclusions drawn will be valid. 
% DMSO KD (µM) ∆G (kcal mol
-1
) 
0 1.639 ± 
0.189 
-7.891 ± 0.294 
5 1.140 ± 
0.131 
-8.107 ± 0.302 
a) b) c) 
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A.4. An overlay of 
1
H-
15
N HSQC experiments of the 
13
C, 
15
N PSD-95 PDZ1 – 5-HT2c complex (P:L = 1:5), acquired at 298K, with a field strength of 600MHz, in either 
20mM phosphate 0.1mM EDTA buffer, pH6.3 or 100% D2O; where the different colour spectra correspond to different buffer and/or time periods and these are detailed in the 
table to the right. The object of this series of 
1
H-
15
N HSQC experiments was to determine those residues of the PSD-95 PDZ1domain forming intramolecular hydrogen bonds, 
so that they could be used as restraints in the PSD-95 PDZ1 – 5-HT2c NMR solution state structure determination process; this was completed by lyophilising a previously 
used NMR complex sample, re-suspending in D2O and then, performing 
1
H-
15
N HSQC experiments at different time intervals overnight. The overlaid spectra shows that 10Ile 
(red dashed rectangle) is an example of a PSD-95 PDZ1 residue forming an intramolecular hydrogen bond as the corresponding peak is present in the normal NMR complex 
(blue), immediately in D2O (red), 30 minutes in D2O (green) and 60 minutes D2O (black) spectra and thus, there is no evidence of backbone NH hydrogen/deuterium 
exchange occurring to cause attenuation of the peak i.e. an intramolecular hydrogen bond is present which prevents this. The residues that were present in all spectra were 
then analysed in the PSD-95 PDZ1 crystal structure (PDB ID = 3GSL) and those residues within hydrogen bond formation distance with other residues were taken as 
hydrogen bond restraints for the PSD-95 PDZ1 domain in the structure determination process. Gly20 (black dashed rectangle) is a PSD-95 PDZ1 residue that does not form 
an intramolecular hydrogen bond. 
1
H 
 
15
N 
Conditions       Colour 
 
Normal Buffer  Blue 
100% D2O (immediately) Red 
100% D2O (30 minutes)  Green 
100% D2O (60 minutes) Black 
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A.5. (continues onto next page) The intermolecular distance restraints used in the PSD-95 PDZ1 – 5-
HT2c complex NMR solution state structure calculation process; the individual PSD-95 PDZ1 and 5-
HT2c residue atoms involved in the given restraint have been detailed, along with the corresponding 
NOE distance restraint and the allowed upper limit. * denotes where the particular protons were 
equivalent. 
 
PSD-95 PDZ1 
Residue 
Atom 5-HT2c 
Residue 
Atom NOE 
Distance 
Restraint (Å) 
Upper 
Limit 
(Å) 
Val78 Hγ1* Ser8 Hβ* 2.695 +1.395 
Val78 Hγ2* Val9 Hβ 2.910 +1.610 
Val78 Hγ2* Ser8 Hβ* 2.515 +1.215 
Leu81 Hβ1 Val9 Hγ* 3.435 +2.135 
Phe21 HN Val9 Hα 3.055 +1.755 
Ser22 HN Ile6 Hδ1* 2.900 +1.600 
Ala24 HN Ile6 Hδ1* 2.760 +1.460 
Thr41 HN Ile6 Hδ1* 2.885 +1.585 
Lys42 HN Ile6 Hδ1* 2.780 +1.480 
Leu19 Hδ* Val9 Hβ 2.750 +1.450 
Leu19 Hδ* Val9 Hγ* 2.690 +1.390 
Ser22 Hβ* Ile6 Hδ1* 2.675 +1.375 
Ser22 Hβ* Ser8 Hβ* 3.080 +1.780 
Ser22 Hβ* Val9 Hα 3.290 +1.990 
Ile23 Hγ1* Ser8 Hβ* 3.070 +1.770 
Ile32 Hδ1* Val1 Hγ* 3.140 +1.840 
Ile32 Hδ1* Val2 Hγ* 3.165 +1.865 
Gly33 HN Val1 Hγ* 3.235 +1.935 
Gly33 HN Val2 Hγ* 3.260 +1.960 
His74 Hε1 Arg5 Hδ* 2.935 +1.635 
Leu81 Hδ* Val9 Hβ 2.525 +1.225 
Lys82 Hγ* Val9 Hβ 2.96 +1.66 
Lys82 Hγ* Val9 Hγ* 3.41 +2.110 
Gly20 HN Val9 Hγ* 3.650 +2.350 
Gly18 HN Val9 Hγ* 3.650 +2.350 
Ile23 HN Ser8 Hβ* 3.265 +1.965 
Ile23 HN Ile6 Hδ1* 2.725 +1.425 
Gly25 HN Ile6 Hδ1* 3.565 +2.265 
Ile23 Hδ1* Ser8 Hβ 3.390 +2.090 
Ser22 Hβ2 Ile6 Hδ1* 2.940 +1.640 
Ser22 Hβ1 Ile6 Hδ1* 2.940 +1.640 
Ile23 Hα Ile6 Hδ1* 2.885 +1.585 
Ala24 Hα Ile6 Hδ1* 2.950 +1.650 
Ala24 Hβ* Ile6 Hδ1* 2.68 +1.380 
Lys82 Hα Val9 Hγ* 2.325 +1.825 
Ile23 Hβ Ile6 Hδ1* 3.120 +1.820 
Ile23 Hδ1* Val9 Hβ 2.770 +1.470 
Ile23 Hγ2* Ile6 Hδ1* 2.590 +1.290 
Ile23 Hγ2* Ser8 Hβ* 2.955 +1.655 
Ala24 Hβ* Ile6 Hγ1* 2.440 +1.140 
Pro30 Hβ2 Ser3 Hα 3.115 +1.815 
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PSD-95 PDZ1 
Residue 
Atom 5-HT2c 
Residue 
Atom NOE 
Distance 
Restraint (Å) 
Upper 
Limit 
(Å) 
Lys42 Hβ2 Ile6 Hδ1* 2.890 +1.590 
Lys42 Hβ1 Ile6 Hδ1* 2.890 +1.590 
Leu81 Hγ Val9 Hβ 3.210 +1.910 
Val78 Hα Val9 Hβ 2.89 +1.590 
Val78 Hγ1* Val9 Hβ 2.665 +1.365 
Val88 Hγ* Val9 Hβ 3.355 +2.055 
 
A.6. The intramolecular PSD-95 PDZ1 hydrogen bond restraints used in the PSD-95 PDZ1 – 5-HT2c 
complex NMR solution state structure calculation process, determined by the process described in 
A.4. The individual PSD-95 PDZ1 residue atoms involved in the particular restraint have been 
detailed; the given restraints were set as 1.80Å ± 0.20Å. 
 
Residue Atom Residue Atom 
Glu8 HN Val92 O 
Ile10 HN Leu90 O 
Leu12 HN Val88 O 
Ser22 HN Lys42 O 
Ala24 HN Phe39 O 
Leu55 HN Ala49 O 
Asp59 HN Arg56 O 
Leu62 HN Tyr91 O 
Phe63 HN Tyr91 O 
Val64 HN Val67 O 
Asn65 HN Arg89 O 
Ala77 HN His74 O 
Val78 HN His74 O 
Glu79 HN Ser75 O 
Leu81 HN Val78 O 
Lys82 HN Val78 O 
Val88 HN Leu12 O 
Tyr91 HN Phe63 O 
Val92 HN Glu8 O 
Met93 HN Asp59 O 
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A.7. The annotated structure of the small molecule inhibitor 3c, with tables of the obtained intra- and 
intermolecular NOE’s of the 3c in the PSD-95 PDZ1-bound form; these NOE distance restraints were 
used as input parameters in the HADDOCK webserver restraint-driven docking process. 
 
 
 
 
 
 
 
 
 
 
 
The intramolecular NOE’s of 3c from a two-Dimensional [13C, 15N]-filtered NOE experiment ([PSD-
95 PDZ1] : [3c] = 1:5) in the PSD-95 PDZ1-bound form. 
Assignment ω1 (ppm) ω2 (ppm) Relative NOE Intensity 
a.
 
d ↔ h 2.151 7.335 w 
d ↔ g 2.154 7.423 m 
d ↔ e 2.154 7.197 s 
d ↔ f 2.154 5.014 m 
l ↔ e 7.448 7.197 m 
l ↔ b 7.449 1.756 m 
l ↔ c 7.448 1.881 m 
b ↔ c 1.757 1.880 s 
a.
 NOE cross-peak intensities were classified as strong (s, 1.8-3.2 Å), medium (m, 1.8-4.5 Å), and 
weak (w, 1.8-6 Å). Distances were calibrated using the distance between h ↔ g as 2.5Å. 
 
The intermolecular NOE’s between the PSD-95 PDZ1 domain and 3c from 3-D [13C, 15N]-filtered 
NOE Experiment ([PSD-95 PDZ1] : [3c] = 1:5). 
Assignment Relative NOE 
Intensity 
a.
 
Assignment Relative NOE 
Intensity 
a.
 
L12 Hδ1 ↔ i m I23 Hγ2 ↔ g m 
L12 Hδ1 ↔ h w I23 Hδ1 ↔ g w 
L12 Hδ1 ↔ g w I44 Hβ ↔ d w 
L19 Hγ ↔ h m I44 Hγ2 ↔ d m 
L19 Hγ ↔ g w I44 Hδ1 ↔ d m 
L19 Hδ2 ↔ g w V78 Hα ↔ i w 
L19 Hδ1 ↔ e w V78 Hγ1 ↔ i m 
L19 Hδ1 ↔ f m V78 Hγ1 ↔ h m 
L19 Hδ2 ↔ f w V78 Hγ2 ↔ h w 
I23 Hδ1 ↔ i w L81 Hδ1 ↔ g w 
I23 Hγ1 ↔ i w L81 Hδ2 ↔ g m 
I23 Hγ1 ↔ h w L81 Hδ1 ↔ f w 
I23 Hδ1 ↔ h m L81 Hδ2 ↔ f w 
a.
 NOE cross-peak intensities were classified as strong (s, 1.8-3.2 Å), medium (m, 1.8-4.5 Å), and 
weak (w, 1.8-6 Å). Distances were calibrated using the distance between h ↔ g as 2.5Å. 
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A.8. The annotated structure of the small molecule inhibitor 4c, with tables of the obtained intra- and 
intermolecular NOE’s of the 4c in the PSD-95 PDZ1-bound form; these NOE distance restraints were 
used as input parameters in the HADDOCK webserver restraint-driven docking process. 
 
 
 
 
 
 
 
 
 
 
The intramolecular NOE’s of 4c from two-Dimensional [13C, 15N]-filtered NOE experiment ([PSD-95 
PDZ1] : [4c] = 1:5) in the PSD-95 PDZ1-bound form. 
Assignment ω1 (ppm) ω2 (ppm) Relative NOE Intensity 
a.
 
e ↔ d 6.942 2.081 s 
e ↔ b 6.942 1.787 w 
f ↔ d 7.856 2.080 w 
f ↔ b 7.859 1.793 m 
f ↔ c 7.859 1.935 w 
f ↔ a 7.858 4.198 w 
a ↔ d 4.222 1.793 w 
a ↔ c 4.223 1.937 w 
a ↔ b 4.222 2.080 m 
a.
 NOE cross-peak intensities were classified as strong (s, 1.8-3.2 Å), medium (m, 1.8-4.5 Å), and 
weak (w, 1.8-6 Å). Distances were calibrated using the distance between d ↔ e as 2.5Å. 
 
The intermolecular NOE’s between the PSD-95 PDZ1 domain and 4c from 3-D [13C, 15N]-filtered 
NOE Experiment ([PSD-95 PDZ1] : [4c] = 1:5). 
Assignment Relative NOE 
Intensity 
a.
 
Assignment Relative NOE 
Intensity 
a.
 
L19 Hδ1 ↔ d m V78 Hγ2 ↔ e w 
L19 Hδ2 ↔ d w V78 Hγ1 ↔ f m 
I23 Hδ1 ↔ d w V78 Hγ2 ↔ f w 
I23 Hγ2 ↔ e w V78 Hγ1 ↔ a w 
I23 Hδ1 ↔ e w L81 Hδ1 ↔ d m 
I38 Hγ2 ↔ e w L81 Hδ2 ↔ d m 
I41 Hγ2 ↔ e w L81 Hδ1 ↔ e w 
V78 Hγ1 ↔ e w L81 Hδ2 ↔ e w 
a.
 NOE cross-peak intensities were classified as strong (s, 1.8-3.2 Å), medium (m, 1.8-4.5 Å), and 
weak (w, 1.8-6 Å). Distances were calibrated using the distance between d ↔ e as 2.5Å. 
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A.9. The Ramachandran analysis of a) the full 20 structure ensemble and b) the representative structure of the PSD-95 PDZ1 – 5-HT2c complex NMR solution state structure, 
performed by iCING and PDBsum respectively.  
a) b) 
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A.10. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of PSD-95 PDZ2 in the free form (blue) and in the presence of 1d (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.11. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ1 in the free form (blue) and in the presence of 1d (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.12. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ2 in the free form (blue) and in the presence of 1d (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.13. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of PSD-95 PDZ2 in the free form (blue) and in the presence of 2c (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.14. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ1 in the free form (blue) and in the presence of 2c (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.15. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ2 in the free form (blue) and in the presence of 2c (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.16. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of PSD-95 PDZ2 in the free form (blue) and in the presence of 3d (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.17. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ1 in the free form (blue) and in the presence of 3d (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.18. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ2 in the free form (blue) and in the presence of 3d (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.19. A 2-D overlay of the 
1
H – 15N HSQC spectra produced of SAP97 PDZ1 in the free form (blue) and in the presence of 4c (P:L = 1:10, red), acquired at 298K, with a 
field strength of 600MHz, in 20mM phosphate buffer, pH6.3.  
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A.20. The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding experiment between 100µM PSD-95 PDZ1 (cell) and 750µM 5-HT2c nonapeptide 
(VVSERISSV, syringe) in 20mM phosphate, pH6.3 with 3c present in both the cell and syringe solutions at PSD-95 PDZ1 : 3c ratios of a) 1:10 and b) 1:25, on an iTC200 
Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the individual ITC experiment to a single set of sites curve-fitting model, using Origin7, resulted in an 
apparent binding affinity (  
   
) of 51.98 and 84.20µM for VVSERISSV to the PSD-95 PDZ1 domain, in the presence 10-fold and 25-fold excess of 3c respectively. These 
experiments were used to determine the inhibitory constant (Ki) of 3c for the PSD-95 PDZ1 – 5HT2c interaction.  
a) b) 
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A.21. The ITC isotherm (top) and resultant curve (bottom) produced by the ITC binding experiment between 100µM PSD-95 PDZ1 (cell) and 750µM 5-HT2c nonapeptide 
(VVSERISSV, syringe) in 20mM phosphate, pH6.3 with 4c present in both the cell and syringe solutions at PSD-95 PDZ1 : 4c ratios of: a) 1:2.5, b) 1:5 and c) 1:7.5, on an 
iTC200 Microcalorimeter (MicroCal) at 298K. Fitting of the curve produced by the individual ITC experiment to a single set of sites curve-fitting model, using Origin7, 
resulted in an apparent binding affinity (  
   
) of 46.51, 54.89 and 73.50µM for VVSERISSV to the PSD-95 PDZ1 domain, in the presence 2.5-fold, 5-fold and 7.5-fold 
excess of 4c respectively. These experiments were used to determine the inhibitory constant (Ki) of 4c for the PSD-95 PDZ1 – 5HT2c interaction. 
a) b) c) 
